<allTrials totalCount="329" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2008-06-30T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-06-30T00:00:00.000Z">95974322</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Brazilian pentavalent vaccine</title>
      <scientificTitle>Immunogenicity and safety of Brazilian combined vaccine against diphtheria, tetanus, pertussis, haemophilus influenzae type B and hepatitis B (DTPw/HB/hib)</scientificTitle>
      <acronym/>
      <studyHypothesis>The Brazilian combined diphtheria, tetanus, pertussis, haemophilus influenzae type B and hepatitis B (DTPw/HB/hib) vaccine is as immunogenic and safe as the current DTPw/Hib and HB vaccines administered separately.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Antibody titres to diphtheria, tetanus, pertussis, haemophilus influenzae (PRP) and hepatitis B, and seroprotection rate, measured after third dose, shoud be non-inferior to that from the reference vaccines (DTP/Hib and HB vaccines given separately).</primaryOutcome>
      <secondaryOutcome>1. Adverse event after each dose shoud be equivalent to reference vaccines
2. Consistency of production evaluated by equivalence in immunogenicity and safety of three lots of the experimental vaccine DTPw/HB/Hib</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Fiocruz Ethics Committee on the 14th January 2007 (ref: 400/07).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN95974322</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ASCLIN/001/2007</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, non-inferiority randomised controlled trial, partially blinded.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-17T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="705a0939-fcc5-4d99-aabe-974459d56b68">
	  <name>Rua Leoplodo Bulhões 1480/820</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>21041-210</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy newborns (newborns and infants up to 7 months of age, of both sexes) whose parents/tutors understand the risk and benefits of the trial and agree to participate with written and informed consent.</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Months" value="7.0"/>
      <gender>Both</gender>
      <targetEnrolment>1200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1200 volunteers</totalTarget>
      <exclusion>Newborns or mothers:
1. Hepatitis B surface antigen (HBsAg) positive
2. Human immunodeficiency virus (HIV) seropositive 
3. With positive serology for syphilis</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-17T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diphtheria, tetanus, pertussis, hepatitis B and haemophilus influenzae type B diseases</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Bacterial infection of unspecified site</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Experimental group: vaccine (DTPw/HB/Hib) at 2, 4 and 6 months of age
2. Control group: DTPw/Hib and HB vaccines in concomitant injections at different sites

Both groups will receive HB vaccine at birth.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Combined diphtheria, tetanus, pertussis, haemophilus influenzae type B and hepatitis B (DTPw/HB/hib) vaccine, DTPw/Hib vaccine, HB vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17918-0</funderId>
      <funderId>Funder17918-1</funderId>
      <contactId>Contact55901_17918</contactId>
      <sponsorId>Sponsor54465</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55901_17918">
    <title>Dr</title>
    <forename>Luiz Antônio Bastos</forename>
    <surname>Camacho</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Leoplodo Bulhões 1480/820 
Manguinhos</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21041-210</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 21 2598 2630</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">luiz.camacho@ensp.fiocruz.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54465">
    <organisation>Bio-Manguinhos/Fiocruz (Brazil)</organisation>
    <website>http://www.bio.fiocruz.br</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Akira Homma 
Director
Avenida Brasil 4365 
Manguinhos</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21040-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.424703.6</gridId>
    <rorId>https://ror.org/05gj5j117</rorId>
  </sponsor>
  <funder id="Funder17918-0">
    <name>Brazilian Ministry of Health (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17918-1">
    <name>Brazilian Ministry of Science and Technology (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-20T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-06-20T00:00:00.000Z">34433965</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentre study of the reduction of steps (measured by an electronic pedometer) after 4 different types of repair for inguinal hernia</title>
      <scientificTitle>Multicentre cohort study evaluating ambulatory activity reduction after LIchtenstein, laparoscopic Totally ExtraPeritoneal, KUgel patch or Polysoft repair of primary inguinal hernia (LITEKUP trial)</scientificTitle>
      <acronym>LITEKUP trial</acronym>
      <studyHypothesis>To compare the short-term functional outcome after four different techniques of inguinal hernia repair in an ambulatory setting, namely, the Lichtenstein repair, the laparoscopic totally extraperitoneal repair, the open retroperitoneal Kugel patch repair and the Polysoft® patch repair.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Count of steps 1 week before and 2 weeks after scheduled inguinal hernia repair, measured with an electronic pedometer.</primaryOutcome>
      <secondaryOutcome>1. Recurrence rate after 12-24 months. This will be assessed by clinical examination during clinical follow-up after 2 weeks, 6, 12 and 24 months. Independent examination will be performed at 12 and 24 months to assess recurrence and chronic pain. 
2. Acute pain at the affected groin side measured daily the week before, the day of and the first 2 weeks after surgery, using a visual analogue scale (VAS) indicating no pain at 0 mm and worst pain ever experienced at 100 mm. 
3. Chronic groin pain syndrome at the operated side after 12-24 months. Classified as follows:
No pain: no discomfort experienced
Mild pain: defined to the patient as discomfort that did not limit activity, with a return to pre-hernia lifestyle
Moderate pain: defined as pain preventing return to normal preoperative activities (i.e. inability to continue with prehernia activities such as golf, tennis and other sports, and inability to lift objects, without pain, that patient had been lifting before the hernia occurrence)
Severe pain: pain that incapacitated the patient at frequent intervals or interfered with activities of daily living (i.e. pain constantly present or intermittently present but so severe as to impair normal activities, such as walking)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Leading Ethical Committee of the University Hospital Brussels (Universitair Ziekenhuis Brussel). Date of approval: 11/10/2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34433965</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>B.U.N. B14320072331</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, multicentre, cohort, observational study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2012-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5a1278bf-bfaf-4f90-b8eb-487ecfc01ac9">
	  <name>Laarbeeklaan 101</name>
	  <address/>
	  <city>Brussels</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>1090</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Consecutive patients (both males and females, &gt;18 years of age) with a diagnosis of primary unilateral inguinal hernia presenting in the participating centres for the surgical repair of their hernia in an ambulatory setting.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>976</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>976</totalTarget>
      <exclusion>1. Incarcerated inguinal hernia
2. Life expectancy less than two years
3. Pregnancy
4. American Society of Anaesthesiology (ASA) class IV or V
5. Extensive lower abdominal surgery or severe local inflammation
6. Inability to sign the informed consent. 
7. Indication for other type of surgery for various reasons
8. Patients unable to walk (paralysed or bedridden patients)
9. Bilateral hernia repair
10. Large scrotal hernias
11. Concomitant abdominal surgery
12. Body mass index (BMI) &gt;= 35 kg/m2
13. Liver cirrhosis (Child C)
14. Known abuse of alcohol or drugs
15. Ongoing long term analgesic or steroid treatment
16. Patients under clopidogrel or warfarin must be switched to subcutaneous (sc) low-molecular-weight (lmw) heparin
17. Severely compromised physical or psychological health, that in the investigator&#146;s opinion will affect patient&#146;s compliance
18. Concurrently participating in another clinical trial</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2012-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Inguinal hernia</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Inguinal hernia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is an observational cohort study comparing the reduction in ambulatory activity (RAA) after four common techniques of inguinal hernia repair of patients with primary inguinal hernia. The four techniques are:
1. Lichtenstein repair
2. Laparoscopic totally extraperitoneal repair
3. Open retroperitoneal Kugel patch repair
4. Polysoft® patch repair

Count of steps will be carried out 1 week before and 2 weeks after scheduled inguinal hernia repair, measured with an electronic pedometer.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17840-0</funderId>
      <contactId>Contact55823_17840</contactId>
      <sponsorId>Sponsor54387</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55823_17840">
    <title>Prof</title>
    <forename>Yves</forename>
    <surname>Van Nieuwenhove</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Laarbeeklaan 101</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54387">
    <organisation>Royal Belgian Society of Surgery, Section of Abdominal Wall Surgery (BSAWS) (Belgium)</organisation>
    <website>http://www.belsurg.org</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Koninklijk Belgisch Genootschap voor Heelkunde
W. Churchill-laan 11/30</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1180</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">amb@skynet.be</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487362.c</gridId>
    <rorId>https://ror.org/04yy1mz94</rorId>
  </sponsor>
  <funder id="Funder17840-0">
    <name>Royal Belgian Society of Surgery, Section of Abdominal Wall Surgery (BSAWS) (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-06-18T00:00:00.000Z">74420611</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of pharmacists ACCESs to clinical information on the quality and the continuity of care in poly-medicamented community patients: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>ACCES</acronym>
      <studyHypothesis>Drug-related problems (DRP) are associated with an increased morbidity and mortality. In the primary care setting, the number of poly-medicamented patients is constantly increasing, resulting in an increased risk of DRP. 

Access to clinical information, such as laboratory results and health problems, should help the community pharmacist detect more DRPs. The detection of these DRPs, and better documented pharmacist's suggestions, can result in an increase of the acceptance rate by general practitioners. To our knowledge, there are few studies on the impact of access to clinical information on the detection of DRPs by community pharmacists.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following will be assessed after two months of follow-up: 
1. Compare the mean number of DRP per patient identified by community pharmacists in both groups (intervention group and control group)
2. Compare the mean number of pharmacotherapy changes per patient between both groups (intervention group and control group)</primaryOutcome>
      <secondaryOutcome>The following will be assessed after two months of follow-up:
1. Compare the proportion of patients in each group for whom at least one intervention was made by the community pharmacists  
2. For each type of intervention, compare the proportion of interventions made by the community pharmacists in both groups
3. Compare the proportion of pharmaceutical opinions that resulted in a pharmacotherapy change in both groups
4. Describe and compare the type of contact made between community pharmacists and Family Medicine Clinic&#146;s pharmacists in both groups</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Centre de santé et de services sociaux [CSSS] de Laval Ethics Committee) on the 24th September 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74420611</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-24T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="51e07670-96b0-4bd9-bc9e-b236611634e1">
	  <name>Resaerch Team in Primary Care</name>
	  <address/>
	  <city>Laval</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H7M 3L9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Family doctors or residents: 
1. Practicing at the Family Medicine Clinic of CSSS de Laval
2. Agree to participate and sign the consent form

Community pharmacists:
1. Practicing in one of the pharmacies in the area of Laval or surrounding areas 
2. Have one or more patients eligible for the study 
3. Agree to participate and sign the consent form 

Patients: 
1. 18 years old or older, either sex 
2. Have an appointment at the Family Medicine Clinic of CSSS de Laval between October 2007 and March 2008 
3. Takes at least five chronic medications 
4. Reports being a patient of one of the participating pharmacies
5. Agrees to participate and sign the consent form 
6. Is considered eligible by his family doctor</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>170</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>170</totalTarget>
      <exclusion>1. Is not able to speak or read French 
2. Is a patient of more than one community pharmacy 
3. Is not able to give a informed consent</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-24T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Drug-related problems from multiple prescription drugs</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Drug-related problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All pharmacists in the area of Laval were invited to a three-hour workshop on the interpretation of laboratory results. They also have access to a consultation service with pharmacists currently working at the Family Medicine Clinic of CSSS de Laval. For all patients, the family doctor asked the community pharmacist to perform an analysis of the pharmacotherapy.

To help the pharmacist analyse the drug profile, the intervention group received the following clinical information: 
1. Most recent laboratory results: 
1.1. Creatinine clearance
1.2. Potassium
1.3. Sodium
1.4. Lipid profile
1.5. Alanine aminotransferase (ALT)
1.6. Creatine kinase (CK)
1.7. Glycosylated haemoglobin (HbA1c)
1.8. Thyroid stimulating hormone (TSH) and free thyroxine (FT4)
1.9. Complete blood count
1.10. Blood levels of certain drugs (phenytoin, digoxin, lithium)
2. Health problems 
3. Drug profile as figured in the medical record 

The control group received usual care. 

The duration of follow-up was 8 weeks in both groups.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17713-0</funderId>
      <contactId>Contact55687_17713</contactId>
      <sponsorId>Sponsor54259</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55687_17713">
    <title>Dr</title>
    <forename>Lyne</forename>
    <surname>Lalonde</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Resaerch Team in Primary Care
CSSS de Laval, Hôpital de la Cité-de-la-Santé 
1755 René-Laennec, room D-S145</address>
      <city>Laval</city>
      <country>Canada</country>
      <zip>H7M 3L9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 450 668 1010 ext. 2743</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lyne.lalonde@umontreal.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54259">
    <organisation>Pfizer (Canada) </organisation>
    <website>http://www.pfizer.ca</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Chideh Motallebi, PhD, MBA
Spécialiste régional médical et de la recherche Cardiovasculaire - QC 
Pfizer Canada Inc. Division Médicale
17300, autoroute Transcanadienne</address>
      <city>Kirkland</city>
      <country>Canada</country>
      <zip>H9J 2M5 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 450 466 3952</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Chideh.Motallebi@Pfizer.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.421137.2</gridId>
    <rorId>https://ror.org/059g90c15</rorId>
  </sponsor>
  <funder id="Funder17713-0">
    <name>Pfizer (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/100004319</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-13T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-06-13T00:00:00.000Z">08911796</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Neuragen® for the relief of neuropathic pain part 2: a randomised, double-blind, placebo controlled clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Neuragen® with a different amount of effective ingredients will reduce neuropathic pain more than the placebo whilst having different levels of effectiveness.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Foot sole pain on 11-point numerical pain scale. 0 - 10 visual analog scale was use to document pain level at 30 minutes before and after the administration of the medication, with 8-hour follow up every hour on the hour.</primaryOutcome>
      <secondaryOutcome>Duration of pain reduction. 0 - 10 visual analog scale was use to document pain level at 30 minutes before and after the administration of the medication, with 8-hour follow up every hour on the hour.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of Louisiana State University as an extension of IRB#2754, approved on 28th September 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08911796</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo controlled clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-05-19T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-09-27T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e12a35df-bca0-4f42-b6d8-ccf76ca5d734">
	  <name>Department of Kinesiology</name>
	  <address/>
	  <city>Baton Rouge</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>70803</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female, over 21 years
2. Diagnosed neuropathic pain for more three months
3. Pain level between 3 - 8 on a 0 - 10 visual pain scale
4. Does not have mental and communication impairments</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Pregnant
2. Have other types of pain
3. Skin condition
4. Central nerve impairment</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-05-19T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-09-27T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Peripheral neuropathy</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Other polyneuropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Topical application of Neuragen® with different amounts of effective ingredients versus a placebo. The medicine was sprayed onto the subjects feet at the sole and on top of the feet. One time application with an 8-hour follow-up.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Neuragen®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17864-0</funderId>
      <contactId>Contact55847_17864</contactId>
      <sponsorId>Sponsor54411</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55847_17864">
    <title>Dr</title>
    <forename>Li</forename>
    <surname>Li</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address> Department of Kinesiology
Louisiana State University </address>
      <city>Baton Rouge</city>
      <country>United States of America</country>
      <zip>70803</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54411">
    <organisation>Origin BioMed, Inc. (Canada)</organisation>
    <website>http://www.originbiomed.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>5162 Duke St, Suite 300 </address>
      <city>Halifax</city>
      <country>Canada</country>
      <zip>B3J 1N7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487321.b</gridId>
    <rorId>https://ror.org/008mcnd42</rorId>
  </sponsor>
  <funder id="Funder17864-0">
    <name>Origin BioMed, Inc. (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-12T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-06-12T00:00:00.000Z">36604462</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of a restraint minimisation education programme on physical restraints use, staff knowledge, attitudes and perceived job strain</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>It is hypothesised that an educational intervention in group dwellings for persons with dementia will increase staff knowledge about and change their attitudes towards the use of physical restraints. This will lead to a reduction in physical restraints use which in turn will have an positive effect on staffs' perceived job strain.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Residents: 
1. Physical restraints were recorded daily for each patient, for three weeks before interventions, and then until the end of interventions (6 months). The information recorded include type of physical restraints used, hours restrained and reasons for restraining. 

Outcomes concerning staff, measured before interventions and at 6 months: 
1. Staff knowledge about current legislation, measured by a seven-item index score ranging between 0-7 (higher values indicate higher knowledge) 
2. Staff subjective knowledge relating to care of people with dementia, measured by a visual analogue scale (VAS) 
3. Staff attitudes, measured by the 17-item Perceptions of Restraint Use Questionnaire (PRUQ) 
4. Job strain, measured by three instruments: 
4.1. The Job-Demand and Social Support Questionnaire
4.2. Stress of Conscience Questionnaire 
4.3. Caring climate, measured by a VAS</primaryOutcome>
      <secondaryOutcome>Outcomes concerning residents:
1. Fall accidents, recorded during the whole study period (8 months [1 month prior to interventions, 6 months during interventions and 1 month after interventions)
2. Psychoactive drug use, assessed before interventions and at 6 months
3. Motor function, vision, hearing and speech, assessed by the Multi-Dimensional Dementia Assessment Scale (MDDAS) before interventions and at 6 months. MDDAS included the Activity of Daily Living (ADL) functions and behavioural and psychiatric symptoms questionnaire. Gottfries cognitive level questionnaire (subscale to the MDDAS) was used for the measurement of cognitive level.
 
Staff characteristics:
4. Demography
5. Education level
6. Years worked
7. Evaluation of the intervention, carried out within one week after the end of intervention</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Medical Faculty of Umeå University. Date of approval: 12/03/2002 (ref: Section 92/02, dnr 02-105)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36604462</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="27d9e973-21de-4321-b88d-b08ee3f6ecfc">
	  <name>Umeå University</name>
	  <address/>
	  <city>Umeå</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-90187</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Residents (both men and women) living in group dwellings for persons with dementia, which have at least 20% of the residents restrained.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>320</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>320 residents</totalTarget>
      <exclusion>Units with less than 20% of the residents restrained.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Use of physical restraints in group dwellings.</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Unspecified dementia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention consisted of an education programme for the nursing staff (registered nurses, licensed practical nurses and nurse aid). The content of the programme included dementia diseases, symptoms, treatment and related complications, fall prevention, prevention and treatment of delirium, interaction and communication in dementia care and negative effects of, alternatives to and legislation directing the use of physical restraints. 

First, the head-nurse at each intervention unit selected one person who underwent the whole education programme compressed during two seminar days. Remaining staff received their education via 30-minute videotaped lectures. Three of the lectures also included a clinical written vignettes forming the basis for group discussions. At each unit it was up to the staff to make arrangements for watching the films and if desired to arrange group discussions. Each unit was responsible for making arrangements for taking part of the lectures and if desired to arrange group discussions. The education programme ran alongside ordinary work at the units without further involvement of the researchers besides distribution of the video taped lectures and data collection. In the education programme the emphasis was on the importance of investigating the underlying causes instead of working in a symptom-oriented manner e.g. a resident that have sustained a fall accident should be investigated for the cause of the fall instead of just using physical restraints. The staff was encouraged to use physical restraints only as the last resort. The intervention/education programme was carried out over six months. 

The control units did not receive any interventions during the study period; they did receive interventions after the study was completed.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17720-0</funderId>
      <funderId>Funder17720-1</funderId>
      <funderId>Funder17720-2</funderId>
      <funderId>Funder17720-3</funderId>
      <contactId>Contact55694_17720</contactId>
      <sponsorId>Sponsor54266</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55694_17720">
    <title>Dr</title>
    <forename>Stig</forename>
    <surname>Karlsson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Umeå University</address>
      <city>Umeå</city>
      <country>Sweden</country>
      <zip>SE-90187</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 90 7869259</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">stig.karlsson@nurs.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54266">
    <organisation>Umeå University (Sweden)</organisation>
    <website>http://www.umu.se/umu/index_eng.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Umeå</address>
      <city>-</city>
      <country>Sweden</country>
      <zip>SE-90187</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 90 7869259</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">stig.karlsson@nurs.umu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.12650.30</gridId>
    <rorId>https://ror.org/05kb8h459</rorId>
  </sponsor>
  <funder id="Funder17720-0">
    <name>Lions Research Foundation for Age Related Diseases (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17720-1">
    <name>King Gustaf V's and Queen Victoria's Freemason Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17720-2">
    <name>The Field Research Centre for the Elderly in Västerbotten (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17720-3">
    <name>The Swedisch Research Council (Grant ref: K2005-27-VX-15357-01A)(Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-06-09T00:00:00.000Z">34920540</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Injectable silicone biomaterial (PTQTM) is more effective than carbon-coated beads (Durasphere®) in treating passive faecal incontinence: a randomised trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare safety and efficacy of PTQTM compared with Durasphere® in treating patients with passive faecal incontinence.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Wexner&#146;s continence score, assessed at 2 and 6 weeks, then 6 and 12 months after treatment</primaryOutcome>
      <secondaryOutcome>The following were assessed at 2 and 6 weeks, then 6 and 12 months after treatment:
1. Faecal incontinence quality of life (FIQL) scale
2. Short Form 12 (SF-12) health survey questionnaire
3. Adverse events</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Human Resource Ethics Committee of Epworth Hospital</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34920540</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
	<country>Hong Kong</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="21fddd8a-03b7-42ef-9c58-48f9232cf0ab">
	  <name>Caritas Medical Centre, 111</name>
	  <address/>
	  <city>Hong Kong</city>
	  <state/>
	  <country>Hong Kong</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females, no age limits
2. Faecal seepage or soiling for more than twice a week caused by internal sphincter (IAS) dysfunction
3. Not responding to treatment with dedicated pelvic floor exercises and stool bulking agents</inclusion>
      <ageRange>Other</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Perianal sepsis
2. Anorectal cancer
3. Immunosuppression
4. Rectal prolapse
5. Inflammatory bowel disease
6. Congenital anorectal malformation
7. Neurological disorders such as Parkinson&#146;s disease
8. Multiple sclerosis
9. Spinal-cord injury
10. Stoma in situ
11. Pregnancy
12. External anal sphincter defect of more than 120º of the circumference
13. Bleeding diathesis, 
14. Mental or physical disability precluding adherence to study protocol</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Passive faecal incontinence</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Faecal incontinence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Injectable bulking agents to augment the bulk of the internal anal sphincter: injectable silicone biomaterial (PTQTM) vs carbon-coated beads (Durasphere®).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>PTQTM,  Durasphere®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17831-0</funderId>
      <contactId>Contact55814_17831</contactId>
      <sponsorId>Sponsor54378</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55814_17831">
    <title>Dr</title>
    <forename>Miranda</forename>
    <surname>Chan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Caritas Medical Centre, 111
Wing Hong Street
Shum Shui Po</address>
      <city>Hong Kong</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+852 3408 7785</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mirchan@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54378">
    <organisation>Epworth Hospital, University of Melbourne (Australia)</organisation>
    <website>http://www.epworth.org.au</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>89 Bridge Road
Richmond</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3121</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.1008.9</gridId>
    <rorId>https://ror.org/01ej9dk98</rorId>
  </sponsor>
  <funder id="Funder17831-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-09T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-06-09T00:00:00.000Z">87385891</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Promoting evidence-informed breast cancer prevention</title>
      <scientificTitle>Do tailored messages promote evidence-informed decision making in breast cancer prevention?</scientificTitle>
      <acronym/>
      <studyHypothesis>Breast cancer is the most common cancer affecting women in Canada and in women under 50 it is the most common cause of death from any cancer. The goal of this study is to evaluate a knowledge transfer and exchange strategy to improve the provision of public health services for breast cancer prevention and early detection. 

Research questions: 
1. Are tailored messages more effective than access to www.health-evidence.ca in facilitating evidence-informed decision making (EIDM) among public health professionals working in breast cancer prevention and early detection? 
2. Are tailored messages more effective than access to www.health-evidence.ca in promoting the use of research evidence in program planning decisions among individual public health decision makers? 
3. Is EIDM influenced by characteristics of the organisation, environment, and individual?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome will be the percentage change in the number of evidence-based interventions from baseline and will be calculated as the outcome variable (this variable can be either negative or greater than 100). Then, the value of this variable will be tabulated per province/territory. For each province/territory multiple measurements for the TM and control groups will be available. If the number of health units for the TM or control group is less than three for a particular province/territory, the data for that province/territory will be amalgamated with the neighboring province/territory. A fixed effect meta-analytic approach will be used to compare the difference between the control group and treatment group. This technique will permit us to report treatment effect size and the corresponding 95% confidence interval.</primaryOutcome>
      <secondaryOutcome>1. To assess whether TMs are more effective than access to www.health-evidence.ca in promoting the use of research evidence in program planning decisions, a multi-level mixed effect regression analysis will be used to compare the perceived self-reported incorporation of research evidence on breast cancer prevention and early detection into decision makers' program planning decision-making. Using this technique we will be able to examine the difference between intervention and control while adjusting for the possible effects of the organisational, the individual and the environment (province/territory).
2. To determine whether EIDM influenced by characteristics of the organisation, environment, and individual, the outcome variable will be the number of breast cancer prevention and early detection interventions implemented by each health unit. A multilevel log-linear model will assess the difference between the TM and control groups while adjusting for characteristics of the organisation, individual, and the environment (province/territory).</secondaryOutcome>
      <trialWebsite>http://www.health-evidence.ca</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval submitted to the Hamilton Health Sciences/Faculty of Health Sciences Research Ethics Board on the 27th May 2008. REB to review on the 17th June 2008 meeting.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87385891</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, mixed methods, single-site study consisting of a stratified randomised controlled trial and a descriptive, qualitative study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a105e69f-0983-4842-96f9-7d48afb9ba2d">
	  <name>1200 Main Street West</name>
	  <address/>
	  <city>Hamilton</city>
	  <state/>
	  <country>Canada</country>
	  <zip>L8N 3Z5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Study participants include public health professionals responsible for making policy or program decisions related to breast cancer prevention directly (e.g. screening, physical activity, healthy eating), including program managers, directors, and medical officers of health working in public health units in Canada.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Approximately 94 health units recruited with approximately 300 participants in total (allowing for 3 - 5 participants per health unit)</totalTarget>
      <exclusion>1. No responsibility for and/or involvement in decision making related to breast cancer prevention
2. Not currently working in a public health unit</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Breast cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Malignant neoplasm of the breast</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A tailored messaging (TM) intervention will be implemented over one year and will be comprised of three distinct components: 

1. An expert consensus panel:
Researchers, health care providers, policy-makers working in breast cancer prevention and early detection across Canada will be convened to identify the most effective and important public health-related interventions. A complete list of interventions shown to be effective in systematic reviews identified by the research team will be generated. Through a Delphi approach experts will identify those breast cancer prevention and early detection interventions for which there is the most convincing evidence of effectiveness and are most important to implement in public health.

2. Three one-day regional workshops:
Recommendations of the expert panel will be presented to decision makers in the TM group. The goal of the workshop is to: 
2.1. Learn about effective interventions for breast cancer prevention and early detection, and
2.2. To discuss and debate how to apply this knowledge in their local settings

3. Tailored messaging (TM) activities:
TM will consist of electronically mailed recommendations from the expert panel, along with the citations, abstracts, summaries (written by the research team) and full text links/or PDF documents of rigorous systematic reviews. All decision makers in each health unit in the TM group will receive the materials and will have access to www.health-evidence.ca, (described under control, to follow) where all of the TM materials will be housed.

Control:
The control group will have access to www.health-evidence.ca, an on-line registry of literature reviews evaluating the effectiveness of public heath interventions. The registry is easily accessible, free of charge, and easy to navigate. In addition to identifying the citation, participants will also be able to access the published abstracts of reviews, the research team&#146;s rating of the methodological quality of the review, and short summaries of the reviews written by the research team. Launched in March 2005, www.health-evidence has as many as 200 hits per day (greater than 20,000 per year), primarily from public health decision makers in Canada. Participants in the control group will be able to access the same materials used in the TM intervention on www.health-evidence.ca. DMs will also receive materials promoting use of the site.

Total duration of the intervention being implemented is one year. Total duration of follow up data collection will be three months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17844-0</funderId>
      <contactId>Contact55827_17844</contactId>
      <sponsorId>Sponsor54391</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55827_17844">
    <title>Dr</title>
    <forename>Maureen</forename>
    <surname>Dobbins</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>1200 Main Street West
HSC - 3N25G</address>
      <city>Hamilton</city>
      <country>Canada</country>
      <zip>L8N 3Z5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 905 525 9140 ext. 22481</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dobbinsm@mcmaster.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54391">
    <organisation>McMaster University (Canada)</organisation>
    <website>http://www-fhs.mcmaster.ca/nursing/ </website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>School of Nursing
1200 Main Street West</address>
      <city>Hamilton</city>
      <country>Canada</country>
      <zip>L8N 3Z5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.25073.33</gridId>
    <rorId>https://ror.org/02fa3aq29</rorId>
  </sponsor>
  <funder id="Funder17844-0">
    <name>Canadian Breast Cancer Foundation - Ontario Region (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-17T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-06-04T00:00:00.000Z">63930220</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Aripiprazole shows comparable efficacy to Haloperidol and better tolerability in paediatric Tic disorders</title>
      <scientificTitle/>
      <acronym>ArHdTic</acronym>
      <studyHypothesis>Tics are defined as rapid and repetitive muscle contractions resulting in movements or vocalisations that are experienced as involuntary. Tic disorders are a group of neuropsychiatic disorders that generally begin in childhood or adolescence and may be constant or wax and wane over time.

Aripiprazole is a candidate atypical antipsychotic for patients with tic disorders due to its unique pharmacodynamic property of dopamine partial agonistic activity with fewer and milder side effects. This study was conducted to determine whether aripiprazole has comparable efficacy to haloperidol, the most widely used typical antipsychotic in the treatment of tic disorders, but which has a higher tolerability. 

The pilot study and efficacy study of this trial have been published as follows:
1. A pilot study of aripiprazole in children and adolescents with Tourette's disorder (http://www.ncbi.nlm.nih.gov/pubmed/16958578)
2. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders (http://www.ncbi.nlm.nih.gov/pubmed/17685747)</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Yale Global Tic Severity Scale (YGTSS): the YGTSS is a semi-structured clinical interview designed to assess current tic severity, which yields three summary scores.

Both primary and secondary outcomes were measured at every visit (baseline, two weeks, four weeks, six weeks, eight weeks).</primaryOutcome>
      <secondaryOutcome>1. The Clinical Global Impressions-Improvement Scale (CGI-I)
2. The CGI-Severity of Illness Scale (CGI-S)
3. The Extrapyramidal Symptom Rating Scale (ESRS) 

Both primary and secondary outcomes were measured at every visit (baseline, two weeks, four weeks, six weeks, eight weeks).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of Asan Medical Centre, Seoul, South Korea on the 30th July 2005 (ref: 2005-0163).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63930220</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, open, parallel trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Korea, South</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="42b5f4b3-6c6d-42d1-8d8e-f03ac8d3de87">
	  <name>Department of Psychiatry</name>
	  <address/>
	  <city>Seoul</city>
	  <state/>
	  <country>Korea, South</country>
	  <zip>138-736</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 6 - 18 years
2. Gender: male or female
3. Diagnosis: tic disorders according to the Korean version of the Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (KSADS-PL) 
4. Severity: total tic scores greater than or equal to 22 on the Korean version of the Yale Global Tic Severity Scale</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="6.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>1. Current mood disorders
2. Psychotic symptoms
3. Anxiety disorders except obsessive-compulsive disorder, which is the most common comorbid anxiety disorder in tic patients
4. Subjects with an intelligence quotient (IQ) of 70 or less by using the Korean version of the Wechsler Intelligence Scale for Children-Revised 
5. Previous or current seizure episodes, electroencephalogram (EEG) abnormalities
6. Subjects had used aripiprazole previously
7. Any significant medical problems
8. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tic disorders</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Tic disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In the aripiprazole group, a child psychiatrist initially prescribed 5.0 mg/d of aripiprazole, and then increased the dose in 5.0 mg/d increments as tolerated at visits every two weeks. The dose was reduced by 2.5 mg/d to 5.0 mg/d when intolerable side effects emerged. The maximum allowable dose was 20 mg/d.

In the haloperidol group, haloperidol was titrated from a commencing dose of 0.75 mg/d to a maximum tolerated dose of 4.5 mg/d in 1.5 - 3.0 mg increments at visits every other week

The total duration of treatment and follow-up were eight weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Aripiprazole, haloperidol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17809-0</funderId>
      <contactId>Contact55787_17809</contactId>
      <sponsorId>Sponsor54356</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55787_17809">
    <title>Prof</title>
    <forename>Hanik</forename>
    <surname>Yoo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychiatry
University of Ulsan College of Medicine
Asan Medical Centre
388-1 Pungnap-2dong, Songpa-gu, </address>
      <city>Seoul </city>
      <country>Korea, South</country>
      <zip>138-736</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hiyoo@amc.seoul.kr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54356">
    <organisation>Asan Medical Centre (South Korea)</organisation>
    <website>http://www.amc.seoul.kr/eng/index.jsp</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Psychiatry
University of Ulsan College of Medicine
388-1 Pungnap-2dong
Songpa-gu</address>
      <city>Seoul </city>
      <country>Korea, South</country>
      <zip>138-736</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hiyoo@amc.seoul.kr</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.413967.e</gridId>
    <rorId>https://ror.org/03s5q0090</rorId>
  </sponsor>
  <funder id="Funder17809-0">
    <name>Investigator initiated and funded (South Korea)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-30T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-05-30T00:00:00.000Z">70474205</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Targeted therapy in patients with advanced pancreatic cancer</title>
      <scientificTitle>A prospective, non-randomised phase II study of trastuzumab and capecitabine in patients with HER2 expressing advanced pancreatic cancer</scientificTitle>
      <acronym/>
      <studyHypothesis>Pancreatic cancer is the fourth most common cause of cancer related death in Western countries. Advantages in surgical techniques, radiation and chemotherapy had almost no impact on the long term survival of affected patients. Therefore, the need for better treatment strategies is urgent. HER2, a receptor tyrosin kinase of the epidermal growth factor receptor (EGFR) family, involved in signal transduction pathways leading to cell growth and differentiation is overexpressed in a number of cancers, including breast and pancreatic cancer. While in breast cancer HER2 has already been successfully used as a treatment target, there are no studies thus far evaluating the effects of inhibiting HER2 tyrosine kinases in patients with pancreatic cancer.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Progression free survival after 12 weeks.</primaryOutcome>
      <secondaryOutcome>1. Progression free survival time
2. Overall survival
3. Time until remission (partial or complete)
4. Duration of remission
5. Rate of 'clinical benefit response' after 12 weeks
6. Quality of life before treatment and after two cycles of chemotherapy

Additional secondary trial endpoints:
7. Toxicity analysis
8. The rate of adverse events 
9. The relationship between progression free survival and CA19-9 plasma levels
10. The relation between HER2/neu overexpression and progression free survival</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of the University of Freiburg, Germany on the 19th April 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN70474205</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>UKF000577</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, open, one-armed multicentric phase II trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e0c6b53a-c6e7-4728-a39c-6ba59de02e1c">
	  <name>Municipal Hospital Esslingen</name>
	  <address/>
	  <city>Esslingen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>73730</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Written informed consent 
2. Aged 18 years or older, either sex
3. Histological verified pancreatic cancer in stage IVb (T1-4N0M1)
4. Staging and CA19-9 serum level not older than four weeks
5. Histological verified over-expression of HER2/neu (immunological score 3+ or 2+ with verification by fluorescent in situ hybridisation [FISH])
6. At least one measurable lesion (greater than or equal to 2 cm in conventional computed tomography [CT] scan or greater than or equal to 1 cm in spiral CT scans)
7. No prior chemotherapy
8. No prior radiotherapy
9. Performace-status 0 - 2 according to World Health Organization [WHO]/Eastern Cooperative Oncology Group [ECOG] or greater than or equal to 60 points on the Karnofsky scale
10. Life expectancy of at least three months
11. Left ventricular excretion fraction greater than 50%
12. Appropriate renal, liver and haematopoetic function defined by:
12.1. Neutrophils greater than or equal to 1.5 x 10^9/l
12.2. Haemoglobin greater than or equal to 80 g/l
12.3. Platelets greater than or equal to 100 x 10^9/l
12.4. Total bilirubin less than 3 x normal
12.5. Creatinine clearance greater than or equal to 30 ml/min (Cockroft Gault)
12.6. Transaminases either less than 2.5 x normal, or less than 5 x normal in case of liver metastasis
13. Possibility of long-term follow up
14. Negative pregnancy testing</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>37</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>37</totalTarget>
      <exclusion>1. Possible surgical resection and/or radiotherapy with curative potential
2. Dihydropyrimidine-dehydrogenase deficiency
3. Gastrointestinal obstruction
4. A known secondary neoplasm except a curative treatable basalioma of the skin or carcinoma in situ of the cervix uteri
5. A known hypersensitivity against any of the applied substances
6. Clinically relevant disorder of the cardiovascular system or other organs or a severe systemic disease that compromises the study protocol or the interpretation of the data
7. Clinically manifest pulmonary disorder
8. Prior polyneuropathy
9. A concomitant treatment with the virustatic agents sorivudin or its analogues
10. Pregnancy, breast feeding or absence of appropriate contraceptive measures
11. Psychiatric disorders, drug abuse or other disorders, that compromise the informed consent 
12. Concomitant participation in other clinical trials or participation within the last four weeks
13. Any other disorder or treatment that poses a risk to the patient or is incompatible with the aims of this study</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2004-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Advanced pancreatic cancer (stage IVb)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Pancreatic cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The trastuzumab loading dose of 4 mg/kg body weight will be given on day one over 90 minutes. For maintenance therapy a weekly dose of 2 mg/kg body weight over 30 minutes will be infused until tumour progression takes place. Patients will be monitored closely for six hours during the first dose of trastuzumab and for two hours after the following rastuzumab infusions to rule out adverse reactions. 

Capecitabine will be applied orally twice daily at a dose of 1250 mg/m^2 on day 1 - 14 followed by a break of seven days. The three weeks cycles will be repeated until tumour progression or until a grade three to four toxicity occurs.

Planned duration of treatment 12 weeks or until disease progression. In the case of stable disease treatment is continued until progression. Follow up is performed until death.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Trastuzumab, rastuzumab, capecitabine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17587-0</funderId>
      <contactId>Contact55554_17587</contactId>
      <sponsorId>Sponsor54133</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55554_17587">
    <title>Prof</title>
    <forename>Michael</forename>
    <surname>Geissler</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Municipal Hospital Esslingen 
Department of Medicine, Gastroenterology and Oncology</address>
      <city>Esslingen</city>
      <country>Germany</country>
      <zip>73730</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54133">
    <organisation>Roche Pharma AG (Germany)</organisation>
    <website>http://www.roche.de</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Emil-Barell-Str. 1</address>
      <city>Grenzach-Wyhlen</city>
      <country>Germany</country>
      <zip>79639</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.424277.0</gridId>
    <rorId>https://ror.org/00sh68184</rorId>
  </sponsor>
  <funder id="Funder17587-0">
    <name>Roche Pharma AG (Germany) - providing chemotherapeutic agents</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-30T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-05-30T00:00:00.000Z">23263429</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of the BELA weight management programme to prevent increase of weight in schizophrenic patients treated with olanzapin (BELA = movement - nutrition - learning - accepting)</title>
      <scientificTitle/>
      <acronym>BELA</acronym>
      <studyHypothesis>To assess the efficacy of preventative effects of the BELA programme on weight and metabolic parameters in schizophrenic patients treated with olanzapin.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Weight changes in kg, measured at week 1 and week 10.</primaryOutcome>
      <secondaryOutcome>1. Influence of the intervention on further risk factors, assessed by the following: 
1.2. Cholesterol at Week 2, 1, 5, 10, 14 and 18 
1.3. low density lipoprotein (LDL) at Week 2, 1, 5, 10, 14 and 18 
1.4. Triglyzeride at Week 2, 1, 5, 10, 14 and 18 
1.5. high density lipoprotein(HDL) at Week 2, 1, 5, 10, 14 and 18 
1.6. HbA1c at Week 1, 10 and 18 
1.7. Glucose at Week 2, 1, 5, 10, 14 and 18 
1.8. Blood-pressure at Week 2, 1, 5, 10, 14 and 18 
1.9. Abdominal girth at Week 2, 1, 5, 10, 14 and 18 
1.10. Body mass index (BMI) at Week 2, 1, 5, 10, 14 and 18 
2. Identification of indicators with regard to weight increase and the response on weight management by acquisition of the following parameters: 
2.1. Age, sex, initial weight 2 weeks prior to intervention 
2.2. Psycho-pathological rating-scales: 
a. Positive and Negative Syndrome Scale (PANSS) 2 weeks before intervention and then at weeks 1, 5, 10, 14 and 18 
b. Personal social achievement rating scale (persönliche soziale Leistungskala [PSL]) at weeks 1, 10 and 18 
c. 36-item Short Form health survey (SF-36) at weeks 1, 10 and 18 
d. Body image assessment questionnaire (Fragebogen zur Beurteilung des eigenen Körpers [FBeK]) at weeks 1, 10 and 18 
e. Type D Personality Scale (DS14) 2 weeks prior to intervention 
f. Global Assessment of Functioning (GAF) at weeks 1, 10 and 18 
2.3. Medical genetics: Polymorphism for weight increase, assessed at week 1 
2.4. Lipometabolism: Participating hormones and interleukine: leptin, ghrelin, adiponektin, cortisone, retinol binding protein 4 (RBP-4), IL-6, TNF-alpha. These will be assessed at weeks 1, 10 and 18 
3. Increase of weight (in kg) of the intervention group in comparison to the control group at the end of the follow-up phase (Week 1 [before the intervention phase] vs Week 18 [after the follow-up phase])</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. Ethics Committee of Medical Faculty of Heinrich-Heine University. Date of approval: 07/02/2008 (ref: MC-LKP-249)
2. Federal Institute for Drugs and Medical Devices (BfArM). Date of approval: 06/12/2007 (ref: 4033665)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23263429</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>GM2_2007</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase IV, multi-centre, open, two-arm randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-04-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-11-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9653efcb-81d2-42b0-85b7-5f42648f78f7">
	  <name>Clinic and Polyclinic for Psychiatry and Psychotherapy</name>
	  <address/>
	  <city>Düsseldorf</city>
	  <state/>
	  <country>Germany</country>
	  <zip>40629</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Both males and females
2. Age 18 - 65 years 
3. Criteria of the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM IV) for schizophrenia or schizoaffective psychosis 
4. Written informed consent 
5. Capability of signing informed consent 
6. Olanzapin medication</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Serious somatic diseases 
2. Changes in weight due to somatic diseases 
3. Pregnancy or lactation 
4. Increase of weight of more than 3 kg over the last 3 months before start of treatment with olanzapin 
5. Co-medication with a weight-reducing potential 
6. Participation in another interventional trial which could interfere with this trial</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet.</patientInfoSheet>
      <recruitmentStart>2008-04-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-11-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Schizophrenia</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Schizophrenia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This trial is taking place at four sites (Düsseldorf, Bochum, Krefeld, Dortmund). Participants will be randomly allocated to the two arms in equal numbers: 
 
Intervention group: Standard therapy + BELA weight management programme  
Control group: Standard therapy only
 
The psychoeducation programme BELA has been developed at the beginning of 2005 for psychiatric patients. The contents of the psychoeducation are based on the knowledge that better nutrition and regular exercise may stabilise the individual course of disease, the detection of bad habits and the implementation, practice and stabilisation of individual, appropriate habits. As far as methods are concerned, these are simple pedagogic and informational modules (adapted to the type of patients) and which result in experiment-orientated, practical exercises. The BELA concept is geared to small groups (6 - 10 patients) in order to, for example, allow the planning, shopping, cooking of a meal. Over a period of 10 weeks there are group meetings, each 60 minutes, with knowledge transfer of nutrition and exercising. 
 
Content of patient-education: 
1. Aim of the course
2. Energy and calories
3. Types of provisions
4. Major nutrients
5. Pathology
6. Planning the day
7. Fats
8. Recipes
9. Cooking with vegetables, etc. (practical)
10. Relevance of exercises</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase IV</phase>
	<drugNames>Olanzapin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17722-0</funderId>
      <funderId>Funder17722-1</funderId>
      <funderId>Funder17722-2</funderId>
      <contactId>Contact55696_17722</contactId>
      <sponsorId>Sponsor54268</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55696_17722">
    <title>Dr</title>
    <forename>Joachim</forename>
    <surname>Cordes </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinic and Polyclinic for Psychiatry and Psychotherapy 
Rheinische Kliniken Düsseldorf 
Bergische Landstr. 2 </address>
      <city>Düsseldorf</city>
      <country>Germany</country>
      <zip>40629</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 211 9223402</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joachim.cordes@lvr.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54268">
    <organisation>Heinrich-Heine University (Germany)</organisation>
    <website>http://www.uni-duesseldorf.de</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr. med. J. Cordes 
Clinic and Polyclinic for Psychiatry and Psychotherapy 
Rheinische Kliniken Düsseldorf 
Bergische Landstr. 2 </address>
      <city>Düsseldorf</city>
      <country>Germany</country>
      <zip>40629</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411327.2</gridId>
    <rorId>https://ror.org/024z2rq82</rorId>
  </sponsor>
  <funder id="Funder17722-0">
    <name>Heinrich-Heine University (Germany)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17722-1">
    <name>Lilly GmbH (Germany)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17722-2">
    <name>Note: This is an investigator initiated trial.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-29T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-05-29T00:00:00.000Z">69559777</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The ACROSS-China trial</title>
      <scientificTitle>Abnormal gluCose Regulation in patients with acute strOke acroSS China: a national multicentre prospective study</scientificTitle>
      <acronym>ACROSS-China</acronym>
      <studyHypothesis>1. The prevalence of abnormal glucose regulation in patients with acute stroke is high
2. The distribution of stroke subtypes is different in the subtypes of the abnormal glucose regulation
3. Patients with or without abnormal glucose regulation will have different outcomes and recurrent risk of stroke
4. Different subtypes of abnormal glucose regulation have different effects on the outcomes and recurrence of stroke</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The prevalence of abnormal glucose regulation after acute stroke in China, measured by OGTT before discharge.</primaryOutcome>
      <secondaryOutcome>1. The distribution of stroke subtypes is different in the subtypes of the abnormal glucose regulation
2. The outcome and recurrence risk of stroke in patients with or without abnormal glucose regulation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Tiantan Hospital Ethics Committee on the 28th August 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN69559777</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ACROSS-protocol 5</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre observational, prospective, cohort study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="843e0089-2948-4c0f-b3eb-99d3b0f50a07">
	  <name>Beijing Tiantan Hospital</name>
	  <address/>
	  <city>Beijing</city>
	  <state/>
	  <country>China</country>
	  <zip>100050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Older than 18, either sex
2. Acute stroke: diagnosed on World Health Organization (WHO) criteria 
3. Acute primary stroke patients within 14 days</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>4000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>4000</totalTarget>
      <exclusion>1. Cerebral infarction without symptoms and signs
2. Non-cerebrovascular events 
3. Stroke patients out of 14 days
4. Without the content of patients or their legal agents</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet.</patientInfoSheet>
      <recruitmentStart>2008-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Abnormal glucose regulation, acute stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Acute stroke</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All participants without a history of diabetes mellitus will be identified as having abnormal glucose regulation or not by using the oral glucose tolerance test (OGTT) three days before discharge. The outcome and recurrence of stroke will be compared between the patients with and without abnormal glucose regulation respectively at three months and one year after the onset of stroke as below:
1. Modified Rankin Scale (mRS)
2. The times of stroke recurrence

The current therapy measures of abnormal glucose regulation in patients with acute stroke will be observed during in-hospital and follow-up.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17402-0</funderId>
      <funderId>Funder17402-1</funderId>
      <contactId>Contact55363_17402</contactId>
      <sponsorId>Sponsor53933</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55363_17402">
    <title>Prof</title>
    <forename>Yongjun</forename>
    <surname>Wang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Beijing Tiantan Hospital
Tiantan Xili 6 
Chongwen District </address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53933">
    <organisation>Bayer (China) Limited </organisation>
    <website>http://www.bayerchina.com.cn</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Corporate Communications 
34/F Jing Guang Centre
Hu Jia Lou, Chaoyang District</address>
      <city>Beijing </city>
      <country>China</country>
      <zip>100020</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.497608.4</gridId>
    <rorId>https://ror.org/05d5yxq17</rorId>
  </sponsor>
  <funder id="Funder17402-0">
    <name>Bayer (China) Limited</name>
    <fundRef/>
  </funder>
  <funder id="Funder17402-1">
    <name>11th Five-year National Supporting Schedule of Science and Technology (China)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-29T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-05-29T00:00:00.000Z">93225273</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The use of alternative therapies to treat geriatric depression</title>
      <scientificTitle>Evaluating the effects of music and animal-assisted therapy on depression in aged care residents</scientificTitle>
      <acronym/>
      <studyHypothesis>The primary aim of this randomised clinical study is to evaluate the efficacy of two alternative therapies, music therapy (MT) and animal-assisted therapy (AAT), to reduce depressive symptomatology in cognitively intact elderly individuals residing in aged care facilities. A secondary aim of this study is to explore neurophysiological mechanisms that may underpin any observed effects of the alternative therapy interventions. The following hypotheses have been formulated on the basis of the above aims:
1. MT and AAT will improve quality of life and reduce the physical, cognitive, affective and interpersonal deficits associated with depression in the elderly to a greater extent than the no intervention control group
2. MT and AAT will produce observable changes in electroencephalogram (EEG) indices of depression to a greater extent than the no intervention control condition
3. Changes observed in psychological indices of depression will correlate with changes observed on physiological measures of depression</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Affective: symptoms of depression will be measured with the mood disorder module of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV (SCID-IV-TR) and the GDS
2. Cognitive: general cognitive status will be assessed using the SMMSE. The more specific domain of executive functioning will be assessed using the Trail Making Test Part A and B, Digit-Symbol Coding and the Controlled Oral Word Association Test (COWA). 
3. General health and well-being: assessed using the Australia Quality of Life (AQoL) Scale. Pain will be assessed the Present Pain Index (PPI) and the Modified Cumulative Illness Rating Scale (MCIRS).

All outcomes will be measured over the course of four days prior to the four week intervention period and in the week following treatment.</primaryOutcome>
      <secondaryOutcome>Neurophysiological measures: 
Two EEG components will be explored. First, previous research has indicated that depression is associated with relative left frontal asymmetry and that pharmacological and psychological treatment for depression may normalise this brain activity pattern. Second, abnormal P300 responses (such as reduced amplitude and increased latency) have also been observed in individuals with depression. Given these findings, this study will explore the effect of alternative therapies on the topographic distribution of spectral power and the amplitude and latency of the P300 evoked potential. 

All outcomes will be measured over the course of four days prior to the four week intervention period and in the week following treatment.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Monash University Standing Ethics Committee on Research Involving Humans (SCERH) on the 20th February 2008</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN93225273</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A multicentre, double-blind, nested, randomised controlled trial with three independent groups</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-08-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b0bc798d-81c2-4705-a74c-70dcfc322c62">
	  <name>School of Psychology, Psychiatry and Psychological Medicine</name>
	  <address/>
	  <city>Melbourne</city>
	  <state/>
	  <country>Australia</country>
	  <zip>3145</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adults (65+ years), either sex 
2. A score of at least 20 on the Standardised Mini Mental Status Examination (SMMSE)
3. A score of at least 5 on the Geriatric Depression Scale (GDS)
4. English fluency</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150 in total</totalTarget>
      <exclusion>1. Diagnosis of dementia or delirium
2. Significant hearing or vision impairments 
3. Unable to provide informed consent (due to mental status)
4. Placed in the facility within the previous three weeks</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-08-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Experimental conditions: 
Music therapy and animal-assisted therapy will each be presented by accredited therapists twice weekly to small groups (N = 5) for four weeks, yielding a total of eight therapeutic sessions. Therapy session will last approximately 45 minutes. Music therapy will comprise listening to preferred music, singing, and playing percussion instruments. Animal-assisted therapy will comprise activities with a temperament-tested dog, such as patting, grooming, playful interaction and watching the animal perform tricks. Participants assigned to either treatment will continue to receive diversional activities already in place at their respective facilities.
 
Control condition: 
The non-intervention control group will continue to receive diversional activities already in place at the respective facilities, but will not receive an additional treatment.  

Post-intervention measures will be taken the week after the interventions have been completed and post-testing will take one week to complete per facility.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17644-0</funderId>
      <funderId>Funder17644-1</funderId>
      <contactId>Contact55615_17644</contactId>
      <sponsorId>Sponsor54190</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55615_17644">
    <title>Dr</title>
    <forename>Samia</forename>
    <surname>Toukhsati</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Psychology, Psychiatry and Psychological Medicine
Building F
Caulfield Campus
Monash University</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3145</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9903 2367</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Samia.Toukhsati@med.monash.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54190">
    <organisation>Monash University (Australia) </organisation>
    <website>http://www.monash.edu.au</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>School of Psychology, Psychiatry and Psychological Medicine
Building F
Caulfield Campus</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3145</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9903 2367</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Samia.Toukhsati@med.monash.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.1002.3</gridId>
    <rorId>https://ror.org/02bfwt286</rorId>
  </sponsor>
  <funder id="Funder17644-0">
    <name>J.O. &amp; J.R. Wicking Trust (Australia and New Zealand [ANZ] Trustees) (Australia)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17644-1">
    <name>Monash University (Australia)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001779</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-22T00:00:00.000Z" version="16">
    <isrctn dateAssigned="2008-05-22T00:00:00.000Z">10637905</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase III clinical trial for the two months safety and efficacy evaluation of Ostem™ (autologous cultured osteoblasts) in patients with fracture</title>
      <scientificTitle>A multicentre, randomised and comparative clinical study of the efficacy and safety of Ostem™ (autologous cultured osteoblasts) injection to treat fractures</scientificTitle>
      <acronym/>
      <studyHypothesis>To accelerate fracture healing, ultrasound and other diverse treatment methods have recently been introduced. In particular, cell therapy suggests a new treatment approach. When using Ostem™ (autologous cultured osteoblasts) rather than bone grafts, problems may develop in the donor area in general autologous bone grafts and immunological problems may develop in allograft, although problems involving the spread of disease are less frequent and a faster patient recovery may be achieved when using Ostem™ (autologous cultured osteoblasts).

The hypothesis for this trial is that patients who implant Ostem™ (autologous cultured osteoblasts) will improve.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Difference of Callus Formation Score for two months after autologous cultured osteoblast injection.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the following institutional review boards:
1. Catholic University College of Medicine (Uijeongbu St. Mary&#146;s Hospital) on 9th March 2006 (ref: UCMC06MT001)
2. Yonsei University College of Medicine on 13th December 2006 (ref: 3-2006-0066)
3. Catholic University College of Medicine (St. Paul&#146;s Hospital) on 5th December 2006 (ref: PCMC06MT011)
4. Inje University College of Medicine on 29th December 2006 (ref: 06-33)
5. Dankook University College of Medicine on 22th January 2007 (ref: 2006-36)
6. Konyang University College of Medicine on 24th January 2007 (ref: 06-17)
7. Catholic University College of Medicine (Kangnam St. Mary&#146;s Hospital) on 16th May 2007 (ref: KCMC06Mt174)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10637905</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>03OST/014</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Korea, South</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="370d8afc-99e4-45d4-9ba0-606f46337f10">
	  <name>Catholic University College of Medicine</name>
	  <address/>
	  <city>Uijeongbu</city>
	  <state/>
	  <country>Korea, South</country>
	  <zip>480-717</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Long bone fracture (femur, tibia, radius, ulna, humerus) patients
2. Aged 15 and 65 years, either sex
3. Approximately six weeks after the first open or closed reduction, the score of callus formation was lower than 3 points
4. Individuals who have completed a written consent form</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>77</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>77</totalTarget>
      <exclusion>1. Patient who is oversensitive to bovine protein 
2. Patients with a known history of anaphylaxis to gentamicin
3. Patients with acute infection in bone defects
4. Patients who have communicable disease (positive reaction against human immunodeficiency virus [HIV], hepatitis C virus [HCV], hepatitis B virus [HBV], cytomegalovirus [CMV], syphilis, human T-lymphotropic virus [HTLV])
5. Patients diagnosed by the investigators to have psychological disorders
6. Patients whose score of callus formation was higher than 4 points</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2006-05-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Long bone fracture</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Fracture</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients will receive standardised first fracture surgery (closed or open reduction). At enrolment patients are randomised to receive either injection (intervention group) or observation (control group).

Intervention group: approximately eight weeks after the first open or closed reduction, this group will receive Ostem™ (autologous cultured osteoblasts)
Control group: approximately eight weeks after the first open or closed reduction, this group will be observed but no other treatments performed.

Total duration of follow-up for both treatment arms is two months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Ostem™ (autologous cultured osteoblasts)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17800-0</funderId>
      <funderId>Funder17800-1</funderId>
      <contactId>Contact55778_17800</contactId>
      <sponsorId>Sponsor54347</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55778_17800">
    <title>Prof</title>
    <forename>Kim</forename>
    <surname>Seok-Jung</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Catholic University College of Medicine
Uijeongbu St. Mary's Hospital, Kumoh-dong</address>
      <city>Uijeongbu</city>
      <country>Korea, South</country>
      <zip>480-717</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54347">
    <organisation>Individual sponsor (South Korea)</organisation>
    <website/>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>c/o Ms Su-Young Lee
802 Wooyoung Techno Center, 273-15 
Seongsu 2ga 3-Dong
Seongdong-Gu</address>
      <city>Seoul</city>
      <country>Korea, South</country>
      <zip>133-831</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17800-0">
    <name>SEWON Cellontech Co., Ltd (South Korea)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17800-1">
    <name>Korea Health Industry Development Institute (KHIDI) (South Korea) (ref : A04-0012)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003710</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-16T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-05-16T00:00:00.000Z">75311338</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An oestrogen cream for the treatment of faecal incontinence</title>
      <scientificTitle>Are topical oestrogens useful in faecal incontinence? A double blind randomised trial</scientificTitle>
      <acronym/>
      <studyHypothesis>A topical application of oestrogens is effective for the symptoms of faecal incontinence in post-menopausal women.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The degree of continence was evaluated by Wexner's FI score at the beginning and end of the protocol (six weeks since the beginning).</primaryOutcome>
      <secondaryOutcome>In order to evaluate the degree of impact on quality of life, we used a quality of life questionnaire validated and accepted for the Spanish language (ECIF), at the beginning and end of the protocol (six weeks since the beginning).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Comite de etica Pontificia Universidad Catolica de Chile on the 3rd April 2007 (ref: C.E. #095/07).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75311338</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double blind, randomised, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Chile</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e8fe974f-6733-45ab-aed4-2cbb27458c97">
	  <name>Marcoleta 350 patio interior</name>
	  <address/>
	  <city>Santiago</city>
	  <state/>
	  <country>Chile</country>
	  <zip>8330033</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Post-menopausal women (at least 1 year) without hormonal substitution
2. Aged 69 years ± 8 (treatment group) and 66 years ± 8 (placebo group)
3. Wexner's faecal incontinence (FI) score greater than 5
4. Anal ultrasound with less than 50% damage to external sphincter
5. Accepted informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>34</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>34 patients</totalTarget>
      <exclusion>1. Perianal lesions
2. History of endometrial, breast or cervix cancer
3. Allergy to oestrogens</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2006-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Faecal incontinence</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Faecal incontinence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Application of topical estriol (Ovestin®) or placebo according to the randomisation. The cream was applied in the anal canal mucosa three times a day (tid) during six weeks. Dosage approximately 1 g every eight hours. 

The total duration of follow-up of all patients was six weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Estriol (Ovestin®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17455-0</funderId>
      <contactId>Contact55417_17455</contactId>
      <sponsorId>Sponsor53995</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55417_17455">
    <title>Dr</title>
    <forename>George</forename>
    <surname>Pinedo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Marcoleta 350 patio interior</address>
      <city>Santiago</city>
      <country>Chile</country>
      <zip>8330033 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53995">
    <organisation>Pontifical Catholic University of Chile (Pontificia Universidad Catolica de Chile) (Chile)</organisation>
    <website>http://www.puc.cl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Departamento de Cirugia Digestiva
Marcoleta 350 patio interior</address>
      <city>Santiago</city>
      <country>Chile</country>
      <zip>8330033</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7870.8</gridId>
    <rorId>https://ror.org/04teye511</rorId>
  </sponsor>
  <funder id="Funder17455-0">
    <name>Pontifical Catholic University of Chile (Pontificia Universidad Catolica de Chile) (Chile) - Department of Digestive Surgery (Departamento de Cirugia Digestiva)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-05-15T00:00:00.000Z">42833283</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of the fixed dose combination of cefpirome and sulbactam</title>
      <scientificTitle>Multicentric, open labelled, non randomised, clinical trial to assess efficacy and safety of the fixed dose combination of cefpirome and sulbactam in bacteraemia/septicaemia and severe infections in intensive care patients</scientificTitle>
      <acronym/>
      <studyHypothesis>The objective of the trial was to study the efficacy of fixed dose combination of cefpirome and sulbactam injections in bacteraemia/septicaemia and severe infections in intensive care patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Improvement in clinical and laboratory parameters, measured at day 0, day 3 and day 7 (completion of treatment).</primaryOutcome>
      <secondaryOutcome>To observe incidence of adverse events as assessed by clinical evaluation and laboratory parameters, measured at day 0, day 3 and day 7 (completion of treatment).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the National Ethic Committee, Ahembdabad on the 28th April 2007 (date of issue of letter: 2nd May 2007) (ref: NEC/04-2007/04/VENUS/CEFPIROME_SULBACTAM/082006A).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN42833283</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>venus/cefpirome_sulbactam/082006A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open labelled, non randomised, multicentric clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ddb28dea-77c4-4262-a24b-3a507606e9c6">
	  <name>Dr R N Cooper Municipal General Hospital</name>
	  <address/>
	  <city>Mumbai</city>
	  <state/>
	  <country>India</country>
	  <zip>400056</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Participants aged greater than 18 years (n = 103), either sex
2. Suffering from bacteraemia/septicaemia and severe infections</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>103</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>103</totalTarget>
      <exclusion>1. History of hypersensitivity reaction or any specific contraindication to beta lactams
2. Presence of hepatic or renal disorders
3. Pregnancy or lactation
4. History of hearing loss
5. Alcoholics
6. Previous history seizure</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bacteraemia/septicaemia and severe infections</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Bacteraemia/septicaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Fixed dose combination of cefpirome and sulbactam (1.5 g to 3 g, intravenous [i.v.] twice daily). Duration of treatment 7 to 10 days, followed for 7 days after the treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cefpirome, sulbactam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17570-0</funderId>
      <contactId>Contact55532_17570</contactId>
      <sponsorId>Sponsor54116</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55532_17570">
    <title>Dr</title>
    <forename>Nitin</forename>
    <surname>Rathod</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dr R N Cooper Municipal General Hospital
Ville Parle</address>
      <city>Mumbai</city>
      <country>India</country>
      <zip>400056</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">drnmrathod@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54116">
    <organisation>Venus Remedies Limited (India) </organisation>
    <website>http://www.venusremedies.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>51 - 52 Industrial Area
Phase - I</address>
      <city>Panchkula, Haryana</city>
      <country>India</country>
      <zip>134113</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research@venusremedies.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.465099.7</gridId>
    <rorId>https://ror.org/0169rv113</rorId>
  </sponsor>
  <funder id="Funder17570-0">
    <name>Venus Remedies Limited (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-05-15T00:00:00.000Z">69844323</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Ceftazidime tobramycin fixed drug combination (FDC) versus ceftazidime in lower respiratory tract infections</title>
      <scientificTitle>Comparative efficacy and synergy establishment of ceftazidime tobramycin fixed drug combination (FDC) versus ceftazidime in lower respiratory tract infections</scientificTitle>
      <acronym/>
      <studyHypothesis>1. To assess efficacy of ceftazidime tobramycin fixed drug combination (FDC) in comparison with ceftazidime monotherapy in lower respiratory tract infections
2. To assess comparative safety of study drugs</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Improvement in clinical and laboratory parameters, measured on day 0 and day 7, followed up to 10 days after the treatment.</primaryOutcome>
      <secondaryOutcome>To observe incidence of adverse events as assessed by clinical evaluation and laboratory parameters, measured on day 0 and day 7, followed up to 10 days after the treatment.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the National Ethic Committee, Ahemdabad on the 28th April 2007 (date of issue of letter: 2nd May 2007) (ref: NEC/04-2007/01/VENUS/TOBCEF/082006A).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN69844323</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>venus/ceftazidime_tobramycin/082006A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open labelled, comparative, randomised, multicentric clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9baee25c-d375-4c3f-ae1d-cd27252729d1">
	  <name>Dr R N Cooper Municipal General Hospital</name>
	  <address/>
	  <city>Mumbai</city>
	  <state/>
	  <country>India</country>
	  <zip>400056</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Participants aged greater than 18 years (n = 240), either sex
2. Hopsitalised patients suffering from lower respiratory tract infections</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240</totalTarget>
      <exclusion>1. Patients having received antibiotic treatment within two weeks of therapy
2. History of hypersensitivity reaction or any specific contraindication to beta lactams
3. Presence of hepatic or renal disorders
4. Pregnancy or lactation
5. History of hearing loss
6. Alcoholics
7. Previous history seizure</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lower respiratory tract infections</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Lower respiratory tract infections</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Ceftazidime (1 g) and tobramycin (120 mg) fixed drug combination (FDC), eight-hourly, intravenous (i.v.) for seven days
2. Ceftazidime (1 g), eight-hourly, i.v. for seven days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ceftazidime tobramycin fixed drug combination (FDC), ceftazidime alone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17571-0</funderId>
      <contactId>Contact55533_17571</contactId>
      <sponsorId>Sponsor54117</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55533_17571">
    <title>Dr</title>
    <forename>Nitin</forename>
    <surname>Rathod</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dr R N Cooper Municipal General Hospital
Ville Parle</address>
      <city>Mumbai</city>
      <country>India</country>
      <zip>400056</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">drnmrathod@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54117">
    <organisation>Venus Remedies Limited (India) </organisation>
    <website>http://www.venusremedies.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>51 - 52 Industrial Area
Phase - 1</address>
      <city>Panchkula, Haryana</city>
      <country>India</country>
      <zip>134113</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research@venusremedies.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.465099.7</gridId>
    <rorId>https://ror.org/0169rv113</rorId>
  </sponsor>
  <funder id="Funder17571-0">
    <name>Venus Remedies Limited (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-05-15T00:00:00.000Z">02965214</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of the fixed dose combination of ceftazidime and sulbactam in lower respiratory tract infections (LRTI)</title>
      <scientificTitle>Multicentric, open labelled, non-randomised, clinical trial to assess efficacy and safety of the fixed dose combination of ceftazidime and sulbactam in lower respiratory tract infections caused by gram negative organisms including pseudomonas aeruginosa</scientificTitle>
      <acronym/>
      <studyHypothesis>The objectives were:
1. To study the efficacy of fixed dose combination of ceftazidime and sulbactam injections in lower respiratory tract infections caused by gram negative organisms including pseudomonas aeruginosa
2. To assess comparative safety of study drug</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Improvement in clinical and laboratory parameters, measured on day 0, day 3 and day 7 (completion of treatment).</primaryOutcome>
      <secondaryOutcome>To observe incidence of adverse events as assessed by clinical evaluation and laboratory parameters, measured on day 0, day 3 and day 7 (completion of treatment).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the National Ethic Committee, Ahembdabad on the 28th April 2007 (date of issue of letter: 2nd May 2007) (ref: NEC/04-2007/03/VENUS/CEFTAZIDIME_SULBACTAM/082006A).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN02965214</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>venus/ceftazidime_sulbactam/082006A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open labelled, non-randomised, multicentric clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4f65a18f-dc75-418e-9b9e-824117df8803">
	  <name>Dr R N Cooper Municipal General Hospital</name>
	  <address/>
	  <city>Mumbai</city>
	  <state/>
	  <country>India</country>
	  <zip>400056</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Participants aged greater than 18 years (n = 104), either sex
2. Suffering from lower respiratory tract infections caused by gram negative organisms including pseudomonas aeruginosa</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>104</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>104</totalTarget>
      <exclusion>1. History of hypersensitivity reaction or any specific contraindication to beta lactams
2. Presence of hepatic or renal disorders
3. Pregnancy or lactation
4. History of hearing loss
5. Alcoholics
6. Previous history of seizures</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lower respiratory tract infections caused by gram negative organisms including pseudomonas aeruginosa</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Lower respiratory tract infections</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Fixed dose combination of ceftazidime and sulbactam (1.5 g to 3 g, intravenous [i.v.] twice daily). Duration of treatment 7 to 10 days, followed for 7 days after the treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ceftazidime, sulbactam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17572-0</funderId>
      <contactId>Contact55534_17572</contactId>
      <sponsorId>Sponsor54118</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55534_17572">
    <title>Dr</title>
    <forename>Nitin</forename>
    <surname>Rathod</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dr R N Cooper Municipal General Hospital
Ville Parle</address>
      <city>Mumbai</city>
      <country>India</country>
      <zip>400056</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">drnmrathod@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54118">
    <organisation>Venus Remedies Limited (India) </organisation>
    <website>http://www.venusremedies.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>51 -52 Industrial Area
Phase - I</address>
      <city>Panchkula, Haryana</city>
      <country>India</country>
      <zip>134113</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research@venusremedies.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.465099.7</gridId>
    <rorId>https://ror.org/0169rv113</rorId>
  </sponsor>
  <funder id="Funder17572-0">
    <name>Venus Remedies Limited (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-05-15T00:00:00.000Z">84455313</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of the fixed dose combination of cefepime and sulbactam</title>
      <scientificTitle>Multicentric, open labelled, non-randomised, clinical trial to assess efficacy and safety of the fixed dose combination of cefepime and sulbactam in complicated upper and lower tract infections</scientificTitle>
      <acronym/>
      <studyHypothesis>The objectives were:
1. To study the efficacy of fixed dose combination of cefepime and sulbactam injections in in complicated upper and lower tract infections
2. To assess comaprative safety of study drug</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Improvement in clinical and laboratory parameters, measured on day 0, day 3 and day 7 (completion of treatment).</primaryOutcome>
      <secondaryOutcome>To observe incidence of adverse events as assessed by clinical evaluation and laboratory parameters, measured on day 0, day 3 and day 7 (completion of treatment).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the National Ethic Committee, Ahembdabad on the 28th April 2007 (date of issue of letter: 2nd May 2007) (ref: NEC/04-2007/02/VENUS/CEFEPIME_SULBACTAM/082006A).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84455313</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>venus/cefepime_sulbactam/082006A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open labelled, non-randomised, multicentric clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8b18754e-8b05-42e4-a6b4-52f848f93e4c">
	  <name>Dr R N Cooper Municipal General Hospital</name>
	  <address/>
	  <city>Mumbai</city>
	  <state/>
	  <country>India</country>
	  <zip>400056</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Participants aged greater than 18 years (n = 102), either sex
2. Suffering from lower respiratory tract infections caused by gram negative organisms including pseudomonas aeruginosa</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>102</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>102</totalTarget>
      <exclusion>1. History of hypersensitivity reaction or any specific contraindication to beta lactams
2. Presence of hepatic or renal disorders
3. Pregnancy or lactation
4. History of hearing loss
5. Alcoholics
6. Previous history seizure</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Complicated upper and lower tract infections</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Upper and lower tract infections</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Fixed dose combination of cefepime and sulbactam (1.5 g to 3 g, intravenous [i.v.] twice daily). Duration of treatment 7 to 10 days, followed for 7 days after the treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cefepime, sulbactam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17573-0</funderId>
      <contactId>Contact55535_17573</contactId>
      <sponsorId>Sponsor54119</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55535_17573">
    <title>Dr</title>
    <forename>Nitin</forename>
    <surname>Rathod</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dr R N Cooper Municipal General Hospital
Ville Parle</address>
      <city>Mumbai</city>
      <country>India</country>
      <zip>400056</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">drnmrathod@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54119">
    <organisation>Venus Remedies Limited (India) </organisation>
    <website>http://www.venusremedies.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>51-52 Industrial Area
Phase - I</address>
      <city>Panchkula, Haryana</city>
      <country>India</country>
      <zip>134113</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research@venusremedies.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.465099.7</gridId>
    <rorId>https://ror.org/0169rv113</rorId>
  </sponsor>
  <funder id="Funder17573-0">
    <name>Venus Remedies Limited (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-05-15T00:00:00.000Z">61799591</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety and efficacy of a fixed dose combination of cefepime and amikacin</title>
      <scientificTitle>An open labelled post marketing surveillance study to evaluate safety and efficacy of a fixed dose combination of cefepime and amikacin in subjects with mild to severe infections</scientificTitle>
      <acronym/>
      <studyHypothesis>To evaluate efficacy of fixed dose combination of cefepime-amikacin in various infections.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Improvement in clinical and laboratory parameters, measured on day 0 and completion of treatment (COT) (i.e. day 5 - 7 or COT).</primaryOutcome>
      <secondaryOutcome>To observe incidence of adverse events as assessed by clinical evaluation and laboratory parameters, measured on day 0 and completion of treatment (COT) (i.e. day 5 - 7 or COT).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. Independent Ethic Committee for Clinical Research, New Delhi on the 11th April 2007 (ref: IEC/Nex/VR//CT-PMS/08901-2007)
2. Ethic Committee, SP Medical College and Associated Hospitals, Bikaner on the 16th July 2008 (ref: SP-EC//Nex/VR//CT-PMS/08901-2007)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61799591</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Nex/VR/CT_PMS_089/01_2007</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open labelled, randomised, multicentric clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-28T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="274bce43-5f2b-44d5-a680-5e76a6eaca61">
	  <name>Subharti Medical College</name>
	  <address/>
	  <city>Merrut, UP</city>
	  <state/>
	  <country>India</country>
	  <zip>250002</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Hospitalised patients of either sex
2. Above 18 years of age
3. Clinically diagnosed subjects with moderate to severe infections of:
3.1. Febrile neutropenia (n = 110)
3.2. Nosocomial pneumonia (n = 110)
3.3. Other bacterial infection (n = 91)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>315</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>315</totalTarget>
      <exclusion>1. History of hypersensitivity reaction or any specific contraindication to penicillin group of drugs 
2. Hepatic or renal disorder or  any heart disorder
3. Pregnancy and/or lactation
4. History of hearing loss
5. Alcoholics</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-28T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Nosocomial pneumonia, febrile neutropenia, other bacterial infections</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Infections</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The subjects were divided in three groups as per the severity of the infection:
1. Group A (severely infected) were given 2.5 g twice daily (BD) of cefepime-amikacin fixed dose combination (FDC) 
2. Group B (moderately infected) were given 1.25 g BD of cefepime-amikacin FDC	
3. Group C (mildly infected) were given 0.625 g BD of cefepime-amikacin FDC

Total duration of therapy 3 - 10 days, followed up for 7 days after the treatment.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cefepime-amikacin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17574-0</funderId>
      <contactId>Contact55536_17574</contactId>
      <sponsorId>Sponsor54120</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55536_17574">
    <title>Dr</title>
    <forename>Tanuraj</forename>
    <surname>Sirohi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Subharti Medical College</address>
      <city>Merrut, UP</city>
      <country>India</country>
      <zip>250002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tsirohi@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54120">
    <organisation>Venus Remedies Limited (India)</organisation>
    <website>http://www.venusremedies.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>51-52 Industrial Area
Phase- I</address>
      <city>Panchkula, Haryana</city>
      <country>India</country>
      <zip>134113</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research@venusremedies.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.465099.7</gridId>
    <rorId>https://ror.org/0169rv113</rorId>
  </sponsor>
  <funder id="Funder17574-0">
    <name>Venus Remedies Limited (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-15T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-05-15T00:00:00.000Z">35300716</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparative pharmacokinetic study of oral mifepristone and vaginal misoprostol in pregnant women</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The present study aims at comparing the pharmacokinetics of the original formulations of mifepristone and misoprostol and a new generic co-packaged product. This is necessary to demonstrate bioequivalence to regulatory authorities.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome of the study will be to ascertain the bioequivalence of each the two formulations of mifepristone and misoprostol, as determined by the measurement of the pharmacokinetic parameters, maximum serum concentration (Cmax), time to maximum serum concentration (tmax) and area under the curve (AUC) in each study group.</primaryOutcome>
      <secondaryOutcome>The secondary outcome will be the efficacy (defined as the proportion of complete abortions in each study group) and side effects of each of the two product regimens. The complete abortion rate and the induction to abortion interval will also be compared. Adverse events, if any, will be analysed on an intention to treat basis.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. World Health Organization (WHO) Scientific and Ethical Review Group, Department of Reproductive Health and Research on the 27th April 2006 (ref: A65037)
2. Ethics Committee of Gynaecology and Obstetrics, Otology, Ophtalmology, Neurology and Neurosurgery of the Hospital District of Helsinki and Uusimaa on the 17th August 2006 (ref: 297/E9/06)
3. WHO Ethics Review Committee on the 13th September 2007 (ref: A65037)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35300716</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A65037</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised single-blind study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-19T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-10-19T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b235ad52-dbfd-4b2f-92c3-01c9dff67aee">
	  <name>World Health Organization (WHO)</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Subjects admitted to the study will fulfil the following criteria: 
1. Good general health
2. Older than the legal age of consent
3. On day one of the study (day of mifepristone administration) the duration of pregnancy is not more than 63 days (counted from the first day of the last menstrual period) in a normal 28-day cycle
4. The duration of the pregnancy corresponds to the length of amenorrhoea when verified by ultrasound; if the gestational length according to ultrasound measurements differ by more than four days, the ultrasound dating will be used
5. The pregnancy is single and intrauterine (single sac)
6. If treatment with misoprostol should fail, subject agrees to surgical termination of pregnancy
7. Willing and able to participate in the study once the objective and study requirements have been explained</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>Subjects will not be recruited if any of the following conditions are present:
1. Allergy towards mifepristone or misoprostol
2. A history or evidence of disorders that represent a contraindication to the use of mifepristone (chronic adrenal failure, severe asthma uncontrolled by corticosteroid therapy, inherited porphyria)
3. A history or evidence of disorders that represent a contraindication to the use of prostaglandins (mitral stenosis, glaucoma, sickle cell anaemia, diastolic pressure over 90 mmHg, bronchial asthma, arterial hypotension)
4. A history or evidence of thrombo-embolism, severe or recurrent liver disease or pruritus of pregnancy
5. Has any medical condition or disease that requires regular treatment with systemic drugs, care or precaution in conjunction with abortion
6. Tendency of abnormal bleeding (such as von Willebrandt's disease)
7. The presence of intrauterine device (IUD) in utero
8. Previous surgery of uterus/uterine cervix is a relative contraindication, however, previous low-segment caesarean section is not a contraindication 
9. Suspicion of any pathology of pregnancy (e.g., molar, non-viable pregnancy, threatened abortion)
10. Suspected or known breast or genital neoplasia
11. Breast-feeding
12. Where difficulties are anticipated in follow-up</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-10-19T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-10-19T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pregnancy</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Pregnancy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>To demonstrate bioequivalence a new generic co-packaged mifepristone (one tablet x 200 mg)/misoprostol (four tablets x 0.2 mg) product (SunPharma, India) with the original formulations of mifepristone (one tablet x 200 mg [Exelgyn, France]) and misoprostol (four tablets x 0.2 mg [Pfizer, USA]).

Contact details for Principal Investigator: 
Dr Oskari Heikinheimo
Department of Obstetrics and Gynaecology
Helsinki University Central Hospital
Helsinki
00029-HUS
Finland
Tel: +358 (0)40 587 1070
Fax: +358 (0)94 717 4801
Email: oskari.heikinheimo@helsinki.fi

Details of joint sponsor:
Concept Foundation (Thailand)
111 Paholyothin Rd
Thailand Science Park
Pathumthani
12120
Thailand
Tel: +66 (0)2 564 8021
Fax: +66 (0)2 564 8024
Email: phall@rhalliance.org
Website: http://www.conceptfoundation.org</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mifepristone, misoprostol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17805-0</funderId>
      <funderId>Funder17805-1</funderId>
      <contactId>Contact55783_17805</contactId>
      <sponsorId>Sponsor54352</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55783_17805">
    <title>Dr</title>
    <forename>Helena</forename>
    <surname>von Hertzen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization (WHO)
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3376</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vonhertzenh@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54352">
    <organisation>World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3376</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vonhertzenh@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder17805-0">
    <name>World Health Organization (WHO) (Switzerland) (ref: A65037)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
  <funder id="Funder17805-1">
    <name>Concept Foundation (Thailand) (ref: BE0101)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-15T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-05-15T00:00:00.000Z">93709209</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Therapy-efficacy of automatic positive airways pressure therapy with A-Flex compared to standard automatic positive airways pressure therapy in obstructive sleep apnoea (OSA) patients</title>
      <scientificTitle/>
      <acronym>A-Flex Validation</acronym>
      <studyHypothesis>A-Flex is as effective as automatic positive airways pressure (APAP) in reducing respiratory events and arousals in patients with obstructive sleep apnoea (OSA).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>A-Flex is as effective as APAP in reducing respiratory events and arousals in patients with OSA, measured with the Apnoea-Hypopnea Index at baseline.</primaryOutcome>
      <secondaryOutcome>1. A-Flex is more comfortable than APAP, measured using the Visual Analogue Scale [VAS] at baseline
2. Compliance (internal clock within the device) is higher on A-Flex compared to APAP, measured at one and three months
3. Subjective daytime sleepiness is improved on A-Flex compared to APAP, measured using the Epworth Sleepiness Scale at baseline, one and three months
4. Quality of life is improved on A-Flex compared to APAP, measured using the Functional Outcomes of Sleep Questionnaire at baseline, one and three months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. France: Ethics of Lille on the 11th February 2008
2. Germany: Charite Ethikkommission, Mitte Campus on the 30th July 2008</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN93709209</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EAME07AFLEX01/02</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, double-blind, cross-over study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ff14579b-33ec-40e6-9665-707a3d8aa711">
	  <name>Charité-Universitätsmedizin Berlin</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10117</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Apnoea-Hypopnoea Index (AHI) greater than 15/h confirmed by full polysomnograph (PSG)
2. Aged greater than or equal to 21 to less than or equal to 65 years, either sex
3. Body mass index (BMI) less than 40 kg/m^2
4. Able to follow the study protocol</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Acute upper respiratory infection, encephalitis, sinusitis or middle ear infection
2. Drug abuse
3. Intake of central relevant drugs, sedatives, or other drugs which impair sleep
4. Alcohol abuse 
5. Psychiatric or neurological diseases resulting in impairment of sleep, therapy or compliance
6. Thyroidal dysfunction
7. Chronic pain syndromes
8. Acute cardiac, pulmonary, and other internal diseases 
9. Chronic cardiac, pulmonary and other internal diseases resulting in impairment of sleep
10. Central sleep related breathing disorders or other disorders resulting in hypoventilation
11. Periodic leg movements (PLM)/restless legs syndrome (RLS)
12. Previous exposure to either continuous positive airways pressure (CPAP) or bi-level therapy
13. Patients experiencing acute dermatitis or other skin lesions or trauma interfering with the application of a mask
14. Participation in another clinical study in the past four weeks</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obstructive sleep apnoea</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Sleep disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A-Flex: automatic positive airways pressure device featuring pressure relief technology
APAP: standard automatic positive airways pressure device

The duration of treatment and follow up during the fixed follow-up period will be three months in both arms.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17724-0</funderId>
      <contactId>Contact55698_17724</contactId>
      <sponsorId>Sponsor54270</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55698_17724">
    <title>Dr</title>
    <forename>Ingo</forename>
    <surname>Fietze</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Charité-Universitätsmedizin Berlin
Campus Mitte
Schlafmedizinisches Zentrum
Zentrale Poliklinik, BT2591
Ebene 02, Zimmer 044
Luisenstr. 13</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54270">
    <organisation>Respironics International Inc. (France)</organisation>
    <website>http://www.respironics.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>20 Rue Hacques Daguerre
Rueil-Malmaison</address>
      <city>Paris</city>
      <country>France</country>
      <zip>92500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.425454.6</gridId>
    <rorId>https://ror.org/05jz46060</rorId>
  </sponsor>
  <funder id="Funder17724-0">
    <name>Respironics International, Inc. (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-23T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-05-15T00:00:00.000Z">22314061</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>CardioPulmonary Exercise Testing in patients with Chronic Obstructive Pulmonary Disease</title>
      <scientificTitle/>
      <acronym>CPET in COPD</acronym>
      <studyHypothesis>1. Gas exchange data assessed by cardiopulmonary exercise testing (CPET) will provide profound prognostic and clinically relevant data to sub-classify patients with severe chronic obstructive pulmonary disease (COPD) 
2. Different predefined standardised exercise protocols won&#146;t show relevant differences concerning CPET results in the assessment of COPD patients

Please note that as of 23/06/2008 the funder and sponsor of this trial was changed to Ambulantes pneumologisches Zentrum GbR (Germany). Previous sponsor details can be found under the interventions section.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Exercise variables
2. Lung function data

Primary and secondary outcomes will be assessed at the end of the study.</primaryOutcome>
      <secondaryOutcome>GOLD stage, assessed at the end of the study.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of the Ernst Moritz Arndt University of Greifswald on the 31st July 2007 (ref: BB48/07).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN22314061</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>001/2008</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational study of consecutive patients</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="83de65ae-e6a6-456f-be59-28fc98bd77a8">
	  <name>Ernst Moritz Arndt University Greifswald</name>
	  <address/>
	  <city>Greifswald</city>
	  <state/>
	  <country>Germany</country>
	  <zip>17489</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Diagnosis of COPD (according to American Thoracic Society [ATS] case definition) meeting all necessary criteria to be classified as Global Initiative for chronic Obstructive Lung Disease (GOLD) III and IV
2. Informed consent for study-related procedure
3. Stable medications for the last two weeks
4. Ability to safely perform the CPET without contraindications
5. Aged 18 - 80 years, both genders</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Existing contraindication for exercise test
2. Patients with clinically relevant congestive heart failure or other diseases which may influence the results of the study (e.g. handicaps)
3. Exacerbation of COPD within the last two weeks before CPET
4. Conditions associated with poor compliance
5. Patients who have participated in a clinical study within the last four weeks</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Other chronic obstructive pulmonary disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients suffering from COPD (according to the GOLD criteria classified as stage III and IV) will undergo CPET according to a standardised exercise protocol. In addition to the previous obtained spirometric and bodyplethysmographic data, a number of CPET data will be investigated. 

Based on this CPET data the aim of the study is to sub-classify patients into clinical and prognostic groups. The data of gas exchange during exercise might provide further insights in the exercise limiting disease related factors. The impact of the data might result in a new sub-classification of patients with severe COPD. 

Previous sponsor prior to 23/06/2008:
Astra Zeneca GmbH (Germany)
Tindsdaler Weg 183 
Wedel, D-22880
Germany</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17755-0</funderId>
      <funderId>Funder17755-1</funderId>
      <funderId>Funder17755-2</funderId>
      <funderId>Funder17755-3</funderId>
      <contactId>Contact55731_17755</contactId>
      <sponsorId>Sponsor54301</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55731_17755">
    <title>Prof</title>
    <forename>Ralf</forename>
    <surname>Ewert</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ernst Moritz Arndt University Greifswald
Department of Internal Medicine
Pulmonary Medicine and Infectious Diseases
Friedrich Loeffler Strasse 23a</address>
      <city>Greifswald</city>
      <country>Germany</country>
      <zip>17489</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ewert@uni-greifswald.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54301">
    <organisation>Ambulantes pneumologisches Zentrum GbR (Germany) </organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Peter-Uwe Haase
Kleine Marktstrasse 3</address>
      <city>Halle</city>
      <country>Germany</country>
      <zip>D-06108</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17755-0">
    <name>Current funder as of 23/06/2008:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17755-1">
    <name>Ambulantes pneumologisches Zentrum GbR (Germany)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17755-2">
    <name>Previous funder:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17755-3">
    <name>Astra Zeneca GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-12T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-05-12T00:00:00.000Z">40295045</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of alfuzosin hydrochloride on female primary bladder neck obstruction</title>
      <scientificTitle>Effect of alpha-1 blocker alfuzosin hydrochloride on female primary bladder neck obstruction</scientificTitle>
      <acronym/>
      <studyHypothesis>To assess the effect of the selective alpha-1 blocker alfuzosin hydrochloride on urodynamic and quality of life issues of female patients with functional bladder outlet obstruction (BOO) and especially primary bladder neck obstruction (PBNO).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Urodynamic parameters related with obstruction (voiding phase). Primary and secondary outcomes were measured only at the eight-week visit (study closure).</primaryOutcome>
      <secondaryOutcome>1. Measurement of Bother Score Index 
2. Global Assessment of Quality of Life
3. Urodynamic parameters related with storage phase

Primary and secondary outcomes were measured only at the 8-week visit (study closure).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>At the time of recruitment for this trial (2000) no formal approval was required for a phase IV trial. Patients were informed orally and informed consent was required.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN40295045</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational, case-control prospective study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Case-control study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Greece</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3d6a6607-d07c-4afd-b1be-8856ec5c713c">
	  <name>Papadiamantopoulou 38 str</name>
	  <address/>
	  <city>Patra</city>
	  <state/>
	  <country>Greece</country>
	  <zip>26225</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Female patients older than 18 years old 
2. Primary bladder neck obstruction</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>25</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>25</totalTarget>
      <exclusion>1. Mechanical causes of obstruction 
2. Neurological disorders of micturition
3. Hypotension</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2000-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Female primary bladder neck obstruction (PBNO)</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Other disorders of bladder</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Pre-treatment:
1. Urodynamic study including free flow, cystometry, pressure flow study and profilometry,  and 
2. Bother Score questionnaire

Post-treatment:
The same as pre-treatment plus a question about the Global Assessment of the treatment result. 

Treatment:
The dosage of the alfuzosin hydrochloride was 5 mg twice daily for eight weeks. Patients were followed up for eight weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Alfuzosin hydrochloride</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17767-0</funderId>
      <contactId>Contact55743_17767</contactId>
      <sponsorId>Sponsor54313</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55743_17767">
    <title>Prof</title>
    <forename>Anastasios</forename>
    <surname>Athanasopoulos</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Papadiamantopoulou 38 str</address>
      <city>Patra</city>
      <country>Greece</country>
      <zip>26225</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 2610 994668</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tassos_athan@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54313">
    <organisation>University Hospital of Patras (Greece) </organisation>
    <website>http://www.upatras.gr/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Urology
Rio-Patra</address>
      <city>Patra</city>
      <country>Greece</country>
      <zip>26500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+30 2610 999385</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">anathan@upatras.gr</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.412458.e</gridId>
    <rorId>https://ror.org/03c3d1v10</rorId>
  </sponsor>
  <funder id="Funder17767-0">
    <name>University Hospital of Patras (Greece)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-12T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-05-12T00:00:00.000Z">74038076</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Sequential maintenance immunosuppression with mycophenolate and prednisolone: a randomised interventional trial in progressive immunoglobulin A nephritis (IgAN)</title>
      <scientificTitle/>
      <acronym>MIgAN</acronym>
      <studyHypothesis>With our investigator-initiated MIgAN study, we should like to test two hypotheses: 
1. Further loss of renal function will occur in cases with progressive type two immunoglobulin A nephritis (IgAN) even after immunosuppressive induction therapy and while on angiotensin converting enzyme (ACE) inhibitor therapy
2. Sequential maintenance immunosuppression with mycophenolate and low dose prednisolone is able to prevent this loss better than ACE inhibition alone</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The frequency of a GFR loss greater than 20% in the mycophenolate group and in controls. The loss is estimated by the difference from the best GFR after induction therapy. The primary end-point will be measured at the end of month 36.</primaryOutcome>
      <secondaryOutcome>1. Urinary protein/creatinine ratio
2. Need for any further temporary or permanent medication (antihypertensives, antidiabetics, antiinfectives, etc.)
3. Hospitalisation
4. Dialysis
5. Death

All secondary end-points will be measured every three months in each patient.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the University of Ulm Ethics Committee on the 9th April 2008 (ref: 13/08).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74038076</doi>
      <eudraCTNumber>2007-000443-99</eudraCTNumber>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EudraCT-Nr: 2007-000443-99</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Investigator-initiated randomised controlled unblinded interventional study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ea5755e2-6714-4d06-b75f-bec941e0e333">
	  <name>Sektion Nephrologie</name>
	  <address/>
	  <city>Ulm</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-89081</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Mesangioproliferative IgA glomerulonephritis in kidney biopsy
2. Steadily progressive type IgAN = loss of renal function of 2 to 3 ml/min per month before immunosuppressive induction therapy
3. Completion of any form of an immunosuppressive induction protocol (Pozzi, Ballardie, Rasche, experimental)
4. Still impaired renal function after induction therapy with a glomerular filtration rate (GFR) less than 60 ml/min  
5. Aged between 18 and 68 years, either sex</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>70</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70</totalTarget>
      <exclusion>1. Secondary forms of IgAN e.g. anti-nuclear antibody positive (ANA+) lupus, anti-neutrophil cytoplasmic antibody positive (ANCA+) vasculitis, human immunodeficiency virus (HIV), liver cirrhosis 
2. Rapidly progressive type three IgAN with crescents in greater than or equal to 30% of glomeruli
3. Serum creatinine less than 130 mcmol/l or greater than 400 mcmol/l after induction therapy</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mesangioproliferative IgA glomerulonephritis</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Nephritic syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After enrolment phase, two patient groups are randomly assigned:
1. The mycophenolate group is treated with daily 2 x 360 mg oral mycophenolate combined with 2 x 2.5 mg oral prednisolone and the supportive standard therapy
2. The control group is treated with the supportive standard therapy alone consisting with an angiotensin-converting-enzyme inhibitor (ACEi) and/or an angiotensin receptor blocker (ARB)

The maximum duration of treatment is 36 months and the total duration of follow-up of all arms is 36 months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mycophenolate, prednisolone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17752-0</funderId>
      <contactId>Contact55728_17752</contactId>
      <sponsorId>Sponsor54298</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55728_17752">
    <title>Prof</title>
    <forename>Frieder</forename>
    <surname>Keller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sektion Nephrologie
Zentrum Innere Medizin
Klinik für Innere Medizin I
Universitätsklinikum
Robert-Koch-Str. 8</address>
      <city>Ulm</city>
      <country>Germany</country>
      <zip>D-89081 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)731 5004 4561</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">frieder.keller@uni-ulm.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54298">
    <organisation>Universitätsklinikum Ulm (Germany)</organisation>
    <website>http://www.uni-ulm.de/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Prof. Dr. Reinhard Marre
Vorsitzender des Klinikumsvorstandes
Albert-Einstein-Allee 29</address>
      <city>Ulm</city>
      <country>Germany</country>
      <zip>D-89081</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">frieder.keller@uni-ulm.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410712.1</gridId>
    <rorId>https://ror.org/05emabm63</rorId>
  </sponsor>
  <funder id="Funder17752-0">
    <name>Novartis Pharma GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-12T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-05-12T00:00:00.000Z">47598408</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of diets to treat moderate childhood malnutrition</title>
      <scientificTitle>Randomised controlled trial comparing the impacts of feeding with milk/peanut ready-to-use therapeutic food (RUTF), soy/peanut RUTF, and corn-soy blend (CSB) among children with moderate acute malnutrition in Malawi</scientificTitle>
      <acronym/>
      <studyHypothesis>12 - 60 month-old children with moderate acute malnutrition (weight-for-height z score [WHZ] greater than -3 and less than -2) whose caretakers are provided with supplements and counseling to feed the child with 75 kcal/kg/day of either milk/peanut ready-to-use therapeutic food (MP-RUTF) or soy/peanut ready-to-use therapeutic food (SP-RUTF) are more likely to recover from moderate acute malnutrition during an eight-week intervention than comparable children receiving isoenergetic rations of corn-soy blend (CSB); in addition among children receiving MP-RUTF or SP-RUTF, the recovery rate will not differ by more than 10%.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Recovery, measured at the completion of the feeding period, usually eight weeks.</primaryOutcome>
      <secondaryOutcome>1. Weight gain, measured after four weeks
2. Height gain, measured after four weeks
3. Mid-upper arm circumference gain, measured after four weeks</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. College of Medicine Research and Ethics Committee (Malawi) on the 17th July 2007 (ref: P.06/07/564)
2. Washington University Human Studies Committee on the 18th July 2007 (ref: 07-0642)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN47598408</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2620-22-0-00-P-0089</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, investigator blinded clinical effectiveness trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Malawi</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7469af2c-d6cf-4cb5-a08c-d7c8cbc4be76">
	  <name>Department of Pediatrics</name>
	  <address/>
	  <city>St. Louis, MO</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>63110</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 12 - 60 months 
2. Moderate acute malnutrition using the World Health Organization (WHO) criteria (WHZ greater than -3 and less than -2) 
3. Reside within 7 km
4. Present to one of seven supplementary feeding sites in southern Malawi during the study recruitment period</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="12.0"/>
      <upperAgeLimit unit="Months" value="60.0"/>
      <gender>Both</gender>
      <targetEnrolment>1400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1400</totalTarget>
      <exclusion>1. Children who are not permanent residents in the vicinity of the local health centre (distance from home to health centre greater than 7 km)
2. Have severe chronic illnesses such as cerebral palsy
3. Have a history of peanut allergy or anaphylaxis resulting from any food
4. Receive other supplementary food from a government or charitable agency
5. Participating in another research study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Moderate malnutrition</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Unspecified protein-energy malnutrition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Feeding with one of three foods:
1. Ready-to-use milk/peanut fortified spread
2. Ready-to-use soy/peanut fortified spread
3. Corn soy blend

Children will receive isoenergetic amounts of one of the above three foods for up to eight weeks. The amount of food given is sufficient to provide 75 kcal/kg/d. The children will be followed biweekly, having weight, length, and mid-upper arm circumference measured; and the number of days of fever, cough and diarrhoea recorded from caretaker's report. Follow-up is for eight weeks.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nutritional supplements</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17768-0</funderId>
      <funderId>Funder17768-1</funderId>
      <contactId>Contact55744_17768</contactId>
      <sponsorId>Sponsor54314</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55744_17768">
    <title>Prof</title>
    <forename>Mark</forename>
    <surname>Manary</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pediatrics
St. Louis Children's Hospital
One Children's Place
NWT 9109</address>
      <city>St. Louis, MO</city>
      <country>United States of America</country>
      <zip>63110</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">manary@kids.wustl.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54314">
    <organisation>Academy for Educational Development (AED) (USA) </organisation>
    <website>http://www.aed.org/index.cfm</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>1825 Connecticut Ave NW</address>
      <city>Washington, DC</city>
      <country>United States of America</country>
      <zip>20009-5721</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.420327.0</gridId>
    <rorId>https://ror.org/034s15752</rorId>
  </sponsor>
  <funder id="Funder17768-0">
    <name>Academy for Educational Development (AED) (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17768-1">
    <name>Allen Foundation Inc. (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-09T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-05-09T00:00:00.000Z">50181543</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Radiation therapy plus capecitabine and oxaliplatin chemotherapy and bevacizumab anti-angiogenetic therapy in locally advanced rectal cancer</title>
      <scientificTitle>Phase II trial: Pre-operative, long-term chemoradiation with capecitabine, oxaliplatin and bevacizumab in locally advanced rectal cancer</scientificTitle>
      <acronym>BevXelOx-RT</acronym>
      <studyHypothesis>Efficacy of neoadjuvant radio-chemotherapy will be improved by an additional angiogenesis-inhibiting therapy using the vascular endothelial growth factor (VEGF) antibody bevacizumab.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Histopathological complete remission rate at time of surgery (approximately 4 weeks following study treatment)</primaryOutcome>
      <secondaryOutcome>1. Pathological downstaging at time of surgery (approximately 4 weeks following study treatment)
2. Regression grading (according to Dvorak) at time of surgery (approximately 4 weeks following study treatment)
3. Sphincter preservation at time of surgery (approximately 4 weeks following study treatment)
4. Acute and subacute toxicity during study treatment, especially:
4.1. (Post)operative complications
4.2. Gastrointestinal perforation
4.3. Wound healing complications
4.4. Bleeding complications</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Medical Faculty, University of Lübeck. Date of approval: 26/02/2008</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN50181543</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Final 01/12.11.07</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open-label, single-arm, non-randomised, phase II study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="15aad13e-15a1-4a03-8d28-13dd84d8aac1">
	  <name>Universitätsklinikum Schleswig-Holstein</name>
	  <address/>
	  <city>Lübeck</city>
	  <state/>
	  <country>Germany</country>
	  <zip>23538</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age &gt;18 years, both males and females 
2. Patients with histologically proven adenocarcinoma of the rectum, tumour = 16 cm from the anal verge, u T3-4 or uN+ or Mason III/IV, staging will must be done by endorectal ultrasound and magnetic resonance imaging (MRI) or by endorectal unltrasound and high resolution computed tomography, no evidence of metastatic disease 
3. No prior treatment, except for ileostomy (if necessary due to ileus) 
4. No fistulas near the tumour 
5. Eastern Cooperative Oncology Group (ECOG) Performance Status &lt;= 1 
6. Adequate bone marrow, hepatic and renal function: 
6.1. Haemoglobin &gt;10.0 g/dL, leucocyte count &gt; 3.5 x 109/L, absolute neutrophil count &gt;1.5 x 109/L, platelet count &gt;100 x 109/L 
6.2. Alkaline phosphatase, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT) &lt;3 x upper limit of normal (ULN) 
6.3. Total bilirubin &lt;= 2 mg/dL 
6.4. Creatinine clearance &gt;50 mL/min 
6.5. Creatinine &lt;= 1.5 x ULN 
7. Patients must have understood the contents of the protocol and signed written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>68</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68</totalTarget>
      <exclusion>1. No presence of adequate contraception in fertile patients 
2. Pregnant or breastfeeding women 
3. Previous or persistent alcohol or drug abuses 
4. Prior radiotherapy or chemotherapy to the pelvis, for any reason 
5. Treatment with any investigational drug, agent nor procedure, (i.e. did not participate in another trial) within 4 weeks before entry in this trial 
6. Treatment with other anti-cancer agents 
7. Patients not able or willing to comply with the protocol treatment and investigations 
8. Patients with uncontrolled severe somatic or psychological diseases, e.g.: 
8.1. Despite medication uncontrolled cardiac diseases, myocardial infarction within the last 6 months prior to enrolment 
8.2. Neurological or psychiatric disorders including seizures and dementia 
8.3. Active, uncontrolled infection and sepsis 
9. Symptomatic peripheral neuropathy &gt;= grade 2 (National Cancer Institute - Common Terminology Criteria for Adverse Events [NCI CTCAE]) 
10. Concurrent malignancies, with the exception of successfully treated cone-biopsied in situ carcinoma of the cervix or basal cell carcinoma of the skin 
11. Chronic diarrhoea &gt; grade 1 (NCI CTCAE) 
12. Chronic inflammatory bowel disease or other pre-existing condition which would deter resorption of drugs (e.g. dumping syndrome, evidence of accelerated small bowel passage, evidence of deterred resorption due to gastric or bowel surgery) 
13. Known hypersensitivity to platinum-containing drugs 
14. Concurrent use of the antiviral agent sorivudine or chemically related analogues 
15. Known dihydropyrimidine dehydrogenase deficiency 
16. Known allergy to any of the study drugs or its ingredients 
17. Interstitial pneumonia or extensive, symptomatic lung fibrosis 
18. Organ allograft requiring immunosuppressive therapy 
19. Severe, non-healing wounds, ulcers or fractures 
20. Thrombosis or severe bleeding (except for bleeding of the tumour) within 6 months prior to enrolment 
21. Bleeding diathesis or thrombophilia 
22. Therapeutic anticoagulation (with marcumar or heparin) 
23. Acetylsalicylic acid &gt;325 mg per day or routine use of non-steroidal anti-inflammatory drugs which inhibit the function of platelets 
24. Ascites nescessitating puncture 
25. Patients with proteinuria &gt;= 1+ at baseline, as long as a 24&#150;hour urine collection demonstrates &gt;500 mg of protein/ 24 hr 
26. Concurrent treatment with St. John's wort 
27. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the preoperative chemoradiation (exceptions: protective ileostomy and the planned resection of the rectal cancer)</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet.</patientInfoSheet>
      <recruitmentStart>2008-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Locally advanced rectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Malignant neoplasm of rectum</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All participants will receive the following (single-arm study):
1. Radiotherapy: 5 × weekly 1.8 Gy to a total dose of 50.4 Gy 
2. Chemotherapy: Capecitabine 1,650 mg/sqm orally (p.o.), (divided in 2 single doses) daily on days 1-14 and 22-35; oxaliplatin 50 mg/sqm intravenously (i.v.) on days 1, 8, 22, 29 over a 120-min infusion with 500 ml 5% glucose; bevacizumab 5 mg/kg i.v. as short time infusion (30-90 min) prior to oxaliplatin administration on days 1, 15, 29.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Capecitabine, oxaliplatin, bevacizumab.</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17702-0</funderId>
      <funderId>Funder17702-1</funderId>
      <contactId>Contact55674_17702</contactId>
      <sponsorId>Sponsor54248</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55674_17702">
    <title>Prof</title>
    <forename>Jürgen</forename>
    <surname>Dunst</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Universitätsklinikum Schleswig-Holstein
Campus Lübeck
Ratzeburger Allee 160</address>
      <city>Lübeck</city>
      <country>Germany</country>
      <zip>23538 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54248">
    <organisation>University Medical Centre Schleswig-Holstein (Universitätsklinikum Schleswig-Holstein) (Germany)</organisation>
    <website>http://www.uk-sh.de</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Campus Lübeck
Ratzeburger Allee 160</address>
      <city>Lübeck</city>
      <country>Germany</country>
      <zip>23538</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.412468.d</gridId>
    <rorId>https://ror.org/01tvm6f46</rorId>
  </sponsor>
  <funder id="Funder17702-0">
    <name>University Medical Centre Schleswig-Holstein (Universitätsklinikum Schleswig-Holstein) (Germany)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17702-1">
    <name>Roche Pharma AG (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-09T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-05-09T00:00:00.000Z">74887957</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness of a sildenafil citrate suspension for pulmonary hypertension in children: a randomised pragmatic trial</title>
      <scientificTitle>Sildenafil citrate suspension versus sildenafil citrate powder paper for reduction of pulmonary hypertension in children during cardiac catheterisation: a randomised pragmatic trial</scientificTitle>
      <acronym/>
      <studyHypothesis>In Brazil, sildenafil citrate is the most accessible option for the treatment of PH and it is widely used in most hospitals. When licensing sildenafil for treatment of PH, the regulating agency kept it forbidden for people under 18 years old. In the absence of an appropriate pharmaceutical formulation for children, the staff usually crush the tablets to be added to liquid food. However, modifying a commercially available medication may lead to increased toxicity, undesirable side effects, decreased efficacy, poor patient compliance because of the medication&#146;s taste and potential hazards to health care workers. Our study hypothesis is that a compounding suspension made by a pharmacist in controlled conditions will do better than the powder papers used in routine.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The proportion of patients in each group that reduce pulmonary arterial hypertension in at least 20% twenty minutes after the administration of sildenafil citrate 0.2 mg/kg, during cardiac catheterisation.</primaryOutcome>
      <secondaryOutcome>1. At 20 minutes measured by cardiac catheterisation after administration of sildenafil citrate: 
1.1. Pulmonary vascular resistance
1.2. Pulmonary vascular resistance/systemic vascular resistance
1.3. Oxygenation index or oxygen requirement
1.4. Cardiac output
1.5. Mean systemic arterial pressure and surgery indication based on the response to sildenafil
2. At 24 hours: any adverse events
3. At 2 months: cardiac surgery and death</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The project was submitted to the Ethics Committee of the Oswaldo Cruz Foundation (ref: CAAE - 0068.0.011.000-07) and will also be submitted to the Ethics Committee of every participating hospital.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74887957</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised pragmatic double-blind multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="419cebca-aa4d-40ec-9dcf-278af93e74cf">
	  <name>National Instutute of Quality Control in Health</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>21040-900</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children from 0 to 18 years old, either sex
2. Diagnosed as having PH associated with congenital heart disease
3. Needing cardiac catheterisation with sildenafil to evaluate the response to the drug as a decision criteria to cardiac surgery</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="0.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>182</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>182</totalTarget>
      <exclusion>Children will be excluded if:
1. The clinician believes that sildenafil represents an additional risk for the patient
2. The carrier refuses to sign the informed consent</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pulmonary hypertension</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Pulmonary hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Power calculations:
60% of patients reduce at least 20% the mean pulmonary arterial pressure after using powder papers of Sildenafil citrate (SC). To demonstrate that at least 80% of patients would present 20% reduction after using SC suspension with an alpha error of 5% and power of 80% it would be necessary to recruit 182 patients. The pilot intends to recruit 20 patients.

Disease information:
Pulmonary hypertension (PH) is a haemodynamic and clinic disease characterised by a progressive increase of pulmonary vascular resistance and a decrease of pulmonary vascular capacitance leading to right ventricular failure and death. It may occur in isolation (idiopathic pulmonary arterial hypertension) or it may be associated to a variety of systemic disorders (scleroderma, lupus, human immunodeficiency virus [HIV] infection) or cardiopulmonary pathologies such as congenital heart disease. PH is a rare condition and secondary pulmonary arterial hypertension prevalence is less than 0.0001% (statistics about secondary pulmonary hypertension, 2007). Although severe pulmonary arterial hypertension is uncommon, the prognosis of these patients is life threatening and treatment options are limited.

Interventions:
A sildenafil citrate suspension developed from the crushed tablets will be compared with the powder papers usually given to the children.
1. Sildenafil citrate suspension: the suspension will be prepared from both commercially available tablets and sildenafil citrate powder and the formulation must be easy to prepare at hospital pharmacies. The physical, chemical and microbiology stability of this suspension will be accessed simulating in-use conditions and the ones established by Brazilian drug laws.
2. Sildenafil citrate powder papers: the powder papers will be prepared from the crushed commercial tablets and addition of a diluent. The tablets will be sent to a private pharmacy to compound sildenafil citrate 5 mg powder papers (sachets) as it&#146;s already done as a routine.

Both arms will receive sildenafil citrate 0.2 mg/kg as a single dose during cardiac catheterisation.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sildenafil citrate (SC)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17476-0</funderId>
      <funderId>Funder17476-1</funderId>
      <funderId>Funder17476-2</funderId>
      <contactId>Contact55438_17476</contactId>
      <sponsorId>Sponsor54018</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55438_17476">
    <title>Dr</title>
    <forename>Gisele</forename>
    <surname>Huf</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>National Instutute of Quality Control in Health 
Oswaldo Cruz Foundation 
Av. Brasil 4365 
Manguinhos </address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21040-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54018">
    <organisation>National Institute of Quality Control in Health - Oswaldo Cruz Foundation (Brazil)</organisation>
    <website>http://www.incqs.fiocruz.br</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Av. Brasil 4365 
Manguinhos </address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21040-900 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418068.3</gridId>
    <rorId>https://ror.org/04jhswv08</rorId>
  </sponsor>
  <funder id="Funder17476-0">
    <name>Oswaldo Cruz Foundation (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17476-1">
    <name>National Institute of Cardiology (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17476-2">
    <name>Pharmaceutical Industrial Technology Lab from Federal University of Rio de Janeiro (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-03T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-05-08T00:00:00.000Z">14318565</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Stellate ganglion block reduces hot flushes and night awakenings in breast cancer survivors: a pilot study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypothesis is that stellate ganglion block decreases hot flushes and night awakenings in breast cancer survivors. The current project is to prove that hypothesis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Hot flush qualitative scores - mild to very severe
2. Quantitative hot flush occurrences per day 
3. Night awakening per night

Data was collected before the intervention and daily after the intervention for 12 weeks.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Alexian Brothers Hospital Network Institutional Review Board on the 5th October 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14318565</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, single-centre, single arm, non-placebo controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="23ec54b9-a4d3-4ac6-979b-536328b34c7d">
	  <name>2260 W. Higgins Rd.</name>
	  <address/>
	  <city>Hoffman Estates</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>60195</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 30 - 70 year old female breast cancer survivors 
2. American Society of Anaesthesiologists (ASA) scores 3 or below</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>13</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>13</totalTarget>
      <exclusion>Does not comply with the above inclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hot flushes, night awakenings</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Menopausal and other perimenopausal disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention used was a stellate ganglion block at C6. Each patient had 1 - 2 blocks depending on the patient. Follow up was from before treatment to 12 weeks post-initial treatment. Observed occurrences were documented before and after intervention.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18485819 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f609d73a-eb5f-40de-b5bb-8541aa578339" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18485819"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17726-0</funderId>
      <contactId>Contact55700_17726</contactId>
      <sponsorId>Sponsor54272</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55700_17726">
    <title>Dr</title>
    <forename>Eugene</forename>
    <surname>Lipov</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>2260 W. Higgins Rd.
Ste. 101</address>
      <city>Hoffman Estates</city>
      <country>United States of America</country>
      <zip>60195</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54272">
    <organisation>Advanced Pain Centers (USA)</organisation>
    <website>http://www.painmngt.com/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>2260 W. Higgins Rd.
Ste 101</address>
      <city>Hoffman Estates</city>
      <country>United States of America</country>
      <zip>60195</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17726-0">
    <name>Investigator initiated and funded (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-01T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-05-01T00:00:00.000Z">87018843</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of pyschosocial treatment by a case manager in patients after a suicide attempt</title>
      <scientificTitle>Effect of proactive psychosocial treatment by the case manager in patients after a suicide attempt: a randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Compared with usual care, intervention group will: 
1. Improve treatment attendance
2. Have less repeated suicide attempts in adults after an initial suicide attempt
3. Have better satisfaction with care</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Treatment adherence, defined as outpatient mental health clinic attendance at 6 and 12 month.</primaryOutcome>
      <secondaryOutcome>The following will be assessed during follow-up periods (6 and 12 month): 
1. Number of suicide attempts (behaviour) 
2. Suicidal ideation
3. Depression score
4. Patients' satisfaction with care</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Mackay Memorial Hospital Institutional Review Board in November 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87018843</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NSC96-2314-B195-011</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Taiwan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="428660c7-3465-4ca8-8026-bba9bcb766aa">
	  <name>Department of Psychiatry</name>
	  <address/>
	  <city>Taipei County</city>
	  <state/>
	  <country>Taiwan</country>
	  <zip>25115</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients who will be discharged from an emergency department of a teaching hospital after a suicide attempt
2. Aged above 18 years old, both men and women
3. Agree to provide written inform consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Patients who are too ill to be interviewed
2. Patients who have immediate and severe suicide risk</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Suicide attempts</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>N/A</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
 
The control group will receive "treatment as usual", which in most cases consists of consultation with an on-site social worker or a psychiatrist at the Emergency Room, provision of a self-help leaflet and referral to a psychiatrist.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17676-0</funderId>
      <contactId>Contact55647_17676</contactId>
      <sponsorId>Sponsor54222</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55647_17676">
    <title>Dr</title>
    <forename>Shen-Ing</forename>
    <surname>Liu</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychiatry
Mackay Memorial Hospital 
No 45
Ming-Shan Road
Tam-Shu
Chu-Wui</address>
      <city>Taipei County</city>
      <country>Taiwan</country>
      <zip>25115</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54222">
    <organisation>National Science Council (Taiwan)</organisation>
    <website>http://web.nsc.gov.tw/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>No. 106
HoPing E Road
Sec 2
Taipei 10622</address>
      <city>Taipei County</city>
      <country>Taiwan</country>
      <zip>25115</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410767.3</gridId>
    <rorId>https://ror.org/02kv4zf79</rorId>
  </sponsor>
  <funder id="Funder17676-0">
    <name>National Science Council (Taiwan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-04-30T00:00:00.000Z">86684957</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of education about pain on illness perceptions in patients with fibromyalgia: a randomised clinical trial with a six-month follow up</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does giving written information about pain and the sensitisation model influence illness perceptions and health status in patients with fibromyalgia? 

Hypothesis: 
Educating patients about pain physiology is effective in changing patients' negative and catastrophising perceptions about their pain and possibly has an indirect de-sensitising effect on the central nervous system.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. The 'rumination' subscale of the PCS 
2. The 'consequences' and the 'psychological attributions' subscales of the IPQ-R

All outcomes will be measured at the same times: at the start of the study, after three weeks, six weeks, and six months.</primaryOutcome>
      <secondaryOutcome>1. The FIQ total score
2. The 'magnification' and 'helplessness' subscales of the PCS
3. The 'identity, 'timeline', 'personal control', 'treatment control', 'illness coherence', 'timeline cyclical', 'emotional representations', 'risk factor attribution', 'immune attribution', 'chance attribution' and 'fibromyalgia specific attribution' subscales of the IPQ-R 

All outcomes will be measured at the same times: at the start of the study, after three weeks, six weeks, and six months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Medical Ethical Committee of University Hospital Antwerpen (Belgium) in October 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86684957</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre randomised single-blind controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2d67a8e8-abf9-411d-b55b-ac8b5f622002">
	  <name>Eyssoniusplein 18</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9714 CE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with fibromyalgia according to the diagnostic criteria by the American College of Rheumatology, both men and women.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200 participants in total, 100 in the intervention group (information about sensitisation) and 100 in the control group (information about relaxation)</totalTarget>
      <exclusion>1. Age under 18 or over 65 years
2. Non-Dutch speaking
3. Pregnant during study period</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-10-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fibromyalgia syndrome, chronic pain, patient education</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Soft tissue disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants in the intervention group receive written information about pain (aetiology, physiology) and central sensitisation, either by email or postal. After two weeks every participant gets a phone call from one of the investigators to ask if the participant received and read the information, to motivate to do so when necessary and to give the participant the possibility to ask questions about the written information. Besides this phone call, every participant can ask questions to the investigators (electronic or by post) about interpretation of the written information and about how to apply this in daily living, with a maximum of two times of contacting the investigators. Patients get a fixed number of weeks (six) to read and absorb the information, to ask questions about it and to incorporate it in their daily lives. 

Participants in the control group receive written information about the possible effects of relaxation exercise and education about how to perform such exercises. The procedures for participants in the control group are exactly the same as for those in the intervention group (one phone call, maximum of two times asking questions, six weeks to read and absorb the information and to ask questions).

Measures: 
1. Fibromyalgia Impact Questionnaire (FIQ)
2. Pain Catastrophising Scale (PCS)
3. Revised Illness Perception Questionnaire (IPQ-R)

The intervention starts after three weeks and lasts for six weeks.

Joint sponsor/affiliation:
University of Applied Sciences Groningen (The Netherlands)
c/o Miriam van Ittersum
Eyssoniusplein 18
9714 CE Groningen
The Netherlands</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17624-0</funderId>
      <funderId>Funder17624-1</funderId>
      <contactId>Contact55595_17624</contactId>
      <sponsorId>Sponsor54170</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55595_17624">
    <title>Mrs</title>
    <forename>Miriam</forename>
    <surname>van Ittersum</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Eyssoniusplein 18</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9714 CE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54170">
    <organisation>University of Antwerp (Belgium)</organisation>
    <website>http://www.ua.ac.be/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Jo Nijs
Keizerstraat 15</address>
      <city>Antwerpen </city>
      <country>Belgium</country>
      <zip>2000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5284.b</gridId>
    <rorId>https://ror.org/008x57b05</rorId>
  </sponsor>
  <funder id="Funder17624-0">
    <name>Hanze University Groningen (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17624-1">
    <name>University of Antwerp (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-04-29T00:00:00.000Z">00260427</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>TransNasal Insufflation for obstructive sleep apnoea (OSA)</title>
      <scientificTitle/>
      <acronym>TNI</acronym>
      <studyHypothesis>H1: Transnasal insufflation (TNI) will reduce significantly the apnoea/hypopnoea index (AHI) and the arousal index (ArI) in newly diagnosed patients with obstructive sleep apnoea (OSA). Apnoeas and hypopnoeas will be examined separately in post hoc analyses. The first hypothesis will be assessed by comparing the AHI at each overnight visit (diagnostic and TNI) employing a paired t-test. If significant findings are obtained, paired t-tests will be employed to examine separately apnoeas and hypopnoeas. 

H2: Patients will rate the comfort of TNI and their confidence to use the device nightly. Hypothesis two will be assessed by collating comfort ratings and examining them visually. These ratings will also be correlated with adherence data. 

H3: Adherence to TNI will be better than historical averages of positive airway pressure (PAP) adherence (e.g., four hours per night). Hypothesis three will be assessed by collating adherence monitoring and comparing these data to historical controls on PAP.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>There are four primary dependent variables for this study: 
1. AHI
2. Arousal index
3. Treatment adherence, and
4. Perception of treatment

AHI and arousal index will be monitored with overnight PSG and comparisons will be made between the baseline, diagnostic PSG and the two PSGs with TNI (initiation and termination). TNI adherence will be monitored objectively by equipping the TNI device with an objective monitor of use time. This will be accomplished using a small infra-red sensor that will be mounted to the cannula and worn by the patient when TNI is operating. The signal will be sent to a Palm Pilot where the objective compliance data will be recorded and downloaded. Adherence is a complicated variable and, if not normally distributed, may be categorised based upon accepted definitions. In such a case, these categories would be employed as dependent measures of this outcome variable (e.g., percentage patients averaging four hours/night and six hours/night). All participants will be informed that adherence will be monitored to reduce deception. Adherence will be compared to historical controls with PAP therapy. Comfort ratings will be obtained along with patient preference during the course of the study, including with PAP on those participants agreeing to be followed with traditional treatment. Comfort ratings will also be correlated with adherence as a validation of the comfort scale. We will also incorporate measures of self-efficacy for OSA treatment. Self-efficacy has been a strong predictor of long-term adherence and will provide insight into one potential mediator of adherence across conditions.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Allendale Investigational Review Board on the 6th December 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN00260427</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MR-0739-TNI-SS</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single site, efficacy, proof of concept trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-12T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-12T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f6b02bb1-53da-44b4-bc26-3f658158a96b">
	  <name>1505 Commonwealth Ave</name>
	  <address/>
	  <city>Brighton</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>02135</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 21 - 65 years, either sex
2. Diagnosis of OSA with a baseline AHI between 15 and 50 events/hour of sleep
3. Able and willing to provide written informed consent
4. English speaking</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Participation in another interventional research study within the last 30 days
2. Major controlled or uncontrolled medical condition such as congestive heart failure, neuromuscular disease, renal failure etc.
3. Prior PAP use or treatment for OSA, excluding split-night PAP exposure
4. Chronic respiratory failure or insufficiency with suspected or known neuromuscular disease, moderate or severe chronic obstructive pulmonary disease (COPD), or any condition with an elevation of arterial carbon dioxide levels while awake (PaCO2 greater than or equal to 55 mmHg)
5. Presence of untreated, non-OSA related sleep disorders, e.g., moderate to severe restless legs (Periodic Limb Movement Index [PLMI] greater than or equal to 10) or insomnia
6. Body mass index (BMI) greater than 40 kg/m^2. Most subjects will have a BMI less than or equal to 35 kg/m^2 but we will include a small subset of subjects with a BMI greater than 35 kg/m^2 but less than or equal to 40 kg/m^2.
7. Severe sleepiness (automobile accident or near accident in the last 12 months due to sleepiness)
8. Severe oxygen desaturation on the polysomnography (PSG) (oxygen saturation [Sa02] less than 70% for 10% of the diagnostic PSG study)
9. Surgery of the upper airway, nose, sinus or middle ear within the past 90 days
10. Currently using supplemental oxygen
11. Regular use of sleeping pills or stimulants
12. Currently working night shift or rotating day/night shift

There will be no exclusion based on gender, race or ethnicity.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-12T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obstructive sleep apnoea</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Sleep disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is a within-subjects study of the efficacy of TNI at reducing sleep disordered breathing (SDB) in participants with newly diagnosed sleep apnoea. Thirty participants with diagnosed OSA will be recruited after a standard diagnostic polysomnographic (PSG) study. For the purposes of this study, if a split night study is completed and PAP titration is initiated, subjects will still be considered naive. 

Individuals who agree to participate in the study will be provided TNI during an overnight PSG. TNI will be set at 22 lpm for all participants. PSG acquisition will follow standard guidelines for diagnosis, but TNI will be operative during the TNI PSG. Participants will be questioned as to their perceived comfort and ease of therapy the morning after the TNI PSG. Participants will then be sent home with the device. Contact will be made at one week to assess comfort, ease of use and adherence. The final assessment of comfort, ease of use and adherence will occur between 14 - 30 days with TNI. At the termination of the study the patients will undergo a second standard PSG with TNI in place. TNI will be set at 22 lpm for all participants. PSG acquisition will follow standard guidelines for diagnosis, but TNI will be operative during the TNI PSG. 

Participants will then be referred for standard clinical treatment as clinically indicated by their original diagnostic PSG. Those participants who elect to receive PAP treatment will be asked if they are willing to fill out a similar comfort questionnaire and to have adherence monitored 14 - 30 days after the start of PAP therapy. Willing participants will receive one additional assessment phone call after 14 - 30 days. Their responses to the questions will be recorded for later analysis.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17640-0</funderId>
      <contactId>Contact55611_17640</contactId>
      <sponsorId>Sponsor54186</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55611_17640">
    <title>Dr</title>
    <forename>David</forename>
    <surname>White</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>1505 Commonwealth Ave
4th floor</address>
      <city>Brighton</city>
      <country>United States of America</country>
      <zip>02135</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54186">
    <organisation>Respironics, Inc. (USA) </organisation>
    <website>http://www.respironics.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>1001 Murry Ridge Lane</address>
      <city>Murrysville</city>
      <country>United States of America</country>
      <zip>15668</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417285.d</gridId>
    <rorId>https://ror.org/03kw6wr76</rorId>
  </sponsor>
  <funder id="Funder17640-0">
    <name>Respironics, Inc. (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-16T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-04-16T00:00:00.000Z">50641733</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The efficacy of nasal cavity lavage with a physiological saline solution in prevention of recurrent acute otitis media: a pilot randomised controlled study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We believe that regular nasal irrigation with a physiological saline solution decreases the occurrence of acute otitis media (AOM) and recurrent acute otitis media (rOMA).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of recurrent acute otitis media (rAOM) defined as the occurrence of two distinct episodes of acute otitis media during the 3-month study period.</primaryOutcome>
      <secondaryOutcome>1. Occurrence of 1 episode of acute otitis media during the 3-month study period
2. Occurrence of adverse events</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Comité d'éthique de la recherche du CHU Saint-Justine on the 28th May 2007 (ref: 2510), last amended 8th January 2008.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN50641733</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled pilot project</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3a32ac6b-4934-4eed-9de0-38164299e693">
	  <name>3175 Cote Sainte-Catherine</name>
	  <address/>
	  <city>Montreal</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H3T 1C5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age is between 6 months and 5 years old (exclusively), either sex
2. Recurrent acute otitis media (AOM) (diagnosed by paediatrician or referring general practitioner):
2.1. Four AOM within 6 months
2.2. Six AOM or more within 1 year</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Years" value="5.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Parents refuse to participate
2. Known disease or syndrome modifying the normal anatomy or physiology or the upper respiratory tract (Downs, Apert, Crouzon, mucopolysaccharidosis, cranio-cerebral trauma, etc.)
3. Malformations:
3.1. Craniofacial, skull base or nose 
3.2. Complete or submucous cleft palate
4. Immunodeficiency: 
4.1. Congenital (according to paediatrician or immunologist)
4.2. Acquired (human immunodeficiency virus [HIV], chemotherapy)
5. Ciliary dysfunction (according to paediatrician or pneumologist)
6. Tympanic membrane perforation
7. Cholesteatoma
8. Acute complication of AOM (intra- or extra-cranial)
9. History of ear, nose and throat (ENT) surgery (adenoidectomy, tonsillectomy, myringotomy or other)
10. Intra-nasal or systemic corticosteroid use (pulmonary steroids not excluded)
11. Adenoid or tonsil hypertrophy with suspicion of obstructive apnoea
12. Multiple allergies to antibiotics
13. Insufficient comprehension of written or spoken French by parents</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet.</patientInfoSheet>
      <recruitmentStart>2007-09-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Recurrent acute otitis media</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Otitis media</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group:
Nasal irrigation with a physiological saline solution. A 0.9% saline solution is used.
1. If the child is not capable of blowing his nose: 1 cc (full dropper) per nostril, repeated twice, performed four times a day (QID) or six times daily during a respiratory infection 
2. If the child is capable of blowing his nose: 5 vaporisations per nostril, blow nose and repeat a second time, perform QID or six times daily during a respiratory infection

Control group:
Patients in the control arm do not perform nasal irrigations.

Treatment lasts 3 months and there are two follow-up visits at 6 weeks intervals.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Saline solution</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17446-0</funderId>
      <contactId>Contact55407_17446</contactId>
      <sponsorId>Sponsor53977</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55407_17446">
    <title>Dr</title>
    <forename>Annie</forename>
    <surname>Lapointe</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>3175 Cote Sainte-Catherine </address>
      <city>Montreal</city>
      <country>Canada</country>
      <zip>H3T 1C5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 345 4857 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">annie.lapointe.hsj@ssss.gouv.qc.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53977">
    <organisation>Sainte-Justine Hospital Research Centre (Centre de recherche du CHU Sainte-Justine) (Canada) </organisation>
    <website>http://www.recherche-sainte-justine.qc.ca/en/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>3175 Côte Sainte-Catherine </address>
      <city>Montreal</city>
      <country>Canada</country>
      <zip>H3T 1C5 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 345 4691 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">centre@recherche-ste-justine.qc.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411418.9</gridId>
    <rorId>https://ror.org/01gv74p78</rorId>
  </sponsor>
  <funder id="Funder17446-0">
    <name>Sainte-Justine Hospital Research Centre (Centre de recherche du CHU Sainte-Justine) (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-16T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-04-16T00:00:00.000Z">75232398</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised study with ciprofloxacine in acute pancreatitis</title>
      <scientificTitle>A double-blind, placebo-controlled trial of ciprofloxacin prophylaxis in patients with acute necrotising pancreatitis</scientificTitle>
      <acronym>CIPRONAP</acronym>
      <studyHypothesis>Our aim was to assess the effects of intravenous prophylactic ciprofloxacin in the incidence of infected necrosis and mortality in patients with necrotising pancreatitis, compared to a control population.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To determine whether prophylaxis with intravenous ciprofloxacin could reduce the incidence of infected pancreatic necrosis.</primaryOutcome>
      <secondaryOutcome>Effects on: 
1. Mortality rate
2. Extra-pancreatic infections
3. Surgical treatment, its timing and the re-operation rate
4. Development of organ failure 2 
5. In-hospital as well as intensive care unit (ICU) length of stay</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of the L'Hospitalet de Llobregat (Spain) on the 12th December 1998 (ref: 129/98).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75232398</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CGD001/98</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised, placebo-controlled, double blind study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f773a7ea-2412-4f94-8d57-540b2613f73c">
	  <name>Joan Fabregat</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08907</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All adult patients of either sex:
1. Without previous antibiotic treatment 
2. With detectable pancreatic necrosis in a contrast-enhanced computed tomography (CT) scan 25 performed within 48 - 72 hours of admission</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Antibiotic allergy 
2. Clinical evidence of sepsis on admission</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute pancreatitis</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Acute pancreatitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients with acute pancreatitis suspected to have the severe form of the disease underwent a dynamic contrast-enhanced CT scanning within 48 - 72 hours of admission. When the CT showed a pancreatic necrosis patients signed a written consent, and were randomly assigned to receive one of the below:
1. Prophylactic antibiotic treatment: 300 mg ciprofloxacin every 12 hours for 10 days (n = 22)
2. Placebo (n = 19) 

All patients were treated medically on admission (aggressive fluid resuscitation along with electrolyte imbalance, complete avoidance of oral intake, pain control and total parenteral nutrition). Patients with organ failure were followed in the intensive care unit (ICU). When infected necrosis was clinically suspected, a CT-guided fine-needle aspiration (FNA) followed by a Gram stain and a bacteriologic culture was carried out. If infection could be diagnosed through these procedures, we indicated surgical treatment. Further indications for surgery were: diagnostic doubt, organ failure despite intensive medical treatment and symptomatic sterile necrosis (defined as persistent abdominal pain or inability to eat after 4 to 6 weeks of medical management).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ciprofloxacin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17485-0</funderId>
      <funderId>Funder17485-1</funderId>
      <contactId>Contact55447_17485</contactId>
      <sponsorId>Sponsor54027</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55447_17485">
    <title>Prof</title>
    <forename>Eduardo</forename>
    <surname>Jaurrieta</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Joan Fabregat
Servei de Cirurgia General i Digestiva, 
Unitat Cirurgia Hepatobilio-Pancreàtica i Trasplantament Hepàtic
Hospitalet de Llobregat</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54027">
    <organisation>Hospital Universitari De Bellvitge (Spain)</organisation>
    <website>http://www.csub.scs.es</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Feixa Llarga S.N.
Hopsitalet de Llobregat</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411129.e</gridId>
    <rorId>https://ror.org/00epner96</rorId>
  </sponsor>
  <funder id="Funder17485-0">
    <name>Bellvitge Hospital (Spain)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17485-1">
    <name>No grant nor payment from the pharmaceutical industry.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-11T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-04-11T00:00:00.000Z">94152783</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness, neuropsychological distress, teamwork, and ergonomics with procedures conducted in the i-Suite surgical environment</title>
      <scientificTitle/>
      <acronym>ENTERPRISE</acronym>
      <studyHypothesis>A novel, integrated operating theatre environment (i-Suite™, Stryker) reduces the average or time in trauma, orthopaedic, and visceral procedures (i.e., the time interval from the patient's entry to discharge from the theatre) compared to a modern, conventional operating room by 20 ± SD 50 minutes (equating a moderate Cohen's effect size of 0.4 = 20/50).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time interval from the patient's entry to discharge from the operating theatre.</primaryOutcome>
      <secondaryOutcome>1. Team-centered endpoints, recorded during operation:
1.1. Stress of surgeons, anaesthetists, and scrub nurses in charge, as measured by short questionnaire assessments and biological markers in saliva (cortisol and beta-endorphine) immediately before and after surgery
1.2. Quantity and quality of distracting events (e.g., phone calls, door openings, technical failures)  that may prolong or compromise the procedure 
1.3. Comfort and climate (e.g., space, noise, and others)
1.4. Perceived success of the procedure
1.5. Team interaction

2. Patient-centered endpoints:
2.1. Critical incidents, intra-  and post-operative complications, monitored during hospital stay until discharge 
2.2. Quality of Life (EuroQol [EQ5D]) questionnaire at baseline, discharge and 6 months after surgery (by post)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institutional Review Board of the Charité University Medical Center. Date of approval: 06/02/2008 (ref: EA1/004/08)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN94152783</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ukb_6.1_2008</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0dcee32b-782a-4c9e-b1df-36124c376cf8">
	  <name>Department of Orthopaedic and Trauma Surgery</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>12683</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Consecutive patients &gt;=18 years of age scheduled for orthopedic and/or trauma, or visceral surgery on weekdays between 8.00 am and 4.00 pm (core working hours)
2. Full ability to provide written informed consent
3. Both men and women</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>"Intent to treat" (ITT) population: 2 x 200 patients</totalTarget>
      <exclusion>1. Acute, emergency, or life-saving surgery
2. Refusal of trial participation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>All elective orthopedic and/or trauma, or visceral surgical procedures.</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>N/A</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Experimental intervention: 

General orthopedic (e.g., total joint replacement), trauma, and surgical procedures (e.g., fracture fixation, abdominal and thoracic surgery) conducted in one of two integrated i-Suite operating theatres.

Control intervention: 
A similar range of procedures, conducted in a conventional, last-generation operating theatre.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17652-0</funderId>
      <funderId>Funder17652-1</funderId>
      <contactId>Contact55623_17652</contactId>
      <sponsorId>Sponsor54198</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55623_17652">
    <title>Prof</title>
    <forename>Axel</forename>
    <surname>Ekkernkamp</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Orthopaedic and Trauma Surgery
Unfallkrankenhaus Berlin
Warener Str. 7</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>12683</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">axel.ekkernkamp@ukb.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54198">
    <organisation>Unfallkrankenhaus Berlin Trauma Center (Germany)</organisation>
    <website>http://www.ukb.de</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Warener Str. 7</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>12683</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dirk.stengel@ukb.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.460088.2</gridId>
    <rorId>https://ror.org/011zjcv36</rorId>
  </sponsor>
  <funder id="Funder17652-0">
    <name>Unfallkrankenhaus Berlin Trauma Center (main funding body) (Germany)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17652-1">
    <name>Additional funding will be sought from Stryker (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-11T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-04-11T00:00:00.000Z">42685776</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised controlled trial of oral versus intravenous therapy for clinically diagnosed acute uncomplicated diverticulitis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Acute uncomplicated diverticulitis is a disease where outpouchings or blisters (termed Diverticulae) of the large bowel become inflamed resulting in pain and tenderness in the lower abdomen. Acute uncomplicated diverticulitis is currently treated with antibiotics although whether the antibiotics should be given through the veins or via the mouth is not known. Answering this question may allow treatment of the condition as an outpatient in the future. 

Diverticulosis affects 5% of western society by the fifth decade, its prevalence increasing to over 50% in the ninth. As less than a quarter of acute admissions necessitate surgery, medical therapy remains the mainstay of management in the majority of cases. There are no prospective data to guide the identification of a specific cohort which may be managed with an oral antibiotic regimen, nor the efficacy of a specific antibiotic regimen.

The authors hypothesise that an oral antibiotic and fluid regimen is equally effective as intravenous antibiotics and 'bowel rest' in acute uncomplicated diverticulitis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Resolution of symptoms. Three surrogates were used: 
1. Resolution of left iliac fossa tenderness, assessed by the Wexford tenderness score (a locally validated score), daily assessment while an in-patient
2. Length of stay 
3. Failure of oral therapy (requiring supplemental parenteral therapy). Follow-up: Until confirmatory/ refuting lower gastrointestinal (GI) series (endoscopic or contrast). Where such a test was not performed, follow-up to last out-patient appointment</primaryOutcome>
      <secondaryOutcome>The following were evaluated as potential surrogates for resolution: 
1. Serial erythrocyte sedimentation rate (ESR). Follow-up: Until confirmatory/ refuting lower GI series (endoscopic or contrast). Where such a test was not performed, follow-up to last out-patient appointment
2. C reactive protein (CRP). Follow-up: Until confirmatory/ refuting lower GI series (endoscopic or contrast). Where such a test was not performed, follow-up to last out-patient appointment
3. White cell count (WCC). Follow-up: Until confirmatory/ refuting lower GI series (endoscopic or contrast). Where such a test was not performed, follow-up to last out-patient appointment
4. Temperature charts, daily assessment while an in-patient</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Waterford Regional Ethics Board in 2002.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN42685776</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-centre randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
	<country>Ireland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="005c6fa9-7412-4fcd-ac57-51f1396002c5">
	  <name>Department of Surgical Oncology</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M5G 2M9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients presented with a clinical syndrome of left iliac fossa pain and local tenderness (Hinchey type I and II)
2. Both men and women</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>76</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>76</totalTarget>
      <exclusion>1. Those with complicated Diverticulitis (Hinchey III and IV)
2. Those in Septic Shock
3. Allergies to antibiotics used in the trial
4. Hepatic or Renal insufficiency
5. Diagnosis is not clear 
6. Co-morbid conditions necessitating prolonged hospital stay   
7. Pregnant women or women who are breast feeding</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute uncomplicated diverticulitis</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Diverticular disease of intestine</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two intervention arms: 
Intravenous arm: Intravenous ciprofloxacin (400 mg twice a day [BID]) and metranidazole (500 mg three times a day [TID]) with bowel rest for at least the first 24 hours. 
Oral arm: Oral ciprofloxacin (500 mg BID) and metranidazole (400 mg TID) without complete bowel rest.

Duration of the interventions was equivalent to the length of stay, with a maximal antibiotic duration decided by the attending physician, typically 7-10 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ciprofloxacin and metranidazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17628-0</funderId>
      <contactId>Contact55599_17628</contactId>
      <sponsorId>Sponsor54174</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55599_17628">
    <title>Dr</title>
    <forename>Paul</forename>
    <surname>Ridgway</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgical Oncology
Room 3-130
Princess Margaret Hospital
610 University Ave</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 2M9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54174">
    <organisation>Wexford General Hospital (Ireland)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Surgery </address>
      <city>-</city>
      <country>Ireland</country>
      <zip>Wexford</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417080.a</gridId>
    <rorId>https://ror.org/00bbdze26</rorId>
  </sponsor>
  <funder id="Funder17628-0">
    <name>Wexford General Hospital, Department of Surgery (Ireland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-08T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-04-08T00:00:00.000Z">13994081</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of tempe and vitamin C rich fruit supplementation during pregnancy on iron status and pregnancy outcomes</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does food-based intervention using tempe and vitamin C rich fruit during pregnancy improve the iron status?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Maternal iron status at gestation 12-20 week: 
1. Haemoglobin
2. Ferritin
3. Soluble transferrin receptors</primaryOutcome>
      <secondaryOutcome>1. Infectious status at gestation 12-20 weeks and 32-36 weeks: 
1.1. C-reactive protein
1.2. A-1 acid glycoprotein
2. Helminth infestation (hookworms, A.lumbricoides, T.trichiura) measured quantitatively (eggs per gram) at gestation 12-20 weeks and 32-36 weeks
3. Gestational age calculated from date of last menstruation and palpation
4. Weight gain of pregnant women and birth weight of infant will be measured with electronic weighing scale
5. Length of infant will be measured with length board
6. Complication deliveries/fetal loss will be measured with verbal autopsy interviews, less than 3 days after delivery</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical Committee for Studies on Human Subjects, Faculty of Medicine, University of Indonesia. Date of approval: 19/02/2007 (ref: 49/PTO2.FK/ETIK/2007)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13994081</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled single-centre trial (unit of randomisation: village).</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Indonesia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ff985f2a-ef4a-4a94-9eb0-c4cf6b623b48">
	  <name>Seameo-Tropmed RCCN-UI</name>
	  <address/>
	  <city>Jakarta</city>
	  <state/>
	  <country>Indonesia</country>
	  <zip>10430</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Pregnant women, gestation 12-20 weeks
2. Age 15-49 years
3. No existing severe maternal illness</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>1. Suffer from chronic disease
2. In medication/antibiotic treatment
3. Do not sign inform consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Anaemia during pregnancy</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The participating villages will be randomly allocated to the following two groups: 

Supplementary group will receive supplementary food, 400 mg albendazole, and health and nutrition
education. The average weekly supplementary food consist of: 600 g tempe (fermented soybean), 30 g red meat/dried anchovy/chicken liver, 45 g soy sauce, 350 g guava, 300 g papaya and 100 g orange. Supplementary food will be given daily at 12-20 week of gestation until delivery at home. 

Control group will receive 400 mg albendazole only.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Tempe and albendazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16910-0</funderId>
      <contactId>Contact54871_16910</contactId>
      <sponsorId>Sponsor53429</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54871_16910">
    <title>Mrs</title>
    <forename>Maria</forename>
    <surname>Wijaya-Erhardt</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Seameo-Tropmed RCCN-UI 
Jl. Salemba Raya 6</address>
      <city>Jakarta</city>
      <country>Indonesia</country>
      <zip>10430</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+62 21 3914017</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mwijaya@seameo-rccn.org</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53429">
    <organisation>Nestle Foundation (Switzerland)</organisation>
    <website>http://www.nestlefoundation.org</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>4, Place de la Gare
PO BOX 581</address>
      <city>Lausanne</city>
      <country>Switzerland</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 21 320 33 51</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">nf@nestlefoundation.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.483854.6</gridId>
    <rorId>https://ror.org/021k07d19</rorId>
  </sponsor>
  <funder id="Funder16910-0">
    <name>Nestle Foundation (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-08T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-04-08T00:00:00.000Z">00203325</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Ultrasound guided jugular vein cannulation</title>
      <scientificTitle>Internal jugular vein cannulation using ultrasound guidance: a prospective randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Real time ultrasound guided cannulation of the internal jugular vein (IJV) is more efficient than catheterisation using ultrasound located landmarks.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Success rate of cannulation, attempts less than or equal to three by the same operator.</primaryOutcome>
      <secondaryOutcome>1. Number of tries
2. Time to complete cannulation
3. Immediate complications (assessed by the operator and his assistance)
4. Place of the catheter using x-ray just after cannulation (assessed by a radiologist)
5. Early complications, measured at days 1, 2 and 5 post cannulation (assesed by a senior surgeon)
6. Later complications (late infections and obstruction of catheters&#146; "life" up to six months, assesed by a physician and/or a senior nurse)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from "Attikon" Hospital Ethics Committee on the 23rd January 2004 (ref: AP. 420/CP "ATTIKON" Hospital).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN00203325</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Greece</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="20ca28e4-9682-4c63-a266-a5e674c3956e">
	  <name>"Attikon" Hospital</name>
	  <address/>
	  <city>Athens</city>
	  <state/>
	  <country>Greece</country>
	  <zip>124 10</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients of the "Attikon" Hospital, in General Surgery, Oncology and Haematology Departments
2. Males and females, from 18 - 80 years of age</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="80.0"/>
      <gender>Both</gender>
      <targetEnrolment>556</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>212 - 556</totalTarget>
      <exclusion>Patients with internal jugular vein thrombosis.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Jugular vein cannulation</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Cannulation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients who need an internal jugular vein catheter are randomised, using sealed envelopes, in two groups:
Group A (real time ultrasound [U/S]): IJV Cannulation using real time ultrasound 
Group B (U/S located landmarks): IJV cannulation using ultrasound located landmarks

Patients with IJV thrombosis were excluded. The success rate of cannulation was measured (attempts less than or equal to three by the same operator), along with the duration of time until successful cannulation and complications.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17622-0</funderId>
      <contactId>Contact55593_17622</contactId>
      <sponsorId>Sponsor54168</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55593_17622">
    <title>Prof</title>
    <forename>Theodore</forename>
    <surname>Liakakos</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>"Attikon" Hospital
3rd Academic Department of Surgery
Haidari</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>124 10</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">theodlia@otenet.gr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54168">
    <organisation>"Attikon" Teaching Hospital (Greece) - University of Athens </organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>1 Rimini Str
Haidari</address>
      <city>Athens</city>
      <country>Greece</country>
      <zip>124 10</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gchklin@med.uoa.gr</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411449.d</gridId>
    <rorId>https://ror.org/03gb7n667</rorId>
  </sponsor>
  <funder id="Funder17622-0">
    <name>"Attikon" Teaching Hospital (Greece) - University of Athens</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-02T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-04-02T00:00:00.000Z">23817011</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Laparoscopic-assisted or -facilitated sigmoidectomy for diverticulitis? A prospective randomised trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Laparoscopic assisted and facilitated sigmoidectomy result in equivalent postoperative outcomes.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Cumulative consumption of piritramid administered over 96 hours using a Patient Controlled Analgesia (PCA) protocol</primaryOutcome>
      <secondaryOutcome>1. The course of postoperative analgesic consumption over 7 days. 
2. Amount of postoperative pain and fatigue. Pain was evaluated daily using a visual analogue scale. It was documented once daily starting on the day prior to surgery and then in the morning of each postoperative day. Fatigue was also measured using a visual analogue scale. Fatigue was measured preoperatively and on days 3, 5, 7, 21 and 42 after surgery. 
3. Resumption of bowel activity - the time-point of first passage of flatus and the first passage of stool were documented. 
4. Pulmonary function, assessed by measuring Forced Vital Capacity (FVC) and forced expiratory volume in 1 second (FEV1) with a mobile spirometer (Renaissance®, Nellcor Puritan Bennett). Pulmonary function was measured the day before surgery and on days 2, 3, 5, and 7. The postoperative data on pulmonary function for each patient were calculated in relation to the preoperative values. 
5. Quality of life, measured using the Gastrointestinal Quality of Life Index. It was determined preoperatively, and on days 7, 21, 42 and after one year after surgery. 
6. Satisfaction with the cosmetic result, evaluated using the Body Image Questionnaire. The evaluation was performed at one year after surgery.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the University of Cologne (ref: 04004)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23817011</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>04004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, unblinded, single-centre, randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7a142e92-8646-4178-be67-bb98cf21d63c">
	  <name>Clinic of Abdominal and General Surgery</name>
	  <address/>
	  <city>Mainz</city>
	  <state/>
	  <country>Germany</country>
	  <zip>55131</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Indication for elective sigmoidectomy for diverticulitis</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>1. Proven or suspected malignancy
2. Prior major abdominal surgery performed through a midline incision
3. Diverticulitis in association with fistula and abscesses (if diagnosed preoperatively)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diverticulitis of the sigmoid colon</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Diverticular disease of intestine</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: Laparoscopic assisted sigmoidectomy with extraction of the specimen via a 5 cm mini-incision in the lower left abdomen 
Group 2: Laparoscopic facilitated sigmoidectomy with laparoscopic mobilisation of the sigmoid colon and conventional resection and anastomosis via a 10-12 cm transverse suprapubic incision</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17387-0</funderId>
      <contactId>Contact55348_17387</contactId>
      <sponsorId>Sponsor53918</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55348_17387">
    <title>Dr</title>
    <forename>Andreas D</forename>
    <surname>Rink</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinic of Abdominal and General Surgery
Johannes Gutenberg University
Langenbeckstr. 1</address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>55131</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)6131 1739 76</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andreas.rink@ukmainz.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53918">
    <organisation>Individual Sponsor (Germany)</organisation>
    <website/>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>Dr. Andreas D. Rink &amp; Prof. Dr. Karl-Heinz-Vestweber
Leverkusen General Hospital
Department of General Surgery
Teaching Hospital of the University of Cologne
Am Gesundheitspark 5</address>
      <city>Leverkusen</city>
      <country>Germany</country>
      <zip>51375 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17387-0">
    <name>Leverkusen General Hospital, University of Cologne (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-02T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2008-04-02T00:00:00.000Z">08109872</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled study of patients seen in a special nurse-led clinic after gastroscopy investigation for symptoms related to indigestion</title>
      <scientificTitle>A randomised controlled trial of structured nurse-led clinic follow-up for dyspeptic patients after direct access gastroscopy</scientificTitle>
      <acronym/>
      <studyHypothesis>The aim is to study patients with a confirmed endoscopic diagnosis of the following: 
1. Mild gastro oesophageal reflux disease (non-erosive and mild oesophagitis)
2. Hiatus hernia (any size)
3. Non-ulcer dyspepsia (normal findings, mild or moderate gastritis and duodenitis)

Study hypothesis: 
An experienced gastrointestinal nurse practitioner providing structured patient-centred advice at follow-up clinic after gastroscopy to patients with mild dyspepsia, would reduce drug costs without adversely affecting symptoms relief or quality of life.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The difference between the nurse group and GP group after intervention in: 
1. GLADYS: 8 questions and a total low score equals to least symptoms with a minimum of 0 and maximum 20
2. SF-12: Six questions (3 have 2 parts and 1 has 4 parts). A total high score in this measurement denotes better health related general well being with a minimum 0 and maximum 900
3. UHD costs 6 months before and after gastroscopy. The UHD cost analysis is based on the price listed in the Drug Tariff (generic items) or MIMS (branded items). They are summed according to class and averaged.</primaryOutcome>
      <secondaryOutcome>Compares before and after intervention within same group in: 
1. GLADYS
2. SF-12
3. UHD costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Southampton &amp; South West Hampshire Research Ethics Committees (B). Date of approval: 22nd March 2002 (REC reference: 050/02)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08109872</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RHM MED0719</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, randomised, placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d0ea9226-f705-4b03-8817-40766e0e1846">
	  <name>Southampton University Hospital NHS Trust</name>
	  <address/>
	  <city>Southampton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SO16 6YD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female patients with dyspepsia
2. Over 18 years old
3. Undergoing direct access gastroscopy</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>186</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>186</totalTarget>
      <exclusion>There are 2 stages of filtering for exclusion as follows: 
1. Before gastroscopy - From referral letters/forms patients with sinister symptoms: 
1.1. Anaemia 
1.2. Weight loss over half a stone in three months 
1.3. Haematemesis 
1.4. Dysphagia 
1.5. Vomiting 
2. After gastroscopy: 
2.1. Peptic ulcer 
2.2. Tumour 
2.3. Severe oesophagitis 
2.4. Barrett's oesophagus 
2.5. Anatomical abnormality and 
2.6. Post-operative stomach</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gastroscopy</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>gastroscopy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is a randomised placebo-controlled trial with concealed allocation (random number table) of study cohorts. Post-intervention assessor is blinded to diagnosis and study status.

Baseline data collection: 
1. Demography
2. Body mass index (BMI)
3. Social habit status 
4. Ulcer healing drugs (UHD; Histamine 2 antagonist, proton pump inhibitor) used in the 6 months before investigation
5. Glasgow dyspepsia severity score (GLADYS) 
6. Health related general well being (12-item short form health survey [SF-12])
 
After gastroscopy, eligible patients are randomised to either normal (control) practice (return to GP for follow-up treatment) or intervention (to nurse follow-up). 

The nurse-led clinic last for 35 minutes and a full medical history is taken. The clinical management is based on national and local guidelines, with reference to findings as well as patients' predominant symptoms. Counselling and lifestyle advice, including bespoke information leaflets given and treatment concordance agreed; further investigation may be initiated if required. For consistency and reproducibility 'History taking' and 'Lifestyle advice' proformas are devised for use. Clinic letter with information on intervention and treatment recommendations is sent to patients' GP after consultation. 

Six months after gastroscopy all patients are contacted by telephone for reassessment of the following:
1. Weight
2. GLADYS
3. SF-12
4. UHD used in the six months after gastroscopy
5. Usefulness of post-investigation follow-up</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16531518 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0960757a-5f86-4583-ae26-43f6251065e0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16531518"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17560-0</funderId>
      <contactId>Contact55522_17560</contactId>
      <sponsorId>Sponsor54106</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55522_17560">
    <title>Dr</title>
    <forename>Praful</forename>
    <surname>Patel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Southampton University Hospital NHS Trust
Department of Gastroenterology
Level D
West wing</address>
      <city>Southampton</city>
      <country>United Kingdom</country>
      <zip>SO16 6YD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54106">
    <organisation>Southampton University Hospitals NHS Trust (UK)</organisation>
    <website>http://www.suht.nhs.uk</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Research and Development Department
Trust Management Office
Mailpoint 18
Treamona Road</address>
      <city>Southampton</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>SO16 6YD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.430506.4</gridId>
    <rorId>https://ror.org/0485axj58</rorId>
  </sponsor>
  <funder id="Funder17560-0">
    <name>This study was investigator-funded with the agreement of the Southampton University Hospital NHS Trust that secretarial and out-patient work force can be utilised as long as it is planned into routine work.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-26T00:00:00.000Z">63412511</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of a three-month course of rosuvastatin in patients with Systemic Lupus Erythematosus</title>
      <scientificTitle/>
      <acronym>Rosuvastatin in SLE</acronym>
      <studyHypothesis>Systemic lupus erythematosus (SLE) is a rheumatologic multi-systemic auto-immune disease particularly affecting joints, skin and kidneys. The aim of this trial was to investigate the effects of rosuvastatin on markers of lipid metabolism and inflammatory parameters in patients with SLE.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Measured at baseline and after three months of treatment:
1. Total cholesterol 
2. Low density lipoprotein (LDL) cholesterol
3. C-reactive protein (CRP)
4. Tumour necrotising factor (TNF)</primaryOutcome>
      <secondaryOutcome>Measured at baseline and after three months of treatment:
1. Interleukin-6 (IL6), interleukin-10 (IL10), interleukin-8 (IL8)
2. Complement C3 and C4q
3. Anti-double stranded deoxyribonucleic acid (anti-dsDNA)
4. Urine protein</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethical Committee of the Slotervaart Hospital (The Netherlands) on the 29th November 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63412511</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, open-labelled, cross-over study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d60ff033-707e-4bb9-a5f6-3d5f440df5ec">
	  <name>Department of Internal Medicine</name>
	  <address/>
	  <city>Maastricht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6229 HX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with chronic, non-acute SLE
2. Greater than 18 years old, either sex</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>19</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>19</totalTarget>
      <exclusion>1. Use of statins
2. Pregnancy
3. Raised liver enzymes
4. Recent (less than three months) major surgery or myocardial infarction</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systemic lupus erythematosus</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Systemic lupus erythematosus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Rosuvastatin 10 mg once daily.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosuvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17593-0</funderId>
      <contactId>Contact55560_17593</contactId>
      <sponsorId>Sponsor54139</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55560_17593">
    <title>Prof</title>
    <forename>Hugo</forename>
    <surname>ten Cate</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Internal Medicine
Academisch Ziekenhuis Maastricht</address>
      <city>Maastricht</city>
      <country>Netherlands</country>
      <zip>6229 HX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">H.Tencate@BIOCH.unimaas.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54139">
    <organisation>AstraZeneca (The Netherlands)</organisation>
    <website>http://www.astrazeneca.nl</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Postbus 599</address>
      <city>Zoetermeer</city>
      <country>Netherlands</country>
      <zip>2700 AN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)79 363 2222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info.nl@astrazeneca.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476086.b</gridId>
    <rorId>https://ror.org/021tmn508</rorId>
  </sponsor>
  <funder id="Funder17593-0">
    <name>AstraZeneca (The Netherlands) - unrestricted research grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-26T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-03-26T00:00:00.000Z">52111135</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of three diagnostic tools for latent tuberculosis in haemodialysis patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Latent tuberculosis is hard to diagnose in immunocompromised hosts like haemodialysis patients, and widespread bacille calmette-guerin (BCG) vaccination make it complicated to interpretate Mantoux test results in Korea. Therefore, we need more sensitive and specific diagnostic tools for latent tuberculosis in haemodialysis patients. 

Hypothesis:
T-spot assay or Quantiferon assay is more sensitive and specific than Mantoux test for latent tuberculosis in haemodialysis patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Skin test: positive or negative
2. Quantiferon-gold: positive or negative
3. T-spot test: positive or negative

These outcomes will be measured on the day of testing.</primaryOutcome>
      <secondaryOutcome>1. Skin test: size of induration
2. Quantiferon-gold: concentration
3. T-spot test: number, mean area

These outcomes will be measured on the day of testing.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board (IRB) of Gachon University of Medicine and Science on the 28th February 2008 (ref: 20080228 tuberculosis in haemodialysis).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52111135</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, observational, cross-sectional, open trial</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cross-section survey</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Korea, South</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f7590e94-2e99-4147-96a9-86319001fdd7">
	  <name>Division of Nephrology</name>
	  <address/>
	  <city>Incheon</city>
	  <state/>
	  <country>Korea, South</country>
	  <zip>405-760</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Chronic maintenance haemodialysis patients who continue to receive haemodialysis for more than three months in the Gil Medical Centre
2. Older than 18 years, and less than 80 years, either sex
3. Agrees to participate in this trial
4. Medical staff in the haemodialysis centre of the Gil Medical Centre</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="80.0"/>
      <gender>Both</gender>
      <targetEnrolment>162</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>162</totalTarget>
      <exclusion>1. Patients who suffer from skin diseases which may interfere with Mantoux test
2. Patients with an active infection, except tuberculosis
3. Patients who cannot make independent decision due to mental disorders</exclusion>
      <patientInfoSheet>Not available in web format, please contact Jaeseok Yang at jcyjs@hanafos.com to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Latent tuberculosis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Agreement of three diagnostic tests for latent tuberculosis will be tested in haemodialysis patients. Blood samples are taken for:
1. Quantiferon-gold assay, an enzyme linked immunosorbent assay (ELISA) assay for interferon gamma in response to tuberculosis specific antigens
2. T-spot assay, an enzyme-linked immunosorbent spot (ELISPOT) assay for interferon gamma

After sampling, the Mantoux test will be performed, and the results will be read in two days. Agreement of three test results will be analysed using kappa coefficients, and results will be analysed per each categories of risk groups such as low risk group, casual contact group, latent tuberculosis patients, and active tuberculosis patients. Agreement will be also analysed in medical staff group with normal immunity.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17617-0</funderId>
      <contactId>Contact55587_17617</contactId>
      <sponsorId>Sponsor54163</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55587_17617">
    <title>Prof</title>
    <forename>Jaeseok</forename>
    <surname>Yang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Division of Nephrology
Department of Internal Medicine
Gil Medical Center
1198 Guwol-dong
Namdong-gu</address>
      <city>Incheon</city>
      <country>Korea, South</country>
      <zip>405-760</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54163">
    <organisation>Gachon University of Medicine and Science (South Korea)</organisation>
    <website>http://home.gachon.ac.kr/icc/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Institutional Review Board (IRB)
Department of Pharmacy
Gil Medical Centre
1198 Guwol-dong
Namdong-gu</address>
      <city>Incheon</city>
      <country>Korea, South</country>
      <zip>405-760</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.256155.0</gridId>
    <rorId>https://ror.org/03ryywt80</rorId>
  </sponsor>
  <funder id="Funder17617-0">
    <name>Gachon University of Medicine and Science (South Korea) - Division of Nephrology, Department of Internal Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">11431649</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>25- versus 29-gauge Quincke spinal needles</title>
      <scientificTitle>Comparison of 25- versus 29-gauge Quincke spinal needles for minor anorectal surgery as well as abdominal caesarean section in respect of patient satisfaction and handling</scientificTitle>
      <acronym/>
      <studyHypothesis>It is considered, that the incidence of post-puncture dural headache is correlated with the size of the spinal needle. For reason of patients' satisfaction and to minimize complications, a 29-gauge spinal needle is suitable for this purpose, especially in pregnant patients and patients undergoing ambulatory surgery. Though, the handling of this very thin spinal needle is described as difficult and therefore denied by several anaesthesiologists. 

The aim of this study is to evaluate the patients' satisfaction, the incidence of post-puncture dural headache and the handling conditions for the anaesthesiologist. 

Hypothesis:
The performance of a spinal anaesthesia with 29-gauge compared to a 25-gauge Quincke needles has a lower incidence of complications in patients undergoing minor anorectal surgery and abdominal caesarean section.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of post-dural puncture headache and other complications, measured one week after anaesthesia.</primaryOutcome>
      <secondaryOutcome>Time for the performance of spinal anaesthesia and occurring complications, measured one week after anaesthesia.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medizinische Ethik-Kommission II: Medizinische Fakultat Mannheim der Ruprecht-Karls-Universitat Heidelberg) on the 19th September 2007 (ref: 2007-236N-MA).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11431649</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>anaesMA2007-03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="75eefce8-88ad-4c92-8d6b-08065f2f0f55">
	  <name>University Clinic Mannheim</name>
	  <address/>
	  <city>Mannheim</city>
	  <state/>
	  <country>Germany</country>
	  <zip>68167</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients (male/female) with minor anorectal surgery, or 
2. Patients (female) for abdominal caesarean section
3. Age 18 - 80 years
4. American Society of Anaesthesiology (ASA) grade I - III
5. No contraindications for spinal anaesthesia</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>1. Contraindications for spinal anaesthesia
2. Allergy against local anaesthetics</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Post-puncture dural headache</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Post-puncture dural headache</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients are 1:1 randomised to either a 25-gauge or a 29-gauge spinal needle. Patients receive a questionnaire to obtain information about satisfaction and occurring complications. The time for the performance of the spinal anaesthesia and problems with the handling of the spinal needle are recorded by the anaesthesiologist.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17347-0</funderId>
      <contactId>Contact55308_17347</contactId>
      <sponsorId>Sponsor53876</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55308_17347">
    <title>Prof</title>
    <forename>Grietje</forename>
    <surname>Beck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Clinic Mannheim
Department of Anaesthesiology and Critical Care Medicine
Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">grietje.beck@anaes.ma.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53876">
    <organisation>B. Braun Melsungen AG (Germany)</organisation>
    <website>http://www.bbraun.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Carl-Braun-Strasse 1</address>
      <city>Melsungen</city>
      <country>Germany</country>
      <zip>34212</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@bbraun.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.462046.2</gridId>
    <rorId>https://ror.org/04nxj7050</rorId>
  </sponsor>
  <funder id="Funder17347-0">
    <name>B. Braun Melsungen AG (Germany) - provided the spinal needles</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">36101176</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Hospital at home care in chronic obstructive pulmonary disease (COPD): a study on the associated health economy and disease-related quality of life</title>
      <scientificTitle>Hospital at home care in exacerbations of chronic obstructive pulmonary disease (COPD)</scientificTitle>
      <acronym>HBKOLS</acronym>
      <studyHypothesis>Previous studies in other countries indicate that home treatment with nursing support is suitable in selected patients with exacerbations of chronic obstructive pulmonary disease (COPD), presenting to hospital as an emergency. 

Hypothesis: 
Three days of hospital at home care in mild to moderate exacerbations of COPD is cost saving in the Norwegian health care system and implies at least the same level of disease-related quality of life as traditional hospital care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Health economy measures.

Time points: 6 weeks, 6 months and 12 months.</primaryOutcome>
      <secondaryOutcome>1. Level of disease-related quality of life, measured with the St. George Respiratory Questionnaire
2. Mental health (level of anxiety and depression), measured with the Hospital Anxiety and Depression Scale

Time points: 6 weeks, 6 months and 12 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Regional Ethics Committee for Medical Research of East Norway on the 21st December 2007 (ref: 1.2007.2613).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36101176</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b38f729-f8b1-4940-9305-8d9f5c94fc4e">
	  <name>HØKH</name>
	  <address/>
	  <city>Lørenskog</city>
	  <state/>
	  <country>Norway</country>
	  <zip>1478</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients under 80 years of age, either sex, with exacerbation of COPD
2. Presenting to the hospital as an emergency</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Serious exacerbation including impending or actual respiratory failure
2. Serious comorbidity</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic obstructive pulmonary disease (COPD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Hospital-at-home group (experimental arm): 
Three days organised by the hospitals with specially trained nurses. In the same period of time the patient can contact the lung department at the hospital by phone for advice. Thereafter, if medical follow up is needed, by the primary care system (primary physician, home nurses).

Hospital group (control arm): 
As long as needed in the hospital. Thereafter, if needed, by the primary care personnel as for the other group. In contrast to the other group, the length of the in-hospital treatment is not specified. 

Follow up for both groups: After 6 weeks, 6 months and 12 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17434-0</funderId>
      <funderId>Funder17434-1</funderId>
      <contactId>Contact55395_17434</contactId>
      <sponsorId>Sponsor53965</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55395_17434">
    <title>Dr</title>
    <forename>Torbjørn </forename>
    <surname>Haugen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>HØKH
Akershus Unversitetssykehus HF
Sykehusveien 27</address>
      <city>Lørenskog</city>
      <country>Norway</country>
      <zip>1478</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53965">
    <organisation>Regional Authorities for Hospital Care, South-East Norway (Helse Sør-Øst Norge RHF) (Norway)</organisation>
    <website>http://www.helse-ost.no</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>PO Box 404</address>
      <city>Hamar</city>
      <country>Norway</country>
      <zip>2301</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+47 625 85 500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">postmottak@helse-ost.no</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.454198.5</gridId>
    <rorId>https://ror.org/02qx2s478</rorId>
  </sponsor>
  <funder id="Funder17434-0">
    <name>Regional Authorities for Hospital Care, South-Eastern Norway (Helse Sør-Øst RHF) (Norway)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17434-1">
    <name>The Norwegian Research Council (Norsk Forskningsråd) (Norway)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">75453816</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dietary fibre supplementation to prevent ulcerative colitis relapse: randomised double-blind placebo controlled clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>By taking 60 g of oat bran daily the relapse rate of patients with ulcerative colitis will be lowered from 40% to 20% at six months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Colitis relapse at six months.</primaryOutcome>
      <secondaryOutcome>The following will be assessed at six months:
1. General health
2. Bowel symptoms 
3. Faecal butyrate concentration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the ethics committee of Linköping University, Sweden (ref: M 159-04)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75453816</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>v.13</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind placebo controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-07-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fa33c085-ab64-4b75-9d53-b0161ff16756">
	  <name>Norrköping Hospital NSÖ stab</name>
	  <address/>
	  <city>Norrköping</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>S-60182</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adults with ulcerative colitis or proctitis in clinical and endoscopic remisson following a colitis relapse within prior 12 months
2. Written consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>130</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>130</totalTarget>
      <exclusion>1. Antibiotics at inclusion
2. Steroids in last two weeks
3. Ongoing treatment with immunosuppressive drugs
4. Pregnancy or planned pregnancy
5. Concomitant serious disorder
6. Inability to comply with study protocol</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (only in Swedish)</patientInfoSheet>
      <recruitmentStart>2006-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-07-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ulcerative colitis and proctitis in remission</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Ulcerative colitis and proctitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>60 g of oat bran to the daily diet for six months versus no intervention.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Oat bran</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17486-0</funderId>
      <funderId>Funder17486-1</funderId>
      <contactId>Contact55448_17486</contactId>
      <sponsorId>Sponsor54028</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55448_17486">
    <title>Prof</title>
    <forename>Claes</forename>
    <surname>Hallert</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norrköping Hospital NSÖ stab</address>
      <city>Norrköping</city>
      <country>Sweden</country>
      <zip>S-60182 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)70 543 8282 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Claes.Hallert@telia.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54028">
    <organisation>Lantmännen Food (Sweden)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Ingmar Börjesson
R&amp;D Department</address>
      <city>Järna</city>
      <country>Sweden</country>
      <zip>153 81</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 519 787 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ingmar.borjesson@lantmannen.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.502516.5</gridId>
  </sponsor>
  <funder id="Funder17486-0">
    <name>Lantmannen Food R&amp;D (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17486-1">
    <name>Medical Research Council of South-East Sweden (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-20T00:00:00.000Z">19821978</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Met-Hb and inflammation markers with tumescence local anaesthesia (TLA)</title>
      <scientificTitle>Met-Hb-concentration and inflammation markers in patients undergoing tumescence local anaesthesia (TLA) with supramaximal dosages of prilocaine</scientificTitle>
      <acronym/>
      <studyHypothesis>Tumescence local anaesthesia (TLA) is an established anaesthesia technique, where large amounts of highly diluted local anaesthetics are used. Due to its low toxicity, prilocaine is used frequently. Though, prilocaine can - dosage-dependant - cause a methemoglobinaemia, leading to a reduced oxygen transport capacity. Furthermore, certain processes of the inflammation cascade are initiated. These effects are important for ambulatory patients and the following healing process. 

The aim of the study is to evaluate the Met-Hb concentration and inflammation markers like  interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8), tumour necrotising factor (TNF), C-reactive protein (CRP) in a chronological sequence.

Hypothesis:
TLA in supramaximal dosages of prilocaine has an influence on plasmatic inflammation markers, which will elevate in the first 48 hours. Furthermore, the Met-Hb production will not be finished within this time.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Met-Hb-concentration over the time, measured over 48 hours.</primaryOutcome>
      <secondaryOutcome>Elevation of inflammation markers, measured over 48 hours.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medizinische Ethik-Komission II: Medizinische Fakultat Mannheim der Ruprechts-Karls-Universitat Heidelberg) on the 22nd November 2007 (ref: 2007-258N-MA)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19821978</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>anaesMA2007-02</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational study until 48 hours after surgery</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="adaa9697-0634-437a-ad35-cd5ebac75cc4">
	  <name>University Clinic Mannheim</name>
	  <address/>
	  <city>Mannheim</city>
	  <state/>
	  <country>Germany</country>
	  <zip>68167</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients (male/female) with operations which are performed in TLA with prilocaine
2. Age: 18 - 85 years
3. American Society of Anaesthesiologists (ASA) grade I - III
4. No allergy against prilocaine</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Allergy against prilocaine
2. Pregnancy
3. Patient denies operation in TLA</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tumescence local anaesthesia (TLA)/established anaesthesia techniques</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Anaesthesia techniques</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>As a standard procedure in our clinic, patients with dermatological operations will receive a TLA with more than 600 mg prilocaine. Seven blood samples (approximately 8 ml) will be taken 0, 1, 2, 4, 12, 24 and 48 hours after TLA, where the following parameters will be determined from:   
1. Demographic data and vital parameters
2. Met-Hb-concentration
3. Prilocaine-concentration
4. IL-1
5. IL-6
6. IL-8
7. TNF-alpha
8. CRP
9. Procalcitonin (PCT)
10. Creatine kinase (CK)
11. Lactate dehydrogenase (LDH)
12. Reticulocytes
13. Myoglobin
14. Haptoglobin 
15. Complications</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prilocaine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17346-0</funderId>
      <contactId>Contact55307_17346</contactId>
      <sponsorId>Sponsor53875</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55307_17346">
    <title>Prof</title>
    <forename>Grietje</forename>
    <surname>Beck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Clinic Mannheim
Department of Anaesthesiology and Critical Care Medicine
Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">grietje.beck@anaes.ma.uni-heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53875">
    <organisation>University Clinic Mannheim (Germany) - Department of Anaesthesiology and Critical Care Medicine </organisation>
    <website>http://www.klinikum-mannheim.de/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Theodor-Kutzer-Ufer 1-3</address>
      <city>Mannheim</city>
      <country>Germany</country>
      <zip>68167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">marc.schmittner@anaes.ma.uni.heidelberg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411778.c</gridId>
    <rorId>https://ror.org/05sxbyd35</rorId>
  </sponsor>
  <funder id="Funder17346-0">
    <name>University Clinic Mannheim (Germany) - Department of Anaesthesiology and Critical Care Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-13T00:00:00.000Z">01121161</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of lifespan in AN69ST with two different heparinization strategies</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Reduction of heparin dose in acute renal failure treated with hemodiafiltration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Filter lifespan, defined as the time period between patient's connection and filter disconnection due to filter clotting.</primaryOutcome>
      <secondaryOutcome>Adverse events, monitored for up to 24 days of treatment</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Local research ethics committee, Göteborg, Sweden. Date of approval: 17/12/2007 (Dnr. 576-07)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN01121161</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1446</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Monocentric, open, randomised and controlled study with two parallel groups.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-12T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ae69dc32-626c-4977-adfb-92a93462aa2d">
	  <name>Sahlgrenska University Hospital</name>
	  <address/>
	  <city>Gothenburg</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE- 413 45</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients requiring continuous renal replacement therapies (CRRT) 
2. Aged 18 and over 
3. Patients weighing 30-120 kg 
4. Patients having signed a written consent to participate in the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>44</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44</totalTarget>
      <exclusion>1. History of heparin antibodies or heparin-induces thrombocytopenia
2. Known hypertensive to any dialysis membrane
3. Current enrolment in another trial which could impact the successful completion of this study
4. Patients under guardianship
5. Patient anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week .These patients  can eventually be included in a later more stable phase
6. Unconscious patients for whom no relative or person of trust can give consent to treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study
7. Patient requiring anticoagulation for other indications e.g., valvular surgery or extracorporeal ventricular assist devices
8. Patients with active bleeding who does not require heparinization</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (in Swedish only)</patientInfoSheet>
      <recruitmentStart>2008-02-12T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute renal failure/  fluid overload</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Acute renal failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The same dialysis membrane, AN69ST, will be used for both the intervention and control treatment. Two different heparinization strategies will be compared: 

Control group (usual heparin doses): Bolus at start (between 1,000 IU - 2,500 IU) + usual infusion dose (10 IU/kg/h)  
Intervention group (Reduction of heparin dose): No bolus at start + infusion decreased by 50% (5 IU/kg/h)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17516-0</funderId>
      <contactId>Contact55478_17516</contactId>
      <sponsorId>Sponsor54061</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55478_17516">
    <title>Dr</title>
    <forename>Beng-Åke</forename>
    <surname>Henriksson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sahlgrenska University Hospital 
Department of Intensive Care (CIVA) </address>
      <city>Gothenburg</city>
      <country>Sweden</country>
      <zip>SE- 413 45</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54061">
    <organisation>Gambro Lundia AB (Sweden)</organisation>
    <website>http://www.gambro.com/int</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Clinical Trial Function
Clinical Affairs
P.O. Box 10101</address>
      <city>Lund</city>
      <country>Sweden</country>
      <zip>SE -220 10</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.420188.7</gridId>
    <rorId>https://ror.org/05mw5ed57</rorId>
  </sponsor>
  <funder id="Funder17516-0">
    <name>Gambro Lundia AB (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-13T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2008-03-13T00:00:00.000Z">09648950</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study to compare spinal cord stimulator implantation with laser treatment of the heart in patients with chronic angina</title>
      <scientificTitle>An open label, single-centre, randomized trial of spinal cord stimulation vs percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial</scientificTitle>
      <acronym>SPIRIT</acronym>
      <studyHypothesis>Refractory angina pectoris leads to significant morbidity. There is an increasing group of patients with 'refractory angina pectoris' who are unsuitable for conventional revascularization by coronary artery bypass surgery or percutaneous intervention. This patient group often have significant disability, with limiting symptoms, multiple medications, and frequent hospital admissions. 

Treatment options include percutaneous myocardial laser revascularization (PMR) and spinal cord stimulation (SCS). The primary objective of this study was to compare the effect of SCS vs PMR on treadmill exercise time on a modified Bruce protocol over a period of 12 months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Total exercise time on a modified Bruce protocol (ETT) at 12 months after SCS compared with PMR. In this study, all tests were terminated by the subject. Both SCS and PMR aim to reduce the frequency and severity of angina, and exercise tolerance is a comparatively objective method of measuring angina-free functional capacity.</primaryOutcome>
      <secondaryOutcome>1. Time to patient-reported angina during exercise test
2. Angina class as measured by the Canadian Cardiovascular Score angina scale
3. Morbidity and mortality
4. Safety profiles of each therapy
5. Health-related quality of life was assessed using questionnaires administered at 3, 12, 24 and 36 month follow-up (disease-specific Seattle Angina Questionnaire, the generic Short Form 36 health survey , and EuroQoL questionnaires)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval was obtained from the Huntingdon Local Research Ethics Committee, UK, prior to study commencement, on 15 August 2000 (ref: H00/557)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09648950</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Version 2.2 dated 5 January 2004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, open, parallel, single-centre, randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a4ccb758-67b1-45f8-baeb-33fee1f20445">
	  <name>Papworth Hospital NHS Foundation Trust</name>
	  <address/>
	  <city>Cambridge</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CB23 3RE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient with limiting angina (Canadian Cardiovascular Society [CCS] III or IV) despite maximally tolerated medical therapy 
2. Documented coronary artery disease (within the last 9 months prior to baseline), which is 
unsuitable for conventional revascularisation techniques
3. Patient has documented reversible ischaemia on nuclear scan (Tc-99 sestamibi) 
4. Patient is limited in daily activities, primarily exercise capability, by their anginal pain 
5. Age 18 or older
6. Patient must understand the therapy and give informed consent
7. Patient must be available for appropriate follow-up times for length of study
8. Non-pregnant women (only women who are post menopausal, surgically sterile or those of 
child bearing potential who are using an acceptable method of contraception) as safety for 
use of SCS during pregnancy or delivery has not been established. Acceptable methods of 
contraception include the following: 
a. Barrier type devices (e.g. female condom, diaphragm and contraceptive sponge) used only in combination with a spermicide 
b. Intrauterine devices (IDUs) 
c. Oral contraceptive agent 
d. Depro-ProveraTM (medroxyprogesterone acetate) 
e. Levonorgestrel implants 
f. Naturally sterile (amenorrheic for at least 1 year) in patients over 50 
Note: Abstinence, the rhythm method or contraception by the partner alone are NOT acceptable methods of contraception</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>68</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68</totalTarget>
      <exclusion>1. Patient who is not a candidate for surgical implantation of the spinal cord stimulation system,
and/or not a candidate for a PMR procedure and/or unable to use the SCS device appropriately for treatment
2. Patient who has had one or more major cardiac events within the last 2 months
3. Patient with a myocardial wall thickness &lt;8 mm in the ischaemic area to be treated as verified
by echocardiography
4. Patient with extensive peripheral vascular disease that precludes vascular access required for
PMR
5. Patient on intravenous therapy to control their symptoms
6. Patient who is unlikely to survive for more than 12 months due to non cardiac condition e.g.
malignancy
7. Patient who has other diseases that are considered of greater clinical significance than the
angina pectoris (e.g. inadequately controlled diabetes mellitus, heart failure) that would impact
the ability of the clinician to adequately assess the incremental effects of the trial treatment
8. Patient with ejection fraction of less than 30% as verified by echocardiography
9. Patient with cause of angina other than coronary artery disease (e.g. syndrome "X" patient)
10. Patient who is unable to perform treadmill exercise test per protocol
11. Patient who was previously enrolled in this study, or is currently in another clinical study, which will interfere with this protocol
12. Patient who has had spinal cord stimulation (SCS) therapy, a transmyocardial laser revascularization (TMLR) or PMR procedure in the past
13. Patient with an implanted pacemaker or defibrillator
14. Patient who has medical conditions which may require Magnetic Resonance Imaging (MRI)
15. Patient with a history of dementia or other persisting mental disorders significantly interfering
with ability to cooperate or comply with the requirements of the study or comprehend informed
consent
16. Patient with history of alcohol or drug abuse</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic angina pectoris</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Angina pectoris</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Trial patients were randomised to either Spinal Cord Stimulation System implant (SCS) or Percutaneous Myocardial Laser Revascularisation (PMR). 

The Spinal Cord Stimulation System used for this trial was a Medtronic fully implantable SCS systems. Either Itrel 3 or Synergy implantable generators were used. The spinal cord stimulation lead was chosen by the investigator from any Medtronic commercially available lead approved for use in refractory angina pectoris. The implant was performed according to the instructions in the technical manuals accompanying the devices. The lead was placed such that adequate/optimal paraesthesia was obtained in the area of angina pain. When adequate paraesthesia coverage was obtained the physician went on to permanent implant of the pulse generator. Proper patient education both pre and post implant of the device is essential. The investigator was responsible for adequately and regularly checking the integrity of the system at 3 months, 12 months and then annually. The stimulator should be used prophylactically by the patient for a minimum of 3 hours per day (for example: 3 times per day for a duration of 1 hour each). However, there is no upper limit and the patient may use the device as much as needed. Parameters for this stimulation vary from patient to patient. Therefore, the physician and patient need to work together to establish an effective and tolerable level. The stimulator should also be used at time of anginal attack to treat the pain. A higher level of stimulation may be used for this acute treatment. The maximum tolerable amplitude should be set for such use. However, it is necessary to assure that this level is not uncomfortable or painful. 

For this trial any commercially available Percutaneous Myocardial Revascularisation could be used. An optical fibre is inserted via the femoral artery under local anaesthesia and passed up into the left ventricle. Energy from a Ho:YAG laser is applied to the endocardial surface of the myocardium to vaporise the myocardial tissue and create channels from the endocardial surface into the myocardium. The co-axial system allows the laser to be manipulated in 3 planes giving access to the whole of the left ventricle. The laser position is monitored by fluoroscopy in orthogonal views. Once the position of the laser has been checked in both views, the laser is fired. Two bursts of the laser are used to create a channel 4-6 mm deep, in the myocardium, except in the apex where only one burst is used. The position is marked in both views on acetate sheets attached to the fluoroscopy monitors. Laser channels are created at a minimum of 1 cm apart, and are placed to cover the target region. Typically 10-15 channels are being made.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16554313 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3ecfb6b5-2300-4e80-b1a6-ab84cb9c90b8" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16554313"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17581-0</funderId>
      <contactId>Contact55543_17581</contactId>
      <sponsorId>Sponsor54127</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55543_17581">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Schofield</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Papworth Hospital NHS Foundation Trust
Papworth Everared</address>
      <city>Cambridge</city>
      <country>United Kingdom</country>
      <zip>CB23 3RE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1480 830541</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">peter.schofield@papworth.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54127">
    <organisation>Medtronic Sàrl (Switzerland)</organisation>
    <website>http://www.medtronic.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Route du molliau</address>
      <city>Tolochenaz</city>
      <country>Switzerland</country>
      <zip>CH-1131 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.471158.e</gridId>
    <rorId>https://ror.org/04pf17v09</rorId>
  </sponsor>
  <funder id="Funder17581-0">
    <name>This study was sponsored by Medtronic SA, who were responsible for funding of the trial related investigations such as perfusion scans and treadmill tests, research staff for data collection and travelling expenses for the subjects. The sponsor had no role in study design, data collection and interpretation, or in the decision to submit the above report for publication.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-10T00:00:00.000Z">14206374</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Posture control after lumbar microdiscectomy</title>
      <scientificTitle>Posture control after lumbar microdiscectomy: effect of transmuscular surgical approach and of early postoperative physiotherapy - a randomised clinical trial</scientificTitle>
      <acronym/>
      <studyHypothesis>1. Transmuscular surgical approach causes less damage to postoperative posture control because it does not damage the back muscle insertions
2. Early postoperative physiotherapy improves short and long term posture control</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Muscle control (assessed by postural balance test and sit-to-stand test), assessed in the lab at two weeks, eight weeks and six months post-operatively.</primaryOutcome>
      <secondaryOutcome>Comfort:
1. Back pain
2. Sciatica
3. Functional status
4. Return to work

Secondary outcome measures are assessed by standardised patient questionnaires preoperatively and at two weeks, eight weeks, six months and one year postoperatively.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Commissie Medische Ethiek of Leuven University Hospitals in November 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14206374</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>S50782</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, randomised, single centre trial with four arms (two variables: early specific physio versus later non-specific physio; transmuscular versus paramedian surgical approach).</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-18T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a8b3dae0-262c-42e2-882b-d1bcbd038e75">
	  <name>Department of Neurosurgery</name>
	  <address/>
	  <city>Leuven</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>3000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. One level disc herniation, either L4-L5 or L5-S1, explaining symptoms and representing operative indication. Purely median disc herniations are excluded.
2. Age: 18 - 60 years, either sex
3. Living within 30 km perimeter of the hospital
4. Informed consent signed</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Emergency operation required
2. Litigation, worker's compensation
3. Clinical suspicion of depression or fibromyalgia (the suffering is not exlusively explained by the disc herniation)
4. Previous lumbar surgery, irrespective of the level
5. Significant neurological deficit (weakness worse than 4/5)
6. Systemic disease significantly affecting patient's functioning (American Society of Anaesthesiologists [ASA] grade greater than 3)
7. Median disc herniation
8. Patient unable to communicate in the Dutch language</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (in Dutch).</patientInfoSheet>
      <recruitmentStart>2008-02-18T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sciatica caused by a lumbar disc herniation</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Other intervertebral disc disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Transmuscular surgical approach versus classic paramedian approach to the disc herniation at surgery
2. Early postoperative physiotherapy, starting two weeks postoperatively, and consisting of an individualised program with standardised goals versus 'conservative' treatment: no physiotherapy in the first six weeks post-operation and after six weeks only when indicated

Follow up is one year for all four arms.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17533-0</funderId>
      <funderId>Funder17533-1</funderId>
      <funderId>Funder17533-2</funderId>
      <contactId>Contact55495_17533</contactId>
      <sponsorId>Sponsor54079</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55495_17533">
    <title>Prof</title>
    <forename>Bart</forename>
    <surname>Depreitere</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Neurosurgery
University Hospitals Leuven
Herestraat 49</address>
      <city>Leuven</city>
      <country>Belgium</country>
      <zip>3000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54079">
    <organisation>University Hospitals Leuven (The Netherlands)</organisation>
    <website>http://www.uzleuven.be/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Herestraat 49</address>
      <city>Leuven</city>
      <country>Belgium</country>
      <zip>3000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410569.f</gridId>
    <rorId>https://ror.org/0424bsv16</rorId>
  </sponsor>
  <funder id="Funder17533-0">
    <name>Contribution for logistic expenses:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17533-1">
    <name>Medtronic B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17533-2">
    <name>Stryker Nederland (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-10T00:00:00.000Z">84003996</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of mesalazine to prevent relapse in paediatric crohn&#146;s disease</title>
      <scientificTitle>Prevention of relapse by mesalazine (Pentasa®) in paediatric crohn's disease: a multicentric double-blind randomised placebo-controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>The trial&#146;s primary objective was to compare the efficacy of mesalazine (Pentasa®, Ferring) versus placebo in maintaining remission in paediatric crohn's disease (CD) patients, when used after the successful treatment of an acute episode with either medication alone or parenteral/enteral nutrition techniques combined or not with medication.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Clinical relapse (HB score greater than or equal to 5, if confirmed within two weeks) 
2. Surgery for an acute complication of CD

Primary and secondary outcomes were measured either at one year of follow up with a medical visit every three months or when the primary or secondary outcomes occur during the one year follow up.</primaryOutcome>
      <secondaryOutcome>Treatment failure, defined as:
1. Relapse
2. Failure of steroid withdrawal (weaning failure)
3. Side-effects intolerance requiring treatment discontinuation
4. Worsening or aggravation of patient status requiring treatment interruption 
5. Initiation of a new treatment as decided by the clinician

Primary and secondary outcomes were measured either at one year of follow up with a medical visit every three months or when the primary or secondary outcomes occur during the one year follow up.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethcis approval received from the Ethics Committee of Paris VII on the 10th January 1991 (ref: Etude Pentacomp/90/01).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84003996</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Etude Pentacomp/90/91</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A multicentric, double-blind, randomised, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1991-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e3e431c1-1ff0-4c65-9ce5-adb87da73520">
	  <name>Hopital Robert Debré 48 Bd Sérurier</name>
	  <address/>
	  <city>Paris</city>
	  <state/>
	  <country>France</country>
	  <zip>75019</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children less than 18 years old, either sex
2. Diagnosed with crohn&#146;s disease before the age of 16 by means of clinical, radiological, endoscopic and histological data
3. Had to be in an active phase defined by:
3.1. A Harvey Bradshaw score (HB) greater than or equal to 5, and
3.2. An erythrocyte sedimentation rate (ESR) greater than or equal to 25 mm at hour one
4. All lesion localisations, except exclusive anorectal localisation, were included, providing patients&#146; lesion extension had been assessed within two years prior to inclusion

After flare-up treatment, inclusion criteria were as follows: 
1. Patients in clinical remission within six months following flare-up treatment initiation at pre-inclusion
2. An HB score under 5
3. An ESR under 25 mm
4. Normal hepatic and renal functions</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60, extended to 120</totalTarget>
      <exclusion>1. Flare-up had been treated with mesalazine or had required immuno-suppressors
2. Patients with known hypersensitivity to salicylate
3. Patients whose flare-up had occurred at pre-inclusion when on a 5-aminosalicylic acid (5-ASA) dose greater than 50 mg/kg/day for over two months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1991-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Paediatric crohn's disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Crohn's disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>At inclusion, patients were randomised per stratum, within each centre, using random permuted two to four sized-blocks (each centre did not know the size of their own block), to the following:
1. 50 mg/kg/day mesalazine dose 
2. Placebo (identical tablets) 

This was taken over a one-year period. Patients were monitored every three months over a one-year period or until endpoint. 

The study treatment was initiated either one week after the interruption of parenteral or enteral nutrition, or at the end of a sulfalazine or metronidazole treatment, or if the prednisone dose during the steroid weaning period was below 0.2 mg/kg. After the study treatment began, only antispasmodic and antidiarrhoeal agents, as well as sedatives were to be given as possible additional medications. 

Following the recruitment of 57 children from 1991 to 1993, trial results showed a trend favouring mesalazine. Recruitment was consequently resumed from 1996 to 1999.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mesalazine (Pentasa®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17517-0</funderId>
      <contactId>Contact55479_17517</contactId>
      <sponsorId>Sponsor54062</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55479_17517">
    <title>Prof</title>
    <forename>Jean Pierre</forename>
    <surname>Cezard</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hopital Robert Debré 48 Bd Sérurier</address>
      <city>Paris</city>
      <country>France</country>
      <zip>75019</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+33 (0)1 40 03 23 62</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jean-pierre.cezard@rdb.aphp.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54062">
    <organisation>Ferring SA (France)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>7 rue Jean Baptiste Clément</address>
      <city>Gentilly</city>
      <country>France</country>
      <zip>94250</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487243.e</gridId>
    <rorId>https://ror.org/03vrwsp35</rorId>
  </sponsor>
  <funder id="Funder17517-0">
    <name>Ferring SA (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-05T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">45000842</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Optimisation of incision hernia surgery treatment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Open mesh repair hernia surgery is better than suture repair hernia surgery of incision hernia treatment
2. The recurrence rate using suture hernia repair technique is much higher than mesh repair technique
3. The recovering time to the normal physical activity after surgery is faster, quality of life is better using mesh repair with sublay technique than mesh repair with onlay technique or suture repair technique of the incision hernia treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Recurrence rate, measured at 2 weeks, 1, 3, 6 and 12 months after surgery
2. Quality of life, measured using the 36-item Short Form health survey version 2 (SF-36 v2)at 2 weeks, 1, 3, 6 and 12 months after surgery</primaryOutcome>
      <secondaryOutcome>1. Postoperative complications, measured at 2 weeks, 1, 3, 6 and 12 months after surgery
2. Change of the blood gas and intra-abdominal pressure, measured before and after surgery
3. Recovering time to the normal physical activity after surgery, measured at 2 weeks, 1, 3, 6 and 12 months after surgery</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Kaunas Biomedical Research Ethics Committee on the 5th June 2007 (ref: BE-2-41).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45000842</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>73/2007</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Blinded, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Lithuania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dab1e29b-4963-4afa-8cd1-4bd21622092f">
	  <name>Eiveniu str. 2</name>
	  <address/>
	  <city>Kaunas</city>
	  <state/>
	  <country>Lithuania</country>
	  <zip>LT50009</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All 18 - 80 years old patients with incision hernia, who will be operated and agree to participate in this clinical trial.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50 patients in each group, 150 patients in all</totalTarget>
      <exclusion>1. Patients older than 80 years
2. Incarcerated incision hernia
3. Mental patients with incision hernia
4. Pregnant women with incision hernia
5. Patients with incision hernia do not agree to participate in this clinical trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hernia</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Hernia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Three groups:
1. Keel technique
2. Onlay technique
3. Sublay technique

The follow up period is 2 weeks, 1, 3, 6 and 12 months after surgery. Surgery, blood gas analysis and intra-abdominal pressure investigation before and after operation.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17283-0</funderId>
      <contactId>Contact55244_17283</contactId>
      <sponsorId>Sponsor53812</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55244_17283">
    <title>Dr</title>
    <forename>Linas</forename>
    <surname>Venclauskas</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Eiveniu str. 2</address>
      <city>Kaunas</city>
      <country>Lithuania</country>
      <zip>LT50009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53812">
    <organisation>Kaunas Medical University Hospital (Lithuania) - Department of Surgery </organisation>
    <website>http://www.kmu.lt/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Eiveniu str. 2</address>
      <city>Kaunas</city>
      <country>Lithuania</country>
      <zip>LT50009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.45083.3a</gridId>
    <rorId>https://ror.org/0069bkg23</rorId>
  </sponsor>
  <funder id="Funder17283-0">
    <name>Kaunas Medical University Hospital (Lithuania) - Department of Surgery</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">72781592</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Short versus long buprenorphine-naloxone treatment in intravenous buprenorphine withdrawal: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>BUNXLOW</acronym>
      <studyHypothesis>1. To investigate the effectiveness of buprenorphine-naloxone compared with treatment as usual (lofexidine) in withdrawal of intravenous buprenorphine dependence
2. To determine whether a longer regime is more effective than a shorter one</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Completion of withdrawal
2. Retention in rehabilitation for one month
3. Abstinence at one month after withdrawal
4. Abstinence at six months after withdrawal</primaryOutcome>
      <secondaryOutcome>1. The extent of withdrawal symptoms experienced, recorded every day during withdrawal
2. The amount of additional medication needed, recorded every day during withdrawal
3. Whether the patient begins naltrexone medication, patients will be offered an opportunity to begin naltrexone three days before finishing withdrawal 
4. Patient satisfaction, measured at the last day of withdrawal, whether at the intended finishing date, or at premature termination of withdrawal. Satisfaction will be measured by a self-made questionnaire of seven questions concerning the satisfaction with the medication, the length of medication, the additional medication, the length of withdrawal, the staff, the opportunity of beginning naltrexone and the overall satisfaction with the withdrawal treatment. Answers will be recorded with a five-grade scale</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. The Ethics Committee for Pediatrics, Adolescent Medicine and Psychiatry/Hospital District of Helsinki and Uusimaa on the 15th May 2007; amendment on the form of informed consent was approved 19th June 2007 (ref: 148/E7/2007)
2. The National Agency for Medicines approval on the 22nd August 2007 (ref: 96/2007)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72781592</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HDL07-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, three-arm, parallel group, single centre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="587bfde4-7c31-404f-a050-a7361d54ff19">
	  <name>Munkkisaarenkatu 16</name>
	  <address/>
	  <city>Helsinki</city>
	  <state/>
	  <country>Finland</country>
	  <zip>01500</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Opiate dependence (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition [DSM IV])
2. Current misuse of buprenorphine intravenously (mimimun 3 mg/day) (use confirmed by urinalysis)
3. Willingness to participate in withdrawal in the treatment centre and in rehabilitation afterwards
4. Aged between 18 and 50</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="50.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120 patients</totalTarget>
      <exclusion>1. Other than buprenorphine as the primary drug of misuse
2. Misuse of other opiates then buprenorphine during the last week (confirmed by urinalysis)
3. Opiate maintenance therapy
4. Psychotic symptoms at recruitment
5. Psychiatric or somatic disease or symptoms that may require hospitalisation at near future
6. Salient increase in alanine aminotransferase (ALAT)
7. Pregnancy
8. Allergy to lofexidine, buprenorphine or naloxone
9. Former participation to the same study
10. Concurrent participation to other intervention studies
11. Native language other than Finnish</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intravenous misuse of buprenorphine</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Opiate dependence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Short buprenorphine-naloxone (Bu-nx) arm: for 9 days: 
Day 1: 8 mg
Days 2 - 3: 8 - 16 mg (dose according to clinical assessment)
Days 4 - 5: 8 mg
Days 6 - 7: 4 mg 
Days 8 - 9: 2 mg

2. Long buprenorphine-naloxone arm: for 25 days: 
Day 1: 8 mg
Days 2 - 3: 8 - 16 mg (dose according to clinical assessment)
Days 4 - 9: 8 mg
Days 10 - 12: 6 mg 
Days 13 - 16: 4 mg 
Days 17 - 20: 2 mg 
Days 21 - 25: 1 mg

3. Lofexidine arm: lofexidine according to clinical assessment, maximum dose 2.4 mg/d divided into two to three doses, maximum duration 21 days

 In all arms, the intended withdrawal duration (in-patient treatment) is 28 +/- 7 days, and the follow-up period is up to six months after that.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Buprenorphine-naloxone, iofexidine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16935-0</funderId>
      <funderId>Funder16935-1</funderId>
      <funderId>Funder16935-2</funderId>
      <contactId>Contact54896_16935</contactId>
      <sponsorId>Sponsor53461</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54896_16935">
    <title>Dr</title>
    <forename>Outi</forename>
    <surname>Kuikanmäki</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Munkkisaarenkatu 16</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>01500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">outi.kuikanmaki@hdl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53461">
    <organisation>Helsinki Deaconess Institute (Finland)</organisation>
    <website>http://www.hdl.fi</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Outi Kuikanmäki
Munkkisaarenkatu 16</address>
      <city>Helsinki</city>
      <country>Finland</country>
      <zip>01500</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">outi.kuikanmaki@hdl.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487156.9</gridId>
    <rorId>https://ror.org/04zqw9t81</rorId>
  </sponsor>
  <funder id="Funder16935-0">
    <name>Academy of Finland (Finland)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002341</fundRef>
  </funder>
  <funder id="Funder16935-1">
    <name>National Public Health Institute (Finland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16935-2">
    <name>Helsinki Deaconess Institute (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-03-04T00:00:00.000Z">84133969</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fractional photothermolysis versus triple therapy for the treatment of melasma: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Fractional photothermolysis may be an effective and safe alternative for the treatment of melasma and the effect of the treatment with fractional photothermolysis may last longer than the effect of the triple therapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Observer blinded clinical score (Melasma Area and Severity Index [MASI] score), measured before treatment and during 3, 12 and 24 weeks of follow-up
2. Objective colour measurement by reflectance spectroscopy, measured before treatment and during 3, 12 and 24 weeks of follow-up</primaryOutcome>
      <secondaryOutcome>1. Visual assessment of side effects and quality of life measurements (skindex):
1.1. Fraxel laser group: after laser treatment and during follow-up (3, 12, 24 weeks)
1.2. Triple group: during follow-up (3, 12, 24 weeks)
2. Registration of side effects noticed by the patient: 
2.1. Fraxel group: after laser treatment and during follow-up
2.2. Triple group: after three weeks of treatment by telephone</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Centrale Commissie Mensgebonden Onderzoek (CCMO) on the 19th September 2007 (ref: NL18605.018.07).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84133969</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>fraxel-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, parallel group, observer blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fe24a693-9360-407e-8947-a0ba8e4e612a">
	  <name>Meibergdreef 35</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients with melasma
2. Skin photo type II - V
3. Subjects attending the outpatient department of the Netherlands Institute for Pigment Disorders
4. Aged at least 18 years
5. Subject is willing and able to give written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Bleaching cream during the past four weeks
2. Local corticosteroids during the past four weeks
3. Subjects with a history of keloids
4. Subjects with active eczema
5. Subjects with active acne in the face
6. Subjects with a history of facial eczema
7. Suspect allergy to lidocaine or the triple therapy
8. Use of roaccutane in the past six months
9. Subjects not competent to understand what is involved
10. Pregnancy
11. Lesion suspicious for malignancy
12. High exposure to sunlight (vacation in southern countries) or ultraviolet (UV) light (UVA or UVB)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Melasma</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Disorders of pigmentation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects will be randomly allocated to one of two groups who receive either triple therapy (bleaching cream [hydrochinon 5%, tretinoin 0.05% and triamcinolon acetonide 0.1% in cremor lanette II]) or fractional photothermilysis using the fraxel laser. 

Triple therapy: 
The triple therapy will be applied once a day in the evening on all hyperpigmented macules for eight weeks. Follow-up will take 3, 12 and 24 weeks post therapy. 

Fractional photothermolysis: 
Subject will receive a total of four laser treatments, with two week intervals. A topical anaesthetic ointment will be applied to the skin before treatment. The treated area will be less than 3% of the body surface. Follow-up will take place 3, 12 and 24 weeks post therapy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Triple therapy bleaching cream (hydrochinon, tretinoin, triamcinolon acetonide)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16718-0</funderId>
      <contactId>Contact54676_16718</contactId>
      <sponsorId>Sponsor53232</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54676_16718">
    <title>Dr</title>
    <forename>Albert</forename>
    <surname>Wolkerstorfer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Meibergdreef 35</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 6955</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.wolkerstorfer@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53232">
    <organisation>Academic Medical Centre (AMC) (The Netherlands) </organisation>
    <website>http://www.amc.uva.nl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Meibergdreef 35</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 6955</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.wolkerstorfer@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16718-0">
    <name>Academic Medical Centre (AMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-23T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2008-02-28T00:00:00.000Z">98703707</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Study protocol for a pragmatic randomised controlled trial in general practice investigating the effectiveness of acupuncture against migraine</title>
      <scientificTitle>Study protocol for a pragmatic randomised controlled trial in general practice investigating the effectiveness of acupuncture against migraine and to examine changes in brain perfusion using SPECT tomography to examine the consequences of the different interventions</scientificTitle>
      <acronym/>
      <studyHypothesis>Individualised acupuncture is able to reduce the intensity and frequency of pain in migraine to a greater extent than the conventional treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The difference in the number of Days With Migraine (DWM) between the baseline period and the period spanning weeks 9-12 (DWM1).</primaryOutcome>
      <secondaryOutcome>1. DWM between the baseline period and the period spanning weeks 21-24 (DWM2) after randomization. 
2. Change in the health-related quality of life between the baseline, final and follow-up periods, assessed by the 12-item Short Form health survey
3. Days free from pain
4. Proportion of patients with at least 50% fewer headaches during the period spanning weeks 9-12, in comparison with the baseline situation
5. Days off work, or of incapacity to perform daily activities
6. Change in the consumption of symptomatic/analgesic and prophylactic medication for migraine attacks, according to the patient's record of the name of the drug and the daily dose consumed, between the baseline period, the end of treatment and after 6 months
7. Change recorded on Goldberg's Depression/Anxiety Scale between the baseline period, the end of treatment and after the follow-up period
8. Difference in the results of the Spanish version of the Headache Impact Test, between the baseline period, the end of treatment and after the follow-up period
9. SPECT: The following values will be calculated for the semi-quantitative analysis of the images:
9.1. Percentage change of the mean value of counts per pixel for each region of interest
9.2. We shall also calculate an Index of Laterality (IL)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. Ethics Committee for Clinical Trials of Andalucia (Comité Autonómico de Ensayos Clínicos de Andalucía). Date of approval: 30 January 2007 (ref: acta 11/06) 
2. Local Ethics Committee for Clinical Trials, University Hospital of Valme of Seville (Comité Local de Ensayos Clínicos Hospital Universitario de Valme de Sevilla), Date of approval 4 December 2006 (ref: acta 30 november 2006) 
3. Research Ethics Committee of the University Hospital, Virgen de las Nieves 
de Granada (Comisión de Investigación del Hospital Universitario Virgen de las Nieves de Granada) Date of approval: 21 March 2006</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN98703707</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PI070694</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled multi-centre pragmatic study, with three arms.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="96ba686c-1557-4277-be64-028d20cd6047">
	  <name>Centro de Salud</name>
	  <address/>
	  <city>Dos Hermanas</city>
	  <state/>
	  <country>Spain</country>
	  <zip>41700</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. At least 18 years old
2. Diagnosed with migraine, in accordance with the principles of the International Headache Society and the recommendations for clinical trials published by the same Society
3. With or without aura
4. With a frequency of migraine attacks of 2-6 times per month
5. With a minimum chronicity of one year
6. Onset of symptoms at an age of less than 50 years
7. Have completed the headache diary
8. Have signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>270</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>270</totalTarget>
      <exclusion>1. Acupuncture during the previous 12 months
2. Incapacity to distinguish between tensional headache and migraine
3. Secondary headaches
4. Contraindication to acupuncture (pregnancy, generalised dermopathy, treatment with anticoagulants, thrombocytopenia) or to the performance of Single-Photon Emission Computed Tomography (SPECT) techniques (cerebrovascular accident, traumatic brain injury, alcohol or drug abuse, severe psychiatric disorders)
5. Inability to complete the questionnaires or to reply to the assessor's questions</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Migraine</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Migraine</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A. Verum acupuncture, 30 min per session, 8 sessions over 8 weeks: Individualized treatment on the basis of diagnosis in accordance with Traditional Chinese Medicine (TCM), which the acupuncture physician may modify in accordance with the evolution of the patient's symptoms 
B. Sham acupuncture, 30 min per session, 8 sessions over 8 weeks: The patients who are randomly assigned to this group will be given minimal acupuncture (the real insertion of acupuncture needles, to a depth of less than 3 mm) at 5 bilateral non-acupuncture points located 1.5 cm from the mean dorsal line and lumbar curve 
C. Conventional treatment for 8 weeks: The patients will be given the conventional treatment prescribed by their GP</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/18410686 Protocol</publicationDetails>
      <publicationStage>Protocol</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="271af6e7-cb89-4d1c-973c-83a0eabc39a6" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2008-04-14T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18410686"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17481-0</funderId>
      <contactId>Contact55443_17481</contactId>
      <sponsorId>Sponsor54023</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55443_17481">
    <title>Dr</title>
    <forename>Jorge</forename>
    <surname>Vas</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centro de Salud
Unidad de Tratamiento del Dolor
C/ Segovia s/n</address>
      <city>Dos Hermanas</city>
      <country>Spain</country>
      <zip>41700</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jorgef.vas.sspa@juntadeandalucia.es</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor54023">
    <organisation>Carlos III Health Institute (Spain)</organisation>
    <website>http://www.isciii.es/htdocs/en</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>C/ Sinesio Delgado, 6</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28029</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413448.e</gridId>
    <rorId>https://ror.org/00ca2c886</rorId>
  </sponsor>
  <funder id="Funder17481-0">
    <name>Healthcare Research Fund of the Carlos III Health Institute (Project No. PI070694) (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-26T00:00:00.000Z">14127815</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The SphynX trail: a randomised clinical trial comparing the outcome of endoluminal fundoplication with EsophyX™ to laparoscopic Nissen fundoplication for refractory gastro-esophageal reflux disease (GERD)</title>
      <scientificTitle/>
      <acronym>SphynX</acronym>
      <studyHypothesis>Endoluminal fundoplication with Esophyx™ will not be less effective than laparoscopic Nissen fundoplication, expressed as the percentage of successful procedures, based on the patient's opinion at six months after surgery.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Effectiveness will be expressed as the percentage of successful procedures, based on the patient's opinion at six months after surgery (Visick grading). Visick classification: grade I: No symptoms, resolved; grade II: Mild occasional symptoms easily controlled, improved; grade III: Mild symptoms not controlled, unchanged; grade IV: Not improved, worsened. Success will be defined as grade I or II and failure will be defined as grade III or IV.</primaryOutcome>
      <secondaryOutcome>1. Success expressed as the percentage of patients with normalisation of acid exposure on pH metry, minus the percentage of patients needing reintervention (dilatation or re-operation) for troublesome dysphagia at six months

Definition of objective normalisation of acid exposure: 
The combination of the following:
a. Upright acid exposure &lt;8.4%
b. Supine acid exposure &lt;3.4 % 
c. Total acid exposure &lt;5.8% on post-operative 24-h pH-monitoring
The presence of troublesome dysphagia will render the procedure unsuccessful. 

2. Percentage of patients free from PPIs at three and six months
3. Quality of Life (QoL) assessment: Visual analogue scale [VAS] score, the 36-item Short Form health survey (SF-36) and EuroQol (EQ-5D) at three and six months
4. Impact of reflux symptoms on QoL: The Gastro-Oesophageal Reflux Disease Health-Related Quality-of-Life scale  (GORD-HRQoL) at three and six months
5. Esophageal symptoms: OES18 score at three and six months
6. Prevalence of esophagitis on upper endoscopy at six months
7. Cost-effectiveness expressed as costs per successfully treated patients and incremental costs per Quality Adjusted Life Year gained at six months</secondaryOutcome>
      <trialWebsite>http://www.esophyx.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Independent central medical ethics committee of the University Medical Center Utrecht has approved the study protocol. Date of approval: 08/01/2008 (EC ref: 07-214; CCMO ref: 1795404107)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14127815</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>07-214</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised non-inferiority multicenter trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2009-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="944ca3ea-fb2a-4784-b3d4-d6b483d46e6a">
	  <name>University Medical Center Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. GERD patients of eight Dutch hospitals with reflux symptoms persisting for over 6 months despite double dose of Proton Pump Inhibitor (PPI) (&gt;40 mg omeprazole/24 hours or comparable therapy) and/or patients who refuse or do not tolerate to take acid suppressing drugs for life.  
2. Documented temporal relation between pathological reflux and symptoms during 24-hr pH monitoring. 
Pathological reflux is defined as upright acid exposure &gt;8.4%, supine acid exposure &gt;3.4 % and/or total acid exposure &gt;5.8% on 24-hr pH monitoring. A documented relation between reflux and symptoms is reflected by a Symptom Association Probability (SAP) &gt;95%. 
3. Patients without a diaphragmatic hernia or a sliding hernia not exceeding 2 cm (endoscopically measured distance from Z-line and impression of the diaphragm). 
4. Age between 18 and 65 years. 
5. Informed consent.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Patients with a diaphragmatic hernia other than of the sliding type and/or larger than 2 cm.
2. Grade C and D esophagitis according to the Los Angeles classification.
3. Histologically proven long-segment Barrett's oesophagus.
4. Patients with severe esophageal or gastric motility disorders. 
5. Patients with a history of esophageal- or gastric surgery. 
6. American Society of Anaesthesiologists classification III and IV patients. 
7. Patients with a psychiatric disease or other conditions making them incapable of filling out the questionnaires or completing the objective esophageal function tests. 
8. Pregnancy.</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2009-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gastro-esophageal reflux disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Gastro-esophageal reflux disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Endoluminal fundoplication with EsophyX™ versus laparoscopic Nissen fundoplication.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17532-0</funderId>
      <funderId>Funder17532-1</funderId>
      <funderId>Funder17532-2</funderId>
      <funderId>Funder17532-3</funderId>
      <funderId>Funder17532-4</funderId>
      <funderId>Funder17532-5</funderId>
      <funderId>Funder17532-6</funderId>
      <funderId>Funder17532-7</funderId>
      <funderId>Funder17532-8</funderId>
      <contactId>Contact55494_17532</contactId>
      <sponsorId>Sponsor54078</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55494_17532">
    <title>Prof</title>
    <forename>H G</forename>
    <surname>Gooszen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht 
P.O. Box 85500 
H.P. G04.228 </address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54078">
    <organisation>University Medical Center Utrecht and seven participating hospitals (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500 
H.P. G04.228</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder17532-0">
    <name>The costs of this trial are internally covered by the eight participating hospitals in the Netherlands:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-1">
    <name>University Medical Center Utrecht</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-2">
    <name>Meander Medical Center Amersfoort</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-3">
    <name>Lange Land Hospital Zoetermeer</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-4">
    <name>Catharina Hospital Eindhoven</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-5">
    <name>Medical Center Leeuwarden</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-6">
    <name>Antonius-Mesos Hospital Nieuwegein-Utrecht</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-7">
    <name>Rivierenland Hospital Tiel</name>
    <fundRef/>
  </funder>
  <funder id="Funder17532-8">
    <name>Amphia Hospital Breda</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-26T00:00:00.000Z">09659857</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Outpatient chemotherapy protocol using 3 cosolidated drugs (cisplatin, 5 fluoururacil and leucovorin) in a different scheme for the treatment of head and neck and oesophageal cancer, designed for patients without surgical and radiation therapy options</title>
      <scientificTitle>Low cost, outpatient, cisplatinum, 5-fluoururacil and leucovorin chemotherapy regimen for advanced head and neck, and upper oesophageal carcinomas</scientificTitle>
      <acronym/>
      <studyHypothesis>Evaluate the combination of bolus CDDP cisplatinum, 5-fluoururacil and leucovorin (CFL) in patients with advanced (residual, metastatic or recurrent) squamous cell carcinoma (SCC) of head (H)/neck (N) and oesophagus (E), aiming at a feasible and low cost chemotherapy (CHT) regimen to circumvent the need of infusion pumps and/or hospital admission.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Quality of life (QoL) evaluated using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) questionnaire, previously used in Portuguese, at the beginning of study and before each cycle
2. Toxicities analysed according to National Cancer Institute (NCI) criteria before each cycle together with KPS, clinical reassessment and laboratory evaluation
3. Response, evaluated by computed tomography (CT) scans after 3rd and 6th cycles of chemotherapy and analysed by response evaluation criteria in solid tumours (RECIST)
4. Performance status by measured with Karnofsky Performance Status (KPS)</primaryOutcome>
      <secondaryOutcome>1. Overall survival - time between enrolment and death
2. Progression Free Survival - time between enrolment and disease progression</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the ABC Medical School Ethics Committee in December 2004 (ref: 185/2004).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09659857</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase II, single arm study conducted at a single Brazilian Institution</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5eb15996-b980-4766-868b-86b9b89146f3">
	  <name>Rua Mere Amedea 833</name>
	  <address/>
	  <city>Sao Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>02125-001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Advanced or recurrent, histologically confirmed, head and neck and oesophagus squamous cell carcinoma
2. Patients have to be 18 years of age or older, either sex
3. Normal renal function
4. Measurable disease by the response evaluation criteria in solid tumours (RECIST)
5. Karnofsky performance status (KPS) equal or greater to 50%</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15 patients</totalTarget>
      <exclusion>1. Not meeting the inclusion criteria
2. Concomitant radiation therapy
3. Not a candidate for chemotherapy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Head and Neck and Upper oesophageal carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Squamous cell carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Chemotherapy as follows:
Leucovorin 20 mg/m^2/day bolus infusion for four days (D1 - D4), followed by 5-fluoururacil  370 mg/m^2/day bolus infusion for four days (D1 - D4), and Cisplatinum 25 mg/m^2/day in 90 minutes infusion for three days (D1 - D3), every 21 to 28 days, depending upon hematological recovery.

Follow up is until patient death, expected to be less then 24 months for each patient.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>CDDP cisplatinum, 5-fluoururacil and leucovorin (CFL)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17436-0</funderId>
      <funderId>Funder17436-1</funderId>
      <contactId>Contact55397_17436</contactId>
      <sponsorId>Sponsor53967</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55397_17436">
    <title>Dr</title>
    <forename>Vanessa</forename>
    <surname>Fabricio</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Mere Amedea 833</address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>02125-001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vcf35@terra.com.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53967">
    <organisation>Hospital Mario Covas (Brazil) </organisation>
    <website>http://www.hospitalmariocovas.org.br</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Rua Henrique Calderazzo, 321
Bairro Paraíso </address>
      <city>Santo Andre</city>
      <country>Brazil</country>
      <zip>09190-615 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sau@hesa-fuabc.org.br</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487168.4</gridId>
    <rorId>https://ror.org/00s7ek396</rorId>
  </sponsor>
  <funder id="Funder17436-0">
    <name>ABC Foundation (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17436-1">
    <name>Hospital Mario Covas (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-22T00:00:00.000Z">76047793</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Adhesion prevention with icodextrin</title>
      <scientificTitle>The effect of 4% icodextrin solution vs lactated Ringer's solution on adhesiolysis during Hartmann's reversal: A multi-centre randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Laparotomy almost always causes peritoneal adhesions, which further causes morbidity and even mortality. A regimen to prevent peritoneal adhesions is urgently needed. Icodextrin has been shown to prevent adhesion formation, and our study investigated further the efficacy of icodextrin in colorectal operation. 

Study hypothesis: 
4% icodextrin solution decreases adhesion formation and time needed to divide them after hartmann's procedure compared to lactated Ringer's solution.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Time needed to separate postoperative adhesions, assessed approximately 3 months after hartmann's reversal procedure
2. Total operative time</primaryOutcome>
      <secondaryOutcome>1. Complications and recovery after Hartmann's reversal procedure. Duration of follow-up: 1 month 
2. Safety of icodextrin. Duration of follow-up: 1 month</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>National approval of the study received on 30 April 2003 from the Ethical Committee of Päijät-Häme Hospital District ETL-code Q36. Further approved by every local ethical committee of participating hospitals.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76047793</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind, multi-centre, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="df6e5043-6d70-403e-b683-1823b1916eaf">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Lahti</city>
	  <state/>
	  <country>Finland</country>
	  <zip>15850</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients having rectosigmoid colon obstruction, perforation or diverticulitis (with or without perforation) for which a Hartmann's operation was planned</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Refusal to consent
2. Pregnancy
3. Peritoneal carcinoma
4. Postoperative radiotherapy before restorative surgery
5. Reoperation violating study protocol
6. Severe concomitant disease or other reason that would probably interfere with the restorative surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Laparotomy/ peritoneal adhesions</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Laparotomy/ peritoneal adhesions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study group receives at the end of Hartmann's procedure 1000 ml of 4 % icodextrin instilled into the abdomen. The control group receives same amount of lactated Ringer's solution.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17400-0</funderId>
      <contactId>Contact55361_17400</contactId>
      <sponsorId>Sponsor53931</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55361_17400">
    <title>Dr</title>
    <forename>Jyrki</forename>
    <surname>Kössi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
Päijät-Häme Central Hospital
Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jyrki.kossi@phsotey.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53931">
    <organisation>Päijät-Häme Central Hospital (Finland)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jyrki.kossi@phsotey.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.440346.1</gridId>
    <rorId>https://ror.org/02v92t976</rorId>
  </sponsor>
  <funder id="Funder17400-0">
    <name>Internally funded by the Päijät-Häme Central Hospital (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-22T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-22T00:00:00.000Z">65305620</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Is misoprostol a safe alternative to manual vacuum aspiration in women with incomplete abortions in developing countries?</title>
      <scientificTitle>Is misoprostol a safe alternative to manual vacuum aspiration in women with early pregnancy failure in a low resource setting?: a randomized controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Misoprostol is just as effective as Manual Vacuum Aspiration (MVA) in treatment of first trimester pregnancy failure, but is more acceptable to clients in a rural setting in low resource countries.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Ultrasonographic endometrium thickness at day 8</primaryOutcome>
      <secondaryOutcome>The following will be assessed at day 8: 
1. Changes in hemoglobin (Hb) level
2. Side effects including pain 
3. Adverse events 
4. Patients satisfaction and acceptability 

If any problem is observed on day 8, the patient will be reviewed again on day 15 (No review at day 15 if no problem is observed).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The National Institute of Medical Research Dar es Salaam, approved on 18 October 2007 (ref: NIMR/HR/R.8a/Vol. IX/628)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65305620</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Evaluator-blinded, single-centre, randomised controlled non-inferiority trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-02-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-02-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e226d8a5-b2b9-4ac5-ba03-7f20cc8cad96">
	  <name>PO box 228</name>
	  <address/>
	  <city>Lindi</city>
	  <state/>
	  <country>Tanzania</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. History of passage of tissue and/or blood and &gt;30 mm endometrial thickness on TransVaginal Sonography (TVS) 
2. On TVS an anembryonic gestation or fetal death with an embryonic crown-rump length between 5 and 62 mm without cardiac activity (in case of a Crown-Rump Length [CRL] of 5-9 mm TVS will be repeated after one week to ensure absence of cardiac activity) or an anembryonic gestational sac of 16-45 mm (TVS will be repeated after one week to ensure growth of the gestational sac is &lt;3 mm and exclude a viable pregnancy)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. On TVS present fetal heart activity, a crown-rump length &gt;62 mm, molar pregnancy or a endometrial thickness less than or equal to 30 mm
2. Fundal height of more than halfway the umbilicus and the symphysis indicating a gestational age &gt;12 weeks
3. Known allergy to prostaglandins
4. Heavy blood loss or a pulse rate of &gt;120/min
5. Axillary temperature of &gt; 38°C or signs of septic abortion such as pus draining from uterus
6. Ectopic pregnancy</exclusion>
      <patientInfoSheet>Patient information form in Kiswahili is available on request. Please use the contact details below to request.</patientInfoSheet>
      <recruitmentStart>2008-02-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-02-11T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>First trimester pregnancy failure</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>First trimester pregnancy failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Misoprostol 600 microgram 3 doses (one dose every 4 hours) sublingually versus MVA</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>misoprostol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17482-0</funderId>
      <contactId>Contact55444_17482</contactId>
      <sponsorId>Sponsor54024</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55444_17482">
    <title>Dr</title>
    <forename>Regine</forename>
    <surname>Unkels</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>PO box 228</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54024">
    <organisation>Tanzanian German Program to Support Health  (TGPSH)  (Tanzania)</organisation>
    <website>http://www.tgpsh.or.tz</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Lindi Office
PO box 97</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17482-0">
    <name>Tanzanian German Program to Support Health (TGPSH) (Tanzania)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2008-02-20T00:00:00.000Z">67086909</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intravitreal versus subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular oedema</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Macular oedema is the main cause of loss of visual acuity in diabetic patients. It may occur at any stage of the retinal disorder and is the most common cause of sight reductions in these subjects.

In the oedema, the haemato-retinal barrier is damaged by an alteration in the tight junction between the retinal capillary endothelial cells and the pigmented epithelial cells with the consequent leakage of water and electrolytes in the retinal tissue.

The use of corticosteroids for the treatment of retinal oedema is linked to their capacity to inhibit the initial arachidonic acid cascade, to determine a down-regulation of the cytokines and to attenuate the tearing of the haemato-retinal barrier.  

Hypothesis:
To assess the efficacy of the intravitreal (IVT) injection of triamcinolone acetonide (TA) as compared to posterior subtenon (SBT) capsule injection for the treatment of cystoid diabetic macular oedema.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, measured every month until the end of follow-up.</primaryOutcome>
      <secondaryOutcome>Macular thickness was measured by optical coherence tomography (OCT), measured every month until the end of follow-up.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Ethics Committee of the S. Orsola-Malpighi Hospital on the 12th September 2006 (ref: OFC06-01).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67086909</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>An interventional randomised double-blind study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-02-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-18T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="57ae7b5b-06b1-4e88-af9f-6a8c3a734b4e">
	  <name>Via Massarenti, 9</name>
	  <address/>
	  <city>Bologna</city>
	  <state/>
	  <country>Italy</country>
	  <zip>40100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients aged between 61 and 74 years (mean 68.3), either sex
2. With type II diabetes mellitus 
3. On insulin treatment
4. Presenting diffuse macular oedema without retinal-vitreous traction</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>28</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>28</totalTarget>
      <exclusion>1. History of focal/grid laser photocoagulation in the macula
2. Record of uveitis episodes
3. Previous ocular surgery, glaucoma and ocular hypertension</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-02-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-18T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Macular oedema</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Macular oedema</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>For the IVT injection, the patient was placed supine and we performed a surface anaesthesia with topical 4% carbocaine followed by a preparation with 5% povidone iodine. A volume of 0.1 ml containing 4 mg preservative-free TA (Kenacort, Bristol-Myers Squibb, Sermoneta, Italy) was injected through the inferotemporal pars-plana (4.0 mm posterior to the limbus) using a 30-gauge needle. 

For the SBT injection, the patient was placed supine and after topical 0.4% oxybuprocaine surface anaesthesia we administered 0.5 ml of a 40 mg/ml peribulbar inferotemporal subtenon injection of preservative-free TA (Kenacort, Bristol-Myers Squibb, Sermoneta, Italy) with a 27-gauge needle. 

The follow-up was of 6 months for all treatment arms.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Triamcinolone acetonide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18366650 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a6972f41-4b8f-469e-ba56-1f90fa96a2f5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18366650"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17491-0</funderId>
      <contactId>Contact55453_17491</contactId>
      <sponsorId>Sponsor54033</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55453_17491">
    <title>Dr</title>
    <forename>Mauro</forename>
    <surname>Cellini</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Via Massarenti, 9</address>
      <city>Bologna</city>
      <country>Italy</country>
      <zip>40100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54033">
    <organisation>St Orsola Malpighi University Hospital Bologna (Italy) </organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Ophthalmology Service
Department of Surgery and Transplant 
via Massarenti, 9  </address>
      <city>Bologna</city>
      <country>Italy</country>
      <zip>40138</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.412311.4</gridId>
    <rorId>https://ror.org/00t4vnv68</rorId>
  </sponsor>
  <funder id="Funder17491-0">
    <name>St Orsola Malpighi University Hospital Bologna (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-15T00:00:00.000Z">82469428</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of intravenous iron and placebo (NaCl) for treatment of Restless Legs Syndrome (RLS)</title>
      <scientificTitle>A randomised, double-blind, comparative, multi-centre study of intravenous iron and placebo (NaCl) for treatment of Restless Legs Syndrome (RLS)</scientificTitle>
      <acronym/>
      <studyHypothesis>Is 5 x 200 mg iron sucrose over 3 weeks more effective in the treatment of restless legs than placebo?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>International RLS Study Group Rating Scale at 11 weeks</primaryOutcome>
      <secondaryOutcome>1. Epworth Sleepiness Scale at baseline, after 3 , 7 and 11 weeks, 5 , 8 and 12 months
2. Incidences and severities of adverse events, assessed after 3 , 7 and 11 weeks, 5, 8 and 12 months
3. To assess the ability of the treatments to correct aberrant haematology and iron status at baseline, after 3 , 7 and 11 weeks, 5 , 8 and 12 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>University Hospital, Uppsala. Date of approval: 13 June 2003 (ref: 03-141)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82469428</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPV-0105</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo-controlled study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-06-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-22T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bbc1ec18-e878-47d5-87a1-f050de824c58">
	  <name>Medical Department</name>
	  <address/>
	  <city>Avesta</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-774 82</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18-70 years
2. RLS defined by four cardinal criteria
3. Ten points or more on the International RLS (IRLS) Study Group Rating Scale 
4. S-ferritin below 45 µg/L, and with folic acid and vitamin B12 within reference values
5. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="70.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Treatment with any of the following: 
1.1. Psychopharmacological treatment with antidepressive and dopaminergic agents, sedatives, anticonvulsants and/or pain relievers, i.e. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or stronger, during the preceding 2 weeks. This was changed in study protocol clarification number 2 to "...i.e. with the exception of NSAIDs - during the last 2 weeks". 
1.2. Calcium antagonists, antihistaminic or antiemetic drugs during the preceding 2 weeks. 
1.3. Iron administration during the preceding 2 months 
1.4. Nutritional supplements or natural pharmaceuticals containing iron 
1.5. Antiepileptics 
1.6. Vitamin B12 or folic acid 
2. Presence of clinically significant disease/dysfunction, which in the opinion of the investigator should disqualify the patient from this study, such as asymptomatic intestinal bleeding 
3. Patients suffering from obstructive sleep apnoea syndrome 
4. S-creatinine &gt;130 µmol/L 
5. Positive result of pregnancy test 
6. Breast-feeding women 
7. Contraindications for iron sucrose</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2003-06-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-22T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Restless legs syndrome</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Restless legs syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>200 mg iron sucrose intravenously 5 times over 3 weeks versus placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>iron sucrose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17503-0</funderId>
      <contactId>Contact55465_17503</contactId>
      <sponsorId>Sponsor54046</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55465_17503">
    <title>Prof</title>
    <forename>Jan</forename>
    <surname>Ulfberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Department
Avesta Hospital</address>
      <city>Avesta</city>
      <country>Sweden</country>
      <zip>SE-774 82 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54046">
    <organisation>Renapharma AB (Sweden)</organisation>
    <website>http://www.renapharma.se</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Box 938</address>
      <city>Uppsala</city>
      <country>Sweden</country>
      <zip>SE-751 09  </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476652.4</gridId>
    <rorId>https://ror.org/03x49ea82</rorId>
  </sponsor>
  <funder id="Funder17503-0">
    <name>Renapharma AB (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">41063599</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Family orientated early intervention enhances social-interactive behaviour of premature infants and mother-infant-interaction</title>
      <scientificTitle/>
      <acronym>PRIMA Study (Prospective Randomized Implementation of the Model-project Augsburg)</acronym>
      <studyHypothesis>Condition: Very preterm children who are at an increased risk of cognitive impairments, poor educational achievement and behavior problems and psychopathology. Most consistently, an increased risk for attention problems, hyperactivity and social or peer relationship problems have been reported across a range of hospital and geographically defined cohorts. Improvements in infant self-regulation and mother-infant-relationship may avert longterm behavioural and social relationship sequelae of very preterm birth. A first step in demonstrating such a link is to test in a randomised controlled trial whether an individualised family based approach can alter infant social-emotional regulation. 

Hypothesis: Does an individualised family-based early support intervention (case management approach) for mothers of prematurely born infants alter 1) the maternal sensitivity and 2) infant social-emotional regulation and reciprocal quality of mother-infant interaction in the first 6 months of life?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure was the improvement in social-interactive behaviour of the infants, mother's sensitivity and the dyadic quality of interaction. Before discharge the nurses assessed the early mother sensitivity with the Boston City Hospital Assessment of Parental Sensitivity (BCHAPS)(Timepoint 1). This questionnaire consists of 13 closed-ended items, evaluating the mother's sensitive responsivness and care giving competence. The items are ranked on 5-point scales from "poor" to "competent" and the scores totalled. 

At 6 months corrected age the infant social-interactive behaviour and mother-infant interaction were assessed with the Mother-Infant Structured Play Assessment (MISPA)(Timepoint 2). This is an 8-minute, semi-structured face-to-face play interaction which includes the Still-Face Paradigm, which provides a method to access infant regulatory capacities and illustrates central qualities of the young infant's capacities for interpersonal engagement. For the interaction records the infants were placed on a blanket or mat on the floor and mothers were asked to sit on the floor opposite their infant. A mirror was mounted at an angle, which enabled the examiner to videotape both the face and body of the infant and the face and upper torso of the mother. Standardised instructions were used to explain the procedure to the mothers. 

Episode 1 involved the mother playing with her baby with a rattle (warm-up). After 2 minutes (Episode 2) she was cued to lay aside the rattle and play (without a toy) with her baby for another 2 minutes. Then she was asked to get her baby to watch her face, which lasted for 1 minute (Episode 3). Next she was asked to make a still-face for 1.5 minutes (Episode 4) and then finally asked to resume playing with her baby for another 1.5 minutes (Episode 5). 

Three existing schemes were modified and adapted to create a suitable coding scheme: 
1. The Play Observation Scheme and Emotion Ratings (POSER)
2. The Emotional Availability Scales (EAS)
3. Tronick and Weinberg's Infant and Caregiver Engagement Phases (ICEP)

Each interaction episode was coded with 5-point scales reflecting maternal sensitivity (apart from episode 4) and infant social regulatory behaviour. Maternal Sensitivity consisted of 5 rating scales (sensitivity, positive response, negative facial emotional expression, verbal involvement, undercontrol) that were totalled to gain a measure of maternal sensitivity. Social Regulatory Behaviour was also assessed using 5 rating scales (emotional state, attentiveness, responsivness, vocalisation, clarity of signals). 

Quality of dyadic interaction consisted of 2 five-point rating scales (Harmony, Control over interaction) and the scores were totalled. Each of the five episodes in the MISPA was scored separately, and infant, maternal and dyadic behaviours were coded individually. The last episode demonstrating mother-infant reunion after perturbation of interaction was decided to be confirmative for the effect of the intervention. This episode presents the infant with a complex and demanding regulatory task: the infant needs to simultaneously cope with the resumption of the maternal behaviour, as well as the carry-over of negative affect from the still-face episode.</primaryOutcome>
      <secondaryOutcome>The demographic characters and the medical and psychosocial burden of the families were recorded with a structured mother-interview at both time points. Several items of the interview ware totalled showing a dyadic adjustment scale and a psyochosocial stress-index.</secondaryOutcome>
      <trialWebsite>http://www.betainstitut.de/fue_erg_prima_studie.php</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics board of Rheinische Friedrich Wilhelms University, Bonn, Germany. Approved on 27/11/2001 (ref: 181/01)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41063599</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, single-blind, single-center trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fb852260-e6c8-4ffe-a509-54be4fc13d92">
	  <name>Stenglinstr. 2</name>
	  <address/>
	  <city>Augsburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D 86156</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Families with premature births &lt;32 weeks Gestational Age (GA) or birth weight below 1500 g and cared for in the Neonatal Intensive Care Unit (NICU) of the University Children Hospital, Bonn, Germany, between 1 January 2002 and 31 December 2003.</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>108</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>87 families with 108 children</totalTarget>
      <exclusion>1. Families living more than 100 km from the hospital
2. Mother did not speak German
3. Infant was transferred to another hospital
4. Infant died or suffered major malformations</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Premature infants</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Premature infants</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>43 families with 55 children were randomized in the intervention group and 44 families with 53 children in the control group.  

The aim of our individualised, family-based intervention was to integrate parents in the care of their babies from the very beginning in the NICU and to support families with social needs by providing parent education, improving care-giving competence, enhancing parent-infant interaction, evaluation of the needs and resources of the family, psychosocial care and emotional support, and establishing a network for the family. Beginning in the first week of life trained nurses, social workers and psychologists as required visited as case managers the mothers in the NICU and at home after discharge of the baby up to six months. The intervention addressed problems in four domains including 1) caregiving environment, 2) infant behaviour and characteristics, 3) home discharge and community resources, and 4) family organisation and functioning. Visiting was every two to three days during hospital stay and 1-2 weekly after discharge as needed by the family. The mean duration of the intervention was 161.9 days (45-277): 35.2 days (1-108) during hospital stay and 126.7 days (14-210) after discharge. The professions involved were: nurses in all families, social workers in 42.6% and psychologists in 4.8%.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17218-0</funderId>
      <funderId>Funder17218-1</funderId>
      <funderId>Funder17218-2</funderId>
      <funderId>Funder17218-3</funderId>
      <contactId>Contact55179_17218</contactId>
      <sponsorId>Sponsor53745</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55179_17218">
    <title>Dr</title>
    <forename>Friedrich</forename>
    <surname>Porz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Stenglinstr. 2</address>
      <city>Augsburg</city>
      <country>Germany</country>
      <zip>D 86156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53745">
    <organisation>Beta Institute for Research and Development in Social Medicine (Germany) </organisation>
    <website>http://www.betainstitut.de</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Kobelweg 95</address>
      <city>Augbsurg</city>
      <country>Germany</country>
      <zip>D 86156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17218-0">
    <name>The study was internally founded by the beta Institute for Research and Development in Social Medicine (beta Institut für Sozialmedizinische Forschung und Entwicklung), Augsburg, Germany.</name>
    <fundRef/>
  </funder>
  <funder id="Funder17218-1">
    <name>The study was also supported by the following institutions:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17218-2">
    <name>Köhler foundation (Köhler Stiftung), Essen, Germany (S112/10020/02)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17218-3">
    <name>Northrine-Westphalia Welfarework Foundation (Stiftung Wohlfahrtspflege Nordrhein-Westfalen), Düsseldorf, Germany (SW-620-4206-Z)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">46090514</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to compare the efficacy, safety and tolerability of PSD502, delivered topically onto the upper vagina and cervix, to placebo in controlling discomfort/pain intensity in subjects undergoing outpatient hysteroscopy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Hysteroscopy is used extensively in the evaluation of common gynaecological problems such as premenopausal menstrual disorders, infertility and postmenopausal bleeding. It allows direct visualisation of the uterine cavity and the opportunity for targeted biopsy, safe removal of endometrial polyps, and treatment of submucous fibroids, septa and adhesions. There is a general consensus that hysteroscopy is the current gold standard for evaluating intrauterine pathology, including submucous myomas, polyps, hyperplasia and cancer.

This study aims to evaluate the efficacy of PSD502 in relieving discomfort/pain at placement of the tenaculum on the anterior lip of the cervix during outpatient hysteroscopy.  Topically delivered agents have a theoretical advantage over cervical injection in terms of ease of administration and the potential for side effects with oral or systemically administered agents.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To evaluate the efficacy of PSD502 in relieving discomfort/pain at placement of the tenaculum on the anterior lip of the cervix assessed using a 100 mm VAPS in subjects undergoing hysteroscopy.</primaryOutcome>
      <secondaryOutcome>1. To evaluate the efficacy of PSD502 in relieving discomfort/pain during insertion of the hysteroscope as assessed using a VAPS in subjects undergoing hysteroscopy
2. To evaluate the efficacy of PSD502 in relieving discomfort/pain during examination of the uterine cavity as assessed using a VAPS in subjects undergoing hysteroscopy
3. To evaluate the efficacy of PSD502 in relieving the worst discomfort/pain experienced during the entire hysteroscopy procedure using a 4-point discomfort/pain scale
4. To evaluate the need for additional analgesia in the 24 hours after the procedure
5. To evaluate the safety and tolerability of PSD502 administered to the cervix and vagina</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics committee (Wojskowy Instytut Medyczny) on the 22nd August 2007 (ref: 121/WIM/2007).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46090514</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PSD502-UP-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group, proof of concept study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-03-13T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Poland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c3d81f41-c69f-495a-8da2-47e687406111">
	  <name>Department of Gynaecology</name>
	  <address/>
	  <city>Warsaw</city>
	  <state/>
	  <country>Poland</country>
	  <zip>00-909</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>A subject will be invited to participate if she meets the following inclusion criteria:
1. Healthy, pre-menopausal female who requires hysteroscopy
2. Aged 18 - 50 years inclusive
3. Clinically insignificant medical history and clinical examination other than the underlying condition requiring treatment, in the opinion of the Investigator
4. Post menstruation, but prior to ovulation at the time of the procedure and has a negative pregnancy test
5. Able to understand and complete the visual analogue pain scale (VAPS) and 4-point discomfort/pain scale, in the opinion of the Investigator
6. Willing and able to provide written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>A subject will be excluded from study participation if she meets any of the following criteria:
1. Contraindication to hysteroscopy
2. Known hypersensitivity to amide-type local anaesthetics
3. Received another investigational product within the previous 3 months
4. Current history of alcohol or drug abuse such that the subject is unable to comply with the study procedures or has resulting clinically significant organ damage, in the opinion of the Investigator
5. Clinically-significant medical history or clinical finding (e.g. bleeding diathesis or coagulopathy) that would affect the subject's ability to take part in the study, in the opinion of the Investigator
6. Previous hysteroscopy with technical difficulties or side effects
7. Used lidocaine or prilocaine preparation within 6 hours before the hysteroscopy procedure</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-01-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-03-13T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Discomfort or pain during hysteroscopy</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Discomfort or pain during hysteroscopy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Study medication (active or placebo) will be sprayed onto the cervix in 10 metered dose sprays (to give a total of 75 mg lidocaine and 25 mg prilocaine, or placebo). The first spray will be to the cervix, followed by each of the 4 vaginal fornices in clockwise fashion from the anterior fornix (anterior, left lateral, posterior, right lateral); the spraying pattern will be repeated immediately to complete 10 sprays in total. The time of final spray application will be recorded. After a minimum of 5 minutes and no more than 10 minutes, the excess fluid will be swabbed away. A tenaculum will then be used to secure the cervix and the hysteroscope will be inserted. The subject will then undergo the hysteroscopy procedure.

Product: PSD502 is a metered dose spray that delivers a eutectic mixture of lidocaine and prilocaine for topical anaesthesia. Each actuation dispenses 7.5 mg lidocaine and 2.5 mg prilocaine in their base forms. The propellant used in this spray is norflurane (HFA-134a), which also serves as a solvent. The spray provides a concentrated film of local anaesthetic base, which facilitates drug penetration and is capable of providing rapid, superficial anaesthesia of non-keratinised skin. 

Dose: Ten metered dose sprays will be used to deliver a total dose of 75 mg lidocaine and 25 mg prilocaine. 

Administration: Topical administration to the vagina and cervix approximately 10 minutes, but no sooner than 5 minutes, prior to hysteroscopy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lidocaine, prilocaine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17292-0</funderId>
      <contactId>Contact55253_17292</contactId>
      <sponsorId>Sponsor53821</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55253_17292">
    <title>Prof</title>
    <forename>Wlodzimierz</forename>
    <surname>Baranowski</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Gynaecology
Military Institute of the Health Services
Szaserow Str 128</address>
      <city>Warsaw</city>
      <country>Poland</country>
      <zip>00-909</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+48 (0)22 510 1175</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wbaranowski@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53821">
    <organisation>Plethora Solutions Limited (UK)</organisation>
    <website>http://www.plethorasolutions.co.uk/index.php </website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>4th Floor
233 High Holborn</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1V 7DN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7269 8630</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sheryl.caswell@plethorasolutions.co.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487437.b</gridId>
    <rorId>https://ror.org/02y9vw172</rorId>
  </sponsor>
  <funder id="Funder17292-0">
    <name>Plethora Solutions Limited (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">35198481</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Therapy of locally advanced rectal cancer of the upper third by quality controlled total versus partial mesorectal excision</title>
      <scientificTitle>Therapy of cUICC stage II/III rectal cancer of the upper third by quality controlled total versus partial mesorectal excision, followed by adjuvant chemotherapy</scientificTitle>
      <acronym>GAST-05</acronym>
      <studyHypothesis>The multicentric GAST-05 study aims at identifying the optimal surgical treatment of locally advanced (cUICC stage II/III) rectal cancer located 12 - 16 cm above the anocutaneous verge. Two established surgical techniques are compared: 
1. Total mesorectal excision (TME), to completely eliminate affected and surrounding tissue, bears the risk of post-surgical complications
2. Partial mesorectal excision (PME) restricts surgery to the afflicted tissue and defined surroundings

PME may be equally effective in eliminating cancer while limiting post-operative complications. No clinical data have been raised to date that show if TME or PME is oncologically superior. To answer this requires a refocus on the principles of both resection techniques, including peri- and post-operative quality control. Post-surgical chemotherapy is identical in both trial arms. Primary endpoint is the disease-free survival after 3 years. 

The GAST-05 study is an add-on study to the ongoing CAO/AIO/ARO-04 trial, which intends to optimise the pre-surgical chemoradiotherapy of cUICC stage II/III cancers in the lower two thirds of the rectum (0 - 12 cm). The comparison of the long-term outcomes of both studies (GAST-05: surgical procecures; CAO/AIO/ARO-04: intensified preoperative treatment) will influence future studies; they will apply the surgical procedure that is identified as being superior during the GAST-05 study. Additional gene expression analyses on pre-therapeutically taken tumour probes will show if gene profiling can help to predict individual prognosis. 

The identification of the oncologically superior of two standardised surgical treatments (TME and PME) of cUICC stage II/III cancers of the upper third of the rectum has not been determined. The identification is a prerequisite for further studies, needed to reduce the side effects of optimised surgical treatments. If both techniques, TME and PME, turn out to be equivalent, that technique will be regarded as superior, which promises less comorbidities, a higher qualitiy of life, and lower health care costs (i.e. PME). 

A cross-comparison of disease-free and overall survival data from the GAST-05 trial and the CAO/ARO/AIO-04 trial will further allow judgement on the need for further studies on multimodal therapies for rectal cancers of the upper third. If the rate of local and distant metastases turns out to be equal or lower in the GAST-05 trial (upper third, no neoadjuvant RT/CT, PME/TME) than in the CAO/ARO/AIO-04-trial (lower two thirds, intensified preoperative treatment), further trials may be unnecessary which test multimodal therapies in cancers of the upper third. Patients with cUICC stage II/III cancers of the upper third of the rectum will then be spared potentially ineffective preoperative radiochemotherapy with its toxicities.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Disease-free survival after 3 years (local and/ or distant recurrences).</primaryOutcome>
      <secondaryOutcome>1. R0-rate of resection
2. Post-operative 30-day lethality
3. Post-operative morbidity (especially rate of anastomotic insufficiencies)
4. Cumulative incidence of local relapses and distant metastases
5. Survival after 3 and 5 years
6. Acute and late toxicity of the chemotherapy according to the Common Toxicity Criteria of the National Cancer Institute (NCI CTC version 2.0) 
7. Post-operative late complications (defaecation problems, anastomotic  stenoses, loss of sphincter function)
8. Quality of TME and PME as assessed
9. Quality of life according to the European Organisation for Research and Treatment of Cancer (EORTC)-Questionnaire QLQ-30 (3.0)

Assessment of safety: TME, PME, and adjuvant chemotherapy are established procedures.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Georg-August-University Gottingen Ethik-Kommission der Medizinischen Fakultat on the 17th January 2007 (ref: 21/11/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35198481</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, multi-centric, prospectively randomised phase II trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2013-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fc2f1f4a-0a47-40dd-b3c1-3f911bac797e">
	  <name>Georg-August University of Gottingen</name>
	  <address/>
	  <city>Göttingen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>37075</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Histologically confirmed advanced primary rectum carcinoma at a level 12 - 16 cm above the anocutaneous verge (as measured by rigid endoscopy), endosonographically classified as uT3-4 or uN+ carcinomas, no evidence for synchronous distant metastases
2. Patients aged 18 - 85 years, either sex 
3. No preliminary treatment of rectum carcinoma</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>360</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>360</totalTarget>
      <exclusion>1. Successfully treated secondary malignoma with the exception of basal cell carcinoma of the skin and in situ cervix carcinoma, respectively, The inclusion of patients with other tumours, that have been treated successfully and have not reappeared during the last 5 years, has to be discussed with the principal investigator 
2. Simultaneous therapy with other anti-cancer drugs 
3. Chronic colonic diseases</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet.</patientInfoSheet>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2013-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Rectal cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>For all procedures, standard operating procedures (SOPs) are available.  

Experimental intervention:
1. Arm A: total mesorectal excision (TME) including surgical and pathological quality control, followed by standard adjuvant chemotherapy. The mesorectum is completely excised downwards to the pelvic floor:
1.1. Dorsally: entire retro-rectal fat body with the lymph tissue under consideration of the fascial system
1.2. Ventrally: including the spatium prerectale along the Denonvilliers-fascia
1.3. Laterally: entire area up to pelvis

2. Arm B: Partial mesorectal excision (PME) including surgical and pathological quality control, followed by adjuvant chemotherapy. PME follows the same surgical principles as in TME with the following exception: the mesorectum is transected at a right angle to the rectal wall 5 cm beyond the gross distal margin of the tumour, as measured in situ

In both trial arms, surgery is followed by adjuvant chemotherapy: 
1. Folinic acid: 400 mg/m^2, 2-hour infusion, day 1
2. Oxaliplatin: 100 mg/m^2 2-hour infusion in 500 ml glucose 5%, day 1
3. 5-Fluorouracil: 2400 mg/m^2 as 46-hour infusion

Perioperative assessment of mesorectal excision (TME/PME):
Staining of the specimen via inferior mesenteric artery, photo-documentation:
Class 1: no leakage, optimal TME/PME
Class 2: punctual leakage(s), good TME/PME
Class 3: extensive leakage(s), incomplete TME/PME

Standardised pathological assessment of TME/PME (in addition to established TNM/UICC criteria): 
Extent: TME/PME?
In case of PME: 
1. Distance between macroscopically visible distal margin of tumour and distal transection margin measured in centimetres. Measuring method: 
1.1. Fresh, non-stretched specimen
1.2. After fixation (non-pinned)
1.3. After fixation (pinned, non-stretched) 
2. Coning (distal transaction in a plane at 90° to the rectal wall): no, yes
3. Macroscopic assessment of the specimen surface in all cases:
3.1. Intact, smooth (lipoma-like)
3.2. Circumscribed defect(s) no greater than 5 mm
3.3. Extensive defect(s), muscular layer of the rectum invisible
3.4. Extensive defect(s), muscular layer of the rectum visible
3.5. Incision into the tumour or tumour torn open

Pathological quality assessment of the specimens after TME/PME:
1. Complete: intact mesorectum, no defects larger than 5 mm, no PME-coning, smooth circumferential resection margin on slicing
2. Moderate: irregular mesorectal surface, moderate PME-coning, muscularis propria invisible with the exception of area of insertion of levator muscles, moderate irregularity of the circumferential resection margin
3. Incomplete: little bulk of mesorectum with defects down into mucularis and/or very irregular circumferential resection margin, PME-coning

Control intervention: 
None

Duration of intervention per patient: 32 weeks  
Follow-up per patient: 3 years</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Folinic acid, oxaliplatin, 5-Fluorouracil</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17442-0</funderId>
      <contactId>Contact55403_17442</contactId>
      <sponsorId>Sponsor53973</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55403_17442">
    <title>Dr</title>
    <forename>Torsten</forename>
    <surname>Liersch</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Georg-August University of Gottingen
Department of General and Visceral Surgery
Robert-Koch-Strasse 40</address>
      <city>Göttingen</city>
      <country>Germany</country>
      <zip>37075</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)5513 983 23</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tliersc@gwdg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53973">
    <organisation>Georg-August University of Gottingen (Georg-August-Universitat Gottingen, Universitatsmedizin) (Germany) </organisation>
    <website>http://www.uni-goettingen.de/en/sh/1.html </website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof. Dr. med. H. Becker and Dr. med. Torsten Liersch
Department of General and Visceral Surgery 
Robert-Koch-Strasse 40</address>
      <city>Göttingen</city>
      <country>Germany</country>
      <zip>37075</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)5513 983 23</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tliersc@gwdg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7450.6</gridId>
    <rorId>https://ror.org/01y9bpm73</rorId>
  </sponsor>
  <funder id="Funder17442-0">
    <name>German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany) (ref: 518)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">02971192</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of acupuncture in pain relief and functional improvement in ankylosing spondylitis: a randomized controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the efficacy of acupuncture for spinal pain relief in patients diagnosed with Ankylosing Spondylitis (AS).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were assessed before and immediately after the interventions: 
1. Patient's assessment of spinal pain (0-10 cm VAS). 
2. Patient's global assessment of disease-activity and function (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Bath Ankylosing Spondylitis Functional Index [BASFI]). The BASDAI measures the severity of fatigue, spinal and peripheral joint pain, localized tenderness, and morning stiffness, assessed on a 10 cm VAS. The BASFI measures the functional status of AS patients, and is also assessed on a 10 cm VAS.
3. Acute-phase reactants (C-Reactive Protein, Erythrocyte Sedimentation Rate [ESR], Immunoglobulin A [IgA]) 
4. Number of analgesic pills per week</primaryOutcome>
      <secondaryOutcome>Subjective assessment of pain, performed before and immediately after the interventions,  using a 7-point Likert scale, where 1 = much worse, 2 = moderately worse, 3 = slightly worse, 4 = no effect, 5 = small improvement, 6 = moderate improvement, 7 = great improvement.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the University Hospital, University of Sao Paulo, School of Medicine, approved on 8 October 2003 (CAPPESQ number: 769-03)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN02971192</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Project number at Institute of Orthopaedics and Traumatology: 371</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind, randomised placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4f0cfbb5-a458-484b-9006-d99f84058203">
	  <name>Rua Guaramembé, 589</name>
	  <address/>
	  <city>Sao Paulo</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>01308-050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age range between 20 and 60 years 
2. Painful complaints in the axial line 
3. Patients who have not received any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or analgesics for three months prior to the inclusion into this trial
4. Those who are referred to the Rheumatology Service, University of São Paulo, University Hospital, School of Medicine with diagnosis of ankylosing spondylitis according to the New York 15 and European 16 criteria for spondyloarthropathies
5. A mean baseline Visual Analogue Scale (VAS) score &gt;= 4 for pain</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Severe psychiatric disease
2. Sensory or motor neurological deficits
3. Fibromyalgia
4. Previous treatment with acupuncture 
5. Unable to visit the hospital for treatment</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pain relief in patients diagnosed with ankylosing spondylitis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Pain relief in patients diagnosed with ankylosing spondylitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomization was performed using colored balls. Patients rated their pain intensity using VAS, disease activity, and function level at baseline. 

Patients were randomly allocated to one of two treatment groups: 

Group A: Classical acupuncture. Participants received classical acupuncture treatment associated with the use of NSAIDs and analgesics. Disposable, sterilized, stainless steel 0.25 mm x 40 mm length needles were employed. 10 acupuncture sessions, twice weekly, 20 minutes per session. Each patient was treated in a separate room. 

Group B: Sham acupuncture. Participants received NSAIDs and analgesics together with non-invasive sham electro acupuncture, which was performed using inactive surface electrodes with audiovisual biofeedback reinforcement, touching patient's skin for seven seconds. 10 acupuncture sessions, twice weekly, 20 minutes per session. Each patient was treated in a separate room. 

Acupuncture points employed in both groups: GV20b, SI3b, BL62b, GB34b and Ex-B2b</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17479-0</funderId>
      <contactId>Contact55441_17479</contactId>
      <sponsorId>Sponsor54021</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55441_17479">
    <title>Dr</title>
    <forename>Liliana</forename>
    <surname>Lourenço Jorge</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Guaramembé, 589 </address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>01308-050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54021">
    <organisation>University of São Paulo (Brazil)</organisation>
    <website>http://www2.usp.br</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>São Carlos
Ribeirão Preto</address>
      <city>Sao Paulo</city>
      <country>Brazil</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11899.38</gridId>
    <rorId>https://ror.org/036rp1748</rorId>
  </sponsor>
  <funder id="Funder17479-0">
    <name>University of São Paulo, University Hospital (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">06098697</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A one month study of the efficacy and safety of SVS20 versus carbomer and saline in patients with bilateral moderate dry eye syndrome: a randomised, double blind, controlled, parallel group, pilot, phase II study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess the efficacy and safety of SVS20 versus saline (as a basic standard reference product) and carbomer (as a standard treatment with a marketing authorisation in most EU countries) in patients with bilateral moderate dry eye syndrome due to Sjogren's syndrome (immune exocrinopathy) or diagnosed as a primary syndrome.

Please note that the results of this study were used to calculate the sample size of a more recent phase III multicentre study conducted in France and UK. For more details on this phase III study, please visit the ISRCTN record at http://www.controlled-trials.com/ISRCTN91412460.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Since this study was a phase II there were no primary or secondary outcomes. Our aim was to analyse the efficacy and safety of SVS20 versus saline and carbomer and to find a parameter that could be used as the primary criterion for the following pivotal phase III study (ISRCTN91412460). Therefore, the following parameters were assessed:
1. Efficacy and tolerability:
1.1. Number of instillations
1.2. Staining with lissamine green
1.3. Symptom intensity and frequency
1.4. Repercussion of symptoms on activities of daily life
1.5. Comfort of the eye drops (presence and duration of blurred vision after instillation)
1.6. Slit lamp examination
1.7. Tear volume (Schirmer I test)
1.8. Tear film BUT
1.9. Corneal staining with fluorescein
1.10. Global evaluation of efficacy

2. Safety: 
2.1. Comfort of the eye drops (presence and duration of blurred vision)
2.2. BCVA
2.3. Impairment of dry eye symptoms
2.4. Ocular adnexa examination 
2.5. Adverse events reporting

Parameters were measured at V1 (Day-16 to Day-12), V2 (Day 0) and V3 (Day 28).</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. The National Ethics Committee for Clinical Pharmacology (KFEB) on the 29th June 2005
2. The Ministry of Health on the 14th July 2005

Thereafter, local Institutional Review Board (IRB) at each centre gave favourable opinions on 13 September 2005 (Dr. Deák), 5 October 2005 (Dr. Sohajda), 18 October 2005 (Dr. Márta), 21 November 2005 (Dr. Zeher) and 2 December 2005 (Dr. Bereczki).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06098697</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>SVS20-HUN-05-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, controlled, parallel group, pilot, phase II study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hungary</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="73a693e1-5579-4240-9240-b80fc77959d8">
	  <name>Szent János Kórház</name>
	  <address/>
	  <city>Budapest</city>
	  <state/>
	  <country>Hungary</country>
	  <zip>1125</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Signed informed consent
2. Male and female patients aged 18 years and over
3. Patients with at least a three-month documented history of bilateral moderate dry eye due to Sjogren's syndrome (immune exocrinopathy) or diagnosed as a primary syndrome
4. Patients with total score of staining with lissamine green of at least 5/12 and not more than 10/12 for each eye
5. Patients with at least two symptoms of dry eye among soreness, scratchiness, dryness, grittiness and burning each:
5.1. Occurring at least often and
5.2. Rated at least 30 mm and not more than 70 mm on the 0 to 100 mm visual analogue scale (VAS)
6. Patients with at least two out of three following objective parameters:
6.1. Schirmer test less than or equal to 10 mm wetting/5 minutes for each eye
6.2. Tear film break-up time (BUT) less than or equal to 10 seconds for each eye
6.3. Staining with fluorescein with a total score greater than or equal to 3/7 for each eye
7. Eligible patients using the following medications should have been taking them continuously for the two months before the screening visit and the dose should not have changed during the whole trial:
7.1. Tricyclic antidepressive agents
7.2. Anti-histaminic agents
7.3. Phenothiazines
7.4. Cholinergic agents
7.5. Antimuscarinic agents
7.6. Non-steroidal anti-inflammatory drugs (NSAIDs)
7.7. Beta-blockers
7.8. Immunomodulators
7.9. Anti-acneic agents
7.10. Diuretic agents
8. Female patients should be post-menopausal or be using a recognised, reliable method of contraception for at least three months before selection
9. Patients complying with the local regulations (e.g. social security system)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>72</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>72 patients were planned for 1:1:1 randomisation to SVS20 (n = 24), saline (n = 24) and carbomer (n = 24)</totalTarget>
      <exclusion>1. Patients who respond to Unilarm® during or at the end of the run-in period so that their inclusion criteria are not met at D0 examinations
2. Patients with unilateral dry eye
3. Severe dry eye syndrome, defined as:
3.1. Staining with fluorescein with a depth score less than 3 in any eye and/or
3.2. Severe bulbar conjunctival hyperaemia (score of 4) in any eye and/or
3.3. Severe limbal hyperaemia (score of 4) in any eye and/or
3.4. Severe palpebral observation (score of 4) in any eye and/or
3.5. Severe blepharitis in any eye
4. Patients who underwent:
4.1. Refractive surgery within the last 12 months before selection and/or
4.2. Any other ocular surgery or ocular trauma within the last four months before selection
5. Patients taking the following systemic concomitant medications within the last two months before selection:
5.1. Corticosteroids and/or
5.2. Tetracyclines
6. Patients requiring concomitant in-eye medication for the whole trial, except Unilarm® during the selection period only
7. Patients with abnormality of the nasolacrimal drainage apparatus
8. Patient with permanent occlusion of lacrimal puncta in any eye
9. Patient with temporary punctal plug within two months before selection in any eye
10. Patients with other diseases or characteristics judged by the investigator to be incompatible with the frequent assessments needed in this study or with reliable instillation of the products (for example disability of the upper limbs)
11. Patients who participated in any other clinical trial within the last 30 days before selection
12. Patients with known hypersensitivity to hyaluronic acid or any component or procedure used in the study
13. Patients who need or intend to wear contact lens during the whole trial
14. Patients with best corrected visual acuity (BCVA) less than 1/10 in any eye
15. Pregnant or lactating females
16. Known human immunodeficiency virus (HIV) positive patients, if they belong to an anamnestic known risk group like drug addicts, etc., or if there is any reasonable doubt about HIV a validated test must be performed
17. Patients with a concomitant diagnosis of sarcoidosis, non-hodgkin lymphoma, bone marrow transplant or any secondary Sjogren's syndrome due to rheumatoid diseases or as an adverse event possibly of any other prior of concomitant medication</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dry eye syndrome</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Disorders of lacrimal system</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>There were three arms: 
1. SVS20
2. Saline 
3. Carbomer

Patients instilled 2 - 4 times a day one of these eye drops. Treatment duration was 1 month with a previous period of wash-out of 112 to 16 days.

The following parameters were measured at V1 (day 16 to day 12), V2 (day 0) and V3 (day 28):
1. BUT
2. Schirmer I test
3. Lissamine and fluorescein staining
4. BCVA
5. Slit lamp examination
6. Symptoms intensity and frequency</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>SVS20, carbomer</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17492-0</funderId>
      <contactId>Contact55454_17492</contactId>
      <sponsorId>Sponsor54034</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55454_17492">
    <title>Prof</title>
    <forename>Margrit</forename>
    <surname>Zeher</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Szent János Kórház
1 Diósárok u.</address>
      <city>Budapest</city>
      <country>Hungary</country>
      <zip>1125</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54034">
    <organisation>TRB Chemedica International SA (Switzerland) </organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>12 rue Michel-Servet </address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487371.e</gridId>
    <rorId>https://ror.org/012pz6314</rorId>
  </sponsor>
  <funder id="Funder17492-0">
    <name>TRB Chemedica International SA (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-08T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-08T00:00:00.000Z">86152982</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of Haemate HS for the treatment of severe intraoperative hemorrhage during aortic-valve replacement in patients with aortic-valve stenosis</title>
      <scientificTitle/>
      <acronym>HAVAS-Study</acronym>
      <studyHypothesis>Evaluation of the efficacy and safety of Haemate HS in this clinical setting</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Intra- and postoperative transfusion requirements according to defined transfusion thresholds.</primaryOutcome>
      <secondaryOutcome>1. Requirement of rethoracotomy, assessed during patients stay at the intensive care unit 
2. Surgeons' subjective rating of therapeutic efficacy after application of Haemate HS or placebo (classification of bleeding after therapy as "better", "equal" or "worse") 
3. Survival (perioperative mortality, mortality during hospital stay, mortality within a 90 day period following surgery) 
4. Duration of treatment on intensive care ward 
5. Adverse events and therapy-related side effects, assessed within the first 10 days after surgery. A second assessment is carried out after 3 month (at day 90)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethics Committee of the Heinrich Heine University Medical Center (Duesseldorf, Germany) on 25 April 2007. First amendment approved on 28 November 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86152982</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BI8021_5101</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Two-arm, randomised, double-blind controlled clinical study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-19T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7fa4256a-350f-48e8-a0ae-2fa2ec0d217f">
	  <name>Department of Hemostasis and Transfusion Medicine</name>
	  <address/>
	  <city>Duesseldorf</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-40225</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with isolated valvular aortic stenosis or combined aortic-valve defect with prevailing stenosis (mean transvalvular gradient &gt;50 mmHg) with severe bleeding during aortic-valve replacement 
2. Age &gt;18 years. 
3. Written informed consent. 
4. All patients that fulfill at least one of the following criteria 15 minutes after the end of extracorporal circulation and application of protamine: 
4.1. Excessive bleeding without surgical explanation according to the surgeons' impression (Classification of bleeding as "normal", "moderate" or "excessive" by the surgeon. Classification as "excessive" bleeding leads to recruitment to the study). 
4.2. Drainage volume &gt;40 ml in 5 minutes following application of protamine and thorax closure.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40 patients (20 per arm)</totalTarget>
      <exclusion>1. Participation in other interventional studies that potentially impair the interpretation of results 
2. History suggestive for inherited or acquired bleeding disorder 
3. Written informed consent not to be obtained 
4. Active endocarditis 
5. Concomitant coronary heart disease 
6. Agents impairing platelet function at the time of surgery 
7. Pregnancy 
8. Known or suspected intolerance against Haemate HS 
9. Previous thromboembolic complications 
10. Known hepatitis B, hepatitis C or HIV infection 
11. Known or suspected intolerance against standard medication (e.g., heparin) 
12. Emergency surgery within the last 7 days 
13. Previous chemotherapy</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-10-19T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe intraoperative hemorrhage during aortic-valve replacement</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Severe intraoperative hemorrhage during aortic-valve replacement</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Intraoperative infusion Haemate HS 500/1000 IU (vWF/F VIII:C concentrate), time of infusion according to inclusion criteria.  
Control group: Intravenous infusion of 0.9% NaCl solution (100 ml)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Haemate HS (intraoperative infusion)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17333-0</funderId>
      <contactId>Contact55294_17333</contactId>
      <sponsorId>Sponsor53862</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55294_17333">
    <title>Dr</title>
    <forename>Rainer</forename>
    <surname>Zotz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Hemostasis and Transfusion Medicine
Heinrich Heine University Medical Center 
Moorenstrasse 5 </address>
      <city>Duesseldorf</city>
      <country>Germany</country>
      <zip>D-40225 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49(0)211 8117474</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Nicola.Moeller@med.uni-duesseldorf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53862">
    <organisation>Heinrich Heine University Duesseldorf (Germany) </organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>c/o Dr Rainer B. Zotz
Department of Hemostasis and Transfusion Medicine
Heinrich Heine University Medical Center
Moorenstrasse 5</address>
      <city>Duesseldorf </city>
      <country>Germany</country>
      <zip>D-40225</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)211 8117474</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">zotz@med.uni-duesseldorf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411327.2</gridId>
    <rorId>https://ror.org/024z2rq82</rorId>
  </sponsor>
  <funder id="Funder17333-0">
    <name>CSL Behring GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-08T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-02-06T00:00:00.000Z">88422298</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of the effectiveness of a nursing intervention aiming at facilitating the hospital to home transition within a cardiologic Emergency Room (ER) [Évaluation de l&#146;efficacité d&#146;un modèle d&#146;interventions infirmières de soutien à la transition hôpital-domicile dans une urgence cardiologique]</title>
      <scientificTitle/>
      <acronym>TRANSIT-ER [TRANSIT-URGENCE]</acronym>
      <studyHypothesis>We are studying the nursing discharge interventions modalities provided in the Emergency Room (ER) of a cardiology tertiary care centre where an important proportion of patients make repeated visits to the ER in the year following their discharge to home (24% of the patients).

It is hypothesised that the return rates to the ER in the month following discharge to home will be less important in the group receiving the intervention than in the control group.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>'Return to ER: the occurrence of any visits to the cardiologic ER in the month following randomisation. This will be measured using the hospital patient's registry.</primaryOutcome>
      <secondaryOutcome>The secondary outcomes will be measured at baseline and one month following randomisation by a telephone interview and are as followed: 
1. Health care continuity using the Heart Continuity of Care Questionnaire (HCCQ), a 41-item questionnaire using a 5 points Likert scale (score 1 to 5, 1 = strongly disagree, 5 = strongly agree) measuring the patients' perception of continuity of care in regard to eight different dimensions. A higher score indicate a better continuity of care process according to the patient.
2. Patient's self-care management using the Therapeutic Self-Care Tool (TSCT), a 12-item questionnaire using a 5 points Likert scale (score 0 to 5, 0 = not at all, 5 = very much so) measuring the patients' ability to initiate and perform activities aiming at maintaining health, managing health problems and restoring functioning. A higher score indicate better self-care capacities in the patient.
3. Medication adherence scale using the Self-Reported Medication-Taking Scale (SR-MTS), a 4-item questionnaire using a dichotomous (yes or no) scale measuring patients' adherence to prescribed medication. A higher score indicate a poorer adherence to medication.
4. Patients' perception of control over the disease and of its consequences using three subscales of the Illness Perception Questionnaire - Revised (IPQ-R), a 38-item questionnaire using a 5 points Likert scale (score 1 to 5, 1 = totally agree, 5 = totally disagree) measuring the patients' perception of his disease. The three subscales used are: 
4.1. Consequences (6 items)
4.2. Personal control (6 items) 
4.3. Treatment control (5 items)
Higher scores on the consequences subscale represent strongly held beliefs about the negative consequences of the disease. Higher scores on the control subscales represent positive beliefs about the controllability of the illness. 
5. Anxiety and depressing feelings using the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire using a 4 points ordinal rating scale and composed of two subscales (anxiety and depression - each score from 0 to 21). A higher score to each of the subscales indicate a higher degree of symptoms (anxiety or depression).
6. Health services utilisation using the medicare provincial registry (Régie de l&#146;assurance maladie du Québec). The occurence of ER visits, hospitalisation or medical consultations by the patient within the province of Québec will be collected at 1, 3, 6 and 12 months following discharge.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the research ethics committee of the Institut de Cardiologie de Montréal on the 7th September 2007 (ref: 07-963).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88422298</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>FRSQ 10187</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial - one ER (single centre)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0aa2b2c1-59d5-4402-b6cb-14c7920a19ab">
	  <name>R-1520</name>
	  <address/>
	  <city>Montreal, Quebec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H1T 1C8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female aged 18 years old or more presenting both of the following repeated visits to the ER criterion: 
1.1. Taking six medications or more a day
1.2. Having made one visit or more to the cardiologic ER in the last 12 months
2. Visiting the ER for an unplanned visit (i.e. not coming to the ER on a planned basis, e.g. to receive a laboratory or diagnosis procedure result)
3. Being discharged from the ER directly to their home
4. Having the physical and cognitive capacities to answer a written questionnaire and to communicate by telephone
5. Being able to communicate in French or in English</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>462</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>462</totalTarget>
      <exclusion>1. Having already another nursing follow-up in the 10 days following discharge (e.g. from another research project or from a specialised clinic) to avoid duplication of the nursing interventions being provided to the patient
2. Having already been recruited in the study in a precedent visit to the cardiologic ER</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Facilitation of hospital to home transition after a visit to the ER</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2>Facilitation of hospital to home transition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All eligible patients will meet with the research nurse after discharge care. Then, the study will be presented to the patient. After informed consent, the participants will be randomly assigned to the intervention or control group. The two groups will answer a questionnaire about the secondary outcomes and the baseline characteristics will be recorded.

Intervention group: 
After randomisation, the nurse will proceed with an assessment of the patient's risks of repeated visits to the ER following discharge to home. The evaluation will include the following themes: 
1. Patient's perception in regard to his discharge to home
2. Patient's self-management of his disease, symptoms and co-morbidities
3. Patient's self-management of his treatment
4. Patient's self-management of his daily living and domestic activities
5. Patient's self-management of his emotions and cognitions
6. Patient's external resources management 
7. Patient's health-services utilisation management

Following the assessment, the nurse will propose tailored interventions to the patient aiming at managing the repeated emergency department visits risk factors identified. Those interventions include: 
1. Teaching
2. Legitimisation and normalisation
3. Listening and empathy
4. Reassurance
5. Reframing
6. Confrontation
7. Recommendations
8. Warnings
9. Reinforcement
10. Referral to external resources 
11. Support to external resources already in place

The research nurse will proceed with this assessment-intervention process thrice: 
1. In person at the patient's discharge from the ER
2. By telephone 4 ± 3 days following discharge 
3. By telephone 10 ± 3 days following discharge

Finally, the patient will be able to contact the nurse by telephone during working hours in the 30 days following discharge for any concerns he would like to address her. 

Control group: 
No specific intervention by the research nurse, the patient will return to home.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17232-0</funderId>
      <contactId>Contact55193_17232</contactId>
      <sponsorId>Sponsor53759</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55193_17232">
    <title>Dr</title>
    <forename>Sylvie </forename>
    <surname>Cossette</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>R-1520
5000, Belanger Street</address>
      <city>Montreal, Quebec</city>
      <country>Canada</country>
      <zip>H1T 1C8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 376 3330 ext. 4012</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sylvie.cossette.inf@umontreal.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53759">
    <organisation>Montreal Heart Institute (MHI) Research Centre (Canada)</organisation>
    <website>http://www.icm-mhi.org/en/index.html</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>5000, Belanger Street</address>
      <city>Montreal, Quebec</city>
      <country>Canada</country>
      <zip>H1T 1C8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 376 3330</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Richard.Maheu@icm-mhi.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.482476.b</gridId>
    <rorId>https://ror.org/03vs03g62</rorId>
  </sponsor>
  <funder id="Funder17232-0">
    <name>Quebec Health Research Fund (Fonds de recherche en Santé du Québec [FRSQ]) (Canada) (ref: 10187)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-05T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-05T00:00:00.000Z">27058472</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in chronic staphylococcal osteomyelitis: a long-term follow-up trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Oral rifampin-cotrimoxazole combination may be as useful as the standard intravenous cloxacillin therapy against chronic osteomyelitis by Staphylococcus aureus.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Treatment failure rate, defined as the number of cases with clinical relapse (appearance or recurrence of local inflammatory signs or sinus tract drainage, with or without microbiological confirmation) during follow-up.</primaryOutcome>
      <secondaryOutcome>1. Treatment tolerability and compliance (number of patients who did not fulfil protocol treatment and reason), from patient inclusion to the end of antibiotic therapy (8 weeks)
2. Length of hospital stay (days) for each treatment schedule; defined as hospitalisation during the diagnosis and treatment of the episode</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Investigation Committee of Hospital de Bellvitge in January 1991.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27058472</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre interventional randomised, active controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1991-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1996-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="36d5acd5-06a6-4943-92d7-dda5e4b64ab5">
	  <name>Hospital de Bellvitge</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08907</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adult patients (greater than 18 years old) of any gender with chronic osteomyelitis by Staphylococcus aureus treated with surgery.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Exploratory study. Fifty patients included</totalTarget>
      <exclusion>1. Prosthetic joint infection
2. Methicillin resistant Staphylococcus aureus
3. Allergy to protocol antibiotics
4. Strain resistance to cotrimoxazole or rifampin</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1991-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1996-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Non-axial chronic osteomyelitis due to Staphylococcus aureus</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Chronic osteomyelitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After surgery and identification of Staphylococcus aureus upon surgical samples, randomisation of patients for antibiotic therapy: 
Group A: intravenous cloxacillin (2 g every four hours [q4h]) for 6 weeks followed by oral cloxacillin (500 mg every six hours [q6h]) for 2 weeks
Group B: oral rifampin-cotrimoxazol combination for 8 weeks (rifampin 600 mg every 24 hours [q24h] plus 7 - 8 mg/kg per day of trimethoprim component, equivalent to three simple strength cotrimoxazole capsules, every 12 hours [q12h])

The total duration of the protocol treatment was 8 weeks for both groups (6 intravenous [iv] and 2 oral [po] in the cloxacillin group and 8 po in the rifampin-cotrimoxazole group). The duration of the follow-up is from the end of antibiotic therapy until 2007 (a median of 10 years).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cloxacillin, rifampin-cotrimoxazole, trimethoprim</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17382-0</funderId>
      <contactId>Contact55343_17382</contactId>
      <sponsorId>Sponsor53913</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55343_17382">
    <title>Prof</title>
    <forename>Javier</forename>
    <surname>Ariza Cardenal</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hospital de Bellvitge
Feixa Llarga s/n
L'Hospitalet de Llobregat</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53913">
    <organisation>Institute of Biomedical Investigations of Bellvitge (Institut d'Investigació Biomèdica de Bellvitge) (IDIBELL) (Spain) </organisation>
    <website>http://www.idibell.es </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Dr. Javier Ariza Cardenal
Hospital de Bellvitge 
Feixa Llarga s/n
L'Hospitalet de Llobregat </address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418284.3</gridId>
    <rorId>https://ror.org/0008xqs48</rorId>
  </sponsor>
  <funder id="Funder17382-0">
    <name>Hospital de Bellvitge (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-05T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-05T00:00:00.000Z">06127083</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of post-caesarean infections in low resource countries: is a single dose as adequate as a multiple dose antibiotic regiment? A randomised controlled trial</title>
      <scientificTitle>Is the administration of a single prophylactic dose of ampicillin and metronidazole before caesarean section as effective as a multiple day regimen of these antibiotics to prevent postpartum maternal infection in a low resource setting? A randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Single dose antibiotic prophylaxes is as effective as a multiple dose scheme in women undergoing a caesarean section in low resource setting in preventing postoperative infections.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The presence of fever, endometritis, urinary tract infection, wound infection or other serious infections (such as pelvic abscess, peritonitis, sepsis). 

Timepoint of evaluation is on discharge (see interventions section): an independent doctor will review the wound and score the wound healing and record if any complication arose or additional antibiotics were given.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the National Instritute for Medical Research, Dar es Salaam (Tanzania) on the 12th November 2007 (ref: NIMR/HQ/R.8a/Vol.IX/633).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06127083</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Evaluator-blind randomised controlled non-inferiority trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="15602248-b215-4db9-ba1c-22ed0b319ee2">
	  <name>PO Box 228</name>
	  <address/>
	  <city>Lindi</city>
	  <state/>
	  <country>Tanzania</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Delivery through caesarean section
2. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Use of antibiotics in the last week
2. Known allergy for any of the antibiotics used
3. Greater than 24 hour rupture of membranes
4. Evident infection or fever pre- or during operation</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (only in Kiswahili)</patientInfoSheet>
      <recruitmentStart>2008-01-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Post-operative infection after caesareans</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Post-operative infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: ampicillin 1000 mg and metronidazole 500 mg intravenous 20 minutes prior to caesarean section 
Group 2: ampicillin 1000 mg and metronidazole 500 mg intravenous 20 minutes prior to caesarean section followed by ampicillin 500 mg 8-hourly for two more doses and metronidazole 500 mg 8-hourly for two more doses. After completion of the intravenous (iv) doses the patients will receive oral medication for four days (total 12 doses) of amoxicillin 500 mg and metronidazole 400 mg. 

The follow up will be until the patients are discharged: for uncomplicated lower segment caesarean section (LSCS) this will be on day five (in case of pfannenstiel incision) and day seven (in case of median incision). When complications arise, the patient will be followed up longer, until discharge.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17448-0</funderId>
      <contactId>Contact55409_17448</contactId>
      <sponsorId>Sponsor53979</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55409_17448">
    <title>Dr</title>
    <forename>Heleen</forename>
    <surname>van Beekhuizen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>PO Box 228</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53979">
    <organisation>Sokoine Regional Hospital (Tanzania)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>PO Box 1011</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17448-0">
    <name>Sokoine Regional Hospital (Tanzania)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-05T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-05T00:00:00.000Z">90960030</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of Functional milk product On the Metabolic Syndrome II</title>
      <scientificTitle>Randomised, controlled, double-blind clinical study on the effect of a functional milk-product on metabolism of men with diagnosed metabolic syndrome: study with extended sample size</scientificTitle>
      <acronym>EFOMS II</acronym>
      <studyHypothesis>The goal of the investigation is the question, to what extent the risk of the metabolic syndrome may be reduced by substances naturally occurring in milk. The pathophysiology of the metabolic syndrome is characterised by an insulin resistance, a dyslipidaemia, an essential hypertension and adiposity of the central type and frequently leads to early manifestation of type 2 diabetes mellitus and atherosclerosis. Such metabolic disturbances increase in the industrialised countries and in the developing countries, too, and represent an important economical and public-health cost factor. It is necessary to identify the relevant factors of human nutrition and to develop potential avoidance strategies, e.g. by development of functional food. 

The cow-milk derived substances, which will be used in this study have had influenced individual components of the metabolic syndrome and lowered the risk of components of the metabolic syndrome in own animal and human trials. 

This study is an extension of a previous human study (ISRCTN41474531 - see http://www.controlled-trials.com/ISRCTN41474531).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change of HOMeostasis model Assessment of Insulin Resistance (HOMA-IR) during the intervention period.</primaryOutcome>
      <secondaryOutcome>1. Blood pressure 
2. Body mass index (BMI), waist-to-hip ratio
3. Mean blood glucose during continuously glucose monitoring
4. Postprandial concentration of several hormones and blood parameters linked mainly to carbohydrate metabolism</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of the Medical Faculty of the Christian-Albrechts-University of Kiel (Germany) on the 26th October 2007 (ref: A171/06 - extended sample size).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN90960030</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study is a randomised double-blind placebo-controlled intervention study over 8 weeks.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-27T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d31222f0-eb82-4940-bf84-52b9b9dca0c1">
	  <name>Institute for Physiology and Biochemistry of Nutrition</name>
	  <address/>
	  <city>Kiel</city>
	  <state/>
	  <country>Germany</country>
	  <zip>24103</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men, 45 - 70 years old
2. A metabolic syndrome as defined by the International Diabetes Federation, 2006 (A new IDF worldwide definition of the metabolic syndrome: the rationale and the results - Diabetes Voice, Vol. 50 Issue 3, 2005)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240 volunteers (120 for each the verum and control group)</totalTarget>
      <exclusion>1. Participation in a clinical study with a medicament or a medicinal product within the last 30 days or simultaneous participation in another clinical examination 
2. Intake of nitrate and/or calcium antagonists and/or alpha-blockers, which affect the blood pressure 
3. Known metabolic or gastro-intestinal diseases, which affects the absorption, metabolism or excretion of food or food components 
4. Condition after operation of the gastro-intestinal tract, which affect gastro-intestinal motility 
5. Haemoglobin less than 12 g/dL 
6. Malfunction of blood coagulation or drugs, leading to malfunction of blood coagulating diabetes 
7. Operation within the last 3 months, which still affects the current state of health 
8. Illness of thyroid gland, which has metabolic and/or cardiovascular effects 
9. Known hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection or chronic liver damage 
10. Kidney insufficiency 
11. Hypercalcaemia 
12. Drug or alcohol abuse 
13. Intake of drugs affecting the absorption, metabolism or excretion of food components or the gastro-intestinal tract 
14. Intake of hormone preparations 
15. Vegetarianism, anorexia, bulimia 
16. Known milk protein allergy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-27T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Metabolic syndrome</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Metabolic syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The volunteers of the verum group will take one portion of the functional milk-product (product code 966125, a non-registered product) once a day after lunch with a dessert for 56 days. The product of the control group is based on meat protein and is isoenergetic and isonitrogenous. 

Primary and secondary outcome measures will be analysed before and at the end of the intervention.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Functional milk-product (product code 966125, a non-registered product)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17367-0</funderId>
      <contactId>Contact55328_17367</contactId>
      <sponsorId>Sponsor53897</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55328_17367">
    <title>Prof</title>
    <forename>Juergen</forename>
    <surname>Schrezenmeir</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Physiology and Biochemistry of Nutrition
Federal Reserach Centre for Nutrition and Food
Hermann-Weigmann-Str. 1</address>
      <city>Kiel</city>
      <country>Germany</country>
      <zip>24103</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)431 609 2220</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">juergen.schrezenmeir@bfel.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53897">
    <organisation>Humana GmbH (Germany) </organisation>
    <website>http://www.humana.de</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bielefelder Strasse 66</address>
      <city>Herford</city>
      <country>Germany</country>
      <zip>32051</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17367-0">
    <name>Humana GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-02-01T00:00:00.000Z">20442117</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of hemodynamic effects of cascade hemofiltration in septic shock</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Evaluation of the hemodynamic improvement using cascade hemofiltration in patients treated for septic shock</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of days without catecholamines at the 28th day of randomization</primaryOutcome>
      <secondaryOutcome>1. Rate of decrease of catecholamines during the first 72h 
2. Number of days without mechanical ventilation at the 90th day 
3. Number of days without Renal Replacement Therapy (RRT) at the 90th day 
4. Number of days without ICU requirement at the 90th day 
5. Death or survivor status at the 90th day</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. Committee for Protection of Research Subjects (Comité de Protection des Personnes [CPP]) Ile de France VI, approved on 16 July 2007 
2. France's Sanitary Safety in Health Products Agency (AFSSAPS), approved on 30 October 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20442117</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1450</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-center, pilot, prospective, parallel-group, randomised controlled study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9dfb7251-5081-41cd-802c-fb80dbccd2fe">
	  <name>Gambro Industries</name>
	  <address/>
	  <city>Lyon</city>
	  <state/>
	  <country>France</country>
	  <zip>69357</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patient with a septic shock diagnosed by the medical staff team
2. Patient mechanically ventilated and treated by high doses of catecholamines after adequate fluid administration (superior or equal to 1.0 mg/h of norepinephrine or epinephrine) for more than 120 minutes and &lt;24h
Note: Patients with renal failure (treated or not) can be included</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Age (years) &lt;18 or &gt;85 
2. Weight &gt;120 kg 
3. Thrombocytopenia 50&lt; G/l or Neutrophils &lt;0.5 Giga/l 
4. Contra indication to heparin anticoagulation 
5. Patient requiring catecholamines (epinephrine or norepinephrine superior or equal to 1 mg/h) for &gt;24h 
6. Patient admitted to the Intensive Care Unit (ICU) superior or equal to 7 days before the inclusion criteria 
7. Patient with intercurrent disease limiting his/her self-sufficiency (need of help before septic shock) 
8. Inclusion (&lt;28 days) in another study interfering with the goals of the current investigation 
9. Pregnancy and patient under guardianship 
10. Immune compromised patients (e.g., being treated for cancer, treated by immunosuppressors or steroids, AIDS)</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Septic shock/ hemofiltration</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Septic shock/ hemofiltration</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Either standard hemofiltration or Cascade hemofiltration (2 types of membrane evaluated)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17411-0</funderId>
      <contactId>Contact55372_17411</contactId>
      <sponsorId>Sponsor53942</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55372_17411">
    <title>Mrs</title>
    <forename>Nathalie</forename>
    <surname>Loughraieb</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Gambro Industries
Clinical Affairs Department
61 Avenue Tony Garnier
BP 7315</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69357</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53942">
    <organisation>Gambro Industries, Clinical Affairs Department (France)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>61 Avenue Tony Garnier
BP 7315</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69357</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487322.8</gridId>
    <rorId>https://ror.org/01mgtdr23</rorId>
  </sponsor>
  <funder id="Funder17411-0">
    <name>Gambro Industries (International)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-29T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-01-29T00:00:00.000Z">88931004</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The learning curve for vitreous surgery</title>
      <scientificTitle>The learning curve for primary vitrectomy without scleral buckling for pseudophakic retinal detachment</scientificTitle>
      <acronym/>
      <studyHypothesis>Pseudophakic retinal detachment is a complication in patients after cataract surgery. Although rare, this represents a high number of patients since the number of cataract extractions is on the rise (500,000 in France). This complication may lead to a severe loss of visual acuity. 

In this study we aim to evaluate the learning curve of junior surgeons in performing primary vitrectomy without scleral buckling for pseudophakic retinal detachment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Reattachment rate with a single procedure at 6-month follow-up</primaryOutcome>
      <secondaryOutcome>1. Number of final successes
2. Number of reoperations and complications</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee for the Protection of Human Subjects in Biomedical Research, Bourgogne (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Bourgogne). Date of approval: 4 Marth 2004 (ref: 2004/19)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88931004</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Retrospective interventional case series in two academic centers.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0d3108ae-881b-4038-8d13-d4ebb1d7fa08">
	  <name>Service d'Ophtalmologie</name>
	  <address/>
	  <city>Dijon</city>
	  <state/>
	  <country>France</country>
	  <zip>21000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients presenting with a pseudophakic retinal detachment and a Proliferative VitreoRetinopathy (PVR) grade A and B</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>280</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>280</totalTarget>
      <exclusion>Patients presenting with a pseudophakic retinal detachment and a PVR grade C and D</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pseudophakic retinal detachment</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Pseudophakic retinal detachment</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Surgical procedure with pars plana vitrectomy under local anesthesia. Drainage of subretinal fluid through the retinal break or a retinotomy. External cryotherapy on the retinal tears. At the end of the procedure, air-gas exchange with inexpansible gas mixture. No scleral buckling added.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17399-0</funderId>
      <contactId>Contact55360_17399</contactId>
      <sponsorId>Sponsor53930</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55360_17399">
    <title>Prof</title>
    <forename>Catherine</forename>
    <surname>Creuzot-Garcher</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Service d'Ophtalmologie
CHU General Hospital </address>
      <city>Dijon</city>
      <country>France</country>
      <zip>21000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53930">
    <organisation>Burgundy Association for Research in Ophthalmology (ABPRO) (France) </organisation>
    <website>http://www.chu-dijon.fr</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Service d'Ophtalmologie
CHU General Hospital</address>
      <city>Dijon</city>
      <country>France</country>
      <zip>21000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17399-0">
    <name>University Hospital Dijon (CHU), General Hospital (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-29T00:00:00.000Z">34357360</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Better Efficacy in Lowering events by General practitioner's Intervention Using remote Monitoring in Heart Failure</title>
      <scientificTitle/>
      <acronym>BELGIUM-HF Registry &amp; Trial</acronym>
      <studyHypothesis>To test the hypothesis that general practitioner's intervention triggered by an alarm generated by an algorithm based on non-invasive vital sign home telemonitoring measurements in moderate to severe heart failure patients may reduce the rate of hospitalisations for heart failure, mortality or both. 

The BELGIUM-HF Registry and Trial is a study that will be conducted in two steps. 
The primary objective of the registry is to identify predictors of death, heart failure recurrence requiring hospitalisation, or both, and to validate simple and robust interventional algorithms based on weight, blood pressure and pulse transmitted by a telemonitoring system and to test those algorithms in subgroups of patients. 

The primary objective of the subsequent randomised trial is to demonstrate a reduction in the incidence of Heart Failure (HF)-related hospitalisations or all-cause mortality in HF subjects managed with the the telemonitoring/interventional algorithm strategy as compared with HF subjects managed with the telemonitoring/usual care strategy over a period of 6 months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary outcome measures in the Randomised Trial: 
1. Incidence of HF-related hospitalisations (Duration of follow-up: 6 months) 
2. All-cause mortality (Duration of follow-up: 6 months)</primaryOutcome>
      <secondaryOutcome>The following secondary end-points in the Randomised Trial will be assessed at 3 and 6 months except the cost-effectiveness evaluation, which will be carried out after the trial: 
1. To demonstrate a reduction in the combined end-point of cardiac death, HF-related hospitalisations and cardiac-related urgent visits and interventions whichever comes first in HF subjects managed with the TeleMonitoring (TM) strategy compared to the Usual Care (UC) strategy 
2. To demonstrate a reduction in HF-related hospitalisations in the TM arm compared to the UC arm 
3. To demonstrate a reduction in all-cause mortality in the TM arm compared to the UC arm 
4. To demonstrate a reduction in cardiac mortality in the TM arm compared to the UC arm 
5. To demonstrate a reduction in the number of days spent at the hospital for HF-related conditions in the TM arm compared to the UC arm 
6. To determine whether TM intervention improves functional status as assessed by a 6-minute walk test 
7. To demonstrate an improvement in quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the TM arm compared to the UC arm 
8. To report a shift from "in-patient" to "out-patient" healthcare utilisation in the TM arm compared to the UC arm 
9. To conduct a cost-benefit comparison between the two strategies</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee for Clinical Trials at the Saint-Jean Clinic (Commission d'éthique Expérimentation Humaine de la Clinique Saint-Jean), Brussels. Date of approval: 10/10/2007 (ref: 2007-284)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34357360</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Parallel-group, prospective, single-centre, phase III, randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-12-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="75ad38d6-9e3c-4f1b-98b2-198c29fb8b98">
	  <name>Boulevard du Jardin Botanique 32</name>
	  <address/>
	  <city>Brussels</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>1000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>BELGIUM-HF will be conducted in two steps: a prospective registry and a subsequent randomised trial. The BELGIUM-HF Registry will be completed before the BELGIUM-HF Randomised Trial starts. Patients who have been included in the Registry are eligible for the subsequent randomised trial if they meet the inclusion criteria at that time and have signed an informed consent regarding the randomised trial. 

Inclusion criteria for both BELGIUM-HF Registry and Randomised Trial: 
1. Subject with left ventricular systolic dysfunction, defined as a left ventricular ejection fraction &lt; or = 40%, documented by echocardiography, contrast ventriculography or radionuclide angioscintigraphy within 6 months prior to inclusion 
2. Subject has been hospitalised within the past 6 months for mild to severe heart failure defined as New York Heart Association (NYHA) class II to IV 
3. Subject has received loop diuretics within 2 weeks prior to inclusion 
4. Subject is at least 18 years of age 
5. Subject or subject's legally representative has signed and dated the study informed consent</inclusion>
      <ageRange>Not Specified</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Registry: 200 patients; Randomised trial: 500 patients</totalTarget>
      <exclusion>1. Subject who is scheduled for corrective valve surgery or coronary revascularisation, i.e. Coronary Artery Bypass Grafting (CABG) or Percutaneous Coronary Intervention (PCI) in a near future 
2. Subject who has significant concurrent illness or condition not related to heart failure (i.e. terminal malignancy), associated with a life expectancy that is anticipated to be shorter than the expected duration of the trial 
3. Subject on chronic renal dialysis 
4. Pregnancy 
5. Subject who has a health condition or psychic condition associated with poor compliance, including active alcoholism, mental illness or drug dependence 
6. Subject directly involved in the execution of this protocol</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-12-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systolic heart failure</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Systolic heart failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>BELGIUM-HF Registry: No intervention. Duration of the Registry: 6 months. Follow-up visits will take place at 3 and 6 months. 

BELGIUM-HF Trial: General practitioner's intervention based on an alarm generated by a predefined algorithm applied to the telemonitoring system and based on daily measured blood pressure, pulse and weight versus usual care (control). Types of intervention: none, medication changes, cardiologist referral, out-patient clinic referral, emergency room referral, hospitalisation. 

Duration of intervention: 6 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17314-0</funderId>
      <contactId>Contact55275_17314</contactId>
      <sponsorId>Sponsor53843</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55275_17314">
    <title>Dr</title>
    <forename>Marc</forename>
    <surname>Castadot</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Boulevard du Jardin Botanique 32</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53843">
    <organisation>Saint-Jean Clinic, Department of Cardiology (Belgium)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Boulevard du Jardin Botanique 32</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.490685.6</gridId>
    <rorId>https://ror.org/01dd1x730</rorId>
  </sponsor>
  <funder id="Funder17314-0">
    <name>Institute for the Encouragement of Scientific Research and Innovation of Brussels (Public funding) (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-25T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-25T00:00:00.000Z">83077547</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>ALAP-1 for the attenuation of nasal provocation with histamine in seasonal allergic rhinitis: a randomised, double-blind, placebo-controlled, three-day dosing, cross-over study and dose finding one month cross-over study</title>
      <scientificTitle/>
      <acronym>BB100A and BB100B</acronym>
      <studyHypothesis>1. To evaluate the ability of ALAP-1 compared with placebo to reduce the signs and symptoms of allergic rhinitis (AR) in the presence of a nasal histamine challenge
2. To evaluate the efficacy of chronic dosing of ALAP-1 compared with placebo on reducing the symptoms of AR induced by nasal histamine challenge</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Peak nasal inspiratory flow meter, measured at 0, 10, 20, 30, 45 and 60 minutes post-histamine challenge on the study visit days.</primaryOutcome>
      <secondaryOutcome>Sneeze score, measured at 0, 10, 20, 30, 45 and 60 minutes post-histamine challenge on the study visit days.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Copernicus Group Institutional Review Board (IRB) on the 19th September 2006 (ref: MED4-06-238).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83077547</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BB100A and BB100B</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind placebo controlled crossover study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5f1ebd8f-02a4-4741-b745-c8b519fe7177">
	  <name>18250 Roscoe Blvd.</name>
	  <address/>
	  <city>Northridge</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>91325</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 18 - 59 years, either sex
2. A history of seasonal allergic rhinitis</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Atrophic rhinitis
2. Rhinitis medicamentosa
3. Nasal polyps
4. Septal deviation
5. Active bacterial or viral sinusitis
6. Severe asthma
7. Peptic ulcer disease or active gastroesophageal reflux disease (GERD)
8. History of anaphylaxis to any allergen
9. Pregnancy
10. Active bacterial or viral rhinitis
11. Nasal surgery within the last eight weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Seasonal allergic rhinitis</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Seasonal allergic rhinitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>ALAP-1 (herbal combination) versus placebo. ALAP-1 is an herbal combination formulated to prevent and reduce AR symptoms. This proprietary formula is a standardised blend of the following eleven botanical extracts: Cullen corylifolium (Psoralea fruit), Xanthium sibiricum (Xanthium fruit), Scutellaria baicalensis (Chinese skullcap root), Gardenia augusta (Gardenia fruit), Bupleurum chinense (Bupleurum root), Chrysanthemum x moriflolium (Chrysanthemum flower), Areca catechu (Areca husk), Schisandra spp. (Schisandra fruit), Ziziphus jujuba var. spinosa (Jujube seed), Nepeta tenuifolia (Schizonepeta aerial parts) and Plantago asiatica (Asian plantain seed).

Three-day study:
Subjects will consume three capsules of ALAP-1 (1350 mg) or placebo per day for two days and return to the research office on the third day for evaluation. Subjects undergo their baseline peak nasal inspiratory flow (PNIF) measurement and then consume four capsules of ALAP-1 (1800 mg) or placebo. Fifteen minutes later, the nasal histamine provocation is performed. Shortly after the histamine challenge, subjects consume an additional 4 capsules of ALAP-1 (1800 mg) or placebo. This dosing regimen simulates the method in which the formula would be used in practice: daily preventive doses during allergy season and a treatment dose in the event of direct exposure to an environmental allergen. Subjects then wash out for 1 week and are then enrolled into the opposite arm (active or placebo). 

One month study:
Subjects will receive ALAP-1 or placebo for 4 weeks total. Initally, ALAP-1 (or placebo) is provided for 2 weeks at a high dose (1350 mg/day) and subjects undergo nasal histamine provocation and peak nasal inspiratory flow (PNIF) measurements. Then subjects are given ALAP-1 or placebo for 2 weeks at a low dose (900 mg/day). Subjects washout for 1 week and then are enrolled in the opposite arm.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>ALAP-1</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17379-0</funderId>
      <contactId>Contact55340_17379</contactId>
      <sponsorId>Sponsor53910</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55340_17379">
    <title>Dr</title>
    <forename>Jay</forename>
    <surname>Udani</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>18250 Roscoe Blvd.
Suite 240</address>
      <city>Northridge</city>
      <country>United States of America</country>
      <zip>91325</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53910">
    <organisation>Radix Bioscience (USA) </organisation>
    <website>http://www.radixbioresearch.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>4436 Reeves Road</address>
      <city>Ojai</city>
      <country>United States of America</country>
      <zip>93023</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.505150.4</gridId>
    <rorId>https://ror.org/024hp8310</rorId>
  </sponsor>
  <funder id="Funder17379-0">
    <name>Radix Bioscience (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-23T00:00:00.000Z">37803178</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety of perioperative patients with obstructive sleep apnoea</title>
      <scientificTitle/>
      <acronym>OSAS</acronym>
      <studyHypothesis>Polysomnographic parameters in patients with obstructive sleep apnoea are influenced by the type of surgery and the type of anaesthesia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Apnoea-hypopnoea index, based on the following: 
1. Continuous polysomnographic measurement. This will be carried out at the following timepoints:
1.1. The night before surgery from 23:00 pm to 7:00 am
1.2. For 2 hours in the recovery room after extubation
1.3. After returning from the recovery room to the ward, until 7:00 am next day 
2. The patients will be asked to rate the intensity/recreative power of the night sleep on a scale, from 1 (not recreative) to 5 (very recreative) the first and second morning 7:00 am</primaryOutcome>
      <secondaryOutcome>1. Patient satisfaction, based on the following: 
1.1. The patients will be asked to rate his contentedness with the anaesthesia on a scale, from 1 (very content) to 5 (not content) the next morning after surgery
1.2. The patients will be asked to rate the pain on a scale from 0 (no pain) to 10 (strongest pain) at the following timepoints:
1.2.1. At the beginning of the anaesthesia
1.2.2. Immediately after extubation
1.2.3. After the first hour in the recovery room
1.2.4. After the second hour in the recovery room
1.2.5. Next morning after surgery
2. Heart rate and blood pressure, measured as part of the continuous polysomnographic measurement (see primary outcome measures)
3. Circulating mediators 
4. Validity of screening</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Charité - Berlin Medical University Ethics Committee on the 18th May 2006 (ref: EA1/016/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37803178</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EA1/016/06</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="eb81e125-6361-4ac6-8c55-ee6a4d0fa1df">
	  <name>Chariteplatz 1</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10117</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Obstructive sleep apnoea (the Epworth Sleepiness Scale [ESS] score greater than 9) 
2. Elective surgery with either general or regional anaesthesia, or airway surgery 
3. Aged greater than 18 years, either sex
4. American Society of Anaesthesiologists (ASA) classification I - III</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Significant cardiovascular or pulmonary disease 
2. Significant liver or renal disease 
3. Significant psychiatric disease rendering the subject unable to participate in the trial 
4. Drug dependency 
5. Chronic opioid therapy 
6. Chronic BiPAP (Bi-level Positive Airway Pressure) ventilator therapy</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet.</patientInfoSheet>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obstructive sleep aponea</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Obstructive sleep aponea</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: 20 patients with surgery with general anaesthesia
Group 2: 20 patients with surgery with regional anaesthesia
Group 3: 20 patients with surgery on the upper airway with general anaesthesia

Randomisation of participants will be carried out between groups 1 and 2. There is no randomisation in group 3.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17209-0</funderId>
      <contactId>Contact55170_17209</contactId>
      <sponsorId>Sponsor53736</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55170_17209">
    <title>Prof</title>
    <forename>Thomas</forename>
    <surname>Volk</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53736">
    <organisation>Charite - University Medicine Berlin (Charite - Universitaetsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder17209-0">
    <name>Charite - University Medicine Berlin (Charite - Universitaetsmedizin Berlin) (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-18T00:00:00.000Z">84220089</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An interventional, randomized, double-blind, placebo-controlled, parallel-assignment, safety/efficacy study for treatment of chronic middle ear infection in adult patients with the antimicrobial peptide OP-145</title>
      <scientificTitle/>
      <acronym>OP-145</acronym>
      <studyHypothesis>The purpose of this study is to determine the safety, tolerability, and efficacy of OP-145 eardrops to the middle ear of patients with chronic otitis media. We hypothesize that OP-145 will improve the middle ear mucosa in patients with chronic otitis media.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety of OP-145 eardrops, which will be determined by the following at baseline and week 1, 2, 4, 8, and 12 (for both Part I and II of the trial): 
1. Hearing levels
2. Blood analysis
3. Antibody detection
4. Bacterial culture of ear and throat swabs
5. Quality of life questionnaires (the 36-item Short Form health survey (SF-36), the Brief Illness Perception Questionnaire and the Chronic Ear Survey)</primaryOutcome>
      <secondaryOutcome>Efficacy of OP-145 eardrops, assessed by the following at baseline and week 1, 2, 4, 8, and 12: 
1. Mucosal endoscopic scores (for both Part I and II of the trial)
2. Quality of life questionnaires (the 36-item Short Form health survey (SF-36), the Brief Illness Perception Questionnaire and the Chronic Ear Survey) (only for Part II of the trial)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Medical Ethics Committee of the Leiden University Medical Center. Approved on the 19th December 2003 (Ref: P02.216/YR/yr)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84220089</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P02.216</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase I/II, double-blind, parallel-assignment, safety/efficacy, randomized placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f78f205a-9198-4106-8aaa-1954d67ac7ff">
	  <name>Leiden University Medical Center</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2333 ZA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Inclusion criteria for the Part I dose finding study: 
1. Adults &gt;= 18 years, males and females 
2. Legally competent, no psychiatric history 
3. Chronic otitis media with a clear perforation of the tympanic membrane &gt;3 months 
4. Chronic proliferative mucosal changes (confirmed by Computerised Tomography (CT) scan) 
5. Antibiotic therapy resistant (Adequately treated with at least 2 different eardrops for &gt;6 weeks) 

Inclusion criteria for the Part II randomised controlled study: 
1. Adults, both males and females, over 18 years of age 
2. Legally competent, with no history of psychiatric disorders 
3. Chronic otitis media with a clear perforation of the tympanic membrane, lasting longer than 6 months 
4. Chronic proliferative mucosal changes  (confirmed with CT scan)
5. Antibiotic therapy resistant (Adequately treated with at least 2 different eardrops for &gt;6 weeks)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Part I: 16 patients; Part II: 52, with an interim analysis after 26 patients.</totalTarget>
      <exclusion>Exclusion criteria for the Part I dose finding study: 
1. Presence of cholesteatoma in the treated ear (confirmed with CT-scan) 
2. History of mastoidectomy in the treated ear (resulting in a 'radicaalholte') 
3. Pregnant and breastfeeding women 
4. Patients that have been using topical, oral or parenteral antibiotics or steroids in the last 30 days 
5. Patients that have been using prednison or any other immunosuppressive agent in the last 30 days 
6. Patients with serious headaches 
7. Patients with Down syndrome or other congenital anomalies in the upper respiratory tract 
8. Immunocompromized patients or patients with auto-immune disorders 
9. History of seizures 
10. Patients with deficits at the nervus facialis 

Exclusion criteria for the Part II randomised controlled study: 
1. Presence of cholesteatoma in the treated ear (confirmed with CT-scan)
2. History of mastoidectomy in the treated ear (resulting in a 'radicaalholte')
3. Pregnant and breastfeeding women 
4. Patients that have been using topical, oral or parenteral antibiotics or steroids in the last 30 days
5. Patients that have been using prednison or any other immunosuppressive agent in the last 30 days
6. Patients with serious headaches
7. Patients with Down syndrome or other congenital anomalies in the upper respiratory tract
8. Immunocompromized patients or patients with auto-immune disorders
9. History of seizures
10. Patients with deficits at the nervus facialis
11. Patients who were included in the Part I dose finding study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic otitis media</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Chronic otitis media</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Part I dose finding study: 

The participants were allocated into four trial arms in the order of inclusion timepoints i.e. the first four participants were allocated to the lowest dose group, second four in the next dose group, etc. 

Arm 1: 0.25 mg/ml OP-145 eardrops twice a day
Arm 2: 0.5 mg/ml OP-145 eardrops twice a day
Arm 3: 1.0 mg/ml OP-145 eardrops twice a day
Arm 4: 2.0 mg/ml OP-145 eardrops twice a day

Duration of intervention: 2 weeks
 
Part II randomised controlled study: 
Based on the results of the Part I study the Part II study was executed with 0.5 mg/ml OP-145 eardops twice a day (control: placebo twice a day) for 2 weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I/II</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16955-0</funderId>
      <contactId>Contact54916_16955</contactId>
      <sponsorId>Sponsor53481</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54916_16955">
    <title>Dr</title>
    <forename>Nanno</forename>
    <surname>F.A.W. Peek</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leiden University Medical Center
Albinusdreef 2</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 ZA </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53481">
    <organisation>OctoPlus N.V. (The Netherlands)</organisation>
    <website>http://www.octoplus.nl/index.cfm/site/OctoPlus/pageid/821DEDEC-E30E-0D4E-CC80F8CDD400753F/index.cfm</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Ewoud-Jan van Hoogdalem 
Zernikedreef 12</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 CL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476342.0</gridId>
    <rorId>https://ror.org/01dn4wg45</rorId>
  </sponsor>
  <funder id="Funder16955-0">
    <name>OctoPlus Inc. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-18T00:00:00.000Z">74707125</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Does Acamprosate Decrease Cue-induced Alcohol Craving?</title>
      <scientificTitle>A randomised placebo-controlled trial of acamprosate effects on alcohol cue reactivity and alcohol priming in dependent patients</scientificTitle>
      <acronym>DADCAC</acronym>
      <studyHypothesis>1. Acamprosate attenuates cue-induced subjectively experienced and physiolological correlates of craving
2. Acamprosate attenuates alcohol-induced subjectively experienced and physiolological correlates of craving</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. The difference in subjectively experienced craving post exposure to non-alcohol related stimuli versus alcohol related stimuli
2. The difference in subjectively experienced craving between pre- and post-consumption of an alcoholic drink

For both measures comparisons are made between acamprosate versus placebo treated patients. Measures are collected post 22 days of treatment. Patients then come to the clinic and go through a series of sessions where they are exposed to alcohol versus non-alcohol related stimuli, and also take part in a alcohol priming paradigm. Present alcohol craving is measured in connection to each exposure.</primaryOutcome>
      <secondaryOutcome>Physiological measures of craving:
1. Pulse
2. Blood-pressure
3. Cortisol in blood
4. Galvanic skin response
5. Skin temperature

Measures are collected post 22 days of treatment. Patients then come to the clinic and go through a series of sessions where they are exposed to alcohol versus non-alcohol related stimuli, and also take part in an alcohol priming paradigm. Present alcohol craving is measured in connection to each exposure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The trial was approved by:
1. The Regional Ethical Review Board in Stockholm on the 23rd March 2005 (ref: 2005/30-31/3)
2. The Swedish Medical Products Agency on the 5th April 2005 (EudraCT number: 2004-004514-17)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74707125</doi>
      <eudraCTNumber>2004-004514-17</eudraCTNumber>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EudraCT number: 2004-004514-17</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study used a randomised, double blind, single-site, placebo-controlled design comparing cue- and alcohol-induced craving for acamprosate and placebo treated patients</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-05T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c942a0cf-9319-4efa-bb72-44bcbf1a268c">
	  <name>Department of Clinical Neuroscience</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>17176</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A male or a non-pregnant/non-nursing female between 18 and 65 years of age
2. A goal of controlled drinking
3. An intact sense of smell
4. Fulfilling the criteria for alcohol dependence according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
5. Willingness to give informed consent and comply with study procedures
6. Alcohol consumption in 15 of the last 90 days</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>56</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>56</totalTarget>
      <exclusion>1. Seeking complete alcohol abstinence
2. Current use of any medication that interferes with salivation
3. A diagnosis of an Axis I psychiatric disorder according to DSM-IV criteria (including all forms of substance dependence other than nicotine and alcohol)
4. A current use of psychoactive medications to manage schizophrenia, bipolar disorder, or major depression
5. Inpatient alcohol detoxification within the last 4 days
6. Acamprosate medication during the last year
7. Use of illegal drugs during the course of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-05T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Alcohol dependence</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Alcohol dependence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were assigned to 22 days of either acamprosate (1998 mg/day) or placebo treatment according to a randomisation process conducted by the Karolinska University Hospital pharmacy. Medication (150 tablets containing 333 mg acamprosate or placebo) was dispensed once per patient, at the start of the trial, with instructions to intake 6 tablets per day (2 in AM, 2 midday, 2 in PM).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Acamprosate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17269-0</funderId>
      <funderId>Funder17269-1</funderId>
      <funderId>Funder17269-2</funderId>
      <funderId>Funder17269-3</funderId>
      <contactId>Contact55230_17269</contactId>
      <sponsorId>Sponsor53798</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55230_17269">
    <title>Dr</title>
    <forename>Johan</forename>
    <surname>Franck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Clinical Neuroscience
Section for Alcohol and Drug dependence Research
Karolinska University Hospital, M4:02</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>17176</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">johan.franck@ki.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53798">
    <organisation>Addiction Centre Stockholm (Beroendecentrum Stockholm) (Sweden)</organisation>
    <website>http://www.beroendecentrum.com</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Box 17914</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>118 95 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476028.f</gridId>
    <rorId>https://ror.org/04g380834</rorId>
  </sponsor>
  <funder id="Funder17269-0">
    <name>AFA insurances (AFA försäkringar) (Sweden) - http://www.afaforsakring.se</name>
    <fundRef/>
  </funder>
  <funder id="Funder17269-1">
    <name>Systembolagets Council for Alcohol Research (Systembolagets råd för alkoholforskning) (Sweden) - http://www.can.se/sa/node.asp?node=1663</name>
    <fundRef/>
  </funder>
  <funder id="Funder17269-2">
    <name>Milan Valverius Foundation (Sweden) - http://www.salusansvar.se/info/default.aspx?FolderID=3063a24d-26b2-416d-b00a-1d4d06810b2e</name>
    <fundRef/>
  </funder>
  <funder id="Funder17269-3">
    <name>Foundation for Research on Psychiatric Diseases (Psykiatrifonden) (Sweden) - http://www.psykiatrifonden.se</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-28T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-01-14T00:00:00.000Z">39902015</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness of the "Smoke-Free Class Competition" (SFC) in delaying the onset of smoking in Polish students: a cluster-randomized controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>SFC shows a preventive effect on knowledge, attitudes and smoking behaviour</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following will be assessed by questionnaires at the end of intervention and at 12- and 18-month follow-up: 
1. Knowledge on smoking consequences 
2. Attitudes towards smoking 
3. Intention to use tobacco 
4. Smoking status</primaryOutcome>
      <secondaryOutcome>The following will be assessed by questionnaires at the end of intervention and at 12- and 18-month follow-up: 
1. Class climate 
2. Bullying</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Bioethics Commission of the University of Medical Sciences in Poznan, Poland. Date of approval: 15 May 2008 (ref: 511/08)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN39902015</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, cluster-randomized, controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
	<country>Poland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2e7b37ef-cd33-49dd-8498-c9cf42765651">
	  <name>Institute for Therapy and Health Research (IFT- Nord)</name>
	  <address/>
	  <city>Kiel</city>
	  <state/>
	  <country>Germany</country>
	  <zip>24105</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Students of public schools 
2. Age between 10&#150;13 years old (10 year on the beginning of the study, 4th grade) 
3. Written consent of parents</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="10.0"/>
      <upperAgeLimit unit="Years" value="13.0"/>
      <gender>Both</gender>
      <targetEnrolment>2940</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>81 schools /  142 classes / 2,940 students</totalTarget>
      <exclusion>1. Students of schools with special pedagogic needs
2. Missing parental consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Smoking prevention</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Smoking prevention</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participating schools will be randomised to the intervention and control groups. 

Intervention group: "Smoke-Free Class Competition" ("Wspólzawodnictwo Klasa Wolna od Dymu") 
Control group: Treatment as usual 

Description of the intervention: Each participating class has to decide if they want to be a "Smoke-free Class" for a six-month period from fall to spring. Classes monitor their (non-) smoking behaviour and report it to the teacher regularly. Classes, in which pupils refrain from smoking for this period of time participate in a prize draw.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17370-0</funderId>
      <contactId>Contact55331_17370</contactId>
      <sponsorId>Sponsor53901</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55331_17370">
    <title>Dr</title>
    <forename>Reiner</forename>
    <surname>Hanewinkel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Therapy and Health Research (IFT- Nord)
Düsternbrooker Weg 2</address>
      <city>Kiel</city>
      <country>Germany</country>
      <zip>24105</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53901">
    <organisation>European Commission</organisation>
    <website>http://ec.europa.eu/index_en.htm</website>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>DG Health and Consumer Protection</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1049</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.270680.b</gridId>
    <rorId>https://ror.org/00k4n6c32</rorId>
  </sponsor>
  <funder id="Funder17370-0">
    <name>European Commission</name>
    <fundRef>http://dx.doi.org/10.13039/501100000780</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-11T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-01-11T00:00:00.000Z">18010960</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Amniocentesis Before rescue Cerclage</title>
      <scientificTitle/>
      <acronym>ABC Trial</acronym>
      <studyHypothesis>We hypothesise that the use of a diagnostic amniocentesis and testing for rapid markers of chorioamnionitis (amniotic fluid lactate dehydrogenase or glucose level) will identify a subset of women without subclinical chorioamnionitis for whom the cerclage is more likely to prolong pregnancy to a viable gestational age and decrease the risk of neonatal and maternal complications.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary comparison will be the prolongation of gestation to greater than 34 weeks of gestation, defined as rescue cerclage success.</primaryOutcome>
      <secondaryOutcome>1. Maternal morbidity: will include complications of cerclage insertion, through gestation and at the time of the delivery
2. Neonatal morbidity: will include complications during the initial admission to the nursery following the delivery</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval is pending as of 31/10/2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18010960</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MSH Reference Number # 07-0080-A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7612215e-3013-4743-a54d-c1960b0f3e06">
	  <name>RM 3201</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M5G 1X8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Singleton gestation 
2. Presence of cervical dilatation 
3. Membranes visible at or protruding through the cervical opening 
4. Absence of any uterine activity 
5. Absence of any overt signs of maternal infection:
5.1. Maternal temperature greater than 37.8°C
5.2. Diffuse abdominal pain
5.3. Foul/pus like discharge
5.4. Maternal or foetal tachycardia</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>46</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>46</totalTarget>
      <exclusion>1. Intrauterine foetal demise or distress 
2. Intrauterine growth restriction 
3. Foetal anomaly 
4. Poly- or oligo-hydramnious 
5. Ruptured foetal membranes 
6. Current history of significant antepartum haemorrhage</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cervical incompetence</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Maternal care for cervical incompetence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Women will be randomised to either:
1. Cerclage group 
2. Amniocentesis and cerclage group

Randomisation will be organised by a random numbers table and assigned by telephone. Women randomised to the amniocentesis group will undergo an aseptic aspiration of amniotic fluid under ultrasound guidance by a single operator. Briefly, the abdomen will be prepared with antiseptic solution and draped with sterile towels. The ultrasound transducer probe will be draped with a sterile plastic cover. Using a sterile water-based ultrasound gel to facilitate visualisation, the operator will identify a pocket of amniotic fluid suitably away from the foetus and placenta. A sterile 22 gauge needle will be passed into the uterine cavity under direct visualisation and approximately 15 cc of amniotic fluid will be aspirated. 

Post procedure, Rhogam™ will be administered to Rhesus negative patients as indicated. Amniotic fluid will be tested for lactate dehydrogenase level (2 cc), glucose level (2 cc), cell count (2 cc), haemoglobin level (2 cc) and Gram staining (2 cc). Amniotic fluid will be sent for confirmatory aerobic, anaerobic and myoplasma/ureaplasma culture (4 cc per culture). 

All tests will be performed by the respective Departments of Biochemistry, Haematology and Microbiology (Mount Sinai Hospital, Canada) using established protocols. While waiting for the fluid test results (approximately 90 - 120 minutes), a tocodynometer will be placed over the uterine fundus to confirm the absence of uterine activity. Those women without evidence of subclinical infection following amniocentesis and those women who were randomised to the cerclage group will have a rescue cerclage placed. 

Rescue cerclage placement will be performed under general anaesthesia. Women will be placed in the lithotomy position with a steep Trendelenberg tilt. The prolapsed membranes will be gently pushed back into the uterine cavity with an inflated Foley catheter. A single purse string suture (#5 Ticron™) will be performed using the technique described by MacDonald. Perioperative tocolysis (indomethacin 100 mg per rectum [pr] followed by 25 mg orally every 6 hours for 48 hours) to prevent the uterine contractions that can be precipitated by cervical manipulation and cerclage insertion and prophylactic antibiotics (clindamycin 900 mg intravenous [iv] three times a day [TID] for 7 days) will be administered. A transvaginal ultrasound to evaluate the cervical placement will be done 48 hours postoperatively. 

Following cerclage insertion, women will be restricted to bedrest until 30 weeks of gestation. Cerclages will be removed electively at 36 weeks or before based on foetal or maternal indication. Thromboprophylaxis with enoxaparin (40 mg subcutaneously [sc] once daily [od]) will be administered to all women on prolonged bed rest.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17236-0</funderId>
      <contactId>Contact55197_17236</contactId>
      <sponsorId>Sponsor53763</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55197_17236">
    <title>Dr</title>
    <forename>Wendy</forename>
    <surname>Whittle</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>RM 3201 
700 University Avenue</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 1X8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wwhittle@mtsinai.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53763">
    <organisation>Mount Sinai Hospital (Canada) </organisation>
    <website>http://www.mtsinai.on.ca/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Dr Wendy Whittle
Department of Obstetrics and Gynaecology
Rm 3201 Ontario Power Generation Building
700 University Avenue </address>
      <city>Toronto </city>
      <country>Canada</country>
      <zip>M5G 1X8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wwhittle@mtsinai.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416166.2</gridId>
    <rorId>https://ror.org/05deks119</rorId>
  </sponsor>
  <funder id="Funder17236-0">
    <name>Mount Sinai Hospital (Canada) - Department of Obstetrics and Gynaecology Research Fund ($5000)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-09T00:00:00.000Z">07427212</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of experimental hyperglycemia and AT1 receptor blockade on renal hemodynamics in impaired glucose tolerance</title>
      <scientificTitle/>
      <acronym>IGT-FRA-oo30-I</acronym>
      <studyHypothesis>The study aim is to investigate whether: 
1. Experimental hyperglycemia reduces renal hemodynamics (glomerula filtration rate, renal plasma flow) 
2. Angiotensin II Type 1 (AT1) receptor blocker treatment prevents hyperglycemia induced changes of renal hemodynamics</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were measured at rest (U1 rest, U2 rest) and during hyperglycemic stress testing (U1 stress, U2 stress) with and without AT1 receptor blocker treatment:
1. Glomerular filtration rate (inulin clearance) 
2. Renal plasma flow (Para-AminoHippurate [PAH] clearance) 

U1: Without AT1 receptor blocker
U2: After a 4-week treatment with valsartan</primaryOutcome>
      <secondaryOutcome>The following were assessed at U1 and U2: 
1. High-sensitivity C-Reactive Protein (CRP) 
2. Adiponectin 
3. HbA1c (blood tests) 

U1: Without AT1 receptor blocker 
U2: After a 4-week treatment with valsartan</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Ethical Committee of the Technical University of Munich.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07427212</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, open, prospective, longitudinal, non-randmoised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="de9d23a8-a9e7-4440-ba4b-1b5baaf9d01a">
	  <name>Nephrology Department</name>
	  <address/>
	  <city>Munich</city>
	  <state/>
	  <country>Germany</country>
	  <zip>81675</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Males 
2. 18-70 years old
3. Impaired Glucose Tolerance (for the intervention group [IGT-Group]) (tested by the oral glucose tolerance test according to the World Health Organisation) and normoglycemic patients (for control group [healthy subjects])</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="70.0"/>
      <gender>Male</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>1. Renal or liver insufficiency 
2. Micro-or macro-albuminuria 
3. Overt diabetes mellitus</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Impaired glucose tolerance/ renal changes in prediabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Impaired glucose tolerance/ renal changes in prediabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>12 participants were recruited in each of the two groups. Statistical calculation was carried out by the Institute of Statistics, Technical University of Munich. 

Participants of both groups (control and IGT-group) received the following two interventions: 
1. Experimental hyperglycemia (clamp technique) 
2. Valsartan (AT1 receptor blocker)(oral, taken once a day in the morning) treatment for 4 weeks. The initial dose was 80 mg/day, and the dosage was increased after 7 +/- 2 days of administration to 160 mg /day. 

A safety visit was made at 5 +/- 2 days after the beginning of the study for the measurement of serum creatintine, potassium and blood pressure.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>AT1 receptor blocker</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17381-0</funderId>
      <contactId>Contact55342_17381</contactId>
      <sponsorId>Sponsor53912</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55342_17381">
    <title>Dr</title>
    <forename>Helga</forename>
    <surname>Frank</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Nephrology Department
Klinikum rechts der Isar
Ismaninger Strasse 22</address>
      <city>Munich</city>
      <country>Germany</country>
      <zip>81675</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53912">
    <organisation>Technical University of Munich (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Ismaninger Strasse 22 </address>
      <city>Munich</city>
      <country>Germany</country>
      <zip>81675</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 89 4140 2231</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Helga.Frank@lrz.tum.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6936.a</gridId>
    <rorId>https://ror.org/02kkvpp62</rorId>
  </sponsor>
  <funder id="Funder17381-0">
    <name>Novartis (International)</name>
    <fundRef>http://dx.doi.org/10.13039/100004336</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-07T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-01-07T00:00:00.000Z">56178790</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The MRS study</title>
      <scientificTitle>Sorafenib (NEXAVAR®) monotherapy in patients with inoperable/recurrent germ cell carcinoma refractory to chemotherapy</scientificTitle>
      <acronym>MRS</acronym>
      <studyHypothesis>Sorafenib prolongs Progression-Free Survival (PFS) in patients with inoperable/recurrent germ cell carcinoma refrectory to chemotherapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Progression Free Survival (PFS)</primaryOutcome>
      <secondaryOutcome>1. Overall Relapse Rate (ORR)
2. Overall Survival (OS)
3. Toxicity
4. Evaluation of panel of biomarkers, will be assessed every 4 weeks
5. Quality of Life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30] version 3.0 pol and testicular cancer module), will be assessed every 12 weeks</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Submitted, not reviewed yet as of 06/12/2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN56178790</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>12602</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single arm, non-randomised, single institution, phase II trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Poland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8902808c-99d9-4f78-a4ef-24c2b5b14b66">
	  <name>Roentgena 5</name>
	  <address/>
	  <city>Warsaw</city>
	  <state/>
	  <country>Poland</country>
	  <zip>02781</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male patients greater than 18 years of age
2. Patients with histologically proven germ cell neoplasm (gonadal or extragonadal primary)
3. Patients must have the disease not amendable to cure with either surgery or chemotherapy 
4. Patients must have failed at least two cisplatin-based combination chemotherapy regimens
5. Failure on prior regimens will be defined as either:
5.1. A greater than or equal to 25% increase in sum of target lesions, new lesions, or
5.2. An increasing Alpha Fetoprotein (AFP) or Human Chorionic Gonadotropin (HCG) above the nadir level
6. Patients with at least one measurable lesion by Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria  
7. Adequate bone marrow, liver and renal function, assessed no longer than 14 days before treatment start, defined by the following laboratory test limits: 
7.1. White Blood Cells (WBC) greater than 2.0 x 10^9/l and platelets greater than 60 x 10^9/l
7.2. Total bilirubin less than 2 x Upper Limit of Normal (ULN)
7.3. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) less than 5 x ULN
7.4. Serum creatinine less than 2 x ULN
8. World Health Organization (WHO) performance status 0, 1, 2 
9. No concurrent chemotherapy or radiotherapy
10. Life expectancy of at least 12 weeks
11. Absence of any physiological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
12. A signed informed consent must be obtained prior to any study specific procedures 
13. All patients must agree to use adequate contraception during the whole study period</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Male</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Patients not fulfilling of inclusion criteria 	
2. Primary radiotherapy in the field of target lesion
3. Major surgery (Retroperitoneal Lymph Node Dissection [RPLND]) within 4 weeks before the start of study drug or concurrent serious non-healing wounds, ulcers or bone fractures.
4. Known serious and active bacterial, viral or fungal infection (greater than grade II Common Terminology Criteria for Adverse Events [CTC-AE]) including Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) carrier state
5. Previous or concurrent malignancy except for basal cell carcinoma of the skin
6. Uncontrolled hypertension
7. Thrombotic or embolic event in last 6 months prior to inclusion
8. Impairment of Gastrointestinal (GI) tract, or GI disease that may influence the bioavailability of oral sorafenib
9. Substance and alcohol abuse (nicotine use is allowed)
10. Known or suspected hypersensitivity to sorafenib
11. Participance in any other clinical trial using investigational drug within 4 weeks prior to study entry
12. Prior use of investigational or licensed angiogenesis and Raf kinase or Mitogen-activated Extracellular-signal-Regulated Kinase (ERK) (MEK) inhibitors
13. Patient unwilling or unable to give informed consent
14. Any condition that may in the investigator&#146;s opinion jeopardize the safety of the patient or his compliance in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Testicular cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Testicular cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>There is only one treatment arm, therefore all participants will receive sorafenib 400 mg (2  tablets of 200 mg twice daily orally) continuously in 4-week cycles till progression or unacceptable toxicity. All patients will be followed/contacted after discontinuation of protocol every 3 months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Sorafenib (NEXAVAR®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17331-0</funderId>
      <contactId>Contact55292_17331</contactId>
      <sponsorId>Sponsor53860</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55292_17331">
    <title>Dr</title>
    <forename>Iwona</forename>
    <surname>Skoneczna</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Roentgena 5</address>
      <city>Warsaw</city>
      <country>Poland</country>
      <zip>02781</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+48 (0)22 5462098</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.skoneczna@coi.waw.pl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53860">
    <organisation>Prof. Grzegorz Madej Memorial Foundation "Win the health" (Fundacja "Wygrajmy Zdrowie" im Prof. Grzegorza Madeja) (Poland)</organisation>
    <website>http://www.wygrajmyzdrowie.pl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 20</address>
      <city>Warsaw 10</city>
      <country>Poland</country>
      <zip>00956</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+48 (0)510 723 802</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.skoneczna@wygrajmyzdrowie.pl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17331-0">
    <name>Bayer Pharmaceuticals Poland Sp. z.o.o. (Poland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2008-01-07T00:00:00.000Z">25350905</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Topical use of adrenaline in different concentrations for endoscopic sinus surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Vasoconstrictors such as cocaine or epinephrine (adrenaline) are routinely applied during functional endoscopic sinus surgery. The goal is to control bleeding because, when surgery is endoscopic, even minor bleeding can be troublesome if it blocks the small end of the endoscope. Nevertheless vasoconstrictors might cause an increase in blood pressure and heart arrhythmias. The ideal adrenaline concentration should be the one to provide optimal operative field with no cardiovascular side effects. Despite its routine use, that concentration is yet to be determined. Concentrations of adrenaline varying from 1:1000 to 1:200,000 have been used both topically and sub-mucosally. Many studies have used both adrenaline and cocaine, which makes it difficult to establish the individual role of each substance on the outcome. We have decided to work with adrenaline solutions applied only topically. 

We study the effects of topical use of adrenaline solution on the nasal mucosa in three different concentrations on systemic absorption of the drug, blood pressure, heart rhythm, operative bleeding and operative time during endoscopic sinus surgery for nasal polyposis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following data were collected during surgery (No assessment was done post-operatively): 
1. Variation of blood pressure during surgery (measured by non-invasive blood pressure measures every 3 minutes)
2. Variation of heart frequency during surgery (measured continuously by 12 lead ECG)
3. Development of heart arrythmias during surgery (measured continuously by 12 lead ECG)
4. Operative bleeding (measured both objectively by the amount of blood aspirated during the procedure and subjectively by visual-analogue scale from 01 = no bleeding to 10 = very high bleeding)
5. Variation of plasma levels of adrenaline measured by three blood samples obtained during each surgery
6. Operative time</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the ethic committee of Federal University of Rio de Janeiro (UFRJ) on 24 November 2004 (ref: 207/04 CEP)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25350905</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind single-centre controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="621fe6be-6b09-4d98-85fb-170c726beeb8">
	  <name>Praia de Botafogo, 422 / 1106</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>+55 22250 040</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Be over 18 years old
2. Need elective endoscopic sinus surgery under general anesthesia for the treatment of nasal polyposis
3. Understand and give written consent to participate in the trial
4. To be classified as grade I or II according to the American Society of Anesthesiology classification of pre-operative assessment</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>1. Patients legally incompetent or unable, for any reason, to read and sign a written consent form 
2. Patients who withdraw their consent in any time during the course of the trial, even if they have signed the consent form 
3. Patients with systemic hypertension, coronary diseases, heart arrythmia, coagulation disorders, collagen disorders, renal or liver insufficiency in any degree, previously diagnosed or detected during pre-operative assessment 
4. Pregnant women 
5. Patients who do not follow the trial protocol for any reason, unless it is related to the use of the adrenaline solution 
6. Patients in use of a number of medications that might interfere with blood pressure or coagulaion, such as anti-inflammatory drugs, oral hypoglicemics, beta agonists, etc</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Nasal polyposis</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Nasal polyposis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were submitted to endoscopic sinus surgery under general anesthesia for treatment of nasal polyposis using different concentrations of adrenaline solution applied topically to the nasal mucosa. 

Concentrations: 
1. Adrenaline 1:2000 with lidocaine 1% (4 ml)
2. Adrenaline 1:10,000 with lidocaine 1% (4 ml)
3. Adrenaline 1:50,000 with lidocaine 1% (4 ml)

The control group consisted of patients submitted to tonsillectomies using the same anesthetic protocol as the study groups but without the use of adrenaline solution during surgery.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>adrenaline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17366-0</funderId>
      <contactId>Contact55327_17366</contactId>
      <sponsorId>Sponsor53896</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55327_17366">
    <title>Dr</title>
    <forename>Krishnamurti</forename>
    <surname>Sarmento Junior</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Praia de Botafogo, 422 / 1106
Botafogo</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>+55 22250 040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krishnamurti.sarmento@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53896">
    <organisation>Federal University of Rio de Janeiro (UFRJ) (Brazil) </organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Av. Pedro Calmon, nº 550
Prédio da Reitoria
2º andar
Cidade Universitária </address>
      <city>Rio de Janeiro </city>
      <country>Brazil</country>
      <zip>CEP 21941-901</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.8536.8</gridId>
    <rorId>https://ror.org/03490as77</rorId>
  </sponsor>
  <funder id="Funder17366-0">
    <name>Federal University of Rio de Janeiro (UFRJ) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-01-07T00:00:00.000Z">99715969</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Immediate in-hospital reactivation of patients with an exacerbation of Chronic Obstructive Pulmonary Disease (COPD): Pulmofit-MST</title>
      <scientificTitle/>
      <acronym>PULMOFIT-MST</acronym>
      <studyHypothesis>Chronic Obstructive Pulmonary Disease (COPD) is a major cause of disability and mortality worldwide. Morbidity and mortality among COPD-patients are strongly related to acute exacerbations of COPD, which can be defined as sustained worsening of the patient&#146;s condition, from stable state and beyond normal day-to-day variations, that is acute in onset and may warrant additional treatment in a patient with underlying COPD. Severe exacerbations may lead to hospital admissions and have a major impact on disease evolution and costs.

Pulmofit-MST, an immediate reactivation programme, will induce a reduction of the length of stay in the hospital, by preventing loss of peripheral muscle force and exercise capacity and thereby initiating a faster recovery of activities of daily living.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Length of hospital stay, defined as number of days between day of admission and day of medical discharge. Day of medical discharge was distinguished from the actual day of discharge because some patients remain in hospital longer than medically necessary (e.g. patients could not yet be referred to a nursing home).</primaryOutcome>
      <secondaryOutcome>1. Walking distance (3 minutes walking test)
2. Dyspnoea (Borg scale)
3. Health status (Clinical COPD Questionnaire)
4. Activities of daily living (Barthel Index)
5. Readmissions due to a COPD-exacerbation (less than 28 days), measured at 28 days

Measurements take place at the day of admission, day 4 and the day of medical discharge.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medisch Etische Toetsingscommissie Medisch Spectrum Twente) on the 16th January 2006 (ref: P06-05).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99715969</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NT1101</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, two armed trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9995600e-9a5b-46d4-8e0a-4fe5a58e5961">
	  <name>Haaksbergerstraat 55</name>
	  <address/>
	  <city>Enschede</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>7513 ER</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria
2. A clinical diagnosis of an exacerbation of COPD for which hospitalisation was required
3. (Ex-) smoker
4. Age above 40 years
5. A life expectancy of at least 3 months
6. Able to understand and read Dutch
7. An informed consent from the subject prior to participation</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Pneumonia
2. Fever (greater than 38.5°C)
3. Severe confusion
4. Severe heart failure, New York Heart Association (NHYA) class III or IV
5. Relevant co-morbidity seriously influencing mobility</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic Obstructive Pulmonary Disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic obstructive pulmonary disease (COPD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The protocol of the programme aimed at an active role of COPD-patients during their stay in the hospital. Patients in the intervention group were asked to perform three daily training sessions of 15 minutes each. One daily session was assisted by a physiotherapist, while the other two had to be performed by the patients themselves. 

PULMOFIT-MST consists of four levels of increasing difficulty. Within four hours after admission, level I was started by the nurse who distributed the workbook with the description of all exercises and who instructed the first exercises to the patient. Within 24 hours after admission, the physiotherapist visited the patient and continued the programme by choosing the appropriate follow-up level and determining the intensity of the exercises. Every day the physiotherapist evaluated the exercises and the appropriateness of the training level and training intensity. A workbook functioned as a daily diary in which the intensities of training exercises were noted by the physiotherapist and daily experiences and improvements by the patient. All disciplines (chest physicians, nurses, and physiotherapists) stimulated patients to perform all three daily PULMOFIT-MST sessions. 

Patients in the control group received usual care, meaning treatment the patients would have received prior to this study. 

The duration of the treatment depends on the length of the hospitalisation. Patients of the intervention group are treated according to the PULMOFIT-MST protocol during the whole hospitalisation period.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17272-0</funderId>
      <contactId>Contact55233_17272</contactId>
      <sponsorId>Sponsor53801</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55233_17272">
    <title>Mrs</title>
    <forename>Tanja </forename>
    <surname>Effing</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Haaksbergerstraat 55
Poli 12</address>
      <city>Enschede</city>
      <country>Netherlands</country>
      <zip>7513 ER</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53801">
    <organisation>Dutch Asthma Foundation (The Netherlands) </organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Postbus 5 </address>
      <city>Leusden</city>
      <country>Netherlands</country>
      <zip>3830 AA </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.483859.b</gridId>
    <rorId>https://ror.org/00ddgbf74</rorId>
  </sponsor>
  <funder id="Funder17272-0">
    <name>Dutch Asthma Foundation (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-03T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-01-03T00:00:00.000Z">48092875</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>N3 fatty acids as adjuvant therapy in rheumatoid arthritis (N3-fettsäuren als adjuvante therapie bei rheumatoider arthritis)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Omega-3 fatty acids infusions may show earlier and superior antiinflammatory effects in patients with rheumatoid arthritis than oral administered ones (as shown in earlier trials), and we presumed the beneficial effects may be maintained by following oral omega-3 fatty acid administration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were assessed at baseline, during infusion phase (after week 1 and after week 2) and during capsule phase (after two weeks [end of month 1] and then monthly until the end of month 6):
1. Swollen joints
2. Tender joints
3. Erythrocyte Sedimentation Rate (ESR)
4. C-Reactive Protein (CRP)</primaryOutcome>
      <secondaryOutcome>The following were assessed at baseline, during infusion phase (after week 1 and after week 2) and during capsule phase (after two weeks [end of month 1] and then monthly until the end of month 6):
1. Disease Activity Score (DAS)
2. Rheumatoid Arthritis Disease Activity Index (RADAI) 
3. Health Assessment Questionnaire (HAQ)
4. 36-item Short Form health survey (SF-36)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This trial was approved by the ethics committee of the Medical University of Graz on 10th July 2000.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48092875</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>10-184 ex 99/00</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, double-blinded, placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-07-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Austria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a9dfa791-fddb-48e3-9746-7c5965360601">
	  <name>State Hospital Muerzzuschlag</name>
	  <address/>
	  <city>Muerzzuschlag</city>
	  <state/>
	  <country>Austria</country>
	  <zip>8680</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients at least 19 years of age and should not be older than 85 years
2. Patients suffering from Rheumatoid Arthritis (RA), according to American College of Rheumatology (ACR) criteria, for at least (&gt;=) 6 months 
3. Patients with active RA who meet following criteria:    
3.1. &gt;= 6 swollen joints 
3.2. &gt;= 6 tender joints
3.3. &gt;= 1 of following criteria: 
a. Joint morning stiffness &gt;= 45 minutes 
b. Erythrocyte Sedimentation Rate (ESR) &gt;= 28 mm 
c. C-Reactive Protein (CRP) &gt;=  20 mg/l (normal range: 0 - 9)
4. No pregnant or breast feeding women allowed; monthly negative pregnancy test in women of reproductive age 
5. Participant doesn't have a severe concomitant physical or mental illness  
6. Participant has to be able to follow the study procedures   
7. No severe malfunctioning of the liver, kidneys, bone marrow, blood clotting system 
8. Stable dosages of RA medication for at least 1 month prior to baseline:  
8.1. DMARD therapy with methotrexate of at least 10 mg per week over 4 months
8.2. Prednisone &lt;=10 mg daily 
9. No injection of glucocorticoids into a joint within 3 month prior to baseline 
10. Participant must not have legal conflict 
11. Participant must not have alcohol or drug abuse problems 
12. Written informed consent signed by the participant</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Known allergy against fish oil or any other substance of the study medication 
2. Participant is younger than 19 years of age 
3. Patient simultaneously participates in another trial  
4. Participant doesn't sign the written informed consent. 
5. No stable dosage of RA medication 1 month prior to baseline 
6. Injection of glucocorticoids into a joint within 3 month prior to baseline 
7. Pregnant or breast feeding women; positive pregnancy test in women of reproductive age 
8. Patient has legal conflicts
9. Patient has alcohol or drug abuse problems 
10. Severe concomitant physical or mental illness  
11. Participant is physically or mentally unable to follow the study procedures  
12. Hereditary disorder of lipid metabolism 
13. Blood triglyceride levels &gt;300 mg/dl 
14. Patients with uncontrolled diabetes mellitus
15. Severe malfunctioning of the liver, kidneys, bone marrow, blood clotting system: 
15.1. Creatinin clearance &lt;=30 ml/min
15.2. Elevated levels of ALanine aminoTransferase (ALT) 2 fold above the upper normal range 
15.3. Leucopenia &lt;=2,500/ml, red blood cells &lt;=2.5 mill/ml, hemoglobin &lt;=9 mg/dl, platelets &lt;=70,000/ml 
16. Severe cardiovascular disease 
17. Known neoplasms</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-07-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Infusions of omega-3 fatty acids once daily for 14 days (Infusion speed: 0.5 ml/kg body weight and hour), followed by oral administration of omega-3 fatty acids up to 6 months. 

Control group: Placebo infusions once daily for 14 days (Infusion speed: 0.5 ml/kg body weight and hour), followed by oral administration of placebo up to 6 months. 

Verum:   
Infusions: Fish oil emulsion (Omegaven® Fresenius). 100 ml Omegaven® contained 10 g fish oil with 2.03 g EicosaPentaenoic Acid (EPA) and 2.26 g DocosaHexaenoic Acid (DHA) (and 0.02 mg a-tocopherol as antioxidat) 
Capsules: Fish oil. One capsule contained 1 g fish oil with 0.20 g EPA and 0.23 g DHA (and 0.02 mg a-tocopherol as antioxidant) 

Placebo: 
Infusions: NaCl 0.9% (physiological sodium chloride solution)
Capsules: Paraffin wax

Randomisation was done by a hospital pharmacist who prepared the bottles and other infusion material, so that neither the patients nor the staff could identify them as verum or placebo. Additionally, the study conducting staff was not allowed to enter the inpatient area while the patients received their infusions.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Omega-3 fatty acids</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17316-0</funderId>
      <funderId>Funder17316-1</funderId>
      <contactId>Contact55277_17316</contactId>
      <sponsorId>Sponsor53845</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55277_17316">
    <title>Dr</title>
    <forename>Babak</forename>
    <surname>Bahadori</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>State Hospital Muerzzuschlag
Department of Internal Medicine
Grazerstr. 63-65</address>
      <city>Muerzzuschlag</city>
      <country>Austria</country>
      <zip>8680</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.bahadori@gmx.at</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53845">
    <organisation>Medical University of Graz (Austria)</organisation>
    <website>http://www.meduni-graz.at/englisch/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Universitätsplatz 3</address>
      <city>Graz</city>
      <country>Austria</country>
      <zip>A-8010 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11598.34</gridId>
    <rorId>https://ror.org/02n0bts35</rorId>
  </sponsor>
  <funder id="Funder17316-0">
    <name>Investigator-funded (This trial is a physician initiated study) (Austria)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17316-1">
    <name>Fresenius Kabi Austria (Provided Omega-3 infusions only)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-09T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-11-06T00:00:00.000Z">63627007</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fibre supplementation in addition to loperamide for faecal incontinence in adults: a randomised trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the efficacy of fibre supplementation and loperamide in comparison to a low-residue diet and lopermide in the conservative treatment of faecal incontinence.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Faecal Incontinence Severity Index (FISI) patient-weighted score, measured at baseline, 6 weeks at cross over and at 12 weeks at conclusion of the second treatment period.</primaryOutcome>
      <secondaryOutcome>1. 36-item Short Form health survey (SF-36)
2. Faecal Incontinence Quality of Life scale (FIQL)

All questionnaires were performed at baseline, 6 weeks at cross over and at 12 weeks at conclusion of the second treatment period.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Otago Ethics Committee on the 30th July 2001.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63627007</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>OEC 01/07/055</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind randomised cross-over trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="744b3bfb-1c90-40e7-8994-486a2654948a">
	  <name>Department of Medical and Surgical Sciences</name>
	  <address/>
	  <city>Dunedin</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>9054</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Over eighteen years of age 
2. Referred to an outpatient colorectal service with the primary presenting problem of chronic incontinence to mucus, liquid and/or solid stool
3. Living independently
4. Able to read and complete the study information and questionnaires</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Full thickness rectal prolapse
2. Inflammatory bowel disease
3. Other pathologies requiring surgery
4. Diabetes (chosen supplement contraindicated) 
5. Previous treatment for faecal incontinence</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Faecal incontinence</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Faecal incontinence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients received loperamide. Most patients were advised to start by taking one tablet (2 mg) twice a day. Patients with a tendency to constipation were advised to start on one tablet daily. All patients were given both verbal instruction and an advice sheet about using loperamide which advised titrating the loperamide dose to firm stool but to avoid constipation. Glycerine suppositories were supplied for use in the event of troublesome constipation. 

Patients were randomised to either combination treatment A or B for six weeks, crossed-over and re-evaluated after a further six weeks. It was assumed that it would take a week or two for the patients to adjust to the new treatment after cross over, and they were advised of this. They were asked to fill out the outcome questionnaires in relation to previous 4 weeks of the 6 weeks treatment period in each arm of the study. Both participants and clinicians/researchers were blinded.

Treatment A:
This consisted of:
1. An untitled dietary advice sheet for a balanced low residue diet
2. Placebo supplement (Karicare infant food thickener - light cream colored course powder containing pregelatinised maize starch, maltodextrin, locust bean gum) to be taken as one rounded teaspoon mixed in a glass of water at breakfast and dinner
3. Loperamide (taken as described above)

Treatment B:
This consisted of:
1. An untitled dietary advice sheet for a balanced diet consisting of both high and low residue items
2. Fibre supplement (psyllium hydrophilic mucilloid) to be taken as one rounded teaspoon with a glass of water at breakfast and dinner
3. Loperamide (taken as described above)

The dietary advice sheets were developed in consultation with the hospital Nutrition department. An important consideration in designing the dietary advice sheets was producing advice that would optimise compliance for a long term change, while encouraging healthy eating.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Loperamide, psyllium hydrophilic mucilloid</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18190615 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d2ab8cbf-fe08-4c62-ae95-c8c3781d843e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18190615"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17214-0</funderId>
      <contactId>Contact55175_17214</contactId>
      <sponsorId>Sponsor53741</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55175_17214">
    <title>Dr</title>
    <forename>Mark</forename>
    <surname>Thompson-Fawcett</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Medical and Surgical Sciences
Dunedin School of Medicine
Universtiy of Otago
P.O. Box 913</address>
      <city>Dunedin</city>
      <country>New Zealand</country>
      <zip>9054</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)3 474 0999</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mark.thompsonfawcett@otago.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53741">
    <organisation>University of Otago (New Zealand)</organisation>
    <website>http://www.otago.ac.nz/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Mark Thompson-Fawcett
Department of Medical and Surgical Science
Dunedin School of Medicine
P.O. Box 913</address>
      <city>Dunedin</city>
      <country>New Zealand</country>
      <zip>9054</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)3 474 0999</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mark.thompsonfawcett@otago.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.29980.3a</gridId>
    <rorId>https://ror.org/01jmxt844</rorId>
  </sponsor>
  <funder id="Funder17214-0">
    <name>University of Otago (New Zealand) - Research Grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-23T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2007-10-29T00:00:00.000Z">19787793</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of pectin liquid on gastroesophageal reflux disease in children with cerebral palsy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Changing feeding style is an alternative therapy for decreasing GastroEsophageal Reflux (GER) -related symptoms. Use of thickeners is common and effective in decreasing frequent episodes of regurgitation or vomiting in infants, and in improving dysphagia in handicapped patients. We hypothesized that thickener is effective for GastroEsophageal Reflux Disease (GERD) in neurologically impaired children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were assessed by the esophageal pH monitoring:  
1. The median values for the % time pH &lt;4 at the lower and upper esophagus
2. Number of refluxes per day
3. Duration of longest reflux 
4. Number of refluxes longer than 5 min</primaryOutcome>
      <secondaryOutcome>The following were assessed using the patient's chart filled by the nurse/clinician daily:
1. Number of episodes of vomiting per day
2. Number of gastric residue with bleeding
3. Volume of gastric residue
4. Cough score (cough and wheezing) 
5. Frequency of oxygen use for dyspnea
6. Total volume of feeding per day
7. Time to return to school</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was approved by the Human Investigation Committee of Gunma University on 17 February 2005. Informed consent was obtained from the mother of each subject.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19787793</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized single-blind controlled cross-over multicentre (2 hospitals) study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Japan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="287af0ec-a538-4e1d-b015-dbee1d3d0765">
	  <name>Department of Pediatrics and Developmental Medicine</name>
	  <address/>
	  <city>Gunma</city>
	  <state/>
	  <country>Japan</country>
	  <zip>371-8511</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Cerebral palsy 
2. Age between 2 to 18</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="2.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>18</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>18</totalTarget>
      <exclusion>Patients who received a surgical operation for GERD.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gastroesophageal Reflux Disease</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Gastroesophageal Reflux Disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>We enrolled 18 patients (16 male and 2 female) with cerebral palsy from 2 hospitals, Gunma University Hospital and Gunma Rehabilitation Centre for the Physically Handicapped Children. The average age of subjects was 11.7 ± 4.4 years old. 

All patients received the enteral formula described below through a naso-gastric tube. 

Phase 1: pH monitoring 
The subjects were randomly allocated to the following 2 groups: 
 
Group A (9 participants): Participants were fed with a high-pectin content diet (enteral formula: pectin liquid = 2:1 [v/v], intervention) and an enteral formula mixed with water added to a similar volume as the pectin liquid (non-pectin diet, control) in a cross-over manner. 
 
Group B (9 participants): Participants were fed with a low-pectin content diet (enteral formula: pectin liquid = 3:1 [v/v], intervention) and a non-pectin diet (control) in a cross-over manner. 
 
Esophageal pH of each participant was monitored over 48 hours while he/she was being fed with the formula described above. 
 
Phase 2: Effects of pectin liquid on GERD symptoms
 
Group A: Nine patients were fed with a high-pectin content diet for 4 weeks (intervention), and with non-pectin diet (control) for 4 weeks in a cross-over manner. 
 
Group B: Nine patients were fed with a low-pectin content diet for 4 weeks (intervention), and with non-pectin diet (control) for 4 weeks in a cross-over manner.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pectin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18412980 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="89d27290-4313-4e18-9fa1-f7a9be729efd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-04-16T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18412980"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17222-0</funderId>
      <contactId>Contact55183_17222</contactId>
      <sponsorId>Sponsor53749</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55183_17222">
    <title>Dr</title>
    <forename>Reiko</forename>
    <surname>Miyazawa</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pediatrics and Developmental Medicine
Gunma University Graduate School
3-39-22
Showa-machi
Maebashi</address>
      <city>Gunma </city>
      <country>Japan</country>
      <zip>371-8511</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+81 27 220 8205</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rmiyazaw@med.gunma-u.ac.jp</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53749">
    <organisation>Gunma University, Department of Pediatrics and Developmental Medicine (Japan) </organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>3-39-22
Showa-machi
Maebashi</address>
      <city>Gunma </city>
      <country>Japan</country>
      <zip>371-8511</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.256642.1</gridId>
    <rorId>https://ror.org/046fm7598</rorId>
  </sponsor>
  <funder id="Funder17222-0">
    <name>The Gunma University Graduate School (Japan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-14T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-10-22T00:00:00.000Z">88815601</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of posterior capsule opacification after two different surgical methods of cataract extraction</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Posterior capsule opacification (PCO) is the most frequent complication of crystalline lens extracapsular extraction. When PCO reaches the central part of IOL (intraocular lens), it can induce a decrease in visual acuity after cataract surgery. Many preventive factors and many surgical techniques decreasing secondary cataract development exist but there is still no extended procedure of its complete eradication. AquaLase is a new crystalline lens removal technology using the method of liquefaction of lens material by the pulses of warmed balanced salt fluid produced just inside the aspiration port of the tip. As the AquaLase tip is made of smooth rounded-bevel polymer rather than metal, the risk of capsule tears is reduced making this method more capsule friendly. Thus the lens epithelial cells (LECs) removal from the capsule bag is much easier which may be preventive for the PCO occurrence and progress. Subjective EPCO 2000 and objective OSCA are systems for computer PCO assessment. 

The study is aimed at comparison of PCO extent after AquaLase and NeoSoniX cataract removal modalities using two types of software for PCO quantification, and at the comparison of these two different methods for PCO measurement. Better results in PCO for AquaLase are expected. While using this device, it is difficult to rupture the posterior capsule. Several studies have shown that the technology may have applications in polishing the capsule through mechanical washing of the lens epithelial cells (LEC) from the capsule bag with the fluid pulses. The reduction of LECs has been shown to help prevent PCO. The OSCA is a newly presented system of PCO computer assessment, evolved from previous systems. It is based on location-sensitive entropy based texture analysis of digital images. It was presented by Aslam in 2006. The OSCA results are compared to EPCO 2000 outcomes in this study. The EPCO 2000 is a computer-assisted system of PCO morphological assessment which incorporates planimetric and grading assessment. No correlation between OSCA and EPCO 2000 outcomes is expected.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following will be measured at 1, 2, 3 and 5 years after surgery: 
1. EPCO index for minimal, mild, moderate and severe opacities and total EPCO index for PCO under entire IOL optic (score 0 = no opacities, 4 = maximal opacities)
2. OSCA score. The possible range is from 0 (no PCO) to approximately 15 (practical expected maximum). Typical OSCA values for images with very little or no PCO is around 0.5. Values for patients that are deemed to warrant laser capsulotomy is typically around 4 - 5.
3. Best corrected visual acuity measured using Snellen optotypes at 6 metres distance</primaryOutcome>
      <secondaryOutcome>The "Nd:YAG" laser capsulotomy rate at 1, 2, 3 and 5 years after surgery. This shows how many capsulotomies are needed for treatment of PCO-induced decrease of BCVA.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee at University Hospital in Hradec Králové, Sokolská 581, 50005 Hradec Králové, Czech republic. Date of approval: 04/10/2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88815601</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, single-centre, randomised controlled study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2012-10-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Czech Republic</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9c734f72-f6aa-4a90-9275-3ea9ad89596d">
	  <name>University Hospital in Hradec Králové</name>
	  <address/>
	  <city>Hradec Králové</city>
	  <state/>
	  <country>Czech Republic</country>
	  <zip>50005</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Bilateral non-brunescent cataract (according to the Buratto classification - a cataract grade less than 5) 
2. Both eyes with cataract with similar density grade 
3. No other severe ocular pathology potentially affecting visual acuity (patients with mild age-related macular degeneration [ARMD] were not excluded) 
4. Age 40 or older 
5. Both males and females  
6. Written informed consent to surgery and willing to participate in the study 
7. Good compliance</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>75</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>75</totalTarget>
      <exclusion>1. Brunescent cataract 
2. Severe ocular pathology potentially affecting visual acuity 
3. Unable to achieve good artificial mydriasis
4. No informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2012-10-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cataracts</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Other cataract</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The AquaLase is used in the right eye and NeoSoniX in the left eye of each patient. The same IOL (Alcon AcrySof® Single Piece Intraocular Lens) is implanted in all eyes. 

Examination is carried out at 1, 2, 3 and 5 years after surgery. Digital retroillumination photographs of pseudophakic anterior segments, after attaining maximal pupil dilatation are obtained using a CSO Epsilon Lyrae photo slit lamp. Exact focusing on the IOL and posterior capsule is also carried out. The images are computer analyzed with the EPCO 2000 and OSCA software. Best corrected visual acuity (BCVA) is measured using Snellen optotypes pre- and postoperatively. The "Nd: YAG" laser capsulotomy incidence is evaluated.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18201683 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9cb413cd-6603-4338-8a6d-fde3d3ca4568" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18201683"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17180-0</funderId>
      <contactId>Contact55141_17180</contactId>
      <sponsorId>Sponsor53706</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55141_17180">
    <title>Dr</title>
    <forename>Jana</forename>
    <surname>Nekolová</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Hospital in Hradec Králové
Department of Ophthalmology
Sokolská 581</address>
      <city>Hradec Králové</city>
      <country>Czech Republic</country>
      <zip>50005</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+420 60 410 6256</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jani.nekolova@seznam.cz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53706">
    <organisation>University Hospital in Hradec Králové (Czech Republic)</organisation>
    <website>http://www.fnhk.cz</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr Jana Nekolová
Department of Ophthalmology
Sokolská 581</address>
      <city>Hradec Králové</city>
      <country>Czech Republic</country>
      <zip>50005</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+420 49 583 3395</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jani.nekolova@seznam.cz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.412539.8</gridId>
    <rorId>https://ror.org/04wckhb82</rorId>
  </sponsor>
  <funder id="Funder17180-0">
    <name>The trial is mainly funded internally by the University Hospital in Hradec Kralove. The trial is also supported by research project grant from the Ministry of Health of Czech Republic (ref: MZO 00179906).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-03T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-10-02T00:00:00.000Z">01606064</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Fetal scalp blood pH or lactate determination in the management of intrapartum fetal distress: A randomised controlled multi-centre trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The analysis of fetal scalp blood pH has been the gold standard in intrapartum management of suspected or known pathological fetal heart rate traces. However, this method has a reported sampling failure rate of 11-21%. Lactate analysis has simplified sampling, mainly due to the minimal amount of blood needed. Lactate is also an end product after anaerobic metabolism, which is of interest to analysis. Our hypothesis is that analysis of lactate in fetal scalp blood is at least as good as pH determination in the prevention of severe acidemia at birth with less sampling failure.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Prevalence of metabolic acidemia or pH less than 7.00</primaryOutcome>
      <secondaryOutcome>Secondary outcome measures: 
1. Protocol violation (mainly due to failed sampling or analysis)
2. Rate of instrumental deliveries 
3. Rate of cesarean section 
4. Apgar score less than 7 at 5 min
5. Admissions to neonatal intensive care unit

Tertiary outcome measures: 
1. Prevalence of pH less than 7.10
2. Rate of intervention due to fetal distress
3. Rate of Hypoxic Ischemic Encephalopathy (HIE)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Karolinska Institute Regional Ethics Committee. Approved in 2002 (ref: 109/02).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN01606064</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-12-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e93a36ac-e7d7-45dd-a203-eae75466be81">
	  <name>Department of Obstetrics and Gynaecology</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>171 76</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women in labour with a singleton pregnancy
2. Gestational age &gt;34 weeks
3. Cephalic presentation
4. Clinical situation where a fetal scalp blood sampling was indicated
5. Those who had given consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Initial target number: 3,000 (3,007 recruited)</totalTarget>
      <exclusion>1. Gestational age &lt;34 weeks
2. Breech or multiple pregnancies</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-12-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Intrapartum fetal monitoring</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Intrapartum fetal monitoring</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Of the 3,007 participants recruited and randomised, 15 participants were excluded due to multiple pregnancies or gestational age &lt;34 weeks. Final analysis was carried out on 2,992 cases, 1,496 in each arm. 

Oral and written information about the trial was given to possible participants at the antenatal clinic in late pregnancy. Oral consent was obtained from the participants at antenatal follow up visits or in early labour. Randomisation of participants to the two arms was performed at the time a clinician decided to perform a fetal scalp blood analysis. 
 
Interventions: Fetal scalp blood analysis for pH or lactate as basis for decision to intervene (cesarean section or instrumental delivery) or not.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18503103 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7b890a70-11a4-49a8-ad7d-1f696de5f020" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-06-07T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18503103"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16952-0</funderId>
      <funderId>Funder16952-1</funderId>
      <funderId>Funder16952-2</funderId>
      <funderId>Funder16952-3</funderId>
      <funderId>Funder16952-4</funderId>
      <funderId>Funder16952-5</funderId>
      <contactId>Contact54913_16952</contactId>
      <sponsorId>Sponsor53478</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54913_16952">
    <title>Dr</title>
    <forename>Lennart</forename>
    <surname>Nordstrom</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Obstetrics and Gynaecology
Karolinska University Hospital</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>171 76</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lennart.nordstrom@karolinska.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53478">
    <organisation>Karolinska University Hospital (c/o Lennart Nordström)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Obstetrics and Gynaecology
Karolinska University Hospital </address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>171 76</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 8 517 70888</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lennart.nordstrom@karolinska.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.24381.3c</gridId>
    <rorId>https://ror.org/00m8d6786</rorId>
  </sponsor>
  <funder id="Funder16952-0">
    <name>Signhild Engqvists Research Foundation (Signhild Engqvists Stiftelse) (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16952-1">
    <name>The Stockholm Public Labour Ward Department Memorial Research Foundation (Allmänna BB's minnesfond) (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16952-2">
    <name>The Regional City Council Research and Development Foundations (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16952-3">
    <name>The Health and Medical Committee of the Region Västra Götland (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16952-4">
    <name>Medexa AB (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16952-5">
    <name>Lomma (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-15T00:00:00.000Z" version="26">
    <isrctn dateAssigned="2007-10-01T00:00:00.000Z">66850051</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase I randomised single-blinded single-centre study comparing doses of Plasmodium falciparum chimeric protein 2.9 (PfCP-2.9) recombinant vaccine adjuvanted with Montanide ISA 720 for safety and immunogenicity</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Primary hypothesis: 
To assess the safety and reactogenicity of PfCP-2.9 vaccine in healthy adult volunteers.

Secondary hypothesis: 
To assess the immunogenicity of PfCP-2.9 vaccine in healthy adult volunteers.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Local and systemic tolerability
2. Reported adverse events</primaryOutcome>
      <secondaryOutcome>1. Antibody titres by Enzyme-Linked Immuno-Sorbent Assay (ELISA)
2. Antibody titres by IFA Test (IFAT)
3. Lymphocyte stimulation indices</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. Independent Ethics Committee, Shanghai Chanhai Hospital on the 29th January 2003 (ref: S001)
2. World Health Organization (WHO) research Ethics Research Committee on the 30th April 2003 (ref: RPC 006)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN66850051</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC 006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Rondomised single-blind placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-11-18T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a7b03964-7d09-4d22-858a-350d87602af4">
	  <name>Initiative for Vaccine Research</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy adult volunteers ages 18 - 45 years.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="45.0"/>
      <gender>Female</gender>
      <targetEnrolment>52</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>52</totalTarget>
      <exclusion>1. History of malaria: persons infected with malaria or with positive markers for antibodies to malaria parasite by Indirect Fluorescent Antibody (IFA) assay
2. History of ever traveling to or residing in a malaria endemic region or malaria exposure within last two years</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-11-18T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Intervention dose group: 20 micrograms PfCP2.9/Montanide ISA 720; administered intramuscularly on Day 0, Day 60 and Day 180
2. Intervention dose group: 50 micrograms PfCP2.9/Montanide ISA 720; administered intramuscularly on Day 0, Day 60 and Day 180
3. Intervention dose group: 100 micrograms PfCP2.9/Montanide ISA 720;administered intramuscularly on Day 0, Day 60 and Day 180
4. Intervention dose group: 200 micrograms PfCP2.9/Montanide ISA 720; administered intramuscularly on Day 0, Day 60 and Day 180
5. Placebo control group: Montanide ISA 720; administered intramuscularly on Day 0, Day 60 and Day 180

Contact information for Principal Investigator:
Dr Jinhong Hu 
Clinical Center of Pharmacology Changhai Hospital
Second Military Medical University
174 Changhai Road
Shanghai 200433
China
Tel: +86 (0)21 25070665
Fax: +86 (0)21 25070665
Email: hjhong2006@gmail.com</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Plasmodium falciparum chimeric protein 2.9 (PfCP-2.9) recombinant vaccine, Montanide ISA 720</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18398475 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="92ed52b5-50cd-463c-8702-47bb6250f8ee" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-04-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18398475"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17167-0</funderId>
      <contactId>Contact55128_17167</contactId>
      <sponsorId>Sponsor53693</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55128_17167">
    <title>Dr</title>
    <forename>Zarifah</forename>
    <surname>Reed</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Initiative for Vaccine Research
World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4760</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">reedz@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53693">
    <organisation>World Health Organization (WHO) (Switzerland)</organisation>
    <website>http://www.who.int/vaccine_research/en/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Initiative for Vaccine Research
Special Programme for Research and Training in Tropical Diseases
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4760</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">reedz@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder17167-0">
    <name>World Health Organization (WHO) (Switzerland) (ref: RPC 006)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-28T00:00:00.000Z">94398181</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised Controlled Trial of Analgaesic Efficacy of Topical Morphine in Treatment of Minor Burns</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN94398181</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0187173589</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-12-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="944d7c5b-72a7-4d1e-8130-e4c9acbf1b71">
	  <name>Portsmouth Hospitals NHS Trust</name>
	  <address/>
	  <city>Porstmouth</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>PO3 6AD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Target: 63   Actual: 59  (2 withdrawn).</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>63</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>63</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-12-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Injury, Occupational Diseases, Poisoning: Burns</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Burns</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Topical morphine vs standard treatment</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Morphine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17513537 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a626c949-12d3-4857-862d-f4a451ef5a57" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17513537"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16968-0</funderId>
      <contactId>Contact54929_16968</contactId>
      <sponsorId>Sponsor53494</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54929_16968">
    <title>Ms</title>
    <forename>Ann</forename>
    <surname>Welling</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Portsmouth Hospitals NHS Trust</address>
      <city>Porstmouth</city>
      <country>United Kingdom</country>
      <zip>PO3 6AD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ann.welling@porthosp.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53494">
    <organisation>Record Provided by the NHSTCT Register - 2007 Update - Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health, Richmond House, 79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder16968-0">
    <name>Portsmouth and Isle of Wight R&amp;D Consortium (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-28T00:00:00.000Z">76293435</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of the effectiveness of endoscopic and microscopic removal of cerumen (wax) from the ear canal</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>What is the best preparation to use for otitis externa in the first instance?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76293435</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0212177259</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="563a1fcd-6767-4778-9b84-bb2997da2fe5">
	  <name>ENT</name>
	  <address/>
	  <city>Bath</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BA1 3NG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with otitis externa</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ear, Nose and Throat: Otitis externa</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Otitis externa</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Dewaxing using microscope
2. Dewaxing using endoscope</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17014445 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3d1cb828-f3d4-4b99-985d-35f98f8f341e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17014445"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder17027-0</funderId>
      <contactId>Contact54988_17027</contactId>
      <sponsorId>Sponsor53553</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54988_17027">
    <title>Mr</title>
    <forename>David</forename>
    <surname>Pothier</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>ENT
Royal United Hospital
B&amp;NES
</address>
      <city>Bath</city>
      <country>United Kingdom</country>
      <zip>BA1 3NG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">David.Pothier@ruh-bath.swest.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53553">
    <organisation>Record Provided by the NHSTCT Register - 2007 Update - Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health, Richmond House, 79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17027-0">
    <name>Royal United Hospital Bath NHS Trust (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-28T00:00:00.000Z">75155444</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Which intravenous fluid should be given for hospitalized patients?: A prospective randomised study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypothesize of the study is that in sick children, moderately hypotonic fluids (such as fluids contain 77 mmol/L sodium) are better tolerated (i.e. induce less hyponatraemia without the risk of hypernatraemia) than conventional intravenous fluids that contain 34 mmol/L sodium.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Association between administration of hypotonic fluids and hospital-acquired hyponatraemia, assessed by the following:
1. Plasma sodium, potassium and osmolality in all blood samples collected at admission (T0) and 12 (T12), 24 (T24), 48 (T48) and 72 (T72) hours of intravenous fluids therapy
2. Plasma urea, creatinine and uric acid, measured in all blood samples collected at T0 and T24</primaryOutcome>
      <secondaryOutcome>To determine contributive factors that may increase hyponatraemia risk, assessed by the following: 
1. Plasma sodium, potassium and osmolality in all blood samples collected at admission (T0) and 12 (T12), 24 (T24), 48 (T48) and 72 (T72) hours of intravenous fluids therapy. 
2. Plasma urea, creatinine and uric acid, measured in all blood samples collected at T0 and T24. 
3. Plasma AntiDiuretic Hormone (ADH), measured at T0. Abnormal ADH function was assessed by serum osmolality and serum sodium determinations.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical Board of Istanbul University, Istanbul Faculty of Medicine, approved on 13 June 2005. Ref: 2005/526.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75155444</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Türkiye</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f4d6d98c-6794-4047-a043-44cc3da8e711">
	  <name>Istanbul University</name>
	  <address/>
	  <city>Istanbul</city>
	  <state/>
	  <country>Türkiye</country>
	  <zip>34390</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All children aged between 3 months to 16 years old who received intravenous fluids</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Years" value="16.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Dehydration
2. Cerebral oedema
3. Nephrotic syndrome
4. Hepatorenal syndrome
5. Plasma sodium level below 135 mmol/L
6. Congestive heart failure
7. Renal failure
8. Inborn error of metabolism
9. Protein energy malnutrition
10. Patients receiving mannitol or diuretics
11. Patients whose fluid therapy was started before admission</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyponatraemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Hyponatraemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients were randomized to one of the three study arms prospectively. Stratified block randomization was performed, with each one-week block featuring a different intravenous solution. Randomization was performed separately for children on the ward and children in the Paediatric Intensive Care Unit (PICU).

Arm 1: 0.2% sodium in 5% dextrose
Arm 2: 0.3% sodium in 3.3% dextrose
Arm 3: 0.45% sodium in 5% dextrose

When hyponatraemia developed in any group during the therapy intravenous fluid sodium composition was increased and fluid therapy was decreased to 80% of the initial volume.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Intravenous Fluid</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16511-0</funderId>
      <contactId>Contact54469_16511</contactId>
      <sponsorId>Sponsor53024</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54469_16511">
    <title>Prof</title>
    <forename>Metin </forename>
    <surname>Karaböcüoğlu</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Istanbul University
Istanbul Faculty of Medicine 
Department of Paediatric Intensive Care
Millet Cad
Fındıkzade	  </address>
      <city>Istanbul</city>
      <country>Türkiye</country>
      <zip>34390</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+01190 5332341818</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mkara63@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53024">
    <organisation>Istanbul University, Faculty of Medicine (Turkey)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Paediatric Intensive Care 
Millet Cad
Fındıkzade </address>
      <city>Istanbul</city>
      <country>Türkiye</country>
      <zip>34390</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.9601.e</gridId>
    <rorId>https://ror.org/03a5qrr21</rorId>
  </sponsor>
  <funder id="Funder16511-0">
    <name>Mainly investigator-funded with support from Ege Medical Company (Turkey)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-09-12T00:00:00.000Z">15330757</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare the efficacy and tolerability of nabilone with dihydrocodeine when used in the treatment of neuropathic pain based upon the following null hypotheses:
1. The analgesic activity of nabilone is not different from that of dihydrocodeine when used in the treatment of neuropathic pain over a six-week period
2. The patient tolerability of nabilone is not different from that of dihydrocodeine when used in the treatment of neuropathic pain over a six-week period
3. The antidepressant effect of nabilone is not different from that of dihydrocodeine when used in the treatment of neuropathic pain over a six-week period
4. Anxiety reducing effects of nabilone are not different from dihydrocodeine when used in the treatment of neuropathic pain over a six-week period</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mean pain score as measured by VAS 0 - 10 for the last two weeks on treatment.</primaryOutcome>
      <secondaryOutcome>1. Sleep was measured as hours slept and if the sleep was interrupted or not in the diary
2. Depression and anxiety were measured with the Hospital Anxiety and Depression Score (HAD) at baseline and after each treatment period
3. Quality of life was measured with the 36-item Short Form questionnaire (SF-36) at baseline and after each treatment period
4. Six psychometric tests were performed at baseline and after each treatment period on a Apple Newton device
5. Side effects were assessed every two weeks with a eight-point questionnaire rating the severity of the side effects on a five point scale plus a field for open comments</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from:
1. South Tees Local Research Ethics Committee on the 20th April 2001 (ref: 00/53)
2. West Ethics Committee Glasgow on the 23rd November 2001 (ref: 01/95)
3. Newcastle and North Tyneside Joint Ethics Committee on the 20th June 2001 (ref: 2000/137)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15330757</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CL0014 Version 5</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-11-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2441c365-7dc1-4e9c-a0fc-d2200bc2cbeb">
	  <name>Pain Management Unit</name>
	  <address/>
	  <city>Adelaide</city>
	  <state/>
	  <country>Australia</country>
	  <zip>5042</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients entering the study will be recruited following written informed consent from pain clinics at participating centres
2. Patients will be in the age range 18 - 90 years with a diagnosis of neuropathic pain made according to the criteria set out below
3. Patients may be taking stable dose regimens of paracetamol, anticonvulsants, antidepressants, opioids or Non-Steroidal Anti-Inflammatory Srugs (NSAIDs)
4. Patients taking excluded medications (see exclusion criteria below) may enter the study after a two week period without these medications

Diagnosis of neuropathic pain:
The term "neuropathic pain" is loosely applied to a variety of heterogeneous conditions and strict diagnostic criteria are difficult to apply. However, for the purposes of this study, the diagnosis will be made on the basis of the following:
1. Pain secondary to an identifiable injury or disease process where damage to the central or peripheral nervous system is suspected
2. Pain persisting for more than three months in the absence of any continuing nociceptive stimulus
3. Pain that is documented as responding poorly to either opioid analgesics or NSAIDs
4. Pain associated with at least two of the following signs/symptoms:
4.1. Abnormal sensation on clinical examination, including sensory loss, paraesthesia, dysaesthesia
4.2. Mechanical allodynia (static or dynamic)
4.3. Pain of a burning character
4.4. Pain of a stabbing or lancinating character
4.5. Signs of sympathetic dysfunction (discolouration, abnormal vasomotor activity, skin trophic changes)

Many conditions may present with neuropathic pain. However, in some conditions the
distinction between primary nociceptive and neuropathic pain is extremely difficult. An
important example of this is in mechanical low back pain where radiation of pain into the legs is commonly reported in the absence of identifiable nerve injury. Given this diagnostic difficulty, for the purpose of this study, patients with lumbar radiculopathy will not be recruited to the study.

The Central Post-Stroke Pain Syndrome seems to have features that are significantly different to other types of neuropathic pain. For this reason, patients with this syndrome will not be included in this study.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>Patients may not enter the study if they have a history of any of the following conditions:
1. Epilepsy
2. Liver disease
3. Psychosis
4. Bipolar disorder
5. Substance misuse
6. Renal failure
7. Adverse reactions to either dihydrocodeine or nabilone
8. Pregnant women, lactating women or women of childbearing potential not using effective methods of contraception
9. Patients involved in ongoing legal action against a third party in which financial compensation is being sought for personal injury alleged to be the cause of the presenting condition

Excluded medications:
Patients may not take the following medications during the study:
1. Dihydrocodeine
2. Antipsychotic drugs
3. Benzodiazepine drugs (excepting stable doses of night-time sedatives)
4. Monoamine oxidase inhibitors

Patients taking dihydrocodeine may enter the study after a washout period of two weeks. Analgesia during this time will be provided with co-proxamol. Patients taking cannabinoid preparations of any kind may not be included in the study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-11-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mixed neuropathic pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The medication was given in identical tablets either containing 240 µg nabilone or 30 mg dihydrocodeine. The dose schedule was one capsule in the first week, two capsules in the third week, four capsules in the third and fourth week and then eight capsules in week five and six. After a two week washout the treatment was crossed over. If there were side effects the dose was not increased further. During the washout rescue medication in the form of eight tablets 30/500 codeine with paracetamol was permitted. So each treatment arm was six weeks with a two week washout after six weeks and in the end. Patients with benefit went then into the open label trial (see ISRCTN38408594: A one year open label assessment of the use of nabilone in the treatment of chronic neuropathic pain). Visual Analogue Scale (VAS) scores and hours slept were recorded in a diary daily and then averaged per week. Only pain scores for the last two weeks were used for the analyses.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nabilone, dihydrocodeine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18182416 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9147c260-9dbb-48dd-8b6b-8e8ca292983e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-26T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18182416"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16745-0</funderId>
      <funderId>Funder16745-1</funderId>
      <contactId>Contact54703_16745</contactId>
      <sponsorId>Sponsor53259</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54703_16745">
    <title>Dr</title>
    <forename>Dilip</forename>
    <surname>Kapur</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Pain Management Unit
Flinders Medical Centre
Flinders Drive
Bedford Park</address>
      <city>Adelaide</city>
      <country>Australia</country>
      <zip>5042</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Dilip.Kapur@fmc.sa.gov.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53259">
    <organisation>Cambridge Laboratories Ltd (UK)</organisation>
    <website>http://www.camb-labs.com/index.html</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Deltic House Newcastle
Kingfisher Way
Silverlink Business Park</address>
      <city>Wallsend</city>
      <country>United Kingdom</country>
      <zip>NE28 9NX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487149.7</gridId>
    <rorId>https://ror.org/001zd1d95</rorId>
  </sponsor>
  <funder id="Funder16745-0">
    <name>Cambridge Laboratories Ltd (UK) - supported by a grant</name>
    <fundRef/>
  </funder>
  <funder id="Funder16745-1">
    <name>The sponsors/funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">82181559</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Minimizing needle poke pain in newborn infants with a pain relieving cream and sugar water</title>
      <scientificTitle>Evaluation of liposomal lidocaine and oral sucrose for treatment of pain in newborn infants undergoing venipuncture: a randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Public title: Minimising needle poke pain in newborn infants with a pain relieving cream and sugar water

Hypothesis 1: Sucrose plus liposomal lidocaine will be superior to either agent alone in reducing pain during venipuncture.
Hypothesis 2: Plasma levels of lidocaine will be below toxicologically significant levels (1 mcg/ml), providing objective evidence of safety.
Hypothesis 3: Plasma levels of endomorphins-1,-2 will be higher in infants pre-medicated with sucrose versus lidocaine, confirming that sucrose exerts its analgesic effects via an opioid-mediated mechanism.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Infant pain during venipuncture as assessed by facial grimacing response - the score will incorporate three facial actions: brow bulge, eye squeezed shut, naso-labial furrow, during venipuncture.</primaryOutcome>
      <secondaryOutcome>1. Visual Analog Scale (VAS), during venipuncture
2. Cry duration, during venipuncture
3. Heart rate, during venipuncture
4. Number of attempts until procedure completion, from first needle poke to completion
5. Endomorphins -1, -2, levels, before and 10 minutes after sucrose/sucrose placebo administration
6. Procedure duration, from first needle poke to completion
7. Lidocaine levels, 5 - 15 minutes after the liposomal lidocaine cream/placebo cream is removed</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval was gained from the Research Ethics Board of Mount Sinai Hospital Toronto, Ontario, Canada on August 03, 2007 (ref: 07-0099-A).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82181559</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-82947</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, double-dummy, single-centre, three arm trial with study participant and investigator, caregiver, outcome assessor, and data analyst blinded.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e640c26a-2100-4f9d-901c-65d07260b924">
	  <name>Department of Pharmacy and Child Health Evaluative Sciences</name>
	  <address/>
	  <city>Toronto, Ontario</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M5G 1X8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All healthy full-term (greater than 37 weeks gestational age) newborn infants (either sex)</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>330</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>330</totalTarget>
      <exclusion>1. Neonatal Intensive Care Unit (NICU) admission
2. Asphyxia, seizures 
3. Major birth defects (heart, brain, genetic syndrome) 
4. Circumcised during study 
5. Receiving analgesia/sedatives</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Newborns undergoing painful procedure</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Infant pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Experimental arm one: 1 g of liposomal lidocaine to the dorsum of hand for 30 - 40 minutes prior to venipuncture and 2 ml of placebo water by mouth using a syringe over 1 - 2 minutes prior to venipuncture.

Experimental arm two: 2 ml of 24% sucrose administered by mouth using a syringe over 1 - 2 minutes prior to venipuncture and 1 g of placebo liposomal lidocaine to the dorsum of hand for 30 - 40 minutes prior to venipuncture.

Experimental arm three: both 1 g of liposomal lidocaine to the dorsum of hand for 30 - 40 minutes prior to venipuncture and 2 ml of 24% sucrose administered by mouth using a syringe over 1 - 2 minutes prior to venipuncture.

Due to double dummy, all infants receive oral sucrose or water (placebo) and all infants receive liposomal lidocaine or placebo. Each baby gets one intervention (experimental arm 1, 2, or 3).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Liposomal lidocaine, oral sucrose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16840-0</funderId>
      <contactId>Contact54798_16840</contactId>
      <sponsorId>Sponsor53355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54798_16840">
    <title>Dr</title>
    <forename>Anna</forename>
    <surname>Taddio</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pharmacy and Child Health Evaluative Sciences
The Hospital for Sick Children
555 University Avenue</address>
      <city>Toronto, Ontario</city>
      <country>Canada</country>
      <zip>M5G 1X8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 783 5263</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">anna.taddio@sickkids.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53355">
    <organisation>The Hospital for Sick Children (Canada)</organisation>
    <website>http://www.sickkids.ca/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Ms. Julie Gibson, Manager
Clinical Research Office
555 University Avenue</address>
      <city>Toronto, Ontario</city>
      <country>Canada</country>
      <zip>M5G 1X8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 813 8481</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">julie.gibson@sickkids.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.42327.30</gridId>
    <rorId>https://ror.org/057q4rt57</rorId>
  </sponsor>
  <funder id="Funder16840-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-82947)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">62421408</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Reduction of OXidative stress in  Chronic Obstructive Pulmonary Disease by Exercise and Nutrition</title>
      <scientificTitle>The effect of nutritional supplementation as adjunct to exercise training on resting and exercise-induced oxidative stress, muscle function and exercise capacity in severe Chronic Obstructive Pulmonary Disease patients</scientificTitle>
      <acronym>ROXCEN</acronym>
      <studyHypothesis>Daily ingestion of a nutritional supplement enriched with antioxidants during eight weeks pulmonary rehabilitation results in a decreased oxidative stress in rest and after exercise in Chronic Obstructive Pulmonary Disease (COPD) patients compared to an iso-caloric placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To assess the effect of daily ingestion of a nutritional supplement enriched with antioxidants during eight weeks pulmonary rehabilitation on resting and exercise-induced oxidative stress in COPD patients compared to an iso-caloric placebo. Oxidative stress will be measured by specific biomarkers in exhaled air, breath condensate, urine and venous blood, measured at the start of the rehabilitation and after eight weeks.</primaryOutcome>
      <secondaryOutcome>To examine the effects of daily ingestion of a nutritional supplement enriched with antioxidants during pulmonary rehabilitation on respiratory and skeletal muscle strength and exercise capacity in COPD patients, measured at the start of the rehabilitation and after eight weeks.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethical Commission of the METC of Maastricht on the 19th September 2007 (ref: NL17788.068.07/MEC 07-3-066).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN62421408</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind placebo controlled parallel intervention study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f1d746fe-5e19-48cd-9ab8-807ebf9516bb">
	  <name>Research, Development and Education</name>
	  <address/>
	  <city>Horn</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6080 NM</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Diagnosis of COPD according to the American Thoracic Society (ATS) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (Forced Expiratory Volume in one second [FEV1] less than 60% predicted and FEV1/Forced Vital Capacity [FVC] less than 70% and less than 10% predicted improvement in FEV1 after b2-agonist inhalation
2. Both male and female, age-range from 40 to 75 years
3. No respiratory tract infection or exacerbation of the disease for at least four weeks before the study
4. Capable to provide informed consent
5. Presence of other chronic diseases is allowed in case the clinical status is stable for at least four weeks before the study</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Inability to perform the incremental cycle ergometer test
2. Chronic use of antioxidants or vitamin supplements
3. Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements
4. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study
5. Specific allergy or intolerance</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic Obstructive Pulmonary Disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Pulmonary diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Nutritional supplement enriched with antioxidants versus iso-caloric placebo.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nutritional supplement</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16860-0</funderId>
      <contactId>Contact54818_16860</contactId>
      <sponsorId>Sponsor53375</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54818_16860">
    <title>Dr</title>
    <forename>E.P.A.</forename>
    <surname>Rutten</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Research, Development and Education
Centre for Integrated Rehabilitation of Organ Failure (CIRO) </address>
      <city>Horn</city>
      <country>Netherlands</country>
      <zip>6080 NM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ericarutten@proteion.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53375">
    <organisation>Numico Research B.V. (The Netherlands)</organisation>
    <website>http://www.numico.com </website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O.Box 7005</address>
      <city>Wageningen</city>
      <country>Netherlands</country>
      <zip>6700 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.433367.6</gridId>
    <rorId>https://ror.org/00aj77a24</rorId>
  </sponsor>
  <funder id="Funder16860-0">
    <name>Numico Research B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-05-19T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-07-25T00:00:00.000Z">49671147</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of a parent training for families with children suffering from Attention-Deficit Hyperactivity Disorder (ADHD)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Primary goal:
The study will examine whether a parent training run by a trainer (pooled individual and group training) leads to a significant and strong long-term decline in problem behaviour among children with Attention-Deficit Hyperactivity Disorder (ADHD) compared with a waiting controls group.

Secondary and further goals:
1. The study will examine whether individual training compared with group training leads to an above random and marked decline in problem behaviour in children with ADHD
2. It will examine whether the above-mentioned between-group comparisons can also be found directly after training 
3. It will examine whether these effects are also reflected in a decline in family stress levels
4. It will examine whether these effects are also reflected in a change of educational behaviour
5. It will perform a cost-benefit analysis to determine which intensity of intervention is needed to attain strong and stable training effects
6. It will analyse which families fail to complete training, do not implement recommended measures adequately, or do not cooperate in the training
7. Finally, it will analyse whether certain forms of training prove to be particularly effective in certain families (e.g., as a function of socioeconomic status, child's age, family status, etc.)</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Intention-to-treat analysis of the reduction in child behaviour problems on the Home Situations Questionnaire (HSQ) by comparing the differences in mean scores on the 16 items (Likert scales from few [1] to very strong [10]) from pretest to follow up across the three conditions.

Comparisons between three randomised matched groups receiving one of the following forms of intervention: individual training, group training, and a waiting controls group.

All endpoints will be assessed at three measurement times:
T1: First measurement at Week 0 (pre)
T2: Second measurement at Week 6 (post)
T3: Third measurement 6 months after Week 11 (follow-up)</primaryOutcome>
      <secondaryOutcome>1. Intention-to-treat analysis of the reduction in child behaviour problems on the Child Behaviour Checklist (CBCL) by comparing differences in means from pretest to follow up across the three conditions
2. Sensitivity-analysis of the reduction in child behaviour problems on the Home Situations Questionnaire by comparing the differences in means from pretest to follow up across the three conditions
3. Analyses of the reduction in degree of family stress on the Parenting Stress Index by comparing differences in means from pretest to follow up across the three conditions
4. Analyses of improvement in educational behaviour on the Being A Parent scales (BAP) by comparing differences in means from pretest to follow up across the three conditions
5. Furthermore, a cost-benefit analysis will be conducted to compare the two forms of intervention

All endpoints will be assessed at three measurement times:
T1: First measurement at Week 0 (pre)
T2: Second measurement at Week 6 (post)
T3: Third measurement 6 months after Week 11 (follow-up)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study will commence only after being granted a positive evaluation by the Ethics Committee of the University of Cologne. At each further study centre, it will also commence only after being granted a positive evaluation by the appropriate Ethics Committee.

The present study protocol and any potential changes to it are, and will continue to be, formulated in line with the October 1996 version of the Helsinki Declaration (48th General Assembly of the World Medical Association, Somerset West, Republic of South Africa).

The study received a positive evaluation by the Ethics Committee of the University of Cologne on the 20th September 2007 (ref: 06-213).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN49671147</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>uni-koeln-707 v2-06</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, multicentre, randomised, control-group study in Germany</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-08-13T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="204eb7e4-07cc-46ea-8fed-d536f8e0cf08">
	  <name>Faculty of Human Sciences</name>
	  <address/>
	  <city>Cologne</city>
	  <state/>
	  <country>Germany</country>
	  <zip>50931</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Parents' age greater than or equal to 18 years
2. Responsibility and legal capacity in parents
3. Diagnosis of ADHD in child (Diagnostic System for Psychiatric Disorders in Childhood and Adolescence [DISYPS])
4. Age of child between 6 and 11 years
5. Informed consent of the parents and the children available</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="6.0"/>
      <upperAgeLimit unit="Years" value="11.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>192</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>To be assessed for eligibility: n = 366 (max. 30% ineligible), to be allocated to trial: n = 258, to be analysed: n = 192 (per protocol)</totalTarget>
      <exclusion>1. Earlier or current participation in other intervention trials that might interfere with the current study
2. The main caregiver is currently receiving psychotherapeutic treatment
3. Developmental disorders in the child
4. Manifest critical life events as listed in Diagnostic and Statistic Manual of Mental Disorders - fourth edition (DSM-IV-TR)
5. Insufficient parental resources to implement the intervention</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-08-13T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Attention-Deficit Hyperactivity Disorder (ADHD)</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Attention-Deficit Hyperactivity Disorder</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Competence training for parents with socially disruptive children diagnosed with ADHD. The parent training will be carried out according to the manual in both intervention conditions. It will take a total of seven weekly sessions:
1. Weeks 1 - 6: six weekly three-hour sessions (regular training)
2. Weeks 7 - 10: four-week pause with no sessions
3. Week 11: single three-hour refresher session
Six months after is the follow up measurement.

Duration of the study for individual clients: 7 x three hours over a period of 11 weeks. Total duration of the whole trial for each participant is approximately 9 months. 

Each training unit pursues one single goal. As a result, each unit addresses one clear topic. All training units follow the same standardised routine:
1. Announcement of the agenda, so that each participant knows what is coming next. This is posted on a notice board
2. Evaluation of the task of the week (therapy homework) agreed upon at the previous session
3. Content-specific units and exercises on the focus of the specific training unit
4. Finding one's own strengths to encourage a solution-oriented and confident attitude in the participants allowing them to go back home feeling stronger
5. Presentation and discussion of the task of the week to be carried out before the next week's session

The treatment branches are:
1. Treatment Branch A: individual training - a trainer works through the seven three-hour training units according to the manual with the main caregiver in the family home
2. Treatment Branch B: group training - a trainer works through the seven three-hour training units according to the manual with a group of 6 - 8 parents at a study centre. Only the main caregiver participates in training
3. Treatment Branch C: waiting controls group - the control group will initially receive the usual treatment. Data on the control group will be gathered at the same times as that on other groups. After the final data collection at the follow up, main caregivers in the control group will be offered the intervention that has proved to be most effective up to then

Contents of Training Sessions:
1. Training unit 1 goal: What needs to change? What can stay the same?
Pinpointing - parents should grasp their current problems as behaviour difficulties, name concrete interaction problems with the child, and formulate their own training goals
2. Training unit 2 goal: Confirming the emotional core - positive play
Strengthening the positive relationship with the child - parents should spend "precious time" with their child every working day. They should find about 30 minutes a day for uninterrupted play
3. Training unit 3 goal: Being aware of one's own feelings and thoughts
ABC scheme for emotional regulation and de-escalation - parents should analyse difficult everyday situations in terms of the thinking patterns associated with them and distinguish between beneficial and dysfunctional patterns
4. Training unit 4 goal: Breaking fixed routines
Changing dysfunctional everyday routines, modifying situational contingencies - parents learn to restructure recurring everyday situations (e.g., going to bed, mealtimes, homework) in a more positive way
5. Training unit 5 goal: Showing how actions have consequences
Strengthening prosocial behaviour, avoiding reinforcement traps - parents learn to provide effective and behaviour-related consequences (reinforcement, punishment)
6. Training unit 6 goal: Making effective demands
Setting clear rules and making demands correctly - parents practice formulating and communicating demands
7. Refresher session goal: Looking Back on the Way Forward
Problem-solving behaviour in the family, structuring in the family - parents review what has been achieved so far and specify unresolved problems. Discussions address how to further reduce family stress and how parents can support each other</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16715-0</funderId>
      <contactId>Contact54673_16715</contactId>
      <sponsorId>Sponsor53229</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54673_16715">
    <title>Prof</title>
    <forename>Gerhard</forename>
    <surname>Lauth</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Faculty of Human Sciences 
University of Cologne
Klosterstr. 79b</address>
      <city>Cologne</city>
      <country>Germany</country>
      <zip>50931</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 221 470 5514</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gerhard.lauth@uni-koeln.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53229">
    <organisation>University of Cologne (Germany)</organisation>
    <website>http://www.uni-koeln.de/index.e.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Faculty of Remedial Sciences
Klosterstr. 79b</address>
      <city>Cologne</city>
      <country>Germany</country>
      <zip>50931</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)221 470 5514</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gerhard.lauth@uni-koeln.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6190.e</gridId>
    <rorId>https://ror.org/00rcxh774</rorId>
  </sponsor>
  <funder id="Funder16715-0">
    <name>German Research Council (Deutsche Forschungsgemeinschaft) (DFG) (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-06-27T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-07-17T00:00:00.000Z">73223855</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of phenobarbitone and phenytoin for newly diagnosed epilepsy in adults</title>
      <scientificTitle/>
      <acronym>AEPEP</acronym>
      <studyHypothesis>To compare the frequency of side effects of phenobarbitone to those of phenytoin as first line treatment of active convulsive epilepsy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Frequency of side effects.</primaryOutcome>
      <secondaryOutcome>1. Time to next seizure after starting treatment using an epilepsy history questionnaire
2. Seizure frequency: frequency of seizures will be monitored using seizure calendars, which the subjects will be educated on keeping
3. Compliance with drugs: drug compliance will be assessed by direct measurement of drug levels in blood at the initial contact and at 12 months; and using saliva samples at the end of 1, 3, 6 and 12 months. This will be reinforced by tablet counting and information elicited from patients/caregivers
4. Quality of life measure as developed for this proposal
5. Cognitive effects: subjects will have a culturally appropriate test of cognitive function performed at 6 months and 1 and 3 years afterwards</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Kemri/National Ethical Review Committee reviewed the proposal, and permission was granted on 21st June 2007 (ref: SSC 786).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73223855</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>KEMRI SCC 786</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open label randomised trial of phenobarbitone versus phenytoin</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-07-09T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Kenya</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="804e8544-43c1-455d-ba7a-75df03b8bc00">
	  <name>P.O. Box 230</name>
	  <address/>
	  <city>Kilifi</city>
	  <state/>
	  <country>Kenya</country>
	  <zip>80108</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adults (greater than 17 years) with active epilepsy, i.e. two or more seizures within the last year and the following seizure types:
1. Tonic-clonic
2. Partial becoming generalised
3. Partial motor</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Subjects who have received antiepileptic drugs in the past
2. Subjects with absence, myoclonic or atonic seizures
3. Subjects with progressive neurological disease
4. Subjects with severe learning difficulties
5. Less than 18 years old</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-07-09T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Epilepsy</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Episodic and paroxysmal disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Phenobarbitone versus phenytoin, in which the assessor is blinded to the treatment allocation and patient is given information on the side effects of both anti-epileptic drugs together, but is not aware which side effects is attributed to which drug.

Treatment: 
The following regimens for the drugs will be used:

Phenobarbitone: adults will be started on 60 mg daily orally in the evening, increasing to 120 mg daily after two weeks. Thereafter the dose will be titrated according to the response and side effects. If seizures are not controlled (greater than one per week) by six months after enrolling into the trial, the subject will be started on phenytoin.

Phenytoin: adults will be started on 50 mg daily, increasing to 100 mg daily (in two doses one in the morning and one in the evening). Thereafter the dose will be titrated according to the response and side effects. If seizures are not controlled (greater than one per week) by six months after enrolling into the trial, the subject will be started on phenobarbitone.

If both drugs prove to be ineffective, i.e., continued seizures after substitution with the other study drug then the subject will be started on dual therapy. 

Monitoring:
All subjects will be seen a month after enrolment into the study, when they will be assessed by a clinician and the dosage of the drug adjusted according to clinical response and side effects. Blood and saliva samples will be taken for concentrations of the Antiepileptic Drug (AED), but the results will only be available at the subsequent visit. 

Thereafter subjects will be seen at 3 months, 6 months and 12 months after starting treatment. At each visit, the subjects will be seen by a fieldworker (blinded to the treatment group), who will administer a Quality Of Life (QOL) questionnaire. Thereafter the subject will be seen by a clinician who will manage the epilepsy according to standard medical practice. 

Subjects will also be asked to bring in the bottle of tablets so that they can be counted, and the excess tablets will be used to aid in estimation of compliance. Furthermore subjects will be visited at home by a designated fieldworker (maximum of 14 visits per day) to promote adherence.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Phenobarbitone, phenytoin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16701-0</funderId>
      <contactId>Contact54659_16701</contactId>
      <sponsorId>Sponsor53214</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54659_16701">
    <title>Prof</title>
    <forename>Charles</forename>
    <surname>Newton</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P.O. Box 230</address>
      <city>Kilifi</city>
      <country>Kenya</country>
      <zip>80108</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cnewton@kilifi.kemri-wellcome.org</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53214">
    <organisation>University of Oxford (UK)</organisation>
    <website>http://www.ox.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>John Radcliffe Hospital
Headington</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX3 9DU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tlang@kilifi.kemri-wellcome.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder16701-0">
    <name>The Wellcome Trust (UK) (grant ref: 077092)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-07-10T00:00:00.000Z">99270116</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Is laser treatment or surgery the best way of treating varicose veins?</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Endovenous laser ablation (EVLA) produces comparable short-term results to surgery (abolition of great saphenous vein [GSV] reflux and improvement in symptoms) for the treatment of primary varicose veins due to sapheno-femoral incompetence with greater saphenous vein reflux.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Abolition of GSV reflux at three months (duplex ultrasound) 
2. Improvement in disease-specific quality of life (Aberdeen Varicose Vein Questionnaire)</primaryOutcome>
      <secondaryOutcome>1. Time to return to work and to normal activity
2. Pain and analgesia use during first week following treatment
3. Overall satisfaction and satisfaction with cosmetic outcome
4. Generic quality of life (36-item Short Form health survey [SF-36]) at 1 and 12 weeks following treatment
5. Complications</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received from Leeds (West) Research Ethics Committee in May 2003 (ref: 03/052).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99270116</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>VS03/2281</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Parallel group, non-blinded, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-06-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9cfbfbd3-f2c9-4de3-a383-9f1bd0ab14ff">
	  <name>Leeds Vascular Institute</name>
	  <address/>
	  <city>Leeds</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LS1 3EX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Symptomatic varicose veins 
2. Primary sapheno-femoral incompetence with greater saphenous vein reflux</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>342</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>342</totalTarget>
      <exclusion>1. Unable to consent
2. Children (under 18 years)
3. Unfit for general anaesthesia
4. Recurrent varicose veins
5. Patients on long-term anticoagulation
6. Patients with anterior thigh branch of greater saphenous vein arising within 10 cm of groin and competent GSV distal to this</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-06-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Varicose veins</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Varicose veins</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Endovenous laser treatment (810 nm diode laser, Diomed) versus sapheno-femoral ligation, greater saphenous vein stripping and avulsions (surgery).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18278775 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c53e0951-6902-41b7-baa3-d782cc85afe7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18278775"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16614-0</funderId>
      <funderId>Funder16614-1</funderId>
      <contactId>Contact54572_16614</contactId>
      <sponsorId>Sponsor53127</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54572_16614">
    <title>Mr</title>
    <forename>Michael</forename>
    <surname>Gough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leeds Vascular Institute
The General Infirmary at Leeds
Great George Street</address>
      <city>Leeds</city>
      <country>United Kingdom</country>
      <zip>LS1 3EX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53127">
    <organisation>Leeds Teaching Hospitals NHS Trust (UK)</organisation>
    <website>http://www.leedsteachinghospitals.com/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Leeds Vascular Institute
The General Infirmary at Leeds
Great George Street</address>
      <city>Leeds</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>LS1 3EX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.415967.8</gridId>
    <rorId>https://ror.org/00v4dac24</rorId>
  </sponsor>
  <funder id="Funder16614-0">
    <name>Leeds Teaching Hospitals NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16614-1">
    <name>Diomed Ltd (UK) - part of research fellow salary paid (£15,000 pa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-04-11T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">48831122</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Elective laparoscopic appendectomy for chronic right lower abdominal pain: outcome of a prospective randomised double-blind controlled surgical trial</title>
      <scientificTitle>Elective laparoscopic appendectomy for chronic right lower abdominal pain</scientificTitle>
      <acronym/>
      <studyHypothesis>Elective laparoscopic appendectomy is a useful procedure in patients with chronic or recurrent right lower abdominal pain.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure was pain scored by the blinded patient at six months postoperatively in the presence of the still blinded surgical resident.</primaryOutcome>
      <secondaryOutcome>The secondary outcome parameter was the relation between clinical improvement and histopathological findings of the removed appendices.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval was received from the local medical ethics committee (Medisch Ethische Toetsings Commissie). The study was considered in 1993 and approved in 1994 (ref: 93-35).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48831122</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NTR955</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blinded, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1994-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="701f5adb-2e20-4474-bb8d-7322ef7755bc">
	  <name>MÁxima Medisch Centrum</name>
	  <address/>
	  <city>Veldhoven</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>5500 MB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Between 15 and 45 years of age
2. Suffering from chronic or recurrent right lower abdominal quadrant pain for more than three months
3. Experience of continuous pain, or should have endured at least one pain attack in the month prior to inclusion</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. (A history of) chronic back pain
2. Previous abdominal surgery (with the exception of diagnostic laparoscopies or a laparoscopic sterilisation)
3. Specific gastro-intestinal entities (such as inflammatory bowel disease)
4. Gynaecological disease (all female patients consulted a gynaecologist)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1994-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic right lower abdominal pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Abdominal and pelvic pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Appendectomy by laparoscopy or not.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18161760 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="19ce138d-4cf3-467d-bfdd-501ed4715806" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18161760"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16562-0</funderId>
      <contactId>Contact54520_16562</contactId>
      <sponsorId>Sponsor53075</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54520_16562">
    <title>Dr</title>
    <forename>Rudi </forename>
    <surname>Roumen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>MÁxima Medisch Centrum
Department of  Surgery
P.O. Box 7777</address>
      <city>Veldhoven</city>
      <country>Netherlands</country>
      <zip>5500 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)40 8888556</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">r.roumen@mmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53075">
    <organisation>Maxima Medical Centre (The Netherlands)</organisation>
    <website>http://www.mmc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of General Surgery
P.O. Box 7777</address>
      <city>Veldhoven</city>
      <country>Netherlands</country>
      <zip>5500 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.414711.6</gridId>
    <rorId>https://ror.org/02x6rcb77</rorId>
  </sponsor>
  <funder id="Funder16562-0">
    <name>Maxima Medical Centre (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-05-02T00:00:00.000Z">48222371</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study on the effects on plasma insulin and glucose after a single meal replacement in patients with type two diabetes mellitus</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>A single oral doses of amino acids may play a role as insulin secretagogues.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Insulin and glucose response</primaryOutcome>
      <secondaryOutcome>Hormones involved in glucose homeostasis</secondaryOutcome>
      <trialWebsite>http://www.chdr.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48222371</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blinded, placebo controlled crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9802d8e7-18ec-4b64-9120-d3bab077a0f9">
	  <name>Center for Human Drug Research</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2333 CL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adult Type two Diabetes Mellitus (T2DM) patients</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>1. Insulin use
2. Significant clinical abnormalities</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes, insulin response</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention with single meals with different composition of amino acids in a double-blind placebo controlled trial.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Plasma insulin, glucose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16479-0</funderId>
      <contactId>Contact54437_16479</contactId>
      <sponsorId>Sponsor52992</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54437_16479">
    <title>Dr</title>
    <forename>J.</forename>
    <surname>Burggraaf</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Center for Human Drug Research
Zernikedreef 10</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 CL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52992">
    <organisation>Dutch State Mines (DSM) (The Netherlands)</organisation>
    <website>http://www.dsm.com/en_US/html/about/about_us_home.htm</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 6500</address>
      <city>Heerlen</city>
      <country>Netherlands</country>
      <zip>6401 JH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10760.30</gridId>
    <rorId>https://ror.org/00k01kt20</rorId>
  </sponsor>
  <funder id="Funder16479-0">
    <name>Dutch State Mines (DSM) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-03-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-04-25T00:00:00.000Z">27453314</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Clinical evidence continuous medical education: randomised educational trial of an e-learning program for transferring evidence based information in primary and secondary care</title>
      <scientificTitle/>
      <acronym>ICEKUBE (Italian Clinical Evidence Knowledge Utilisation Behaviour Evaluation)</acronym>
      <studyHypothesis>This trial is designed to test the effectiveness of ECCE (the Italian acronym for Continuing Education Clinical Evidence) e-learning program for transferring evidence based information to medical doctors after three months of ECCE usage and the retention of the transferred information after six months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome is the basic knowledge of Clinical Evidence contents assessed through the scoring of clinical vignettes selected from ECCE. The test will consist of fixed and multiple choice questions of the selected valid and reliable vignettes and will be administered before (pre-test), immediately after (12 weeks post-test one), and six months after the intervention (post-test two).</primaryOutcome>
      <secondaryOutcome>Satisfaction with the information source and its perceived value for the medical education and clinical practice.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the local research ethics committee (Research Ethics Board Azienda Sanitaria Locale &#147;Città di Milano&#148;, Milano) on the 15th December 2007 (ref: 43-06 SO).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27453314</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>43-06 SO</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A before and after pragmatic educational randomised controlled trial utilising a two by two incomplete block design.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="595541a4-729a-4656-955e-731234e1778a">
	  <name>Italian Cochrane Centre</name>
	  <address/>
	  <city>Milano</city>
	  <state/>
	  <country>Italy</country>
	  <zip>20156</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All Italian doctors naïve to ECCE who voluntarily adhere to participate. New users to ECCE who connect to ECCE are automatically invited to participate.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>162</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>A sample size of 54 practitioners per study arm</totalTarget>
      <exclusion>There are no exclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Knowledge of the best available evidence for effective healthcare.</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2>Healthcare knowledge</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Please note that as of 20/07/2007 the anticipated end date has been extended to 31/09/2007 due to a low recruitment rate. The previous end date of this trial was 31/07/2007. On 18/12/2007 the anticipated end date was extended again to 01/04/2008 due to a continued low recruitment rate. On the 05/03/2008 the anticipated end date was again amended to show the end date as the 29/02/2008 - this is the date this trial was closed to enrolment. 

Sample size/power calculation:
Based on a preliminary examination, we determined that the &#147;minimal&#148; important difference for this intervention to be considered useful was a 20% absolute improvement.

Based on a preliminary test of 300 doctors, we determined that the &#147;mean&#148; improvement due to the intervention, was a 28% absolute improvement. Therefore we calculated our sample size to detect a 0.7 standardised difference in the primary outcome, set the α error rate at 0.05 (two-sided), and the β error at 0.10 (power 90%) &#150; this yielded a sample size of 45 practitioners per study arm. If the accrual period is two months and the maximum follow-up period is six months with a loss during follow-up of 20% at the end of the study, the total number of practitioners to be randomised has been adjusted upwards to 162 (54 per intervention group).

Intervention:
ECCE is an e-learning tool that uses interactive clinical vignettes based on chapters in Clinical Evidence and a predefined sequence of questions. ECCE has four components: 
1. The Clinical Evidence chapter (e.g. headache, chronic tension-type), a clinical vignette derived from the Clinical Evidence chapter gives a plausible medical scenario (e.g. Margaret says to her family doctor: &#147;This time I didn&#146;t come for me, but to talk about Rachel, my 25-year-old daughter&#133;)
2. The lead-in for the clinical vignette and related questions that gives the doctors instructions on what to do (e.g. "more than one answer may be correct&#148;)
3. The questions addressing the recall of Clinical Evidence facts or the application of Clinical Evidence facts to the medical scenario, based on which the doctor is to select the correct answer
4. And finally the potential answers (e.g. a list of potential efficacy descriptors for a therapeutic regimen relevant to the theme) 

Group one access to ECCE for Clinical Evidence chapters and vignettes lot A and provides control data for Clinical Evidence chapters and vignettes lot B.
Group two access to ECCE for lot B and provides control data for lot A. 

To determine the possible Hawthorne effect of this trial, we added to the two-block design arms a third control arm (classical design), in which a minimal intervention was defined. The minimal intervention consisted of one of the elements of the complete intervention, namely the concise printed version of Clinical Evidence and access to the on-line full-text version.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16347-0</funderId>
      <contactId>Contact54304_16347</contactId>
      <sponsorId>Sponsor52857</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54304_16347">
    <title>Dr</title>
    <forename>Lorenzo</forename>
    <surname>Moja</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Italian Cochrane Centre
Mario Negri Institute
Via La Masa 19</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>20156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 02 3901 4517</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">moja@marionegri.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52857">
    <organisation>Italian Cochrane Centre (Italy)</organisation>
    <website>http://www.icc.cochrane.org</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o  Dr Lorenzo Moja 
Mario Negri Institute
Via La Masa 19</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>20156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 02 3901 4517</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">moja@marionegri.it</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7548.e</gridId>
    <rorId>https://ror.org/02d4c4y02</rorId>
  </sponsor>
  <funder id="Funder16347-0">
    <name>Italian Drug Agency (AIFA) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>